[/O Autosomal/O dominant/O limb/O -/O girdle/O muscular/O dystrophy/O associated/O with/O conduction/O defects/O (/O LGMD1B/O )/O :/O a/O description/O of/O 8/O new/O families/O with/O the/O LMNA/O gene/O mutations/O ]/O ./O
La/O dystrophie/O musculaire/O des/O ceintures/O autosomique/O dominante/O associée/O à/O des/O troubles/O de/O la/O conduction/O cardiaque/O (/O LGMD1B/O )/O ./O
Description/O de/O 8/O nouvelles/O familles/O avec/O mutations/O du/O gène/O LMNA/O ./O
INTRODUCTION/O :/O Limb/B-Disease girdle/I-Disease muscular/I-Disease dystrophy/I-Disease type/I-Disease 1b/I-Disease (/O LGMD1B/O )/O ,/O due/B-Reg to/I-Reg LMNA/B-Gene gene/O mutations/B-Var ,/O is/O a/O relatively/O rare/O form/O of/O LGMD/O characterized/O by/O proximal/O muscle/O involvement/O associated/O with/O heart/O involvement/O comprising/O atrio/O -/O ventricular/O conduction/O blocks/O and/O dilated/O cardiomyopathy/O ./O
Its/O clinical/O and/O genetic/O diagnosis/O is/O crucial/O for/O cardiac/O management/O and/O genetic/O counselling/O ./O
Seven/O LMNA/O mutations/O have/O been/O previously/O reported/O to/O be/O responsible/O for/O LGMD1B./O PATIENTS/O AND/O METHODS/O :/O We/O describe/O the/O neurological/O and/O cardiologic/O features/O of/O 14/O patients/O belonging/O to/O 8/O families/O in/O whom/O we/O identified/O 6/O different/O LMNA/O mutations/O ,/O 4/O of/O them/O having/O never/O been/O reported/O ./O
Results/O ./O
Eleven/O patients/O had/O an/O LGMD1B/O phenotype/O with/O scapulohumeral/O and/O pelvic/O -/O femoral/O involvement/O ./O
Thirteen/O patients/O had/O cardiac/O disease/O associating/O conduction/O defects/O (/O 12/O patients/O )/O or/O arrhythmias/O (/O 9/O patients/O )/O ./O
Seven/O patients/O needed/O cardiac/O device/O (/O pacemaker/O or/O implantable/O cardiac/O defibrillator/O )/O and/O two/O had/O heart/O transplantation/O ./O
CONCLUSION/O :/O This/O study/O allowed/O us/O to/O specify/O the/O clinical/O characteristics/O of/O this/O entity/O and/O to/O outline/O the/O first/O phenotype/O //O genotype/O relations/O resulting/O from/O these/O observations/O ./O
Genetics/O of/O laminopathies/O ./O
Laminopathies/O are/O now/O recognized/O as/O a/O group/O of/O disorders/O due/O to/O mutations/O of/O the/O LMNA/O gene/O ,/O which/O encodes/O A/O -/O type/O lamins/O ./O
Primarily/O ,/O mutations/B-Var in/O LMNA/B-Gene have/O been/O associated/B-Reg to/I-Reg the/O autosomal/O forms/O of/O Emery/B-Disease -/I-Disease Dreifuss/I-Disease muscular/I-Disease dystrophy/I-Disease ,/O a/O rare/O slowly/O progressive/O humero/O -/O peroneal/O muscular/O dystrophy/O accompanied/O by/O early/O contractures/O and/O dilated/O cardiomyopathy/O with/O conduction/O defects/O ./O
LMNA/O mutations/O have/O been/O reported/O to/O be/O responsible/O for/O up/O to/O 10/O distinct/O phenotypes/O that/O affect/O specifically/O either/O the/O skeletal/O and/or/O cardiac/O muscle/O ,/O the/O adipose/O tissue/O ,/O the/O peripheral/O nervous/O tissue/O ,/O the/O bone/O tissue/O or/O more/O recently/O premature/O ageing/O ./O
So/O far/O more/O than/O 180/O different/O LMNA/O mutations/O have/O been/O identified/O in/O 903/O individuals/O ./O
The/O first/O studies/O of/O phenotype/O //O genotype/O relationships/O revealed/O no/O dear/O relation/O between/O the/O phenotype/O and/O the/O type/O and/or/O the/O localization/O of/O the/O mutation/O ,/O except/O perhaps/O for/O the/O globular/O tail/O domain/O of/O lamins/O A/O //O C./O Studies/O of/O the/O consequences/O of/O LMNA/O mutations/O in/O the/O skin/O cultured/O fibroblasts/O from/O the/O patients/O reveal/O abnormal/O nuclei/O in/O variable/O proportions/O ,/O with/O dysmorphic/O nuclei/O exhibiting/O abnormal/O patterns/O of/O expression/O of/O B/O -/O type/O lamins/O and/O emerin/O ./O
Finally/O ,/O the/O development/O of/O KO/O and/O KI/O LMNA/O mice/O ,/O will/O certainly/O give/O further/O insight/O into/O the/O pathophysiological/O mechanisms/O associated/O with/O LMNA/O mutations/O ./O
For/O example/O ,/O Lmna(H222P/O //O H222P/O )/O mice/O harbour/O phenotypes/O reminiscent/O of/O Emery/O -/O Dreifuss/O muscular/O dystrophy/O ./O
Mutations/B-Var in/O the/O mouse/O Lmna/B-Gene gene/O causing/B-Reg progeria/B-Disease ,/O muscular/B-Disease dystrophy/I-Disease and/O cardiomyopathy/B-Disease ./O
At/O least/O ten/O different/O diseases/O have/O been/O linked/O to/O mutations/O in/O proteins/O associated/O with/O the/O nuclear/O envelope/O (/O NE/O )/O ./O
Eight/O of/O these/O diseases/O are/O associated/O with/O mutations/O in/O the/O lamin/O A/O gene/O (/O LMNA/O )/O ./O
These/O diseases/O include/O the/O premature/O ageing/O or/O progeric/O diseases/O Hutchinson/O -/O Gilford/O progeria/O and/O atypical/O Werner/O 's/O syndrome/O ,/O diseases/O affecting/O striated/O and/O cardiac/O muscle/O including/O muscular/O dystrophies/O and/O dilated/O cardiomyopathies/O ,/O lipodystrophies/O affecting/O white/O fat/O deposition/O and/O skeletal/O development/O and/O a/O peripheral/O neuropathy/O resulting/O in/O motor/O neuron/O demyelination/O ./O
To/O understand/O how/O these/O diseases/O arise/O from/O different/O mutations/O in/O the/O same/O protein/O ,/O we/O established/O mouse/O lines/O carrying/O some/O of/O the/O same/O mutations/O found/O in/O the/O human/O LMNA/O gene/O ,/O as/O both/O mouse/O and/O human/O lamin/O genes/O show/O a/O very/O high/O degree/O of/O sequence/O conservation/O ./O
We/O have/O generated/O mice/O with/O different/O mutations/O resulting/O in/O progeria/O ,/O muscular/O dystrophy/O and/O dilated/O cardiomyopathy/O ./O
Our/O mouse/O lines/O are/O providing/O novel/O insights/O into/O how/O changes/O to/O the/O nuclear/O lamina/O affect/O the/O mechanical/O integrity/O of/O the/O nucleus/O and/O in/O turn/O intracellular/O signalling/O ,/O such/O as/O the/O NF/O -/O kappaB/O pathway/O ,/O as/O well/O as/O cell/O proliferation/O and/O survival/O ,/O cellular/O functions/O that/O ,/O when/O disrupted/O ,/O may/O be/O the/O basis/O for/O the/O origin/O of/O such/O diseases/O ./O
A/O novel/O mutation/B-Var of/O the/O cathepsin/B-Gene C/I-Gene gene/O in/O a/O thai/O family/O with/B-Reg Papillon/B-Disease -/I-Disease Lefevre/I-Disease syndrome/I-Disease ./O
BACKGROUND/O :/O Papillon/O -/O Lefevre/O syndrome/O (/O PLS/O )/O is/O a/O rare/O autosomal/O recessive/O disorder/O characterized/O by/O palmar-/O plantar/O hyperkeratosis/O and/O rapid/O periodontal/O destruction/O of/O both/O primary/O and/O permanent/O dentitions/O ./O
It/O has/O been/O shown/O that/O the/O disease/O is/O caused/O by/O cathepsin/O C/O gene/O (/B-Gene CTSC/I-Gene )/I-Gene mutation/B-Var leading/O to/O the/O deficiency/B-NegReg of/O cathepsin/B-Enzyme C/I-Enzyme enzymatic/I-Enzyme activity/B-MPA ./O
This/O study/O demonstrates/O the/O clinical/O manifestations/O and/O CTSC/O mutational/O and/O enzymatic/O activity/O analyses/O in/O a/O 5-year/O -/O old/O Thai/O male/O PLS/O patient/O and/O his/O parents/O ./O
METHODS/O :/O Peripheral/O blood/O samples/O were/O obtained/O for/O genomic/O DNA/O isolation/O ./O
All/O exons/O of/O the/O CTSC/O gene/O were/O amplified/O by/O polymerase/O chain/O reaction/O (/O PCR/O )/O using/O specific/O primers/O ./O
Mutations/O were/O identified/O by/O DNA/O sequencing/O ./O
Verification/O of/O the/O mutation/O was/O performed/O by/O digestion/O of/O PCR/O products/O by/O restriction/O endonucleases/O ./O
The/O cathepsin/O C/O enzymatic/O activity/O was/O determined/O using/O the/O synthetic/O substrate/O glycyl-/O L/O -/O arginine-7-amino-4-methylcoumarin/O ./O
RESULTS/O :/O The/O patient/O demonstrated/O classical/O characteristics/O of/O PLS/O ,/O including/O hyperkeratotic/O skin/O lesions/O ./O
By/O the/O age/O of/O 5/O ,/O all/O of/O his/O primary/O teeth/O were/O extracted/O due/O to/O severe/O periodontal/O infection/O ./O
The/O parents/O had/O no/O physical/O abnormalities/O ./O
The/O periodontal/O examination/O revealed/O localized/O mild/O periodontal/O destruction/O ./O
Sequence/O analysis/O showed/O a/O nucleotide/O change/O at/O position/O 90/O from/O C/O >/O A/O (/B-Var c.90C/I-Var >/I-Var A/I-Var )/I-Var which/O resulted/B-Reg in/I-Reg a/O change/O from/O cysteine/O residue/O to/O a/O premature/B-MPA stop/I-MPA codon/I-MPA at/O the/O amino/O acid/O position/O 30/O in/O the/O exon/O 1/O ./O
The/O HpyCH4V/O digestion/O revealed/O that/O the/O patient/O was/O homozygous/O ,/O whereas/O both/O the/O father/O and/O mother/O were/O heterozygous/O carriers/O of/O this/O mutation/O ./O
The/O cathepsin/O C/O activity/O was/O reduced/O in/O the/O patient/O 's/O mother/O ,/O and/O the/O activity/O in/O the/O patient/O was/O almost/O completely/O lost/O ./O
CONCLUSIONS/O :/O This/O is/O the/O first/O study/O to/O demonstrate/O a/O CTSC/B-Gene gene/O mutation/O in/O a/O Thai/O family/O with/O PLS/O ./O
The/O identified/O mutation/B-Var is/O novel/O and/O potentially/O leads/O to/O the/O drastic/O reduction/B-NegReg of/O the/O cathepsin/B-Enzyme C/I-Enzyme enzymatic/I-Enzyme activity/B-MPA ./O
This/O suggests/O that/O the/O mutation/O is/O pathogenetic/O ,/O causing/B-Reg the/O PLS/B-Disease ./O
Mutational/O analysis/O in/O more/O members/O of/O the/O family/O is/O warranted/O to/O identify/O whether/O the/O mutation/O is/O inherited/O from/O a/O common/O ancestor/O ./O
Mutations/O of/O COL10A1/O in/O Schmid/O metaphyseal/O chondrodysplasia/O ./O
Schmid/B-Disease metaphyseal/I-Disease chondrodysplasia/I-Disease (/O SMCD/O )/O is/O a/O dominantly/O inherited/O cartilage/O disorder/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O gene/O for/O the/O hypertrophic/O cartilage/O extracellular/O matrix/O structural/O protein/O ,/O collagen/O X/O (/B-Gene COL10A1/I-Gene )/I-Gene ./O
Thirty/O heterozygous/O mutations/O have/O been/O described/O ,/O about/O equally/O divided/O into/O two/O mutation/O types/O ,/O missense/O mutations/O ,/O and/O mutations/O that/O introduce/O premature/O termination/O signals/O ./O
The/O COL10A1/O mutations/O are/O clustered/O (/O 33/36/O )/O in/O the/O 3/O '/O region/O of/O exon/O 3/O ,/O which/O codes/O for/O the/O C/O -/O terminal/O NC1/O trimerization/O domain/O ./O
The/O effect/O of/O COL10A1/O missense/O mutations/O have/O been/O examined/O by/O in/O vitro/O expression/O and/O assembly/O assays/O and/O cell/O transfection/O studies/O ,/O which/O suggest/O that/O a/O common/O consequence/O is/O the/O disruption/O of/O collagen/O X/O trimerization/O and/O secretion/O ,/O with/O consequent/O intracellular/O degradation/O ./O
The/O effect/O of/O COL10A1/B-Gene nonsense/B-Var mutations/I-Var in/O cartilage/O tissue/O has/O been/O examined/O in/O two/O patients/O ,/O demonstrating/O that/O the/O mutant/B-Var mRNA/B-MPA is/O completely/O removed/B-NegReg by/O nonsense/B-MPA mediated/I-MPA mRNA/I-MPA decay/B-NegReg ./O
Thus/O for/O both/O classes/O of/O mutations/O ,/O functional/O haploinsufficiency/O is/O the/O most/O probable/O cause/O of/O the/O clinical/O phenotype/O in/O SMCD/O ./O
Sjögren/B-Disease -/I-Disease Larsson/I-Disease syndrome/I-Disease :/I-Disease diversity/O of/B-Reg mutations/B-Var and/O polymorphisms/O in/O the/O fatty/O aldehyde/O dehydrogenase/O gene/O (/B-Gene ALDH3A2/I-Gene )/I-Gene ./O
Sjögren/B-Disease -/I-Disease Larsson/I-Disease syndrome/I-Disease (/O SLS/O )/O is/O an/O autosomal/O recessive/O disorder/O characterized/O by/O ichthyosis/O ,/O mental/O retardation/O ,/O and/O spastic/O diplegia/O or/O tetraplegia/O ./O
The/O disease/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O ALDH3A2/B-Gene gene/O (/O also/O known/O as/O FALDH/B-Gene and/O ALDH10/B-Gene )/I-Gene on/O chromosome/O 17p11.2/O that/O encodes/O fatty/O aldehyde/O dehydrogenase/O (/O FALDH/O )/O ,/O an/O enzyme/O that/O catalyzes/O the/O oxidation/O of/O long/O -/O chain/O aldehydes/O derived/O from/O lipid/O metabolism/O ./O
In/O SLS/O patients/O ,/O 72/O mutations/O have/O been/O identified/O ,/O with/O a/O distribution/O that/O is/O scattered/O throughout/O the/O ALDH3A2/O gene/O ./O
Most/O mutations/O are/O private/O but/O several/O common/O mutations/O have/O been/O detected/O ,/O which/O probably/O reflect/O founder/O effects/O or/O recurrent/O mutational/O events/O ./O
Missense/O mutations/B-Var comprise/O the/O most/O abundant/O class/O (/O 38/O %/O )/O and/O expression/O studies/O indicate/O that/O most/O of/O these/O result/O in/O a/O profound/O reduction/B-NegReg in/O enzyme/B-Enzyme activity/B-MPA ./O
Deletions/O account/O for/O about/O 25/O %/O of/O the/O mutations/O and/O range/O from/O single/O nucleotides/O to/O entire/O exons/O ./O
Twelve/O splice/O -/O site/O mutations/B-Var have/O been/O demonstrated/O to/O cause/B-Reg aberrant/B-MPA splicing/I-MPA in/O cultured/O fibroblasts/O ./O
To/O date/O ,/O more/O than/O a/O dozen/O intragenic/O ALDH3A2/O polymorphisms/O consisting/O of/O SNPs/O and/O one/O microsatellite/O marker/O have/O been/O characterized/O ,/O although/O none/O of/O them/O alter/O the/O FALDH/O protein/O sequence/O ./O
The/O striking/O mutational/O diversity/O in/O SLS/O offers/O a/O challenge/O for/O DNA/O -/O based/O diagnosis/O ,/O but/O promises/O to/O provide/O a/O wealth/O of/O information/O about/O enzyme/O structure/O -/O function/O correlations/O ./O
Genetic/O screening/O of/O familial/O Mediterranean/O fever/O mutations/O in/O the/O Palestinian/O population/O ./O
OBJECTIVE/O :/O To/O investigate/O the/O spectrum/O of/O mutations/B-Var and/O genotypes/O in/O the/O pyrin/B-Gene gene/O in/B-Reg familial/B-Disease Mediterranean/I-Disease fever/I-Disease (/O FMF/O )/O patients/O ./O
METHODS/O :/O Blood/O samples/O of/O 511/O suspected/O FMF/O patients/O ,/O received/O from/O the/O Molecular/O Genetics/O Laboratory/O ,/O Makassed/O Islamic/O Charitable/O Hospital/O ,/O Mount/O Olives/O ,/O Jerusalem/O during/O the/O period/O from/O June/O 1999/O to/O August/O 2004/O ,/O were/O investigated/O by/O genotyping/O 24/O different/O MEFV/O mutations/O ./O
RESULTS/O :/O Our/O work/O revealed/O the/O presence/O of/O 14/O different/O mutations/O from/O the/O identified/O 24/O mutations/O in/O the/O gene/O which/O are/O assembled/O in/O 6/O homozygous/O ,/O 9/O heterozygous/O and/O 16/O compound/O heterozygous/O genotypes/O ./O
The/O homozygous/O genotypes/O represent/O the/O predominant/O format/O among/O our/O patients/O representing/O approximately/O 38/O %/O of/O the/O revealed/O genotypes/O ./O
Interestingly/O ,/O in/O 94/O (/O 31.4/O %/O )/O of/O the/O tested/O subjects/O ,/O only/O one/O mutation/O in/O the/O pyrin/O gene/O could/O be/O identified/O while/O the/O other/O mutant/O allele/O remains/O unidentified/O ./O
Moreover/O ,/O the/O genotype/O of/O 3/O (/O 1/O %/O )/O patients/O revealed/O the/O presence/O of/O triplet/O mutations/O in/O the/O pyrin/O gene/O ./O
CONCLUSION/O :/O The/O results/O of/O our/O study/O clearly/O suggest/O that/O the/O origin/O of/O FMF/O among/O the/O Palestinian/O population/O is/O mostly/O homozygous/O ./O
The/O identification/O of/O a/O significant/O number/O of/O patients/O with/O one/O known/O mutation/O indicates/O potentially/O the/O presence/O of/O new/O mutations/O in/O the/O gene/O which/O will/O be/O investigated/O in/O the/O future/O ./O
Novel/O CLN3/B-Gene mutation/B-Var predicted/O to/O cause/O complete/O loss/B-NegReg of/O protein/B-Protein function/B-MPA does/O not/O modify/O the/O classical/O JNCL/O phenotype/O ./O
Juvenile/B-Disease Neuronal/I-Disease Ceroid/I-Disease Lipofuscinosis/I-Disease (/O JNCL/O )/O ,/O or/O Batten/O disease/O ,/O is/O a/O childhood/O neurodegenerative/O disease/O that/O is/O characterized/O clinically/O by/O progressive/O visual/O loss/O ,/O seizures/O ,/O dementia/O ,/O and/O motor/O incoordination/O ./O
Children/O affected/O with/O this/O disease/O tend/O to/O develop/O normally/O for/O the/O first/O 5/O years/O of/O life/O ./O
However/O ,/O once/O disease/O onset/O occurs/O ,/O they/O decline/O rapidly/O and/O die/O in/O their/O late/O 20s/O to/O early/O 30s/O ./O
Though/O this/O represents/O the/O typical/O disease/O course/O ,/O the/O onset/O and/O severity/O of/O disease/O symptoms/O can/O vary/O ./O
This/O variability/O is/O presumed/O to/O be/O the/O result/O of/O both/O differences/O in/O the/O causative/O genetic/O mutation/O in/O the/O CLN3/O gene/O as/O well/O as/O environmental/O influences/O ./O
Most/O cases/O of/O JNCL/B-Disease are/O caused/B-Reg by/I-Reg a/O 1/O kb/O deletion/B-Var in/O the/O CLN3/B-Gene gene/O ,/O resulting/B-Reg in/I-Reg a/O frameshift/B-Var mutation/I-Var predicted/O to/O leave/O the/O first/O 153/O amino/O acids/O of/O the/O CLN3/O protein/O intact/O ,/O followed/O by/O the/O addition/O of/O 28/O novel/O amino/O acids/O ./O
Here/O we/O report/O the/O discovery/O of/O a/O novel/O mutation/O identified/O as/O a/O G/O to/O T/O transversion/O at/O nucleotide/O 49/O (/B-Var G49/I-Var T/I-Var )/I-Var in/O exon/O 2/O of/O CLN3/B-Gene ,/O introducing/B-Reg a/O premature/O stop/O codon/O (/B-Var E17X/I-Var )/I-Var near/O the/O N/O -/O terminus/O ./O
This/O mutation/O represents/O the/O most/O 5/O '/O mutation/O described/O to/O date/O ./O
The/O patient/O examined/O in/O this/O study/O was/O heterozygous/O for/O the/O common/O 1/O kb/O deletion/O and/O E17X./O She/O had/O classical/O disease/O progression/O ,/O suggesting/O that/O this/O mutation/O in/O CLN3/O mimics/O the/O more/O prevalent/O 1/O kb/O deletion/O and/O that/O progression/O of/O JNCL/O is/O predominantly/O the/O result/O of/O loss/O of/O CLN3/O function/O ./O
Identification/O of/O a/O novel/O founder/O mutation/O in/O the/O DYSF/O gene/O causing/O clinical/O variability/O in/O the/O Spanish/O population/O ./O
BACKGROUND/O :/O Mutations/B-Var in/O the/O dysferlin/O (/B-Gene DYSF/I-Gene )/I-Gene gene/O cause/B-Reg 3/O different/O phenotypes/O of/O muscular/O dystrophies/O :/O Miyoshi/B-Disease myopathy/I-Disease ,/O limb/B-Disease -/I-Disease girdle/I-Disease muscular/I-Disease dystrophy/I-Disease type/I-Disease 2B/I-Disease ,/O and/O distal/B-Disease anterior/I-Disease compartment/I-Disease myopathy/I-Disease ./O
OBJECTIVE/O :/O To/O present/O the/O results/O of/O clinical/O and/O molecular/O analysis/O of/O 8/O patients/O with/O dysferlinopathy/O from/O 5/O unrelated/O families/O ./O
DESIGN/O :/O Clinical/O assessment/O was/O performed/O with/O a/O standardized/O protocol/O ./O
A/O muscle/O biopsy/O specimen/O was/O obtained/O and/O studied/O by/O immunohistochemistry/O ./O
Genetic/O analysis/O was/O performed/O using/O single/O -/O stranded/O conformation/O polymorphism/O and/O direct/O sequencing/O of/O genomic/O DNA/O ./O
RESULTS/O :/O All/O the/O patients/O presented/O the/O R1905X/O mutation/O in/O the/O DYSF/O gene/O in/O homozygosity/O ,/O and/O the/O haplotype/O analysis/O at/O the/O DYSF/O locus/O revealed/O that/O it/O was/O a/O novel/O and/O founder/O mutation/O ./O
A/O C/B-Var -/I-Var to/I-Var -/I-Var T/I-Var transition/I-Var at/O nucleotide/O position/O 6086/O changes/O an/O arginine/O into/O a/O stop/O codon/O ,/O leading/B-Reg to/I-Reg premature/B-MPA termination/I-MPA of/I-MPA translation/I-MPA ./O
This/O mutation/O was/O expressed/O as/O 3/O different/O clinical/O phenotypes/O (/O limb/O -/O girdle/O muscular/O dystrophy/O type/O 2B/O ,/O Miyoshi/O distal/O myopathy/O ,/O and/O distal/O anterior/O dysferlinopathy/O )/O ,/O but/O only/O 1/O phenotype/O was/O found/O in/O the/O same/O family/O ./O
CONCLUSIONS/O :/O The/O new/O R1905X/O DYSF/O founder/O mutation/O produced/O the/O 3/O possible/O dysferlinopathy/O phenotypes/O without/O intrafamilial/O heterogeneity/O ./O
This/O homogeneous/O population/O in/O Sueca/O ,/O Spain/O ,/O should/O be/O helpful/O in/O studying/O the/O modifying/O factors/O responsible/O for/O the/O phenotypic/O variability/O ./O
A/O novel/O frameshift/B-Var mutation/O (/O +/O G/O )/O at/O codons/O 15/16/O in/O a/O beta0/B-Gene thalassaemia/I-Gene gene/I-Gene results/O in/O a/O significant/O reduction/B-NegReg of/O beta/B-MPA globin/I-MPA mRNA/I-MPA values/O ./O
AIMS/O :/O To/O identify/O a/O novel/O beta/O globin/O gene/O mutation/O found/O in/O a/O Chinese/O family/O ,/O and/O also/O to/O assess/O its/O functional/O consequences/O ./O
METHODS/O :/O Haematological/O analysis/O was/O performed/O on/O all/O family/O members/O ./O
The/O 23/O common/O mutations/O of/O beta/O thalassaemia/O found/O in/O Chinese/O populations/O were/O detected/O by/O means/O of/O a/O reverse/O dot/O blot/O method/O ./O
Direct/O DNA/O sequencing/O of/O polymerase/O chain/O reaction/O (/O PCR/O )/O amplified/O complete/O beta/O globin/O gene/O was/O carried/O out/O to/O identify/O the/O novel/O mutation/O ./O
A/O real/O time/O ,/O one/O step/O reverse/O transcription/O PCR/O assay/O was/O used/O to/O measure/O beta/O globin/O mRNA/O in/O the/O reticulocytes/O of/O heterozygous/O patients/O ./O
RESULTS/O :/O A/O novel/O frameshift/O mutation/O -/O an/O insertion/B-Var of/O G/O between/O codons/O 15/O and/O 16/O in/O a/O homonucleotide/O run/O of/O four/O guanines/O -/O was/O determined/O ,/O which/O generates/B-Reg a/O new/O premature/B-MPA chain/I-MPA terminator/I-MPA at/O the/O 22nd/O codon/O ./O
Relative/O quantitative/O analysis/O of/O the/O beta/O globin/O mRNA/O in/O heterozygous/O subjects/O demonstrated/O a/O 39.83/O %/O reduction/O compared/O normal/O controls/O ./O
CONCLUSIONS/O :/O The/O significantly/O lower/B-NegReg amounts/B-MPA of/I-MPA beta/I-MPA globin/I-MPA mRNA/I-MPA found/O in/O mutation/B-Var carriers/O is/O probably/O caused/B-Reg by/I-Reg the/O rapid/O nonsense/O mediated/O degradation/B-MPA of/O the/O mutant/O mRNA/O ./O
These/O data/O ,/O combined/O with/O haematological/O analysis/O ,/O suggest/O that/O this/O novel/O mutation/B-Var of/O CDs/O 15/16/O (/O +/O G/O )/O results/B-Reg in/I-Reg a/O beta(0/B-Disease )/I-Disease thalassaemia/I-Disease phenotype/O ./O
Increased/O risk/O of/O idiopathic/O chronic/O pancreatitis/O in/O cystic/O fibrosis/O carriers/O ./O
Cystic/B-Disease fibrosis/I-Disease (/O CF/O )/O is/O a/O recessive/O disease/O caused/B-Reg by/I-Reg mutations/B-Var of/O the/O CF/O transmembrane/O conductance/O regulator/O (/B-Gene CFTR/I-Gene )/I-Gene gene/O ./O
The/O risk/O of/O idiopathic/O chronic/O pancreatitis/O (/O ICP/O )/O is/O increased/O in/O individuals/O who/O have/O CFTR/O genotypes/O containing/O a/O CF/O -/O causing/O mutation/O plus/O a/O second/O pathogenic/O allele/O ./O
It/O is/O unknown/O whether/O the/O risk/O of/O ICP/O is/O increased/O in/O CF/O carriers/O who/O have/O one/O CF/O -/O causing/O mutation/O plus/O one/O normal/O allele/O ./O
In/O this/O study/O ,/O 52/O sporadic/O cases/O of/O ICP/O were/O ascertained/O through/O the/O European/O Registry/O of/O Hereditary/O Pancreatitis/O and/O Familial/O Pancreatic/O Cancer/O ./O
Individuals/O with/O pathogenic/O cationic/O trypsinogen/O mutations/O were/O excluded/O ./O
DNA/O was/O comprehensively/O tested/O for/O CFTR/O mutations/O using/O a/O robotically/O enhanced/O ,/O multiplexed/O ,/O and/O highly/O redundant/O form/O of/O single/O -/O strand/O conformation/O polymorphism/O (/O SSCP/O )/O analysis/O followed/O by/O DNA/O sequencing/O ./O
Fifteen/O subjects/O had/O a/O total/O of/O 18/O pathogenic/O CFTR/O alleles/O ./O
Eight/O subjects/O had/O common/O CF/O -/O causing/O mutations/O ./O
This/O group/O included/O seven/O CF/O carriers/O in/O whom/O the/O second/O CFTR/O allele/O was/O normal/O (/O 4.3/O times/O the/O expected/O frequency/O ,/O P=0.0002/O )/O ./O
Three/O subjects/O had/O compound/O heterozygotes/O genotypes/O containing/O two/O pathogenic/O alleles/O (/O 31/O times/O the/O expected/O frequency/O ,/O P<0.0001/O )/O ./O
A/O variant/O allele/O of/O uncertain/O significance/O (/O p/O ./O R75Q/O )/O was/O detected/O in/O eight/O of/O the/O 52/O ICP/O subjects/O and/O at/O a/O similar/O frequency/O (/O 13/96/O )/O in/O random/O donors/O ./O
ICP/O differs/O from/O other/O established/O CFTR/O -/O related/O conditions/O in/O that/O ICP/O risk/O is/O increased/O in/O CF/O carriers/O who/O have/O one/O documented/O normal/O CFTR/O allele/O ./O
Having/O two/O CFTR/O mutations/O imparts/O a/O higher/O relative/O risk/O ,/O while/O having/O only/O one/O mutation/O imparts/O a/O higher/O attributable/O risk/O ./O
Mutation/O identification/O in/O a/O canine/O model/O of/O X/O -/O linked/O ectodermal/O dysplasia/O ./O
X/B-Disease -/I-Disease linked/I-Disease hypohidrotic/I-Disease ectodermal/I-Disease dysplasia/I-Disease (/O XHED/O )/O ,/O an/O inherited/O disease/O recognized/O in/O humans/O ,/O mice/O ,/O and/O cattle/O ,/O is/O characterized/O by/O hypotrichosis/O ,/O a/O reduced/O number/O or/O absence/O of/O sweat/O glands/O ,/O and/O missing/O or/O malformed/O teeth/O ./O
In/O a/O subset/O of/O affected/O individuals/O and/O animals/O ,/O mutations/B-Var in/O the/O EDA/B-Gene gene/O (/O formerly/O EDI/O )/O ,/O coding/O for/O ectodysplasin/O ,/O have/O been/O found/O to/O cause/B-Reg this/O phenotype/O ./O
Ectodysplasin/O is/O a/O homotrimeric/O transmembrane/O protein/O with/O an/O extracellular/O TNF/O -/O like/O domain/O ,/O which/O has/O been/O shown/O to/O be/O involved/O in/O the/O morphogenesis/O of/O hair/O follicles/O and/O tooth/O buds/O during/O fetal/O development/O ./O
Some/O human/O XHED/B-Disease patients/O also/O have/O concurrent/O immunodeficiency/O ,/O due/B-Reg to/I-Reg mutations/B-Var in/O the/O NF/O -/O kappaB/O essential/O modulator/O protein/O (/B-Gene IKBKG/I-Gene ;/I-Gene formerly/O NEMO/O )/O ,/O which/O is/O also/O encoded/O on/O the/O X/O chromosome/O ./O
In/O a/O breeding/O colony/O of/O dogs/O with/O XHED/O ,/O immune/O system/O defects/O had/O been/O suspected/O because/O of/O frequent/O pulmonary/O infections/O and/O unexpected/O deaths/O resulting/O from/O pneumonia/O ./O
To/O determine/O if/O defects/O in/O EDA/O or/O IKBKG/O cause/O XHED/O in/O the/O dogs/O ,/O linkage/O analysis/O and/O sequencing/O experiments/O were/O performed/O ./O
A/O polymorphic/O marker/O near/O the/O canine/O EDA/O gene/O showed/O significant/O linkage/O to/O XHED/O ./O
The/O canine/O EDA/B-Gene gene/O was/O sequenced/O and/O a/O nucleotide/B-Var substitution/I-Var (/O G/O to/O A/O )/O in/O the/O splice/O acceptor/O site/O of/O intron/O 8/O was/O detected/O in/O affected/O dogs/O ./O
In/O the/O presence/O of/O the/O A/O residue/O ,/O a/O cryptic/O acceptor/O site/O within/O exon/O 9/O is/O used/O ,/O leading/B-Reg to/I-Reg a/O frame/B-MPA shift/I-MPA and/O use/O of/O a/O premature/B-MPA stop/I-MPA codon/I-MPA that/O truncates/B-NegReg the/O translation/B-MPA of/O both/O isoforms/O ,/O EDA/O -/O A1/O and/O EDA/O -/O A2/O ,/O resulting/O in/O the/O absence/B-NegReg of/O the/O TNF/B-MPA -/I-MPA like/I-MPA homology/I-MPA domain/I-MPA ,/O the/O receptor/O -/O binding/O site/O of/O ectodysplasin/O ./O
Familial/O Mediterranean/O fever/O (/O FMF/O )/O in/O Lebanon/O and/O Jordan/O :/O a/O population/O genetics/O study/O and/O report/O of/O three/O novel/O mutations/O ./O
Familial/B-Disease Mediterranean/I-Disease fever/I-Disease (/O FMF/O )/O is/O an/O autosomal/O recessive/O disease/O mostly/O frequent/O in/O Mediterranean/O populations/O ./O
Over/O 50/O mutations/B-Var have/O been/O identified/O in/O the/O gene/O responsible/B-Reg for/I-Reg the/O disease/O ,/O MEFV/B-Gene ./O
The/O present/O study/O reports/O the/O frequencies/O of/O MEFV/B-Gene mutations/B-Var in/B-Reg 558/O Lebanese/O and/O 55/O Jordanian/O FMF/B-Disease patients/O and/O points/O out/O the/O severity/O of/O the/O M694V/O frequently/O observed/O mutation/O among/O these/O patients/O ./O
Three/O novel/O mutations/O ,/O T177I/O ,/O S108R/O and/O E474/O K/O were/O also/O identified/O in/O the/O Lebanese/O group/O ./O
An/O excess/O of/O homozygotes/O and/O a/O deficit/O of/O heterozygotes/O were/O observed/O in/O both/O samples/O when/O compared/O to/O the/O expected/O number/O of/O observed/O genotypes/O under/O the/O Hardy/O -/O Weinberg/O hypothesis/O ./O
Homozygotes/O for/O M694V/O and/O M694I/O were/O still/O in/O excess/O in/O the/O Lebanese/O group/O of/O patients/O ,/O even/O after/O consanguinous/O homozygotes/O were/O removed/O ,/O or/O population/O structure/O was/O considered/O ./O
This/O excess/O is/O therefore/O neither/O due/O to/O consanguinity/O nor/O to/O subgroups/O in/O the/O Lebanese/O population/O ,/O but/O rather/O to/O more/O remote/O consanguinity/O or/O to/O a/O selection/O bias/O favoring/O the/O census/O of/O these/O genotypes/O ./O
The/O fact/O that/O FMF/O female/O patients/O were/O less/O censed/O than/O male/O patients/O may/O be/O due/O to/O the/O greater/O resistance/O of/O females/O to/O pain/O and/O to/O the/O possibility/O of/O confusing/O abdominal/O and/O gynecological/O pain/O ./O
The/O phenotypic/O heterogeneity/O of/O the/O FMF/O could/O then/O originate/O both/O from/O genetic/O causes/O like/O allelic/O heterogeneity/O or/O modulating/O genes/O ,/O and/O cultural/O background/O facing/O the/O physiological/O consequences/O of/O genotypes/O at/O risk/O ./O
[/O Mutational/O and/O clinical/O features/O of/O Japanese/O patients/O with/O dysferlinopathy/O (/O Miyoshi/O myopathy/O and/O limb/O girdle/O muscular/O dystrophy/O type/O 2B/O )/O ]/O ./O
Mutations/B-Var in/O the/O dysferlin/B-Gene gene/O cause/B-Reg both/O Miyoshi/B-Disease myopathy/I-Disease (/O MM/O )/O and/O limb/B-Disease girdle/I-Disease muscular/I-Disease dystrophy/I-Disease 2B/I-Disease (/O LGMD2B/O )/O ./O
We/O examined/O patients/O with/O dysferlinopathy/O in/O Japan/O ,/O and/O identified/O 28/O and/O 12/O different/O mutations/O respectively/O in/O MM/O and/O LGMD2B/O patients/O ./O
The/O mean/O age/O at/O onset/O of/O the/O patients/O with/O MM/O was/O 22/O +/O /-/O 9/O years/O (/O range/O 12/O -/O 48/O years/O )/O and/O that/O of/O the/O patients/O with/O LGMD2B/O was/O 26/O +/O /-/O 10/O years/O (/O range/O 11/O -/O 43/O years/O )/O ./O
On/O the/O average/O ,/O the/O first/O use/O of/O a/O cane/O was/O at/O 33/O years/O (/O 14/O years/O after/O the/O onset/O )/O for/O MM/O and/O 39/O years/O (/O 15/O years/O after/O onset/O )/O for/O LGMD/O 2B./O Patients/O became/O wheelchair/O -/O bound/O at/O 41/O years/O (/O 21/O years/O after/O onset/O )/O in/O MM/O and/O 45/O years/O (/O 21/O years/O after/O onset/O )/O for/O LGMD2B./O The/O mean/O maximum/O serum/O CK/O level/O at/O any/O age/O of/O the/O patients/O was/O 5,829/O +/O /-/O 4,273/O IU/O //O l/O (/O range/O 1,289/O -/O 12,566/O IU/O //O l/O )/O for/O MM/O and/O 3,787/O +/O /-/O 2,493/O IU/O //O l/O (/O 627/O -/O 10,000/O IU/O //O l/O )/O for/O LGMD2B/O :/O in/O both/O disorders/O ,/O the/O serum/O CK/O level/O fell/O in/O proportion/O to/O the/O duration/O of/O the/O illness/O ./O
We/O have/O identified/O four/O common/O four/O mutations/O (/O C1939/O G/O ,/O G3370/O T/O ,/O 3746delG/O ,/O and/O 4870delT/O )/O in/O Japanese/O patients/O with/O MM/O ,/O accounting/O for/O 48/O percent/O of/O all/O MM/O mutations/O in/O this/O population/O ./O
Two/O of/O the/O four/O mutations/O (/O G3370/O T/O ,/O and/O 4870delT/O )/O accounted/O for/O 52/O percent/O of/O the/O mutations/O in/O LGMD2B/O patients/O ,/O while/O the/O 3746delG/O mutation/O was/O not/O found/O in/O patients/O with/O LGMD2B./O The/O G3370/B-Var T/I-Var mutation/O may/O be/O associated/B-Reg with/I-Reg a/O milder/O form/O of/O MM/B-Disease and/O LGMD2B./B-Disease By/O contrast/O ,/O the/O G3510A/B-Var mutation/O appears/O to/O be/O associated/B-Reg with/I-Reg a/O severe/O form/O of/O MM/B-Disease ./O
[/O Molecular/O pathomechanism/O of/O distal/O myopathy/O with/O rimmed/O vacuoles/O ]/O ./O
Distal/B-Disease myopathy/I-Disease with/I-Disease rimmed/I-Disease vacuoles/I-Disease (/O DMRV/O )/O and/O hereditary/B-Disease inclusion/I-Disease body/I-Disease myopathy/I-Disease (/O HIBM/O )/O are/O genetically/O identical/O autosomal/O recessive/O muscle/O disorders/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O GNE/B-Gene gene/O ./O
This/O gene/O encodes/O a/O bifunctional/O protein/O with/O UDP/O -/O GlcNAc/O 2-epimerase/O and/O ManNAc/O kinase/O activities/O that/O catalyze/O the/O rate/O limiting/O step/O and/O the/O succeeding/O step/O ,/O respectively/O ,/O in/O the/O sialic/O acid/O biosynthetic/O pathway/O ./O
V572L/O mutation/O is/O the/O most/O prevalent/O among/O Japanese/O DMRV/O patients/O and/O accounts/O for/O about/O 60/O %/O of/O mutant/O alleles/O ./O
Clinical/O spectrum/O of/O DMRV/O //O HIBM/O seems/O to/O be/O wider/O than/O previously/O thought/O in/O terms/O of/O both/O the/O severity/O of/O the/O disease/O and/O the/O range/O of/O affected/O organs/O ./O
There/O are/O rare/O asymptomatic/O homozygotes/O with/O missense/O GNE/O mutations/O ,/O indicating/O the/O presence/O of/O mitigating/O factors/O ./O
Surprisingly/O ,/O more/O than/O 10/O %/O of/O the/O patients/O had/O a/O variety/O of/O cardiac/O abnormalities/O ,/O suggesting/O that/O skeletal/O muscle/O may/O not/O be/O the/O only/O organ/O involved/O ./O
Studies/O on/O recombinant/O GNE/B-Gene demonstrate/O a/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg nature/O of/O the/O missense/O mutations/B-Var identified/O ./O
Patients/O '/O cells/O show/O decreased/B-NegReg sialylation/B-MPA status/I-MPA which/O can/O be/O recovered/O by/O adding/O GNE/O metabolites/O ,/O such/O as/O ManNAc/O and/O NeuAc/O ./O
This/O indicates/O the/O possibility/O of/O developing/O a/O therapy/O for/O DMRV/O //O HIBM/O by/O giving/O these/O metabolites/O to/O patients/O although/O we/O have/O to/O await/O the/O model/O mice/O that/O are/O currently/O being/O produced/O at/O several/O laboratories/O ./O
X/B-Disease linked/I-Disease cone/I-Disease -/I-Disease rod/I-Disease dystrophy/I-Disease ,/O CORDX3/O ,/O is/O caused/B-Reg by/I-Reg a/O mutation/B-Var in/O the/O CACNA1F/B-Gene gene/O ./O
BACKGROUND/O :/O X/B-Disease linked/I-Disease cone/I-Disease -/I-Disease rod/I-Disease dystrophy/I-Disease (/O CORDX/O )/O is/O a/O recessive/O retinal/O disease/O characterised/O by/O progressive/O dysfunction/O of/O photoreceptors/O ./O
It/O is/O genetically/O heterogeneous/O ,/O showing/O linkage/O to/O three/O X/O chromosomal/O loci/O ./O
CORDX1/B-Disease is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O RPGR/B-Gene gene/O (/O Xp21.1/O )/O ,/O CORDX2/O is/O located/O on/O Xq27.2/O -/O 28/O ,/O and/O we/O recently/O localised/O CORDX3/O to/O Xp11.4-q13.1/O ./O
We/O aimed/O to/O identify/O the/O causative/O gene/O behind/O the/O CORDX3/O phenotype/O ./O
METHODS/O :/O All/O 48/O exons/O of/O the/O CACNA1F/O gene/O were/O screened/O for/O mutations/O by/O DNA/O sequencing/O ./O
RNA/O from/O cultured/O lymphoblasts/O and/O peripheral/O blood/O activated/O T/O lymphocytes/O was/O analysed/O by/O RT/O -/O PCR/O and/O sequencing/O ./O
RESULTS/O :/O A/O novel/O CACNA1F/O mutation/O ,/O IVS28/O -/O 1/O GCGTC/O >/O TGG/O ,/O in/O the/O splice/O acceptor/O site/O of/O intron/O 28/O was/O identified/O ./O
Messenger/O RNA/O studies/O indicated/O that/O the/O identified/O mutation/B-Var leads/O to/O altered/B-Reg splicing/B-MPA of/O the/O CACNA1F/B-Gene transcript/B-MPA ./O
Aberrant/B-Var splice/I-Var variants/I-Var are/O predicted/O to/O result/B-Reg in/I-Reg premature/B-MPA termination/I-MPA and/O deletions/B-Var of/O the/O encoded/B-Protein protein/I-Protein ,/O Ca(v)1.4/O alpha1/O subunit/O ./O
CONCLUSION/O :/O CACNA1F/B-Gene mutations/B-Var cause/B-Reg the/O retinal/B-Disease disorder/I-Disease ,/O incomplete/O congenital/B-Disease stationary/I-Disease night/I-Disease blindness/I-Disease (/O CSNB2/O )/O ,/O although/O mutations/O have/O also/O been/O detected/O in/O patients/O with/O divergent/O diagnoses/O ./O
Our/O results/O indicate/O that/O yet/O another/O phenotype/O ,/O CORDX3/B-Disease ,/O is/O caused/B-Reg by/I-Reg a/O mutation/B-Var in/O CACNA1F./B-Gene Clinically/O ,/O CORDX3/O shares/O some/O features/O with/O CSNB2/O but/O is/O distinguishable/O from/O CSNB2/O in/O that/O it/O is/O progressive/O ,/O can/O begin/O in/O adulthood/O ,/O has/O no/O nystagmus/O or/O hyperopic/O refraction/O ,/O has/O only/O low/O grade/O astigmatism/O ,/O and/O in/O dark/O adaptation/O lacks/O cone/O threshold/O and/O has/O small/O or/O no/O elevation/O of/O rod/O threshold/O ./O
Considering/O all/O features/O ,/O CORDX3/O is/O more/O similar/O to/O other/O X/O chromosomal/O cone/O -/O rod/O dystrophies/O than/O to/O CSNB2/O ./O
Novel/O JARID1C/O //O SMCX/O mutations/O in/O patients/O with/O X/O -/O linked/O mental/O retardation/O ./O
X/B-Disease -/I-Disease linked/I-Disease mental/I-Disease retardation/I-Disease (/O XLMR/O )/O is/O a/O heterogeneous/O disorder/O that/O affects/O approximately/O 2/O in/O 1000/O males/O ./O
JARID1C/O //O SMCX/O is/O relatively/O new/O among/O the/O known/O XLMR/O genes/O ,/O and/O seven/O different/O mutations/O have/O been/O identified/O previously/O in/O this/O gene/O [/O Jensen/O LR/O et/O al/O ./O
,/O Am/O ./O
J./O Hum/O ./O
Genet/O ./O
76:227/O -/O 236/O ,/O 2005/O ]/O ./O
Here/O ,/O we/O report/O five/O novel/O JARID1C/B-Gene mutations/O in/B-Reg five/O XLMR/B-Disease families/O ./O
The/O changes/O comprise/O one/O nonsense/O mutation/O (/B-Var p/I-Var ./I-Var Arg332X/I-Var )/I-Var and/O four/O missense/O mutations/O (/B-Var p/I-Var ./I-Var Asp87Gly/I-Var ;/I-Var p/B-Var ./I-Var Phe642Leu/I-Var ;/I-Var p/B-Var ./I-Var Arg750Trp/I-Var ;/I-Var p/B-Var ./I-Var Tyr751Cys/I-Var )/I-Var affecting/O evolutionarily/O conserved/O amino/O acids/O ./O
The/O degree/O of/O mental/O retardation/O in/O the/O affected/O males/O ranged/O from/O mild/O to/O severe/O ,/O and/O some/O patients/O suffered/O from/O additional/O disorders/O such/O as/O epilepsy/O ,/O short/O stature/O ,/O or/O behavioral/O problems/O ./O
This/O study/O brings/O the/O total/O number/O of/O reported/O JARID1C/O mutations/O to/O twelve/O ./O
In/O contrast/O to/O other/O XLMR/O genes/O in/O which/O mutations/O were/O found/O only/O in/O single/O or/O very/O few/O families/O ,/O JARID1C/O appears/O to/O be/O one/O of/O the/O more/O frequently/O mutated/O genes/O in/O this/O disorder/O ./O
Missense/B-Var mutations/I-Var in/O SH2D1A/B-Gene identified/O in/O patients/O with/B-Reg X/B-Disease -/I-Disease linked/I-Disease lymphoproliferative/I-Disease disease/I-Disease differentially/O affect/O the/O expression/O and/O function/O of/O SAP/O ./O
X/B-Disease -/I-Disease linked/I-Disease lymphoproliferative/I-Disease disease/I-Disease (/O XLP/O )/O is/O an/O immunodeficiency/O resulting/B-Reg from/I-Reg mutations/B-Var in/O SH2D1A/B-Gene ,/O which/O encodes/O signalling/O lymphocytic/O activation/O molecule/O (/O SLAM)-associated/O protein/O (/O SAP/O )/O ./O
In/O addition/O to/O SLAM/O ,/O SAP/O associates/O with/O several/O other/O cell/O -/O surface/O receptors/O including/O 2B4/O (/O CD244/O )/O ,/O Ly9/O (/O CD229/O )/O ,/O CD84/O and/O NTB/O -/O A./O SAP/O contains/O a/O single/O src/O -/O homology-2/O domain/O and/O acts/O as/O an/O intracellular/O adaptor/O protein/O by/O recruiting/O the/O protein/O tyrosine/O kinase/O FynT/O to/O the/O cytoplasmic/O domains/O of/O some/O of/O these/O receptors/O ,/O which/O results/O in/O the/O initiation/O of/O specific/O downstream/O signal/O transduction/O pathways/O ./O
XLP/O is/O likely/O to/O result/O from/O perturbed/O signalling/O through/O one/O or/O more/O of/O these/O SAP/O -/O associating/O receptors/O ./O
In/O this/O study/O ,/O we/O identified/O missense/O (/O Y54C/O ,/O I84/O T/O and/O F87S/O )/O and/O insertion/O (/O fs82/O --/O >/O X103/O )/O mutations/O in/O four/O different/O kindreds/O affected/O by/O XLP/O ./O
Each/O mutation/B-Var dramatically/O reduced/B-NegReg the/O half/B-MPA -/I-MPA life/I-MPA of/O SAP/B-Protein ,/O thus/O diminishing/B-NegReg its/O expression/B-MPA in/O primary/O lymphocytes/O as/O well/O as/O in/O transfected/O cell/O lines/O ./O
Interestingly/O ,/O although/O the/O Y54C/B-Var and/O F87S/B-Var mutations/O compromised/B-NegReg the/O ability/B-MPA of/O SAP/B-Protein to/O associate/B-Interaction with/O different/O receptors/O ,/O the/O I84/O T/O mutation/O had/O no/O effect/O on/O the/O ability/O of/O SAP/O to/O bind/O SLAM/O ,/O CD84/O or/O 2B4/O ./O
However/O ,/O signalling/B-MPA downstream/I-MPA of/I-MPA SLAM/I-MPA was/O reduced/B-NegReg in/O the/O presence/O of/O SAP/B-Protein bearing/O the/O I84/B-Var T/I-Var mutation/O ./O
These/O findings/O indicate/O that/O ,/O irrespective/O of/O the/O type/O of/O mutation/O ,/O signalling/O through/O SAP/O -/O associating/O receptors/O in/O XLP/O can/O be/O impaired/O by/O reducing/O the/O expression/O of/O SAP/O ,/O the/O ability/O of/O SAP/O to/O bind/O surface/O receptors/O and/or/O its/O ability/O to/O activate/O signal/O transduction/O downstream/O of/O the/O SLAM/O -/O SAP/O complex/O ./O
The/O R110C/B-Var mutation/O in/O Notch3/B-Gene causes/B-Reg variable/O clinical/O features/O in/O two/O Turkish/O families/O with/O CADASIL/B-Disease syndrome/I-Disease ./O
Mutations/B-Var in/O Notch3/B-Gene gene/O are/O responsible/B-Reg for/O the/O cerebral/B-Disease autosomal/I-Disease dominant/I-Disease arteriopathy/I-Disease with/I-Disease subcortical/I-Disease infarcts/I-Disease and/I-Disease leukoencephalopathy/I-Disease (/O CADASIL/O )/O ./O
It/O is/O a/O late/O onset/O neurological/O disorder/O recognized/O by/O recurrent/O strokes/O and/O dementia/O ./O
We/O describe/O here/O the/O clinical/O and/O molecular/O findings/O of/O three/O unrelated/O Turkish/O families/O with/O CADASIL/O syndrome/O ./O
Two/O of/O the/O families/O were/O identified/O to/O have/O the/O same/O mutation/O ,/O p/O ./O R110C/O (/O c/O ./O
C328/O T/O )/O ,/O located/O in/O exon/O 3/O of/O the/O Notch3/O gene/O ./O
Interestingly/O ,/O the/O phenotypic/O expression/O of/O the/O disease/O in/O these/O two/O families/O was/O markedly/O different/O in/O severity/O and/O age/O of/O onset/O implicating/O additional/O genetic/O and/or/O non/O -/O genetic/O modulating/O factors/O involved/O in/O the/O pathogenesis/O ./O
In/O addition/O ,/O we/O identified/O the/O novel/O p/O ./O C201R/O (/O c/O ./O
T601C/O )/O mutation/O in/O exon/O 4/O of/O the/O Notch3/O gene/O in/O a/O proband/O of/O the/O third/O family/O with/O two/O consecutive/O stroke/O -/O like/O episodes/O and/O typical/O MRI/O findings/O ./O
Mutations/B-Var described/O here/O cause/B-Reg an/O odd/B-MPA number/I-MPA of/I-MPA cysteines/I-MPA in/I-MPA the/I-MPA N/I-MPA -/I-MPA terminal/I-MPA of/I-MPA the/I-MPA EGF/I-MPA domain/I-MPA of/O Notch3/B-Gene protein/B-Protein ,/O which/O seems/O to/O have/O an/O important/O functional/O effect/B-Reg in/O the/O pathophysiology/O of/O CADASIL/B-Disease ./O
The/O phenotypic/O variability/O in/O families/O carrying/O the/O same/O molecular/O defect/O as/O presented/O here/O makes/O the/O prediction/O of/O prognosis/O inconceivable/O ./O
Although/O DNA/O analysis/O is/O effective/O and/O valuable/O in/O diagnosing/O approximately/O 90/O %/O of/O the/O CADASIL/O patients/O ,/O lack/O of/O genotype/O -/O phenotype/O correlation/O and/O prognostic/O parameters/O makes/O the/O presymptomatic/O genetic/O counseling/O very/O difficult/O ./O
Entries/O in/O the/O Leiden/O Duchenne/O muscular/O dystrophy/O mutation/O database/O :/O an/O overview/O of/O mutation/O types/O and/O paradoxical/O cases/O that/O confirm/O the/O reading/O -/O frame/O rule/O ./O
The/O severe/O Duchenne/B-Disease and/O milder/O Becker/B-Disease muscular/I-Disease dystrophy/I-Disease are/O both/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O DMD/B-Gene gene/O ./O
This/O gene/O codes/O for/O dystrophin/O ,/O a/O protein/O important/O for/O maintaining/O the/O stability/O of/O muscle/O -/O fiber/O membranes/O ./O
In/O 1988/O ,/O Monaco/O and/O colleagues/O postulated/O an/O explanation/O for/O the/O phenotypic/O difference/O between/O Duchenne/O and/O Becker/O patients/O in/O the/O reading/O -/O frame/O rule/O :/O In/O Duchenne/B-Disease patients/O ,/O mutations/B-Var induce/B-Reg a/B-MPA shift/I-MPA in/I-MPA the/I-MPA reading/I-MPA frame/I-MPA leading/B-Reg to/O prematurely/B-MPA truncated/I-MPA ,/O dysfunctional/B-NegReg dystrophins/B-Protein ./O
In/O Becker/B-Disease patients/O ,/O in/B-Var -/I-Var frame/I-Var mutations/I-Var allow/B-Reg the/O synthesis/B-MPA of/I-MPA internally/I-MPA deleted/I-MPA ,/O but/O largely/B-PosReg functional/I-PosReg dystrophins/B-Protein ./O
Currently/O ,/O over/O 4700/O mutations/O have/O been/O reported/O in/O the/O Leiden/O DMD/O mutation/O database/O ,/O of/O which/O 91/O %/O are/O in/O agreement/O with/O this/O rule/O ./O
In/O this/O study/O we/O provide/O an/O update/O of/O the/O mutational/O variability/O in/O the/O DMD/O gene/O ,/O particularly/O focusing/O on/O genotype/O -/O phenotype/O correlations/O and/O mutations/O that/O appear/O to/O be/O exceptions/O to/O the/O reading/O -/O frame/O rule/O ./O
Prevalence/O of/O disease/O -/O causing/O mutations/O in/O families/O with/O autosomal/O dominant/O retinitis/O pigmentosa/O :/O a/O screen/O of/O known/O genes/O in/O 200/O families/O ./O
PURPOSE/O :/O To/O survey/O families/O with/O clinical/O evidence/O of/O autosomal/B-Disease dominant/I-Disease retinitis/I-Disease pigmentosa/I-Disease (/O adRP/O )/O for/O mutations/O in/O genes/O known/O to/O cause/O adRP/O ./O
METHODS/O :/O Two/O hundred/O adRP/O families/O ,/O drawn/O from/O a/O cohort/O of/O more/O than/O 400/O potential/O families/O ,/O were/O selected/O by/O analysis/O of/O pedigrees/O ./O
Minimum/O criteria/O for/O inclusion/O in/O the/O adRP/O cohort/O included/O either/O evidence/O of/O at/O least/O three/O generations/O of/O affected/O individuals/O or/O two/O generations/O with/O evidence/O of/O male/O -/O to/O -/O male/O transmission/O ./O
Probands/O from/O each/O family/O were/O screened/O for/O mutations/B-Var in/O 13/O genes/O known/O to/O cause/B-Reg adRP/B-Disease :/I-Disease CA4/B-Gene ,/O CRX/B-Gene ,/O FSCN2/B-Gene ,/O IMPDH1/B-Gene ,/O NRL/B-Gene ,/O PRPF3/B-Gene (/O RP18/O )/O ,/O PRPF8/B-Gene (/O RP13/O )/O ,/O PRPF31/B-Gene (/O RP11/O )/O ,/O RDS/B-Gene ,/O RHO/B-Gene ,/O ROM1/B-Gene ,/O RP1/B-Gene ,/O and/O RP9/B-Gene ./O
Families/O without/O mutations/O in/O autosomal/O genes/O and/O in/O which/O an/O X/O -/O linked/O mode/O of/O inheritance/O could/O not/O be/O excluded/O were/O tested/O for/O mutations/O in/O ORF/O 15/O of/O X/O -/O linked/O RPGR/O ./O
Potentially/O pathogenic/O variants/O were/O evaluated/O based/O on/O a/O variety/O of/O genetic/O and/O computational/O criteria/O ,/O to/O confirm/O or/O exclude/O pathogenicity/O ./O
RESULTS/O :/O A/O total/O of/O 82/O distinct/O ,/O rare/O (/O nonpolymorphic/O )/O variants/O were/O detected/O among/O the/O genes/O tested/O ./O
Of/O these/O ,/O 57/O are/O clearly/O pathogenic/O based/O on/O multiple/O criteria/O ,/O 10/O are/O probably/O pathogenic/O ,/O and/O 15/O are/O probably/O benign/O ./O
In/O the/O cohort/O of/O 200/O families/O ,/O 94/O (/O 47/O %/O )/O have/O one/O of/O the/O clearly/O pathogenic/O variants/O and/O 10/O (/O 5/O %/O )/O have/O one/O of/O the/O probably/O pathogenic/O variants/O ./O
One/O family/O (/O 0.5/O %/O )/O has/O digenic/O RDS/O -/O ROM1/O mutations/O ./O
Two/O families/O (/O 1/O %/O )/O have/O a/O pathogenic/O RPGR/O mutation/O ,/O indicating/O that/O families/O with/O apparent/O autosomal/O transmission/O of/O RP/O may/O actually/O have/O X/O -/O linked/O genetic/O disease/O ./O
Thus/O ,/O 107/O families/O (/O 53.5/O %/O )/O have/O mutations/O in/O known/O genes/O ,/O leaving/O 93/O whose/O underlying/O cause/O is/O still/O unknown/O ./O
CONCLUSIONS/O :/O Together/O ,/O the/O known/O adRP/O genes/O account/O for/O retinal/O disease/O in/O approximately/O half/O of/O the/O families/O in/O this/O survey/O ,/O mostly/O Americans/O of/O European/O origin/O ./O
Among/O the/O adRP/O genes/O ,/O IMPDH1/O ,/O PRPF8/O ,/O PRPF31/O ,/O RDS/O ,/O RHO/O ,/O and/O RP1/O each/O accounts/O for/O more/O than/O 2/O %/O of/O the/O total/O ;/O CRX/O ,/O PRPF3/O ,/O and/O RPGR/O each/O accounts/O for/O roughly/O 1/O %/O ./O
Disease/O -/O causing/O mutations/O were/O not/O found/O in/O CA4/O ,/O FSCN2/O ,/O NRL/O ,/O or/O RP9/O ./O
Because/O some/O mutations/O are/O frequent/O and/O some/O regions/O are/O more/O likely/O to/O harbor/O mutations/O than/O others/O ,/O more/O than/O two/O thirds/O of/O the/O detected/O mutations/O can/O be/O found/O by/O screening/O less/O than/O 10/O %/O of/O the/O total/O gene/O sequences/O ./O
Among/O the/O remaining/O families/O ,/O mutations/O may/O lie/O in/O regions/O of/O known/O genes/O that/O were/O not/O tested/O ,/O mutations/O may/O not/O be/O detectable/O by/O PCR/O -/O based/O sequencing/O ,/O or/O other/O loci/O may/O be/O involved/O ./O
Clinical/O and/O genetic/O analysis/O of/O Korean/O patients/O with/O Miyoshi/O myopathy/O :/O identification/O of/O three/O novel/O mutations/O in/O the/O DYSF/O gene/O ./O
Miyoshi/B-Disease myopathy/I-Disease (/O MM/O )/O is/O an/O autosomal/O recessive/O distal/O muscular/O dystrophy/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O dysferlin/O gene/O (/B-Gene DYSF/I-Gene )/I-Gene on/O chromosome/O 2p13/O ./O
Although/O MM/O patients/O and/O their/O mutations/O in/O the/O DYSF/O gene/O have/O been/O found/O from/O all/O over/O the/O world/O ,/O there/O is/O only/O one/O report/O of/O genetically/O confirmed/O case/O of/O MM/O in/O Korea/O ./O
Recently/O ,/O we/O encountered/O three/O unrelated/O Korean/O patients/O with/O MM/O and/O two/O of/O them/O have/O previously/O been/O considered/O as/O having/O a/O type/O of/O inflammatory/O myopathy/O ./O
The/O clinical/O and/O laboratory/O evaluation/O showed/O typical/O features/O of/O muscle/O involvement/O in/O MM/O in/O all/O patients/O but/O one/O patient/O initially/O had/O moderate/O proximal/O muscle/O involvement/O and/O another/O showed/O incomplete/O quadriparesis/O with/O rapid/O progression/O ./O
Direct/O sequencing/O analysis/O of/O the/O DYSF/O gene/O revealed/O that/O each/O patient/O had/O compound/O heterozygous/O mutations/O (/O Gln832X/O and/O Trp992Arg/O ,/O Gln832X/O and/O Trp999Cys/O ,/O and/O Lys1103X/O and/O Ile1401HisfsX8/O ,/O respectively/O )/O among/O which/O three/O were/O novel/O ./O
Although/O MM/O has/O been/O thought/O to/O be/O quite/O rare/O in/O Korea/O ,/O it/O should/O be/O considered/O in/O a/O differential/O diagnosis/O of/O patients/O exhibiting/O distal/O myopathy/O ./O
UBE2A/B-Gene ,/O which/O encodes/O a/O ubiquitin/O -/O conjugating/O enzyme/O ,/O is/O mutated/B-Var in/B-Reg a/O novel/O X/B-Disease -/I-Disease linked/I-Disease mental/I-Disease retardation/I-Disease syndrome/I-Disease ./O
We/O report/O a/O mutation/B-Var of/O UBE2A/B-Gene //I-Gene HR6A/I-Gene ,/O which/O encodes/O a/O ubiquitin/O -/O conjugating/O enzyme/O (/O E2/O )/O ,/O a/O member/O of/O the/O ubiquitin/O proteasome/O pathway/O ,/O as/O the/O cause/B-Reg of/O a/O novel/O X/B-Disease -/I-Disease linked/I-Disease mental/I-Disease retardation/I-Disease (/I-Disease XLMR/I-Disease )/I-Disease syndrome/I-Disease that/O affects/O three/O males/O in/O a/O two/O -/O generation/O family/O ./O
A/O single/O -/O nucleotide/O substitution/O ,/O c.382C-->T/B-Var in/O UBE2A/B-Gene ,/O led/B-Reg to/I-Reg a/O premature/O UAG/O stop/O codon/O (/B-Var Q128X/I-Var )/I-Var ./O
As/O a/O consequence/O ,/O the/O predicted/O polypeptide/O lacks/O the/O 25/O C/O -/O terminal/O amino/O acid/O residues/O ./O
The/O importance/O of/O this/O terminal/O sequence/O for/O UBE2/O function/O is/O inferred/O by/O its/O conservation/O in/O vertebrates/O and/O in/O Drosophila/O ./O
UBE2A/O mutations/O do/O not/O appear/O to/O significantly/O contribute/O to/O XLMR/O ,/O since/O no/O UBE2A/O mutations/O were/O identified/O in/O 15/O families/O with/O nonsyndromic/O and/O 4/O families/O with/O syndromic/O idiopathic/O XLMR/O previously/O mapped/O to/O intervals/O encompassing/O this/O gene/O ./O
This/O is/O the/O first/O description/O of/O a/O mutation/O in/O a/O ubiquitin/O -/O conjugating/O enzyme/O gene/O as/O the/O cause/O of/O a/O human/O disease/O ./O
Twenty/O -/O one/O novel/O mutations/B-Var in/O the/O GLB1/B-Gene gene/O identified/O in/B-Reg a/O large/O group/O of/O GM1-gangliosidosis/B-Disease and/O Morquio/B-Disease B/I-Disease patients/O :/O possible/O common/O origin/O for/O the/O prevalent/O p/O ./O R59H/O mutation/O among/O gypsies/O ./O
GM1-gangliosidosis/B-Disease and/O Morquio/B-Disease B/I-Disease disease/O are/O rare/O lysosomal/O storage/O disorders/O caused/B-Reg by/I-Reg beta/B-MPA -/I-MPA galactosidase/I-MPA deficiency/B-NegReg due/O to/O mutations/B-Var in/O the/O GLB1/B-Gene gene/O ./O
Three/O major/O clinical/O forms/O of/O GM1-gangliosidosis/O have/O been/O established/O on/O the/O basis/O of/O age/O of/O onset/O and/O severity/O of/O symptoms/O :/O infantile/O ,/O late/O infantile/O //O juvenile/O ,/O and/O adult/O ./O
We/O performed/O mutation/O analysis/O on/O 30/O GM1-gangliosidosis/O and/O five/O Morquio/O B/O patients/O ,/O mainly/O of/O Spanish/O origin/O ,/O and/O all/O the/O causative/O mutations/O were/O identified/O ./O
Thirty/O different/O mutations/O were/O found/O ,/O 21/O of/O which/O were/O novel/O ./O
With/O the/O exception/O of/O two/O adults/O and/O one/O juvenile/O patient/O ,/O all/O the/O GM1-gangliosidosis/O patients/O were/O affected/O by/O the/O infantile/O form/O ./O
Clinical/O findings/O are/O presented/O for/O all/O patients/O ./O
We/O report/O the/O association/O of/O the/O novel/O mutations/O p/O ./O T420/O K/O and/O p/O ./O L264S/O with/O the/O adult/O form/O and/O the/O juvenile/O form/O ,/O respectively/O ./O
In/O addition/O ,/O the/O novel/O mutation/O p/B-Var ./I-Var Y83C/I-Var was/O associated/B-Reg with/I-Reg Morquio/B-Disease B/I-Disease disease/O ./O
Among/O the/O 30/O GM1-gangliosidosis/O patients/O ,/O 6/O were/O of/O Gypsy/O origin/O (/O Roma/O )/O ./O
Moreover/O ,/O those/O six/O Gypsy/O patients/O shared/O not/O only/O the/O same/O mutation/O (/O p/O ./O R59H/O )/O but/O also/O a/O common/O haplotype/O ./O
This/O observation/O indicates/O a/O possible/O founder/O effect/O in/O this/O group/O and/O suggests/O that/O screening/O of/O the/O p/O ./O R59H/O mutation/O may/O be/O appropriate/O in/O GM1-gangliosidosis/O patients/O of/O Gypsy/O origin/O ./O
This/O is/O the/O first/O exhaustive/O mutational/O analysis/O performed/O in/O a/O large/O group/O of/O Iberian/O GM1-gangliosidosis/O and/O Morquio/O B/O patients/O ./O
Misregulation/O of/O alternative/O splicing/O causes/O pathogenesis/O in/O myotonic/O dystrophy/O ./O
Myotonic/B-Disease dystrophy/I-Disease (/O DM/O )/O ,/O the/O most/O common/O form/O of/O adult/O onset/O muscular/O dystrophy/O ,/O affects/O skeletal/O muscle/O ,/O heart/O ,/O and/O the/O central/O nervous/O system/O (/O CNS/O )/O ./O
Mortality/O results/O primarily/O from/O muscle/O wasting/O and/O cardiac/O arrhythmias/O ./O
There/O are/O two/O forms/O of/O the/O disease/O :/O DM1/O and/O DM2/O ./O
DM1/O ,/O which/O constitutes/O 98/O %/O of/O cases/O ,/O is/O caused/O by/O a/O CTG/O expansion/O in/O the/O 3/O '/O untranslated/O region/O (/O UTR/O )/O of/O the/O DMPK/O gene/O ./O
DM2/B-Disease is/O caused/B-Reg by/I-Reg a/O CCTG/B-Var expansion/I-Var in/O the/O first/O intron/O of/O the/O ZNF9/B-Gene gene/O ./O
RNA/O containing/O CUG-/O or/O CCUG/O -/O expanded/O repeats/O are/O transcribed/O but/O are/O retained/O in/O the/O nucleus/O in/O foci/O ./O
Disease/O pathogenesis/O results/O primarily/O from/O a/O gain/B-PosReg of/I-PosReg function/I-PosReg of/O the/O expanded/B-MPA RNAs/I-MPA ,/O which/O alter/B-Reg developmentally/B-MPA regulated/I-MPA alternative/I-MPA splicing/I-MPA as/O well/O as/O pathways/B-Pathway of/I-Pathway muscle/I-Pathway differentiation/I-Pathway ./O
The/O toxic/O RNA/O has/O been/O implicated/O in/O sequestration/O of/O splicing/O regulators/O and/O transcription/O factors/O thereby/O causing/O specific/O symptoms/O of/O the/O disease/O ./O
Here/O we/O review/O the/O proposed/O mechanisms/O for/O the/O toxic/O effects/O of/O the/O expanded/O repeats/O and/O discuss/O the/O molecular/O mechanisms/O of/O splicing/O misregulation/O and/O disease/O pathogenesis/O ./O
Clinical/O aspects/O and/O physiopathology/O of/O Brugada/O syndrome/O :/O review/O of/O current/O concepts/O ./O
Brugada/B-Disease syndrome/I-Disease (/O BS/O )/O is/O an/O inherited/O cardiac/O disorder/O characterized/O by/O typical/O electrocardiographic/O patterns/O of/O ST/O segment/O elevation/O in/O the/O precordial/O leads/O ,/O right/O bundle/O branch/O block/O ,/O fast/O polymorphic/O ventricular/O tachycardia/O in/O patients/O without/O any/O structural/O heart/O disease/O ,/O and/O a/O high/O risk/O of/O sudden/O cardiac/O death/O ./O
The/O incidence/O of/O BS/O is/O high/O in/O male/O vs./O female/O (/O i.e./O ,/O 8/O -/O 10/1/O :/O male/O //O female/O )/O ./O
The/O disorder/O is/O caused/O by/O mutations/O in/O the/O SCN5A/O gene/O encoding/O Nav1.5/O ,/O the/O cardiac/O sodium/O channel/O ,/O which/O is/O the/O only/O gene/O in/O which/O mutations/O were/O found/O to/O cause/O the/O disease/O ./O
Mutations/B-Var in/O SCN5A/B-Gene associated/O with/O the/O BS/B-Disease phenotype/O usually/O result/O in/O a/O loss/B-NegReg of/O channel/B-CPA function/I-CPA by/O a/O reduction/B-NegReg in/O Na+/B-CPA currents/I-CPA ./O
We/O review/O the/O clinical/O aspects/O ,/O risk/O stratification/O ,/O and/O therapeutic/O management/O of/O this/O important/O syndrome/O ./O
[/O McLeod/O syndrome/O :/O Multisystem/O involvement/O associated/O with/O neuroacanthocytosis/O linked/O to/O X/O chromosome/O ./O
report/O of/O two/O related/O cases/O ]/O ./O
Síndrome/O de/O McLeod/O :/O compromiso/O multisistémico/O asociado/O a/O neuroacantocitosis/O ligada/O al/O cromosoma/O X/O ,/O en/O una/O familia/O chilena/O ./O
Neurological/O abnormalities/O associated/O with/O spiculated/O ,/O "/O acanthocytic/O "/O red/O cells/O in/O blood/O have/O been/O described/O as/O neuroacanthocytosis/O ./O
This/O is/O a/O heterogeneous/O group/O of/O conditions/O that/O can/O be/O clearly/O subdivided/O on/O the/O basis/O of/O recent/O genetic/O findings/O ./O
The/O McLeod/B-Disease Syndrome/I-Disease ,/O one/O of/O the/O core/O neuroacanthocytosis/B-Disease syndromes/I-Disease ,/O is/O a/O rare/O X/O -/O linked/O disorder/O caused/B-Reg by/I-Reg mutations/B-Var of/O the/O XK/B-Gene gene/O ,/O an/O X/O -/O chromosomal/O gene/O of/O unknown/O function/O characterized/O by/O haemopoietic/O abnormalities/O and/O late/O -/O onset/O neurological/O and/O muscular/O defects/O ./O
We/O report/O two/O Chilean/O brothers/O with/O the/O McLeod/O phenotype/O who/O showed/O important/O psychiatric/O features/O ./O
The/O diagnosis/O may/O be/O elusive/O if/O the/O presence/O of/O acanthocytosis/O is/O not/O properly/O studied/O ./O
We/O describe/O a/O method/O which/O allowed/O the/O diagnosis/O that/O unmasked/O acanthocytosis/O ./O
Otherwise/O the/O condition/O could/O have/O remained/O undiagnosed/O as/O it/O had/O been/O for/O decades/O in/O this/O family/O ./O
This/O syndrome/O must/O be/O considered/O when/O assessing/O a/O familial/O movement/O disorder/O ,/O specially/O affecting/O males/O with/O relevant/O psychiatric/O features/O ./O
A/O reliable/O test/O for/O acanthocytosis/O assessment/O is/O available/O ./O
A/O new/O variant/O database/O for/O mismatch/O repair/O genes/O associated/O with/O Lynch/O syndrome/O ./O
Mutations/B-Var in/O some/O mismatch/O repair/O (/B-Gene MMR/I-Gene )/I-Gene genes/O are/O associated/B-Reg with/I-Reg Lynch/B-Disease syndrome/I-Disease (/O LS/O ;/O also/O called/O hereditary/O nonpolyposis/O colorectal/O cancer/O [/O HNPCC/O ]/O )/O ,/O an/O autosomal/O dominant/O cancer/O susceptibility/O syndrome/O ./O
Colorectal/O cancer/O (/O CRC/O )/O is/O the/O most/O frequent/O cancer/O observed/O in/O LS/O ./O
However/O ,/O tumors/O occur/O at/O a/O variety/O of/O extracolonic/O sites/O and/O individuals/O may/O have/O multiple/O primary/O cancers/O ./O
LS/O is/O the/O most/O common/O hereditary/O form/O of/O CRC/O ,/O accounting/O for/O approximately/O 1/O %/O of/O all/O CRC/O ./O
Since/O the/O first/O account/O of/O mutations/B-Var in/O MSH2/B-Gene causing/B-Reg this/O cancer/B-Disease susceptibility/O syndrome/O in/O 1993/O ,/O mutations/B-Var in/O three/O additional/O MMR/O genes/O ,/O MLH1/B-Gene ,/O MSH6/B-Gene ,/O and/O PMS2/B-Gene ,/O have/O been/O shown/O to/O cause/B-Reg LS/B-Disease ./O
More/O than/O 1,500/O different/O variants/O have/O been/O identified/O in/O these/O four/O genes/O and/O approximately/O 80/O %/O of/O the/O alterations/O have/O been/O identified/O in/O MLH1/O and/O MSH2/O ./O
There/O have/O been/O a/O few/O previous/O attempts/O to/O systematically/O record/O MMR/O variants/O associated/O with/O LS/O patients/O ;/O however/O ,/O they/O were/O not/O complete/O nor/O were/O they/O continuously/O updated/O ./O
Thus/O ,/O it/O was/O our/O goal/O to/O generate/O and/O maintain/O a/O comprehensive/O catalogue/O of/O MMR/O variants/O from/O genes/O known/O to/O be/O mutated/O in/O LS/O (/O http://www.med.mun.ca/MMRvariants/O ;/O last/O accessed/O 8/O February/O 2007/O )/O ./O
Providing/O such/O a/O resource/O should/O aid/O investigators/O in/O understanding/O the/O significance/O of/O the/O variants/O ./O
Complete/O androgen/O insensitivity/O without/O Wolffian/O duct/O development/O :/O the/O AR/O -/O A/O form/O of/O the/O androgen/O receptor/O is/O not/O sufficient/O for/O male/O genital/O development/O ./O
BACKGROUND/O :/O The/O androgen/O receptor/O (/O AR/O )/O is/O essential/O for/O the/O differentiation/O of/O male/O external/O and/O internal/O genitalia/O ./O
It/O is/O normally/O present/O in/O two/O forms/O ,/O a/O full/O -/O length/O form/O B/O and/O an/O N/O -/O terminal/O truncated/O form/O A/O with/O still/O unknown/O function/O ./O
Mutations/B-Var in/O the/O AR/B-Gene gene/O cause/B-Reg androgen/B-Disease insensitivity/I-Disease syndrome/I-Disease (/O AIS/O )/O ,/O which/O is/O divided/O into/O subgroups/O according/O to/O the/O degree/O of/O undermasculinization/O ./O
Patients/O with/O completely/O female/O external/O genitalia/O are/O classified/O as/O complete/O AIS/O (/O CAIS/O )/O ./O
However/O ,/O a/O recent/O study/O has/O shown/O that/O some/O CAIS/O patients/O have/O signs/O of/O internal/O male/O genital/O differentiation/O due/O to/O missense/O mutations/O that/O show/O some/O degree/O of/O residual/O function/O ./O
OBJECTIVE/O :/O We/O aimed/O to/O study/O the/O expression/O of/O the/O different/O forms/O of/O the/O AR/O in/O two/O CAIS/O patients/O in/O relation/O to/O the/O development/O of/O male/O internal/O genital/O structures/O ./O
One/O patient/O had/O a/O mutation/O (/O L7fsX33/O )/O that/O affects/O only/O the/O full/O -/O length/O AR/O -/O B/O form/O of/O the/O AR/O ,/O whereas/O the/O other/O had/O a/O nonsense/O mutation/O (/O Q733X/O )/O affecting/O both/O isoforms/O ./O
MEASUREMENTS/O AND/O RESULTS/O :/O We/O thoroughly/O analysed/O internal/O genitalia/O at/O surgery/O and/O by/O histological/O examination/O ./O
No/O signs/O of/O Wolffian/O duct/O (/O WD/O )/O development/O were/O present/O in/O any/O of/O the/O patients/O ./O
Western/O blotting/O of/O proteins/O from/O gonadal/O and/O genital/O skin/O fibroblasts/O was/O performed/O with/O AR/O antibodies/O directed/O against/O different/O AR/O epitopes/O ./O
The/O N/O -/O terminally/O truncated/O A/O form/O was/O expressed/O in/O normal/O amounts/O in/O the/O patient/O with/O the/O L7fsX33/O mutation/O while/O no/O AR/O was/O detected/O in/O the/O other/O patient/O ./O
CONCLUSION/O :/O The/O presence/O of/O the/O AR/O -/O A/O form/O does/O not/O seem/O to/O be/O sufficient/O for/O WD/O maintenance/O and/O differentiation/O ./O
Comprehensive/O analysis/O of/O the/O gene/O encoding/O filaggrin/O uncovers/O prevalent/O and/O rare/O mutations/O in/O ichthyosis/O vulgaris/O and/O atopic/O eczema/O ./O
We/O recently/O reported/O two/O common/O filaggrin/O (/B-Gene FLG/I-Gene )/I-Gene null/O mutations/B-Var that/O cause/B-Reg ichthyosis/B-Disease vulgaris/I-Disease and/O predispose/B-Disease to/I-Disease eczema/I-Disease and/O secondary/B-Disease allergic/I-Disease diseases/I-Disease ./O
We/O show/O here/O that/O these/O common/O European/O mutations/O are/O ancestral/O variants/O carried/O on/O conserved/O haplotypes/O ./O
To/O facilitate/O comprehensive/O analysis/O of/O other/O populations/O ,/O we/O report/O a/O strategy/O for/O full/O sequencing/O of/O this/O large/O ,/O highly/O repetitive/O gene/O ,/O and/O we/O describe/O 15/O variants/O ,/O including/O seven/O that/O are/O prevalent/O ./O
All/O the/O variants/B-Var are/O either/O nonsense/O or/O frameshift/O mutations/O that/O ,/O in/O representative/O cases/O ,/O resulted/O in/O loss/B-NegReg of/O filaggrin/B-MPA production/I-MPA in/O the/O epidermis/O ./O
In/O an/O Irish/O case/O -/O control/O study/O ,/O the/O five/O most/O common/O European/O mutations/O showed/O a/O strong/O association/O with/O moderate/O -/O to/O -/O severe/O childhood/O eczema/O (/O chi2/O test/O :/O P/O =/O 2.12/O x/O 10(-51/O )/O ;/O Fisher/O 's/O exact/O test/O :/O heterozygote/O odds/O ratio/O (/O OR/O )/O =/O 7.44/O (/O 95/O %/O confidence/O interval/O (/O c.i/O ./O
)/O =/O 4.9/O -/O 11.3/O )/O ,/O and/O homozygote/O OR/O =/O 151/O (/O 95/O %/O c.i/O ./O
=/O 20/O -/O 1,136/O )/O )/O ./O
We/O found/O three/O additional/O rare/O null/O mutations/O in/O this/O case/O series/O ,/O suggesting/O that/O the/O genetic/O architecture/O of/O filaggrin/O -/O related/O atopic/O dermatitis/O consists/O of/O both/O prevalent/O and/O rare/O risk/O alleles/O ./O
Increased/O chromosome/O instability/O and/O accumulation/O of/O DNA/O double/O -/O strand/O breaks/O in/O Werner/O syndrome/O cells/O ./O
Werner/B-Disease syndrome/I-Disease (/O WS/O )/O is/O a/O premature/O aging/O syndrome/O caused/B-Reg by/I-Reg mutations/B-Var of/O the/O WRN/B-Gene gene/O ./O
Here/O ,/O we/O demonstrate/O that/O a/O strain/O of/O WS/O fibroblast/O cells/O shows/O abnormal/O karyotypes/O characterized/O by/O several/O complex/O translocations/O and/O 50-fold/O more/O frequency/O of/O abnormal/O metaphases/O including/O dicentric/O chromosomes/O without/O fragments/O than/O normal/O cells/O when/O examined/O at/O a/O similar/O culture/O stage/O ./O
Further/O ,/O telomere/O fluorescence/O in/O situ/O hybridization/O indicates/O that/O the/O abnormal/O signals/O ,/O extra/O telomere/O signal/O and/O loss/O of/O telomere/O signal/O ,/O emerge/O two-/O to/O three/O -/O fold/O more/O frequently/O in/O WS/O cells/O than/O in/O normal/O cells/O ./O
Taken/O together/O ,/O these/O results/O indicate/O that/O chromosome/O instability/O including/O dysfunction/O of/O telomere/O maintenance/O is/O more/O prominent/O in/O WS/O cells/O than/O in/O normal/O cells/O ./O
In/O addition/O ,/O the/O accumulation/O of/O DNA/O double/O -/O strand/O breaks/O (/O DSBs/O )/O at/O the/O G(1/O )/O phase/O ,/O including/O those/O at/O telomeres/O ,/O detected/O by/O phosphorylated/O ATM/O (/O ataxia/O telangiectasia/O mutated/O )/O foci/O is/O accelerated/O in/O WS/O cells/O even/O at/O a/O low/O senescence/O level/O ./O
The/O increased/O accumulation/O of/O DSBs/O in/O WS/O cells/O is/O reduced/O in/O the/O presence/O of/O anti/O -/O oxidative/O agents/O ,/O suggesting/O that/O enhanced/O oxidative/O stress/O in/O WS/O cells/O is/O involved/O in/O accelerated/O accumulation/O of/O DSBs/O ./O
These/O results/O indicate/O that/O WS/O cells/O are/O prone/O to/O accumulate/B-PosReg DSBs/B-MPA spontaneously/O due/O to/O a/O defect/B-Var of/O WRN/B-Gene ,/O which/O leads/O to/O increased/B-PosReg chromosome/B-MPA instability/I-MPA that/O could/O activate/B-PosReg checkpoints/B-MPA ,/O resulting/O in/O accelerated/B-PosReg senescence/B-CPA ./O
A/O novel/O mutation/B-Var in/O TRIM37/B-Gene is/O associated/B-Reg with/I-Reg mulibrey/B-Disease nanism/I-Disease in/O a/O Turkish/O boy/O ./O
Mulibrey/O nanism/O is/O a/O rare/O autosomal/O -/O recessive/O disorder/O characterized/O by/O prenatal/O onset/O severe/O growth/O retardation/O and/O pericardial/O constriction/O associated/O with/O abnormalities/O of/O muscle/O ,/O liver/O ,/O brain/O and/O eye/O ./O
More/O than/O 80/O %/O of/O previously/O reported/O patients/O are/O of/O Finnish/O origin/O in/O whom/O a/O founder/O mutation/O in/O the/O TRIM37/O gene/O have/O been/O described/O ./O
We/O report/O on/O a/O 7-year/O -/O old/O Turkish/O boy/O who/O presented/O with/O classical/O phenotypic/O features/O of/O mulibrey/O nanism/O ./O
Mutation/O screening/O of/O the/O TRIM37/O gene/O revealed/O that/O the/O proband/O had/O a/O homozygous/O two/O base/O pair/O deletion/O ,/O c.1894_1895delGA/B-Var ,/O resulting/B-Reg in/I-Reg a/O frame/B-Var -/I-Var shift/I-Var and/O a/O premature/B-MPA termination/I-MPA codon/O ./O
Our/O proband/O is/O one/O of/O the/O rare/O examples/O of/O mulibrey/O nanism/O outside/O Finland/O and/O extends/O the/O mutation/O spectrum/O in/O this/O disorder/O ./O
Phenotype/O -/O genotype/O correlation/O in/O eight/O Polish/O patients/O with/O inherited/O Factor/O XIII/O deficiency/O :/O identification/O of/O three/O novel/O mutations/O ./O
Inherited/B-Disease factor/I-Disease XIII/I-Disease (/O FXIII/O )/O deficiency/O is/O known/O as/O one/O of/O the/O most/O rare/O blood/O coagulation/O disorder/O in/O humans/O ./O
In/O the/O present/O study/O ,/O phenotype/O and/O genotype/O of/O eight/O FXIII/O deficient/O Polish/O patients/O from/O five/O unrelated/O families/O were/O compared/O ./O
The/O patients/O presented/O with/O a/O severe/O phenotype/O demonstrated/O by/O a/O high/O incidence/O of/O intracerebral/O haemorrhages/O (/O seven/O of/O eight/O patients/O )/O ,/O haemarthrosis/O (/O six/O patients/O )/O and/O bleeding/O due/O to/O trauma/O (/O five/O patients/O )/O ./O
Introduction/O of/O regular/O substitution/O with/O FXIII/O concentrate/O prevented/O spontaneous/O bleeding/O in/O seven/O patients/O ./O
In/O all/O patients/O ,/O mutations/O within/O the/O F13A/B-Gene gene/O have/O been/O identified/O revealing/O four/O missense/O mutations/O (/B-Var Arg77Cys/I-Var ,/O Arg260Cys/B-Var ,/O Ala378Pro/B-Var ,/O Gly420Ser/B-Var )/I-Var ,/O one/O nonsense/O mutation/O (/B-Var Arg661X/I-Var )/I-Var ,/O one/O splice/O site/O mutation/O (/B-Var IVS5/I-Var -/I-Var 1/I-Var G/I-Var >/I-Var A/I-Var )/I-Var and/O one/O small/O deletion/O (/B-Var c.499/I-Var -/I-Var 512del/I-Var )/I-Var ./O
One/O homozygous/O large/O deletion/O involving/O exon/O 15/O was/O detected/O by/O failure/O of/O PCR/O product/O ./O
The/O corresponding/O mutations/B-Var resulted/O in/O severely/O reduced/B-NegReg FXIII/B-MPA activity/I-MPA and/O FXIII/B-MPA A/I-MPA -/I-MPA subunit/I-MPA antigen/I-MPA concentration/I-MPA ,/O while/O FXIII/O B/O -/O subunit/O antigen/O remained/O normal/O or/O mildly/O decreased/O ./O
Structural/O analysis/O demonstrated/O that/O the/O novel/O Ala378Pro/B-Var mutation/O may/O cause/O a/O disruption/B-NegReg of/O the/O FXIII/B-MPA catalytic/I-MPA triad/I-MPA leading/O to/O a/O non/B-NegReg -/I-NegReg functional/I-NegReg protein/B-Protein which/O presumably/O undergoes/O premature/B-MPA degradation/I-MPA ./O
In/O conclusion/O ,/O the/O severe/O phenotype/O with/O high/O incidence/O of/O intracranial/O bleeding/O and/O haemarthrosis/O was/O in/O accordance/O with/O laboratory/O findings/O on/O FXIII/O and/O with/O severe/O molecular/O defects/O of/O the/O F13A/O gene/O ./O
Effects/O of/O prolonged/O dark/O adaptation/O in/O patients/O with/O retinitis/O pigmentosa/O of/O Bothnia/O type/O :/O an/O electrophysiological/O study/O ./O
Bothnia/B-Disease dystrophy/I-Disease (/O BD/O )/O is/O a/O variant/O of/O recessive/O retinitis/O punctata/O albescens/O (/O RPA/O )/O ,/O caused/B-Reg by/I-Reg the/O missense/O mutation/O R233W/B-Var in/O cellular/O retinaldehyde/O -/O binding/O protein/O (/B-Protein CRALBP/I-Protein )/I-Protein ,/O which/O is/O localized/O in/O the/O retinal/O pigment/O epithelium/O (/O RPE/O )/O and/O Müller/O cells/O of/O the/O retina/O ./O
The/O purpose/O of/O this/O study/O was/O ,/O by/O examining/O the/O electrophysiological/O responses/O of/O the/O retina/O ,/O to/O evaluate/O the/O capacity/O of/O recovery/O of/O the/O whole/O retinal/O area/O and/O different/O cell/O types/O induced/O by/O extremely/O prolonged/O dark/O adaptation/O (/O DA/O )/O in/O BD/O disease/O and/O to/O gain/O further/O understanding/O of/O the/O pathogenesis/O of/O BD/O ./O
Six/O young/O patients/O underwent/O bilateral/O full/O -/O field/O ERGs/O after/O 24/O h/O of/O DA/O in/O one/O eye/O and/O standard/O DA/O in/O the/O fellow/O eye/O ./O
The/O results/O were/O also/O compared/O with/O the/O effect/O of/O prolonged/O DA/O (/O 10/O h/O )/O ,/O previously/O studied/O in/O the/O same/O patients/O ./O
After/O extremely/O prolonged/O DA/O (/O 24/O h/O )/O the/O rod/O b/O -/O wave/O and/O the/O mixed/O rod/O -/O cone/O a/O -/O wave/O responses/O reached/O normal/O though/O delayed/O amplitudes/O ./O
An/O increase/O ,/O up/O to/O normal/O level/O ,/O in/O the/O oscillatory/O response/O was/O found/O ./O
There/O was/O no/O obvious/O recovery/O of/O the/O cone/O response/O ./O
We/O conclude/O that/O in/O young/O BD/O patients/O during/O extremely/O prolonged/O DA/O there/O is/O a/O significant/O additional/O capacity/O of/O recovery/O of/O rod/O function/O and/O also/O significant/O gain/O of/O activity/O in/O the/O inner/O retinal/O layer/O ./O
A/O continuous/O but/O slow/O regeneration/O of/O rod/O photopigment/O seems/O to/O occur/O at/O least/O up/O to/O 24/O h./O The/O visual/O process/O in/O the/O RPE/O is/O retarded/O and/O CRALBP/O acts/O in/O this/O process/O ;/O also/O ,/O the/O Müller/O cells/O of/O the/O retina/O seem/O to/O be/O involved/O ./O
The/O findings/O also/O support/O an/O extremely/O slow/O synthesis/O of/O photopigments/O and/O irreversibly/O disturbed/O cone/O function/O early/O in/O BD/O ./O
A/O case/O of/O lethal/O hypophosphatasia/O providing/O new/O insights/O into/O the/O perinatal/O benign/O form/O of/O hypophosphatasia/O and/O expression/O of/O the/O ALPL/O gene/O ./O
Hypophosphatasia/B-Disease is/O a/O rare/O inherited/O bone/O disease/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O alkaline/O phosphatase/O liver/O -/O type/O gene/O (/B-Gene ALPL/I-Gene )/I-Gene gene/O ,/O with/O extensive/O allelic/O heterogeneity/O leading/O to/O a/O range/O of/O clinical/O phenotypes/O ./O
We/O report/O here/O a/O patient/O who/O died/O from/O severe/O lethal/O hypophosphatasia/O ,/O who/O was/O compound/O heterozygous/O for/O the/O mutation/O c.1133A/O >/O T/O (/O D361V/O )/O and/O the/O newly/O detected/O missense/O mutation/O c791A/O >/O G/O ,/O and/O whose/O parents/O were/O both/O healthy/O ./O
Because/O the/O c.1133A/O >/O T/O (/O D361V/O )/O mutation/O was/O previously/O reported/O to/O have/O a/O dominant/O -/O negative/O effect/O and/O to/O be/O responsible/O for/O the/O uncommon/O perinatal/O benign/O form/O of/O the/O disease/O ,/O we/O studied/O the/O expression/O of/O the/O ALPL/O gene/O in/O this/O family/O ./O
Analysis/O at/O the/O messenger/O RNA/O (/O mRNA/O )/O level/O ,/O both/O quantitative/O and/O qualitative/O ,/O showed/O that/O the/O paternal/O c.1133A/B-Var >/I-Var T/I-Var (/O D361V/O )/O mutation/O was/O associated/O with/O over/B-MPA -/I-MPA expression/I-MPA of/O the/O ALPL/B-Gene gene/O and/O that/O the/O maternal/O c.791A/B-Var >/I-Var G/I-Var mutation/O lead/B-Reg to/I-Reg complete/O skipping/B-Var of/I-Var exon/I-Var 7/I-Var ./O
The/O results/O provide/O an/O explanation/O of/O the/O lethal/O phenotype/O in/O the/O patient/O where/O the/O two/O ALPL/O alleles/O are/O non/O -/O functional/O and/O in/O the/O asymptomatic/O father/O where/O over/O -/O expression/O of/O the/O normal/O allele/O could/O counteract/O the/O effect/O of/O the/O c.1133A/O >/O T/O (/O D361V/O )/O mutation/O by/O providing/O an/O increased/O level/O of/O normal/O mRNA/O ./O
This/O may/O also/O explain/O the/O variable/O expression/O of/O hypophosphatasia/O observed/O in/O parents/O of/O patients/O with/O the/O perinatal/O benign/O form/O ./O
Choreoacanthocytosis/O in/O a/O Mexican/O family/O ./O
BACKGROUND/O :/O Choreoacanthocytosis/B-Disease (/O CHAC/O )/O (/O Online/O Mendelian/O Inheritance/O in/O Man/O accession/O No/O ./O
200150/O )/O is/O a/O hereditary/O neurodegenerative/O syndrome/O characterized/O by/O movement/O disorders/O ,/O cognitive/O decline/O ,/O myopathy/O ,/O behavioral/O changes/O ,/O and/O acanthocytosis/O and/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O VPS13A/B-Gene gene/O ./O
OBJECTIVE/O :/O To/O describe/O the/O cases/O of/O 2/O Mexican/O women/O with/O clinical/O and/O molecular/O characteristics/O compatible/O with/O CHAC/O ./O
DESIGN/O :/O Case/O reports/O ./O
Patients/O Choreoacanthocytosis/O was/O identified/O in/O 2/O Mexican/O mestizo/O sisters/O with/O healthy/O consanguineous/O parents/O ./O
Clinical/O manifestations/O began/O at/O different/O ages/O ./O
RESULTS/O :/O The/O onset/O of/O signs/O and/O symptoms/O of/O CHAC/O in/O the/O proband/O was/O at/O age/O 32/O years/O and/O was/O characterized/O by/O balancing/O problems/O followed/O by/O chorea/O ,/O compulsive/O lip/O and/O tongue/O biting/O with/O buccolingual/O self/O -/O mutilation/O ,/O dysarthria/O ,/O dysphagia/O ,/O and/O weight/O loss/O ./O
The/O first/O clinical/O manifestations/O in/O the/O proband/O 's/O sister/O occurred/O at/O age/O 45/O years/O and/O included/O multiple/O motor/O and/O verbal/O tics/O ,/O with/O coprolalia/O ,/O followed/O by/O lip/O and/O tongue/O biting/O ,/O self/O -/O mutilation/O ,/O and/O chorea/O ./O
The/O clinical/O findings/O in/O both/O sisters/O were/O remarkable/O for/O acanthocytosis/O that/O developed/O late/O ,/O when/O neurologic/O changes/O were/O already/O evident/O ./O
Mutation/O screening/O of/O the/O VPS13A/O gene/O revealed/O homozygosity/O for/O the/O frameshift/O mutation/O c.3556_3557dupAC/O in/O exon/O 33/O ./O
Currently/O ,/O the/O proband/O 's/O sister/O ,/O in/O whom/O neurologic/O defects/O developed/O 13/O years/O after/O onset/O of/O CHAC/O in/O the/O proband/O ,/O is/O the/O least/O affected/O ./O
CONCLUSIONS/O :/O The/O same/O mutation/O of/O the/O VPS13A/O gene/O can/O be/O expressed/O differently/O in/O the/O same/O family/O ./O
This/O observation/O confirms/O the/O notion/O that/O there/O is/O considerable/O heterogeneity/O in/O the/O clinical/O manifestation/O of/O CHAC/O ./O
[/O Phenotype/O -/O genotype/O study/O in/O 154/O French/O NF2/O mutation/O carriers/O ]/O ./O
Analyse/O phénotypique/O de/O 154/O patients/O porteurs/O d'une/O mutation/O constitutionnelle/O du/O gène/O NF2/O ./O
INTRODUCTION/O :/O Germline/B-Var mutations/I-Var in/O the/O NF2/B-Gene gene/O are/O responsible/B-Reg for/O 80/O p.cent/O of/O neurofibromatosis/B-Disease type/I-Disease 2/I-Disease typical/O cases/O ./O
Mutations/O are/O mainly/O truncating/O mutations/O or/O deletions/O ,/O missense/O mutations/O having/O been/O reported/O in/O few/O cases/O ./O
An/O important/O phenotypic/O variability/O is/O observed/O among/O gene/O carriers/O ./O
To/O assess/O whether/O the/O phenotypic/O variability/O of/O neurofibromatosis/O 2/O could/O be/O linked/O to/O genotype/O ,/O clinical/O data/O of/O 154/O patients/O whose/O NF2/O germline/O alteration/O had/O been/O identified/O in/O our/O laboratory/O have/O been/O collected/O ./O
METHODS/O :/O A/O retrospective/O questionnaire/O was/O sent/O to/O the/O physicians/O in/O charge/O of/O these/O patients/O ./O
Statistical/O analyses/O regarding/O genotypic/O and/O phenotypic/O data/O were/O performed/O by/O comparisons/O of/O average/O values/O and/O correlation/O tests/O ./O
RESULTS/O :/O In/O French/O patients/O ,/O type/O of/O mutation/O was/O correlated/O neither/O with/O patients/O '/O sex/O ,/O nor/O with/O disease/O occurrence/O mode/O (/O de/O novo/O or/O inherited/O mutation/O )/O ./O
Disease/O associated/O with/O missense/O mutations/O occurred/O later/O ,/O with/O a/O less/O severe/O symptomatology/O ./O
Patients/O with/O nonsense/O or/O frameshift/O mutations/O were/O more/O frequently/O affected/O with/O meningiomas/O and/O spinal/O tumours/O ,/O in/O addition/O to/O VIII/O nerve/O schwannomas/O ,/O an/O observation/O that/O underlies/O the/O genetic/O determination/O of/O the/O number/O and/O type/O of/O NF2-related/O tumours/O ./O
CONCLUSION/O :/O Results/O from/O the/O literature/O as/O well/O as/O from/O our/O study/O tend/O to/O show/O that/O only/O few/O correlations/O exist/O between/O genotype/O and/O phenotype/O in/O the/O NF2/O disease/O ./O
It/O also/O recognizes/O that/O missense/O mutations/O have/O a/O lower/O level/O of/O evolution/O ,/O severity/O and/O mortality/O risk/O ./O
Nonsense/O and/O frameshift/O mutations/O seem/O to/O be/O associated/O with/O a/O higher/O number/O of/O meningiomas/O and/O spinal/O tumours/O ./O
Therefore/O ,/O NF2/O gene/O screening/O keeps/O its/O indications/O in/O both/O typical/O and/O moderate/O forms/O of/O the/O disease/O ./O
Mutations/O are/O responsible/O of/O 80/O p.cent/O of/O typical/O forms/O ;/O in/O moderate/O forms/O ,/O identification/O of/O a/O missense/O mutation/O seems/O linked/O to/O a/O lower/O disease/O evolution/O ./O
In/O any/O case/O ,/O assessment/O and/O supervision/O should/O be/O identical/O ./O
Finally/O ,/O in/O a/O small/O number/O of/O cases/O ,/O the/O NF2/O gene/O appears/O to/O be/O implicated/O in/O clinical/O forms/O different/O from/O those/O defined/O by/O NIH/O and/O it/O might/O be/O of/O interest/O to/O enlarge/O the/O clinical/O features/O suggestive/O of/O the/O disease/O ./O
Do/O we/O know/O all/O there/O is/O to/O know/O about/O Familial/O Adenomatous/O Polyposis/O ?/O Familial/B-Disease Adenomatous/I-Disease Polyposis/I-Disease (/O FAP/O )/O and/O Attenuated/B-Disease FAP/I-Disease (/O AFAP/O )/O are/O caused/B-Reg by/I-Reg a/O germline/B-Var mutation/I-Var in/O the/O Adenomatous/O polyposis/O coli/O (/B-Gene APC/I-Gene )/I-Gene gene/O ./O
Recently/O ,/O a/O new/O pathway/O characterized/O by/O a/O biallelic/O mutation/O in/O the/O MYH/O gene/O ,/O with/O a/O recessive/O model/O of/O inheritance/O was/O discovered/O for/O this/O inherited/O syndrome/O ./O
This/O report/O describes/O a/O Tunisian/O patient/O with/O an/O attenuated/O FAP/O phenotype/O ,/O presenting/O seven/O colon/O polyps/O and/O an/O adenocarcinoma/O but/O no/O detectable/O germline/O mutations/O in/O the/O FAP/O target/O genes/O ./O
A/O well/O known/O somatic/O mutation/O was/O found/O in/O the/O APC/O mutation/O cluster/O region/O (/O MCR/O )/O ./O
This/O case/O shows/O that/O further/O studies/O are/O needed/O to/O fully/O understand/O all/O the/O pathways/O of/O the/O FAP/O syndrome/O ./O
Mutations/B-Var in/O NALP12/B-Gene cause/B-Reg hereditary/B-Disease periodic/I-Disease fever/I-Disease syndromes/I-Disease ./O
NALP/O proteins/O ,/O also/O known/O as/O NLRPs/O ,/O belong/O to/O the/O CATERPILLER/O protein/O family/O involved/O ,/O like/O Toll/O -/O like/O receptors/O ,/O in/O the/O recognition/O of/O microbial/O molecules/O and/O the/O subsequent/O activation/O of/O inflammatory/O and/O immune/O responses/O ./O
Current/O advances/O in/O the/O function/O of/O NALPs/O support/O the/O recently/O proposed/O model/O of/O a/O disease/O continuum/O bridging/O autoimmune/O and/O autoinflammatory/O disorders/O ./O
Among/O these/O diseases/O ,/O hereditary/O periodic/O fevers/O (/O HPFs/O )/O are/O Mendelian/O disorders/O associated/O with/O sequence/O variations/O in/O very/O few/O genes/O ;/O these/O variations/O are/O mostly/O missense/O mutations/O whose/O deleterious/O effect/O ,/O which/O is/O particularly/O difficult/O to/O assess/O ,/O is/O often/O questionable/O ./O
The/O growing/O number/O of/O identified/O sporadic/O cases/O of/O periodic/O fever/O syndrome/O ,/O together/O with/O the/O lack/O of/O discriminatory/O clinical/O criteria/O ,/O has/O greatly/O hampered/O the/O identification/O of/O new/O disease/O -/O causing/O genes/O ,/O a/O step/O that/O is/O ,/O however/O ,/O essential/O for/O appropriate/O management/O of/O these/O disorders/O ./O
Using/O a/O candidate/O gene/O approach/O ,/O we/O identified/O nonambiguous/O mutations/O in/O NALP12/O (/O i.e./O ,/O nonsense/O and/O splice/O site/O )/O in/O two/O families/O with/O periodic/O fever/O syndromes/O ./O
As/O shown/O by/O means/O of/O functional/O studies/O ,/O these/O two/O NALP12/B-Gene mutations/B-Var have/O a/O deleterious/O effect/B-Reg on/O NF/B-Pathway -/I-Pathway kappaB/I-Pathway signaling/I-Pathway ./O
Overall/O ,/O these/O data/O identify/O a/O group/O of/O HPFs/O defined/O by/O molecular/O defects/O in/O NALP12/O ,/O opening/O up/O new/O ways/O to/O manage/O these/O disorders/O ./O
The/O identification/O of/O these/O first/O NALP12/B-Gene mutations/B-Var in/O patients/O with/B-Reg autoinflammatory/B-CPA disorder/I-CPA also/O clearly/O demonstrates/O the/O crucial/O role/O of/O NALP12/O in/O inflammatory/O signaling/O pathways/O ,/O thereby/O assigning/O a/O precise/O function/O to/O this/O particular/O member/O of/O an/O emerging/O family/O of/O proteins/O whose/O putative/O biological/O properties/O are/O currently/O inferred/O essentially/O through/O in/O vitro/O means/O ./O
ABCA4/O gene/O analysis/O in/O patients/O with/O autosomal/O recessive/O cone/O and/O cone/O rod/O dystrophies/O ./O
The/O ATP/O -/O binding/O cassette/O (/O ABC/O )/O transporters/O constitute/O a/O family/O of/O large/O membrane/O proteins/O ,/O which/O transport/O a/O variety/O of/O substrates/O across/O membranes/O ./O
The/O ABCA4/O protein/O is/O expressed/O in/O photoreceptors/O and/O possibly/O functions/O as/O a/O transporter/O for/O N/O -/O retinylidene/O -/O phosphatidylethanolamine/O (/O N/O -/O retinylidene/O -/O PE/O )/O ,/O the/O Schiff/O base/O adduct/O of/O all/O -/O trans/O -/O retinal/O with/O PE/O ./O
Mutations/B-Var in/O the/O ABCA4/B-Gene gene/O have/O been/O initially/O associated/B-Reg with/I-Reg autosomal/O recessive/O Stargardt/B-Disease disease/I-Disease ./O
Subsequent/O studies/O have/O shown/O that/O mutations/B-Var in/O ABCA4/B-Gene can/O also/O cause/B-Reg a/O variety/O of/O other/O retinal/B-Disease dystrophies/I-Disease including/O cone/B-Disease rod/I-Disease dystrophy/I-Disease and/O retinitis/B-Disease pigmentosa/I-Disease ./O
To/O determine/O the/O prevalence/O and/O mutation/O spectrum/O of/O ABCA4/O gene/O mutations/O in/O non/O -/O Stargardt/O phenotypes/O ,/O we/O have/O screened/O 64/O unrelated/O patients/O with/O autosomal/O recessive/O cone/O (/O arCD/O )/O and/O cone/O rod/O dystrophy/O (/O arCRD/O )/O applying/O the/O Asper/O Ophthalmics/O ABCR400/O microarray/O followed/O by/O DNA/O sequencing/O of/O all/O coding/O exons/O of/O the/O ABCA4/O gene/O in/O subjects/O with/O single/O heterozygous/O mutations/O ./O
Disease/O -/O associated/O ABCA4/O alleles/O were/O identified/O in/O 20/O of/O 64/O patients/O with/O arCD/O or/O arCRD/O ./O
In/O four/O of/O 64/O patients/O (/O 6/O %/O )/O only/O one/O mutant/O ABCA4/O allele/O was/O detected/O and/O in/O 16/O patients/O (/O 25/O %/O )/O ,/O mutations/O on/O both/O ABCA4/O alleles/O were/O identified/O ./O
Based/O on/O these/O data/O we/O estimate/O a/O prevalence/O of/O 31/O %/O for/O ABCA4/O mutations/O in/O arCD/O and/O arCRD/O ,/O supporting/O the/O concept/O that/O the/O ABCA4/O gene/O is/O a/O major/O locus/O for/O various/O types/O of/O degenerative/O retinal/O diseases/O with/O abnormalities/O in/O cone/O or/O both/O cone/O and/O rod/O function/O ./O
Premature/O termination/O codons/O in/O PRPF31/O cause/O retinitis/O pigmentosa/O via/O haploinsufficiency/O due/O to/O nonsense/O -/O mediated/O mRNA/O decay/O ./O
Dominant/B-Var mutations/I-Var in/O the/O gene/O encoding/O the/O mRNA/O splicing/O factor/O PRPF31/B-Gene cause/B-Reg retinitis/B-Disease pigmentosa/I-Disease ,/O a/O hereditary/O form/O of/O retinal/O degeneration/O ./O
Most/O of/O these/O mutations/O are/O characterized/O by/O DNA/O changes/O that/O lead/O to/O premature/O termination/O codons/O ./O
We/O investigated/O 6/O different/O PRPF31/O mutations/O ,/O represented/O by/O single/O -/O base/O substitutions/O or/O microdeletions/O ,/O in/O cell/O lines/O derived/O from/O 9/O patients/O with/O dominant/O retinitis/O pigmentosa/O ./O
Five/O of/O these/O mutations/B-Var lead/B-Reg to/I-Reg premature/B-MPA termination/I-MPA codons/I-MPA ,/O and/O 1/O leads/B-Reg to/I-Reg the/O skipping/B-MPA of/I-MPA exon/I-MPA 2/I-MPA ./O
Allele/O -/O specific/O measurement/O of/O PRPF31/O transcripts/O revealed/O a/O strong/O reduction/B-NegReg in/O the/O expression/B-MPA of/O mutant/B-Var alleles/O ./O
As/O a/O consequence/O ,/O total/O PRPF31/B-Gene protein/B-Protein abundance/B-MPA was/O decreased/B-NegReg ,/O and/O no/O truncated/O proteins/O were/O detected/O ./O
Subnuclear/O localization/O of/O the/O full/O -/O length/O PRPF31/O that/O was/O present/O remained/O unaffected/O ./O
Blocking/O nonsense/O -/O mediated/O mRNA/O decay/O significantly/O restored/O the/O amount/O of/O mutant/O PRPF31/O mRNA/O but/O did/O not/O restore/O the/O synthesis/O of/O mutant/O proteins/O ,/O even/O in/O conjunction/O with/O inhibitors/O of/O protein/O degradation/O pathways/O ./O
Our/O results/O indicate/O that/O most/O PRPF31/B-Gene mutations/B-Var ultimately/O result/O in/O null/B-NegReg alleles/B-MPA through/O the/O activation/B-PosReg of/O surveillance/B-MPA mechanisms/I-MPA that/O inactivate/B-NegReg mutant/B-Var mRNA/I-Var and/O ,/O possibly/O ,/O proteins/B-Protein ./O
Furthermore/O ,/O these/O data/O provide/O compelling/O evidence/O that/O the/O pathogenic/O effect/O of/O PRPF31/O mutations/O is/O likely/O due/O to/O haploinsufficiency/O rather/O than/O to/O gain/O of/O function/O ./O
Xeroderma/O pigmentosum/O -/O variant/O patients/O from/O America/O ,/O Europe/O ,/O and/O Asia/O ./O
Xeroderma/B-Disease pigmentosum/I-Disease -/I-Disease variant/I-Disease (/O XP/O -/O V/O )/O patients/O have/O sun/O sensitivity/O and/O increased/O skin/O cancer/O risk/O ./O
Their/O cells/O have/O normal/O nucleotide/O excision/O repair/O ,/O but/O have/O defects/O in/O the/O POLH/O gene/O encoding/O an/O error/O -/O prone/O polymerase/O ,/O DNA/O polymerase/O eta/O (/O pol/O eta/O )/O ./O
To/O survey/O the/O molecular/O basis/O of/O XP/O -/O V/O worldwide/O ,/O we/O measured/O pol/O eta/O protein/O in/O skin/O fibroblasts/O from/O putative/O XP/O -/O V/O patients/O (/O aged/O 8/O -/O 66/O years/O )/O from/O 10/O families/O in/O North/O America/O ,/O Turkey/O ,/O Israel/O ,/O Germany/O ,/O and/O Korea/O ./O
Pol/O eta/O was/O undetectable/O in/O cells/O from/O patients/O in/O eight/O families/O ,/O whereas/O two/O showed/O faint/O bands/O ./O
DNA/O sequencing/O identified/O 10/O different/O POLH/O mutations/O ./O
There/O were/O two/O splicing/O ,/O one/O nonsense/O ,/O five/O frameshift/O (/O 3/O deletion/O and/O 2/O insertion/O )/O ,/O and/O two/O missense/O mutations/O ./O
Nine/O of/O these/O mutations/O involved/O the/O catalytic/O domain/O ./O
Although/O affected/O siblings/O had/O similar/O clinical/O features/O ,/O the/O relation/O between/O the/O clinical/O features/O and/O the/O mutations/O was/O not/O clear/O ./O
POLH/O mRNA/O levels/O were/O normal/O or/O reduced/O by/O 50/O %/O in/O three/O cell/O strains/O with/O undetectable/O levels/O of/O pol/O eta/O protein/O ,/O indicating/O that/O nonsense/O -/O mediated/O message/O decay/O was/O limited/O ./O
We/O found/O a/O wide/O spectrum/O of/O mutations/B-Var in/O the/O POLH/B-Gene gene/O among/B-Reg XP/B-Disease -/I-Disease V/I-Disease patients/O in/O different/O countries/O ,/O suggesting/O that/O many/O of/O these/O mutations/O arose/O independently/O ./O
Four/O novel/O FXI/B-Gene gene/O mutations/B-Var in/B-Reg three/O factor/B-Disease XI-/I-Disease deficient/I-Disease patients/O ./O
Hereditary/O factor/O XI/O deficiency/O is/O a/O mild/O bleeding/O disorder/O ,/O which/O is/O highly/O prevalent/O among/O Ashkenazi/O Jews/O ,/O but/O has/O been/O reported/O in/O all/O populations/O ./O
In/O Ashkenazi/O Jews/O ,/O two/O factor/O XI/O gene/O mutations/O Glu/O 117X/O (/O type/O II/O )/O and/O Phe283Leu/O (/O type/O III/O )/O are/O particularly/O common/O ./O
In/O other/O ethnic/O groups/O ,/O factor/B-Disease XI/I-Disease deficiency/I-Disease is/O a/O rare/O bleeding/O disorder/O and/O is/O related/B-Reg to/I-Reg a/O variety/O of/O mutations/B-Var throughout/O the/O factor/B-Gene XI/I-Gene gene/O ./O
Three/O cases/O of/O quantitative/O factor/O XI/O deficiency/O in/O relation/O with/O four/O novel/O missense/O mutations/O are/O reported/O :/O a/O compound/O heterozygosity/O for/O two/O novel/O mutations/O (/B-Var Ala/I-Var 181/I-Var Val/I-Var and/O Ala/B-Var 412/I-Var Thr/I-Var )/I-Var with/O a/O severe/O factor/O XI/O deficiency/O and/O two/O missense/O mutations/O (/B-Var His/I-Var 388/I-Var Pro/I-Var and/O Trp/B-Var 407/I-Var Cys/I-Var )/I-Var in/B-Reg heterozygous/O patients/O with/O partial/O factor/B-Disease XI/I-Disease deficiency/I-Disease ./O
[/O A/O novel/O mutation/B-Var in/O the/O SEDL/B-Gene gene/O leading/B-Reg to/I-Reg X/B-Disease -/I-Disease linked/I-Disease spondyloepiphyseal/I-Disease dysplasia/I-Disease tarda/I-Disease in/O a/O large/O Chinese/O pedigree/O ]/O ./O
OBJECTIVE/O :/O To/O identify/O the/O genetic/O defect/O in/O a/O four/O -/O generation/O pedigree/O with/O X/O -/O linked/O recessive/O spondyloepiphyseal/O dysplasia/O tarda/O (/O SEDT/O )/O from/O Southwest/O China/O ./O
METHODS/O :/O Linkage/O analysis/O with/O one/O panel/O of/O fluorescently/O labeled/O microsatellite/O markers/O on/O chromosome/O X/O and/O mutation/O screening/O of/O SEDL/O gene/O by/O direct/O sequencing/O were/O performed/O ./O
RESULTS/O :/O Linkage/O between/O SEDT/O and/O Xp22.2-Xp23.1/O was/O established/O with/O maximum/O LOD/O score/O of/O 3.82/O (/O theta/O =/O 0/O )/O between/O DXS987/O and/O DXS8051/O ./O
Upon/O sequence/O analysis/O ,/O a/O point/O mutation/O within/O exon/O 4/O of/O the/O SEDL/B-Gene gene/O (/B-Var c.239A/I-Var to/I-Var G/I-Var )/I-Var was/O found/O which/O resulted/B-Reg in/I-Reg substitution/O of/O histidine/O with/O arginine/O at/O codon/O 80/O (/B-Var His80Arg/I-Var )/I-Var ./O
CONCLUSION/O :/O A/O novel/O missense/O mutation/O (/O H80R/O )/O was/O identified/O for/O SEDL/O gene/O in/O the/O large/O Chinese/O SEDT/O pedigree/O ./O
MLPA/O analysis/O //O complete/O sequencing/O of/O the/O DMD/O gene/O in/O a/O group/O of/O Bulgarian/O Duchenne/O //O Becker/O muscular/O dystrophy/O patients/O ./O
Duchenne/B-Disease //I-Disease Becker/I-Disease muscular/I-Disease dystrophy/I-Disease (/O DMD/O //O BMD/O )/O ,/O the/O most/O common/O X/O -/O linked/O muscular/O dystrophy/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O enormously/O large/O DMD/B-Gene gene/O ,/O encoding/O the/O protein/O called/O dystrophin/O ./O
This/O gene/O was/O screened/O in/O a/O group/O of/O 27/O unrelated/O Bulgarian/O DMD/O //O BMD/O patients/O by/O MLPA/O analysis/O //O complete/O sequencing/O ./O
We/O managed/O to/O clarify/O the/O disease/O -/O causing/O mutation/O in/O 96.3/O %/O of/O the/O analyzed/O families/O ./O
The/O MLPA/O analysis/O revealed/O 17/O deletions/O (/O including/O a/O deletion/O of/O the/O very/O last/O exon/O 79/O )/O ,/O 6/O duplications/O and/O 1/O point/O mutation/O ./O
Two/O additional/O point/O mutations/O (/O one/O of/O them/O novel/O )/O were/O detected/O after/O complete/O sequencing/O of/O the/O DMD/O gene/O ./O
Altogether/O ,/O 25/O carriers/O and/O 11/O noncarriers/O were/O detected/O in/O our/O families/O ./O
The/O MLPA/O test/O proved/O to/O be/O a/O powerful/O tool/O in/O detecting/O deletions/O //O duplications/O and/O in/O some/O cases/O point/O mutations/O //O polymorphisms/O along/O the/O DMD/O gene/O ./O
Using/O this/O approach/O in/O combination/O with/O a/O direct/O gene/O sequencing/O a/O number/O of/O Bulgarian/O DMD/O //O BMD/O patients/O are/O genetically/O clarified/O and/O prepared/O for/O gene/O therapy/O in/O future/O ./O
A/O case/O of/O Bernard/B-Disease -/I-Disease Soulier/I-Disease Syndrome/I-Disease due/B-Reg to/I-Reg a/O homozygous/O four/O bases/O deletion/B-Var (/O TGAG/O )/O of/O GPIbalpha/B-Gene gene/I-Gene :/I-Gene lack/O of/O GPIbalpha/O but/O absence/O of/O bleeding/O ./O
More/O than/O 20/O DNA/O mutations/O with/O different/O inheritance/O pattern/O have/O been/O described/O in/O patients/O with/O Bernard/O -/O Soulier/O Syndrome/O (/O BSS/O )/O ,/O leading/O to/O abnormal/O or/O absent/O synthesis/O and/or/O expression/O of/O GPIbalpha/O ./O
Clinical/O phenotype/O shows/O considerable/O variation/O between/O individuals/O ,/O such/O as/O bleeding/O ,/O platelet/O count/O and/O the/O percentage/O of/O large/O platelets/O ./O
We/O describe/O in/O a/O BSS/O patient/O the/O first/O case/O of/O homozygous/O four/O bases/O deletion/O (/O TGAG/O )/O in/O the/O gpIbalpha/O gene/O coding/O sequence/O ,/O leading/O to/O a/O premature/O stop/O codon/O ./O
In/O the/O propositus/O ,/O blood/O smears/O revealed/O giant/O platelets/O (/O 30/O x/O 10(9/O )/O platelets/O //O L/O )/O ,/O and/O platelet/O agglutination/O to/O ristocetin/O was/O absent/O ./O
Propositus/O '/O parents/O are/O consanguineous/O ./O
His/O father/O and/O paternal/O grandmother/O showed/O a/O mild/O thrombocytopenia/O (/O 108/O x/O 10(9)/L/O and/O 120/O x/O 10(9)/L/O platelets/O respectively/O )/O while/O mothers/O and/O sister/O 's/O referred/O normal/O platelet/O counts/O ./O
The/O surface/O expression/O of/O GPIbalpha/O was/O practically/O undetectable/O by/O flow/O -/O cytometry/O and/O western/O blot/O in/O the/O patient/O and/O was/O reduced/O in/O the/O father/O ./O
Proband/O 's/O DNA/O analysis/O revealed/O a/O homozygous/O four/O -/O base/O -/O pair/O deletion/B-Var (/O TGAG/O )/O ,/O starting/O from/O the/O last/O base/O of/O the/O codon/O for/O Ser39/O ,/O leading/B-Reg to/I-Reg a/O coding/O frame/O shift/O with/O a/O new/O termination/B-MPA codon/I-MPA after/O 11/O novel/O amino/O acids/O ./O
The/O same/O mutation/O was/O seen/O in/O heterozygosis/O in/O both/O parents/O ./O
This/O is/O the/O first/O report/O of/O GPIbalpha/O TGAG/O deletion/O in/O homozygous/O state/O even/O if/O the/O defect/O has/O already/O been/O described/O in/O a/O case/O of/O compound/O heterozygosis/O ./O
Surprisingly/O ,/O the/O propositus/O does/O not/O report/O any/O spontaneous/O bleeding/O tendency/O ./O
Common/O mutations/B-Var in/B-Reg Cuban/O cystic/B-Disease fibrosis/I-Disease patients/O ./O
So/O far/O ,/O more/O than/O 1500/O mutations/O have/O been/O reported/O in/O the/O cystic/O fibrosis/O transmembrane/O conductance/O regulator/O (/B-Gene CFTR/I-Gene )/I-Gene gene/O ./O
Mutational/O spectrum/O varies/O in/O accordance/O with/O geographic/O and/or/O ethnic/O origin/O ./O
In/O this/O study/O ,/O we/O have/O analyzed/O seven/O common/B-Reg CF/B-Disease mutations/O (/B-Var p/I-Var ./I-Var F508del/I-Var ,/O p/B-Var ./I-Var G542X/I-Var ,/O p/B-Var ./I-Var R1162X/I-Var ,/O p/B-Var ./I-Var N1303/I-Var K/I-Var ,/O p/B-Var ./I-Var R334W/I-Var ,/O p/B-Var ./I-Var R553X/I-Var and/O c.3120/B-Var +/I-Var 1G/I-Var >/I-Var A/I-Var )/I-Var taking/O into/O account/O the/O ethnic/O origin/O of/O the/O Cuban/O population/O which/O is/O mainly/O influenced/O by/O Spanish/O and/O sub/O -/O Sahara/O African/O contribution/O ./O
All/O but/O p/O ./O N1303/O K/O have/O been/O detected/O in/O our/O patients/O ,/O the/O p/O ./O F508del/O being/O the/O most/O prevalent/O (/O 37.9/O %/O )/O ./O
Overall/O ,/O six/O mutations/O showed/O frequencies/O above/O 1/O %/O accounting/O for/O 55.5/O %/O of/O the/O Cuban/O CF/O alleles/O ./O
Mutation/B-Var in/O BAG3/B-Gene causes/B-Reg severe/O dominant/O childhood/B-Disease muscular/I-Disease dystrophy/I-Disease ./O
OBJECTIVE/O :/O Myofibrillar/O myopathies/O (/O MFMs/O )/O are/O morphologically/O distinct/O but/O genetically/O heterogeneous/O muscular/O dystrophies/O in/O which/O disintegration/O of/O Z/O disks/O and/O then/O of/O myofibrils/O is/O followed/O by/O ectopic/O accumulation/O of/O multiple/O proteins/O ./O
Cardiomyopathy/O ,/O neuropathy/O ,/O and/O dominant/O inheritance/O are/O frequent/O associated/O features/O ./O
Mutations/O in/O alphaB/O -/O crystallin/O ,/O desmin/O ,/O myotilin/O ,/O Zasp/O ,/O or/O filamin/O -/O C/O can/O cause/O MFMs/O and/O were/O detected/O in/O 32/O of/O 85/O patients/O of/O the/O Mayo/O MFM/O cohort/O ./O
Bag3/B-Protein ,/O another/O Z/O -/O disk/O -/O associated/O protein/O ,/O has/O antiapoptotic/O properties/O ,/O and/O its/O targeted/O deletion/B-Var in/O mice/O causes/B-Reg fulminant/B-Disease myopathy/I-Disease with/O early/O lethality/O ./O
We/O therefore/O searched/O for/O mutations/O in/O BAG3/O in/O 53/O unrelated/O MFM/O patients/O ./O
METHODS/O :/O We/O searched/O for/O mutations/O in/O BAG3/O by/O direct/O sequencing/O ./O
We/O analyzed/O structural/O changes/O in/O muscle/O by/O histochemistry/O ,/O immunocytochemistry/O ,/O and/O electron/O microscopy/O ,/O examined/O mobility/O of/O the/O mutant/O Bag3/O by/O nondenaturing/O electrophoresis/O ,/O and/O searched/O for/O abnormal/O aggregation/O of/O the/O mutant/O protein/O in/O COS-7/O (/O SV-40/O transformed/O monkey/O kidney/O fibroblast-7/O )/O cells/O ./O
RESULTS/O :/O We/O identified/O a/O heterozygous/O p/O ./O Pro209Leu/O mutation/O in/O three/O patients/O ./O
All/O presented/O in/O childhood/O ,/O had/O progressive/O limb/O and/O axial/O muscle/O weakness/O ,/O and/O experienced/O development/O of/O cardiomyopathy/O and/O severe/O respiratory/O insufficiency/O in/O their/O teens/O ;/O two/O had/O rigid/O spines/O ,/O and/O one/O a/O peripheral/O neuropathy/O ./O
Electron/O microscopy/O showed/O disintegration/O of/O Z/O disks/O ,/O extensive/O accumulation/O of/O granular/O debris/O and/O larger/O inclusions/O ,/O and/O apoptosis/O of/O 8/O %/O of/O the/O nuclei/O ./O
On/O nondenaturing/O electrophoresis/O of/O muscle/O extracts/O ,/O the/O Bag3/O complex/O migrated/O faster/O in/O patient/O than/O control/O extracts/O ,/O and/O expression/O of/O FLAG/O -/O labeled/O mutant/O and/O wild/O -/O type/O Bag3/O in/O COS/O cells/O showed/O abnormal/O aggregation/O of/O the/O mutant/O protein/O ./O
INTERPRETATION/O :/O We/O conclude/O mutation/O in/O Bag3/O defines/O a/O novel/O severe/O autosomal/O dominant/O childhood/O muscular/O dystrophy/O ./O
Network/O analyses/O of/O differentially/O expressed/O proteins/O in/O amniotic/O fluid/O supernatant/O associated/O with/O abnormal/O human/O karyotypes/O ./O
OBJECTIVE/O :/O To/O investigate/O the/O functional/O roles/O of/O differentially/O expressed/O proteins/O in/O the/O amniotic/B-Disease fluid/I-Disease supernatant/I-Disease (/O AFS/O )/O with/O abnormal/O karyotypes/O ./O
DESIGN/O :/O Basic/O and/O clinical/O research/O ./O
SETTING/O :/O University/O hospital/O ./O
PATIENT(S/O )/O :/O Samples/O of/O AFS/O from/O 34/O fetuses/O with/O normal/O -/O karyotype/O ,/O 17/O with/O trisomy/O 18/O ,/O and/O 19/O with/O trisomy/O 21/O ./O
INTERVENTION(S/O )/O :/O Two/O -/O dimensional/O chromatography/O followed/O by/O mass/O spectrometry/O to/O identify/O the/O proteins/O differentially/O expressed/O in/O AFS/O of/O trisomy-18/O or/O trisomy-21/O fetuses/O ./O
MAIN/O OUTCOME/O MEASURE(S/O )/O :/O Differentially/O expressed/O proteins/O were/O confirmed/O with/O Western/O blot/O analysis/O and/O ELISA/O ./O
The/O roles/O of/O biologic/O networks/O in/O the/O pathophysiology/O of/O aneuploidies/O were/O analyzed/O using/O MetaCore/O mapping/O tools/O ./O
RESULT(S/O )/O :/O Levels/B-MPA of/O apolipoprotein/B-Protein A1/I-Protein ,/O AP-3mu/B-Protein ,/O and/O antitrypsin/B-Protein were/O significantly/O decreased/B-NegReg in/O trisomy-18/B-Var AFS/O ,/O whereas/O placental/B-Protein protein-14/I-Protein was/O increased/B-PosReg ./O
On/O the/O other/O hand/O ,/O apolipoprotein/B-Protein A1/I-Protein was/O decreased/B-NegReg in/O trisomy-21/B-Var AFS/O ,/O but/O antitrypsin/B-Protein ,/O prealbumin/B-Protein ,/O and/O transferrin/B-Protein were/O increased/B-PosReg in/O trisomy/B-Var 21/I-Var ./O
Biologic/O network/O analyses/O revealed/O that/O the/O proteins/O of/O the/O trisomy-18/O AFS/O network/O were/O involved/O in/O immune/O processes/O ,/O dysfunction/O of/O skin/O pigmentation/O ,/O and/O platelet/O disorders/O ,/O whereas/O those/O of/O trisomy/O 21/O were/O associated/O with/O dysfunctional/O lipid/O and/O cholesterol/O metabolism/O ,/O processes/O of/O metal/O ion/O transport/O ,/O adenosine/O triphosphate/O metabolism/O ,/O and/O energy/O -/O coupled/O protein/O transport/O ./O
CONCLUSION(S/O )/O :/O The/O combined/O use/O of/O quantitative/O proteomics/O and/O functional/O network/O analyses/O may/O integrally/O analyze/O the/O pathophysiology/O of/O abnormal/O karyotypes/O ./O
Canonical/O WNT/O signalling/O determines/O lineage/O specificity/O in/O Wilms/O tumour/O ./O
Wilms/O tumours/O (/O WTs/O )/O have/O two/O distinct/O types/O of/O histology/O with/O or/O without/O ectopic/O mesenchymal/O elements/O ,/O suggesting/O that/O WTs/O arise/O from/O either/O the/O mesenchymal/O or/O epithelial/O nephrogenic/O lineages/O ./O
Regardless/O of/O the/O presence/O or/O absence/O of/O CTNNB1/O mutations/O ,/O nuclear/O accumulation/O of/O beta/O -/O catenin/O is/O often/O observed/O in/O WTs/O with/O ectopic/O mesenchymal/O elements/O ./O
Here/O ,/O we/O addressed/O the/O relationship/O between/O the/O WNT/O -/O signalling/O pathway/O and/O lineage/O in/O WTs/O by/O examining/O CTNNB1/O and/O WT1/O mutations/O ,/O nuclear/O accumulation/O of/O beta/O -/O catenin/O ,/O tumour/O histology/O and/O gene/O expression/O profiles/O ./O
In/O addition/O ,/O we/O screened/O for/O mutations/B-Var in/O WTX/B-Gene ,/O which/O has/O been/O proposed/O to/O be/O a/O negative/B-NegReg regulator/O of/O the/O canonical/O WNT/B-Pathway -/I-Pathway signalling/I-Pathway pathway/I-Pathway ./O
Unsupervised/O clustering/O analysis/O identified/O two/O classes/O of/O tumours/O :/O mesenchymal/O lineage/O WNT/O -/O dependent/O tumours/O ,/O and/O epithelial/O lineage/O WNT/O -/O independent/O tumours/O ./O
In/O contrast/O to/O the/O mesenchymal/O lineage/O specificity/O of/O CTNNB1/O mutations/O ,/O WTX/O mutations/O were/O surprisingly/O observed/O in/O both/O lineages/O ./O
WTX/B-Var -/I-Var mutant/I-Var WTs/O with/O ectopic/O mesenchymal/O elements/O had/O nuclear/O accumulation/B-PosReg of/O beta/B-Protein -/I-Protein catenin/I-Protein ,/O upregulation/B-PosReg of/O WNT/B-Gene target/I-Gene genes/I-Gene and/O an/O association/B-Reg with/I-Reg CTNNB1/B-Gene mutations/B-Var in/O exon/O 7/O or/O 8/O ./O
However/O ,/O epithelial/O lineage/O WTs/O with/O WTX/O mutations/O had/O no/O indications/O of/O active/O WNT/O signalling/O ,/O suggesting/O that/O the/O involvement/O of/O WTX/O in/O the/O WNT/O -/O signalling/O pathway/O may/O be/O lineage/O dependent/O ,/O and/O that/O WTX/O may/O have/O an/O alternative/O function/O to/O its/O role/O in/O the/O canonical/O WNT/O -/O signalling/O pathway/O ./O
Apparent/B-Disease mineralocorticoid/I-Disease excess/I-Disease syndrome/I-Disease in/O a/O Brazilian/O boy/O caused/B-Reg by/I-Reg the/O homozygous/O missense/O mutation/O p/B-Var ./I-Var R186C/I-Var in/O the/O HSD11B2/B-Gene gene/O ./O
The/O apparent/O mineralocorticoid/O excess/O syndrome/O (/O AME/O )/O is/O a/O rare/O autosomal/O recessive/O disorder/O due/O to/O the/O deficiency/O of/O 11beta/O -/O hydroxysteroid/O dehydrogenase/O type/O 2/O enzyme/O (/O 11beta/O -/O HSD2/O )/O ./O
The/O 11beta/O -/O HSD2/O enzyme/O ,/O encoded/O by/O HSD11B2/O gene/O ,/O metabolizes/O active/O cortisol/O in/O cortisone/O ./O
Mutations/B-Var on/O HSD11B2/B-Gene gene/O affect/B-Reg the/O enzyme/B-Enzyme activity/B-MPA by/O leading/O to/O an/O excess/B-PosReg of/O cortisol/B-MPA ,/O which/O causes/B-Reg its/O inappropriate/O access/B-MPA to/I-MPA mineralocorticoid/I-MPA receptor/I-MPA ./O
Therefore/O ,/O cortisol/O will/O bind/O mineralocorticoid/O receptor/O ./O
The/O human/O HSD11B2/O gene/O maps/O to/O chromosome/O 16q22/O and/O consists/O of/O five/O exons/O encoding/O a/O protein/O of/O 405/O amino/O acids/O ./O
We/O present/O here/O clinical/O and/O molecular/O studies/O on/O a/O Brazilian/O boy/O who/O was/O born/O pre/O -/O term/O after/O an/O oligodramnious/O pregnancy/O ./O
He/O was/O diagnosed/O as/O having/O AME/O at/O the/O age/O of/O 26/O months/O ./O
His/O parents/O are/O second/O cousins/O ./O
Molecular/O characterization/O of/O the/O HSD11B2/O gene/O revealed/O the/O homozygous/O mutation/O p/O ./O R186C./O The/O patient/O described/O here/O is/O the/O second/O case/O of/O HDS11B2/B-Gene gene/O mutation/B-Var reported/O in/O Brazilian/O patients/O with/B-Reg AME/B-Disease ./O
[/O Primary/O hiperoxaluria/O :/O a/O new/O mutation/O in/O gen/O AGXT/B-Gene (/B-Var R197Q/I-Var )/I-Var cause/B-Reg of/I-Reg neonatal/B-Disease convulsions/I-Disease ]/I-Disease ./O
Hiperoxaluria/O primaria/O :/O una/O nueva/O mutación/O en/O el/O gen/O AGXT/O (/O r197q/O )/O causante/O de/O convulsiones/O neonatales/O ./O
Primary/O hyperoxaluria/O is/O a/O congenital/O innate/O error/O of/O the/O metabolism/O of/O the/O amino/O acids/O ,/O that/O is/O transmitted/O like/O an/O autosomal/O recessive/O character/O ./O
Two/O types/O of/O hyperoxaluria/O exist/O :/O the/O primary/O type/O I/O ,/O that/O corresponds/O to/O the/O peroxisomal/O enzymatic/O deficit/O of/O the/O alanine/O glyoxylate/O aminotransferase/O in/O the/O liver/O (/O AGT/O )/O and/O type/O II/O ,/O due/O to/O the/O deficit/O of/O the/O glyoxylate/O reductase/O //O hydroxypyruvate/O reductase/O deficiency/O (/O GRHPR/O )/O ./O
The/O primary/O type/O I/O (/O AGT/O )/O is/O the/O most/O frequenty/O ./O
We/O report/O the/O case/O of/O a/O female/O infant/O of/O one/O month/O of/O age/O ,/O that/O on/O her/O first/O day/O post/O birth/O ,/O presented/O myoclonic/O convulsions/O and/O tonic/O spasms/O ,/O both/O during/O wakefullness/O and/O sleep/O periods/O ,/O that/O became/O more/O frequent/O and/O did/O not/O respond/O to/O the/O use/O of/O anticonvulsants/O ./O
The/O ictal/O Electroencephalogram/O presented/O an/O intermittent/O activity/O of/O spikes/O and/O spike/O -/O waves/O of/O high/O voltage/O in/O the/O right/O hemisphere/O ./O
Eight/O minutes/O after/O the/O intravenous/O administration/O of/O 150/O mg/O of/O pyridoxine/O ,/O it/O was/O observed/O a/O diminution/O of/O the/O epileptic/O activity/O ,/O as/O well/O as/O the/O clinical/O manifestations/O ./O
The/O determination/O of/O organic/O acids/O in/O urine/O revealed/O an/O increase/O in/O the/O concentration/O levels/O of/O oxalic/O acid/O (/O 3064/O mmol/O //O mol/O of/O creatinine/O )/O ./O
The/O molecular/O genetic/O study/O of/O the/O AGXT/O gene/O ,/O showed/O the/O existence/O of/O a/O R197Q/O mutation/O in/O exón/O 5/O of/O the/O patient/O and/O her/O father/O ./O
She/O received/O treatment/O with/O pyridoxine/O at/O a/O dose/O of/O 50/O mg/O //O day/O ./O
When/O she/O reached/O the/O age/O of/O three/O months/O both/O a/O normal/O electroencephalogram/O and/O biochemistry/O were/O obtained/O ./O
Although/O it/O is/O a/O rare/O cause/O of/O neonatal/O convulsions/O ,/O hyperoxaluria/O ,/O due/O to/O new/O mutations/O is/O an/O underdiagnosed/O disease/O by/O neonatologists/O and/O paediatricias/O ./O
Identification/O of/O the/O CLCN7/B-Gene gene/O mutations/B-Var in/O two/O Chinese/O families/O with/B-Reg autosomal/B-Disease dominant/I-Disease osteopetrosis/I-Disease (/I-Disease type/I-Disease II/I-Disease )/I-Disease ./O
Here/O we/O report/O the/O identification/O of/O two/O different/O mutations/O in/O chloride/O channel/O 7/O gene/O in/O two/O unrelated/O patients/O with/O autosomal/O dominant/O osteopetrosis/O type/O II/O ./O
We/O determined/O that/O one/O patient/O (/O a/O 32-year/O -/O old/O woman/O )/O carried/O a/O heterozygous/O gene/O for/O a/O R767W/O mutation/O in/O exon/O 24/O ,/O and/O another/O patient/O (/O a/O 17-year/O -/O old/O boy/O )/O carried/O a/O heterozygous/O gene/O for/O a/O novel/O frameshift/O mutation/O (/O Glu798FS/O )/O in/O exon/O 25/O ./O
Recent/O studies/O have/O reported/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O the/O chloride/O channel/O 7/O (/B-Gene CLCN7/I-Gene )/I-Gene gene/O as/O a/O cause/O of/O autosomal/B-Disease dominant/I-Disease osteopetrosis/I-Disease type/I-Disease II/I-Disease (/I-Disease ADO/I-Disease -/I-Disease II/I-Disease )/I-Disease ./O
The/O identification/O of/O gene/O mutations/O in/O Chinese/O with/O ADO/O has/O not/O been/O reported/O previously/O ./O
In/O this/O study/O ,/O we/O identified/O mutations/O of/O the/O CLCN7/O gene/O in/O two/O unrelated/O Chinese/O families/O with/O ADO/O -/O II/O ./O
Two/O probands/O with/O ADO/O -/O II/O were/O diagnosed/O based/O on/O their/O bone/O characteristics/O on/O X/O -/O rays/O and/O their/O laboratory/O results/O ./O
All/O 25/O exons/O of/O the/O CLCN7/O gene/O ,/O including/O the/O exon/O -/O intron/O boundaries/O ,/O were/O sequenced/O ./O
We/O found/O in/O family/O 1/O that/O the/O proband/O (/O a/O 32-year/O -/O old/O woman/O )/O was/O heterozygous/O for/O a/O CLCN7/O mutation/O ./O
The/O nonsynonymous/O mutation/O consisted/O of/O a/O heterozygous/O C/O //O T/O transition/O at/O codon/O 2327/O in/O exon/O 24/O ,/O which/O resulted/O in/O an/O arginine/O (/O CGG)-to/O tryptophan/O (/O TGG/O )/O substitution/O at/O position/O 767/O (/O R767W/O )/O ./O
The/O same/O heterozygous/O mutation/O (/O C/O //O T/O )/O was/O determined/O in/O her/O father/O and/O son/O ,/O who/O were/O asymptomatic/O with/O normal/O skeleton/O radiography/O ./O
In/O family/O 2/O ,/O we/O found/O that/O the/O proband/O (/O a/O 17-year/O -/O old/O boy/O )/O carried/O a/O novel/O frameshift/O mutation/O (/O Glu798FS/O )/O resulting/O from/O a/O G/O insertion/O between/O codon/O 60/O and/O codon/O 61/O in/O exon/O 25/O ./O
The/O heterozygous/O -/G/O insertion/O is/O predicted/O to/O elongate/O the/O peptide/O of/O CLCN7/O by/O 120/O amino/O acids/O after/O position/O 797/O amino/O acids/O ./O
Similarly/O ,/O some/O individuals/O of/O this/O family/O carried/O the/O same/O heterozygous/O mutation/O ,/O but/O they/O are/O all/O asymptomatic/O ./O
Furthermore/O ,/O the/O R767W/O and/O Glu798FS/O mutations/O were/O not/O found/O in/O 100/O unrelated/O controls/O ./O
Our/O present/O findings/O suggest/O that/O the/O novel/O Glu798FS/B-Var mutation/O in/O exon/O 25/O and/O R767W/B-Var in/O exon/O 24/O in/O the/O CLCN7/B-Gene gene/O were/O responsible/B-Reg for/O ADO/B-Disease -/I-Disease II/I-Disease in/O these/O Chinese/O patients/O ./O
A/O case/O of/O factor/B-Disease XI/I-Disease deficiency/I-Disease caused/B-Reg by/I-Reg compound/O heterozygous/O F11/B-Gene gene/O mutation/B-Var ./O
Inherited/O factor/O XI/O (/O FXI/O )/O deficiency/O is/O a/O rare/O autosomal/O recessive/O bleeding/O disorder/O in/O most/O populations/O except/O for/O Ashkenazi/O Jews/O ./O
In/O this/O report/O ,/O a/O 25-year/O -/O old/O Chinese/O female/O FXI/O deficiency/O case/O has/O been/O studied/O ./O
Routine/O clotting/O tests/O showed/O significantly/O prolonged/O activated/O partial/O thromboplastin/O time/O (/O 69.5/O s/O ,/O control/O 35/O +/O /-/O 10/O s/O )/O while/O prothrombin/O time/O (/O 12.3/O s/O ,/O control/O 13/O +/O /-/O 3/O s)was/O normal/O ./O
FXI/O :/O C/O and/O FXI/O :/O Ag/O were/O 2.6/O %/O and/O 2.5/O %/O ,/O respectively/O ,/O indicating/O that/O this/O case/O was/O cross/O -/O reacting/O material/O negative/O ./O
The/O activities/O of/O other/O coagulation/O factors/O and/O liver/O function/O were/O in/O normal/O range/O ./O
The/O DNA/O sequence/O results/O of/O the/O 15/O exons/O and/O their/O boundaries/O of/O F11/O gene/O revealed/O a/O novel/O G3733C/O missense/O mutation/O in/O exon/O 2/O ,/O and/O a/O recurrent/O C16642/O T/O nonsense/O mutation/O in/O exon/O 8/O ./O
The/O G3733C/B-Var mutation/O caused/B-Reg G-1R/B-Var substitution/I-Var in/O FXI/B-Protein signal/I-Protein peptide/I-Protein ,/O which/O might/O impair/B-NegReg the/O protein/B-MPA 's/I-MPA secretion/I-MPA and/O introduced/B-PosReg a/O new/O BssSI/O enzyme/B-Enzyme digestion/B-MPA site/O ./O
The/O C16642/B-Var T/I-Var mutation/O led/B-Reg a/O premature/B-MPA stop/I-MPA codon/I-MPA at/O amino/O acid/O position/O 263(Q263Term/B-Var )/I-Var ./O
G-1R/B-Var and/O Q263Term/B-Var compound/O heterozygous/O mutations/O in/O F11/B-Gene gene/O were/O the/O cause/B-Reg of/O FXI/B-Disease deficiency/I-Disease for/O this/O proband/O ./O
G-1R/B-Var mutation/O was/O a/O novel/O F11/B-Gene gene/O mutation/O causing/B-Reg inherited/O FXI/B-Disease deficiency/I-Disease ./O
Accelerated/O inactivation/O of/O the/O L/O -/O type/O calcium/O current/O due/O to/O a/O mutation/O in/O CACNB2b/O underlies/O Brugada/O syndrome/O ./O
Recent/O studies/O have/O demonstrated/O an/O association/B-Reg between/O mutations/B-Var in/O CACNA1c/B-Gene or/O CACNB2b/B-Gene and/O Brugada/B-Disease syndrome/I-Disease (/O BrS/O )/O ./O
Previously/O described/O mutations/O all/O caused/O a/O loss/O of/O function/O secondary/O to/O a/O reduction/O of/O peak/O calcium/O current/O (/O I(Ca/O )/O )/O ./O
We/O describe/O a/O novel/O CACNB2b/B-Gene mutation/B-Var associated/O with/O BrS/O in/O which/O loss/O of/O function/O is/O caused/O by/O accelerated/O inactivation/B-NegReg of/O I(Ca/B-MPA )/I-MPA ./O
The/O proband/O ,/O a/O 32/O year/O old/O male/O ,/O displayed/O a/O Type/O I/O ST/O segment/O elevation/O in/O two/O right/O precordial/O ECG/O leads/O following/O a/O procainamide/O challenge/O ./O
EP/O study/O was/O positive/O with/O induction/O of/O polymorphic/O VT/O //O VF/O ./O
Interrogation/O of/O implanted/O ICD/O revealed/O brief/O episodes/O of/O very/O rapid/O ventricular/O tachycardia/O ./O
He/O was/O also/O diagnosed/O with/O vasovagal/O syncope/O ./O
Genomic/O DNA/O was/O isolated/O from/O lymphocytes/O ./O
All/O exons/O and/O intron/O borders/O of/O 15/O ion/O channel/O genes/O were/O amplified/O and/O sequenced/O ./O
The/O only/O mutation/O uncovered/O was/O a/O missense/O mutation/O (/O T11I/O )/O in/O CACNB2b/O ./O
We/O expressed/O WT/O or/O T11I/O CACNB2b/O in/O TSA201/O cells/O co/O -/O transfected/O with/O WT/O CACNA1c/O and/O CACNA2d/O ./O
Patch/O clamp/O analysis/O showed/O no/O significant/O difference/O between/O WT/O and/O T11I/O in/O peak/O I(Ca/O )/O density/O ,/O steady/O -/O state/O inactivation/O or/O recovery/O from/O inactivation/O ./O
However/O ,/O both/O fast/O and/O slow/O decays/O of/O I(Ca/O )/O were/O significantly/O faster/O in/O mutant/O channels/O between/O 0/O and/O +/O 20/O mV./O Action/O potential/O voltage/O clamp/O experiments/O showed/O that/O total/O charge/O was/O reduced/O by/O almost/O half/O compared/O to/O WT/O ./O
We/O report/O the/O first/O BrS/O mutation/O in/O CaCNB2b/O resulting/O in/O accelerated/O inactivation/O of/O L/O -/O type/O calcium/O channel/O current/O ./O
Our/O results/O suggest/O that/O the/O faster/O current/O decay/O results/O in/O a/O loss/O -/O of/O -/O function/O responsible/O for/O the/O Brugada/O phenotype/O Electrophysiological/O studies/O in/O a/O mouse/O model/O of/O Schwartz/O -/O Jampel/O syndrome/O demonstrate/O muscle/O fiber/O hyperactivity/O of/O peripheral/O nerve/O origin/O ./O
Schwartz/B-Disease -/I-Disease Jampel/I-Disease syndrome/I-Disease (/O SJS/O )/O is/O an/O autosomal/O -/O recessive/O condition/O characterized/O by/O muscle/O stiffness/O and/O chondrodysplasia/O ./O
It/O is/O due/O to/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg hypomorphic/O mutations/B-Var in/O the/O HSPG2/B-Gene gene/O that/O encodes/O for/O perlecan/O ,/O a/O proteoglycan/O secreted/O into/O the/O basement/O membrane/O ./O
The/O origin/O of/O muscle/O stiffness/O in/O SJS/O is/O debated/O ./O
To/O resolve/O this/O issue/O ,/O we/O performed/O an/O electrophysiological/O investigation/O of/O an/O SJS/O mouse/O model/O with/O a/O missense/O mutation/O in/O the/O HSPG2/O gene/O ./O
Compound/O muscle/O action/O potential/O amplitudes/O ,/O distal/O motor/O latencies/O ,/O repetitive/O nerve/O stimulation/O tests/O ,/O and/O sensory/O nerve/O conduction/O velocities/O of/O SJS/O mice/O were/O normal/O ./O
On/O electromyography/O (/O EMG/O )/O ,/O neuromyotonic/O discharges/O ,/O that/O is/O ,/O bursts/O of/O motor/O unit/O action/O potentials/O firing/O at/O high/O rates/O (/O 120/O -/O 300/O HZ/O )/O ,/O were/O constantly/O observed/O in/O SJS/O mice/O in/O all/O muscles/O ,/O except/O in/O the/O diaphragm/O ./O
Neuromyotonic/O discharges/O were/O not/O influenced/O by/O general/O anesthesia/O and/O disappeared/O with/O curare/O administration/O ./O
They/O persisted/O after/O complete/O motor/O nerve/O section/O ,/O terminating/O only/O with/O Wallerian/O degeneration/O ./O
These/O results/O demonstrate/O that/O perlecan/O deficiency/O in/O SJS/O provokes/O a/O neuromyotonic/O syndrome/O ./O
The/O findings/O further/O suggest/O a/O distal/O axonal/O localization/O of/O the/O generator/O of/O neuromyotonic/O discharges/O ./O
SJS/O should/O now/O be/O considered/O as/O an/O inherited/O disorder/O with/O peripheral/O nerve/O hyperexcitability/O ./O
MEFV/B-Gene mutation/B-Var carriage/O in/O Israeli/O Jewish/O individuals/O from/O ethnicities/O with/O low/O risk/O for/B-Reg familial/B-Disease Mediterranean/I-Disease fever/I-Disease ./O
Familial/B-Disease Mediterranean/I-Disease fever/I-Disease (/O FMF/O )/O is/O a/O disease/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O MEditerranean/O FeVer/O gene/O (/B-Gene MEFV/I-Gene )/I-Gene ,/O and/O in/O Israel/O it/O most/O commonly/O affects/O Jews/O of/O North/O African/O extraction/O ,/O in/O whom/O the/O mutation/O carrier/O rate/O is/O as/O high/O as/O 1/O in/O 5/O ./O
To/O assess/O the/O protective/O as/O well/O as/O the/O modulating/O affect/O of/O MEFV/O mutation/O carriage/O on/O various/O inflammatory/O disease/O states/O ,/O we/O sought/O to/O define/O the/O frequency/O of/O MEFV/O mutations/O in/O Israeli/O Jewish/O individuals/O of/O various/O ethnicities/O ,/O including/O those/O with/O low/O frequency/O of/O FMF/O ,/O which/O were/O not/O in/O the/O focus/O of/O our/O attention/O hitherto/O ./O
A/O total/O of/O 163/O adults/O of/O Bucharian/O ,/O Turkish/O ,/O Georgian/O ,/O Yemenite/O and/O Bulgarian/O origin/O comprised/O the/O study/O group/O ./O
The/O prevalence/O of/O the/O most/O frequent/O MEFV/O mutations/O in/O the/O Israeli/O Jewish/O population/O ,/O namely/O :/O M694V/O ,/O V726A/O and/O E148Q/O ,/O was/O assessed/O ./O
The/O association/O of/O mutation/O carriage/O with/O a/O personal/O history/O of/O FMF/O -/O like/O phenomena/O ,/O as/O well/O as/O various/O inflammatory/O and/O non/O -/O inflammatory/O diseases/O ,/O was/O evaluated/O ./O
A/O high/O MEFV/O mutation/O frequency/O was/O found/O among/O Jews/O of/O Bucharian/O ,/O Georgian/O and/O Bulgarian/O origin/O (/O 20/O %/O )/O ,/O whereas/O intermediate/O and/O low/O rates/O were/O detected/O in/O Jews/O of/O Turkish/O and/O Yemenite/O extraction/O (/O 14/O and/O 8/O %/O ,/O respectively/O )/O ./O
FMF/O -/O like/O manifestations/O and/O related/O diseases/O were/O observed/O more/O often/O in/O MEFV/O mutation/O carriers/O than/O in/O their/O counterparts/O ./O
MEFV/O mutation/O frequency/O ,/O directly/O assessed/O by/O DNA/O analysis/O ,/O exceeds/O the/O rate/O calculated/O from/O disease/O prevalence/O in/O Israeli/O Jewish/O individuals/O originated/O from/O ethnicities/O with/O a/O low/O prevalence/O of/O FMF/O ./O
MEFV/O mutation/O carriage/O in/O this/O subgroup/O is/O associated/O with/O various/O inflammatory/O disorders/O ./O
In/O vivo/O laser/O confocal/O microscopy/O findings/O and/O mutational/O analysis/O for/O Schnyder/O 's/O crystalline/O corneal/O dystrophy/O ./O
OBJECTIVE/O :/O To/O identify/O any/O mutation/O of/O the/O UbiA/O prenyltransferase/O domain/O -/O containing/O protein/O 1/O (/O UBIAD1/O )/O gene/O in/O Japanese/O patients/O with/O Schnyder/B-Disease 's/I-Disease crystalline/I-Disease corneal/I-Disease dystrophy/I-Disease (/O SCCD/O )/O and/O to/O investigate/O in/O vivo/O microstructural/O phenotype/O and/O genotype/O correlations/O using/O laser/O scanning/O confocal/O microscopy/O (/O Heidelberg/O Retina/O Tomograph/O 2/O Rostock/O Cornea/O Module/O ;/O Heidelberg/O Engineering/O GmbH/O ,/O Dossenheim/O ,/O Germany/O )/O ./O
DESIGN/O :/O Small/O ,/O comparative/O case/O series/O ./O
PARTICIPANTS/O :/O Three/O patients/O from/O 3/O pedigrees/O (/O 3/O males/O )/O with/O clinically/O diagnosed/O SCCD/O and/O their/O relatives/O (/O 2/O males/O ,/O 1/O female/O )/O participated/O in/O this/O study/O ./O
TESTING/O :/O All/O participants/O were/O examined/O genetically/O and/O by/O slit/O -/O lamp/O biomicroscopy/O and/O in/O vivo/O laser/O confocal/O microscopy/O ./O
MAIN/O OUTCOME/O MEASURES/O :/O Genomic/O DNA/O from/O the/O patients/O and/O 100/O unrelated/O healthy/O volunteers/O (/O 200/O chromosomes/O )/O was/O isolated/O from/O blood/O samples/O and/O used/O for/O mutation/O screening/O of/O the/O UBIAD1/O gene/O ./O
Selected/O confocal/O images/O of/O corneal/O layers/O were/O evaluated/O qualitatively/O for/O shape/O and/O degree/O of/O light/O reflection/O of/O deposits/O ./O
RESULTS/O :/O Novel/O mutations/O in/O the/O UBIAD1/O gene/O (/O Y174C/O ,/O K181R/O ,/O and/O N233H/O )/O were/O identified/O ./O
Additionally/O ,/O cosegregation/O of/O the/O mutation/O (/B-Var Y174C/I-Var )/I-Var and/O SCCD/O was/O confirmed/O in/O 1/O pedigree/O ,/O indicating/O that/O the/O mutation/O of/O the/O UBIAD1/B-Gene gene/O is/O causative/B-Reg for/O SCCD/B-Disease ./O
The/O 3/O mutations/O were/O absent/O in/O all/O 200/O control/O chromosomes/O ./O
In/O vivo/O laser/O confocal/O microscopy/O demonstrated/O subepithelial/O highly/O reflective/O crystals/O in/O 4/O cases/O ;/O the/O shapes/O of/O the/O crystals/O were/O needle/O -/O shaped/O (/O 3/O cases/O )/O or/O rectangular/O (/O 1/O case/O )/O ./O
A/O phenotype/O and/O genotype/O correlation/O was/O demonstrated/O in/O 1/O pedigree/O ,/O and/O phenotypic/O heterogeneity/O (/O SCCD/O with/O or/O without/O crystals/O caused/O by/O a/O same/O mutation/O of/O Y174C/O in/O the/O UBIAD1/O gene/O )/O also/O was/O demonstrated/O in/O 1/O pedigree/O ./O
CONCLUSIONS/O :/O Nonsynonymous/O novel/O mutations/O in/O the/O UBIAD1/O gene/O were/O detected/O in/O 3/O unrelated/O Japanese/O pedigrees/O with/O SCCD/O ,/O confirming/O the/O genetic/O heterogeneity/O of/O this/O disorder/O ./O
In/O vivo/O laser/O confocal/O microscopy/O is/O capable/O of/O identifying/O characteristic/O corneal/O microstructural/O changes/O related/O to/O genetically/O mapped/O SCCD/O with/O high/O resolution/O ,/O and/O phenotypic/O heterogeneity/O was/O presented/O ./O
Further/O confocal/O and/O mutational/O analysis/O using/O a/O larger/O number/O of/O patients/O with/O SCCD/O is/O required/O to/O elucidate/O in/O vivo/O microstructural/O phenotype/O and/O genotype/O correlations/O ./O
FINANCIAL/O DISCLOSURE(S/O )/O :/O The/O author(s/O )/O have/O no/O proprietary/O or/O commercial/O interest/O in/O any/O materials/O discussed/O in/O this/O article/O ./O
Neutral/B-Disease lipid/I-Disease storage/I-Disease disease/I-Disease :/I-Disease genetic/O disorders/O caused/B-Reg by/I-Reg mutations/B-Var in/O adipose/B-Enzyme triglyceride/I-Enzyme lipase/B-Gene //I-Gene PNPLA2/I-Gene or/O CGI-58/B-Gene //I-Gene ABHD5/I-Gene ./O
Neutral/O lipid/O storage/O disease/O (/O NLSD/O )/O is/O a/O group/O of/O autosomal/O recessive/O disorders/O characterized/O by/O the/O excessive/O accumulation/O of/O neutral/O lipids/O in/O multiple/O tissues/O ./O
Recently/O ,/O two/O genes/O ,/O adipose/O triglyceride/O lipase/O (/O ATGL/O //O PNPLA2/O )/O and/O comparative/O gene/O identification-58/O (/O CGI-58/O //O ABHD5/O )/O ,/O have/O been/O shown/O to/O cause/O NLSD/O ./O
ATGL/O specifically/O hydrolyzes/O the/O first/O fatty/O acid/O from/O triacylglycerols/O (/O TG/O )/O and/O CGI-58/O //O ABHD5/O stimulates/O ATGL/O activity/O by/O a/O currently/O unknown/O mechanism/O ./O
Mutations/B-Var in/O both/O the/O ATGL/B-Gene and/O the/O CGI-58/B-Gene genes/O are/O associated/B-Reg with/I-Reg systemic/B-MPA TG/I-MPA accumulation/I-MPA ,/O yet/O the/O resulting/O clinical/O manifestations/O are/O not/O identical/O ./O
Patients/O with/O defective/O ATGL/O function/O suffer/O from/O more/O severe/O myopathy/O (/O NLSDM/O )/O than/O patients/O with/O defective/O CGI-58/O function/O ./O
On/O the/O other/O hand/O ,/O CGI-58/B-Gene mutations/B-Var are/O always/O associated/B-Reg with/I-Reg ichthyosis/O (/B-Disease NLSDI/I-Disease )/I-Disease ,/O which/O was/O not/O observed/O in/O patients/O with/O defective/O ATGL/O function/O ./O
These/O observations/O indicate/O an/O ATGL/O -/O independent/O function/O of/O CGI-58/O ./O
This/O review/O summarizes/O recent/O findings/O with/O the/O goal/O of/O relating/O structural/O variants/O of/O ATGL/O and/O CGI-58/O to/O functional/O consequences/O in/O lipid/O metabolism/O ./O
A/O heterozygous/B-Var null/I-Var mutation/I-Var combined/O with/O the/O G1258A/B-Var polymorphism/O of/O SPINK5/B-Gene causes/O impaired/B-NegReg LEKTI/B-MPA function/I-MPA and/O abnormal/B-MPA expression/I-MPA of/I-MPA skin/I-MPA barrier/I-MPA proteins/I-MPA ./O
BACKGROUND/O :/O Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O the/O Kazal/O -/O type/O serine/O protease/O inhibitor/O ,/O LEKTI/O ,/O encoded/O by/O the/O SPINK5/B-Gene gene/O cause/O the/O rare/O autosomal/O recessive/O skin/O disease/O Netherton/B-Disease syndrome/I-Disease (/O NS/O )/O ./O
G1258A/O polymorphism/O in/O SPINK5/O may/O be/O associated/O with/O atopic/O dermatitis/O ,/O which/O shares/O several/O clinical/O features/O with/O NS/O ./O
OBJECTIVES/O :/O To/O determine/O if/O the/O phenotype/O of/O NS/O can/O be/O caused/O by/O a/O single/O null/O mutation/O in/O SPINK5/O combined/O with/O the/O homozygous/O G1258A/O polymorphism/O ./O
METHODS/O :/O We/O screened/O mutations/O in/O the/O gene/O SPINK5/O by/O direct/O DNA/O sequencing/O and/O position/O cloning/O and/O examined/O the/O expressions/O of/O the/O SPINK5-encoded/O protein/O LEKTI/O and/O other/O relevant/O proteins/O by/O immunostaining/O and/O immunoblot/O ./O
RESULTS/O :/O We/O describe/O here/O a/O patient/O who/O was/O clinically/O diagnosed/O with/O NS/O and/O carried/O a/O single/O null/O mutation/O in/O SPINK5/O combined/O with/O the/O homozygous/O G1258A/O polymorphism/O ./O
SPINK5/O mRNA/O was/O present/O at/O normal/O levels/O and/O LEKTI/O was/O expressed/O in/O the/O epidermis/O ./O
Nonetheless/O ,/O the/O putative/O downstream/O LEKTI/O substrates/O stratum/O corneum/O trypsin/O -/O like/O enzyme/O (/O SCTE/O )/O ,/O desmoglein/O 1/O and/O protein/O markers/O of/O keratinocyte/O differentiation/O were/O expressed/O abnormally/O ,/O similar/O to/O that/O seen/O in/O NS/O if/O two/O null/O mutant/O alleles/O are/O present/O ./O
CONCLUSION/O :/O This/O finding/O indicates/O that/O haploinsufficiency/O of/O SPINK5/O can/O cause/O the/O NS/O phenotype/O in/O the/O presence/O of/O one/O null/O mutation/O with/O homozygous/O G1258A/O polymorphisms/O in/O SPINK5/O ,/O and/O this/O could/O impair/O the/O function/O of/O LEKTI/O and/O therefore/O acts/O as/O a/O true/O mutation/O ./O
MEFV/B-Gene mutations/B-Var in/O patients/O with/B-Reg Familial/B-Disease Mediterranean/I-Disease Fever/I-Disease from/O the/O Aegean/O region/O of/O Turkey/O ./O
Familial/B-Disease Mediterranean/I-Disease Fever/I-Disease (/O FMF/O )/O which/O is/O frequently/O present/O in/O Mediterranean/O populations/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O MEFV/B-Gene gene/O ./O
According/O to/O recent/O data/O ,/O MEFV/O mutations/O are/O not/O the/O only/O cause/O of/O FMF/O ,/O but/O these/O are/O major/O genetic/O determinants/O which/O cause/O FMF/O ./O
It/O has/O also/O been/O suggested/O that/O there/O may/O be/O a/O number/O of/O other/O genes/O causing/O FMF/O ./O
The/O MEFV/O gene/O is/O located/O at/O 16p13.3/O and/O encodes/O a/O protein/O ,/O pyrin/O //O marenostrin/O ./O
More/O than/O 70/O disease/O associated/O mutations/O and/O totally/O 186/O mutations/O and/O polymorphisms/O have/O been/O defined/O in/O affected/O individuals/O ./O
We/O have/O retrospectively/O evaluated/O the/O molecular/O test/O results/O of/O 1,201/O patients/O identified/O as/O having/O FMF/O clinical/O symptoms/O referred/O to/O the/O Molecular/O Genetics/O Laboratory/O of/O the/O Department/O of/O Medical/O Genetics/O ,/O Faculty/O of/O Medicine/O ,/O Ege/O University/O ,/O Izmir/O //O Turkey/O over/O the/O last/O 4/O years/O ./O
Patients/O were/O tested/O for/O 12/O common/O mutations/O in/O the/O MEFV/O gene/O using/O a/O strip/O assay/O method/O (/O Innogenetics/O ,/O Belgium/O )/O ./O
Out/O of/O the/O 1,201/O patients/O tested/O (/O 2,402/O chromosomes/O )/O in/O the/O Aegean/O region/O in/O Turkey/O ,/O 654/O (/O 54.45/O %/O )/O did/O not/O carry/O any/O mutations/O ,/O among/O the/O 547/O (/O 45.55/O %/O )/O patients/O with/O mutations/O 246/O patients/O were/O either/O homozygous/O (/O 101/O )/O or/O compound/O heterozygous/O (/O 145/O )/O ,/O 296/O carried/O only/O one/O detected/O mutation/O ,/O and/O five/O patients/O had/O three/O mutations/O ./O
Allelic/O frequencies/O for/O the/O four/O most/O common/O mutations/O in/O the/O mutation/O positive/O groups/O were/O 47.60/O %/O (/O M694V/O )/O ,/O 16.75/O %/O (/O E148Q/O )/O ,/O 12.95/O %/O (/O V726A/O )/O ,/O 11.94/O %/O (/O M680I/O G/O //O C).The/O remaining/O alleles/O (/O 10.76/O %/O )/O showed/O rare/O mutations/O which/O were/O R761H/O ,/O P369S/O ,/O A744S/O ,/O K695R/O ,/O F479L/O ,/O M694I./O When/O the/O frequencies/O of/O mutations/O detected/O in/O our/O group/O were/O compared/O to/O the/O frequencies/O reported/O in/O the/O other/O regions/O of/O Turkey/O ,/O an/O increase/O in/O V726A/O mutation/O frequency/O was/O observed/O ./O
No/O patient/O showed/O a/O I692del/O mutation/O which/O is/O sometimes/O evident/O in/O other/O Mediterranean/O populations/O ./O
Factor/B-Protein VIII/I-Protein mutations/B-Var in/B-Reg 42/O Moldovan/O haemophilia/B-Disease A/I-Disease families/O ,/O including/O 12/O that/O are/O novel/O ./O
Haemophilia/B-Disease A/I-Disease (/O HA/O )/O is/O a/O bleeding/O disorder/O caused/B-Reg by/I-Reg mutations/B-Var within/O the/O X/O -/O linked/O F8/B-Gene gene/O ./O
A/O series/O of/O 42/O unrelated/O Moldovan/O patients/O with/O HA/O had/O their/O disease/O -/O causative/O mutation/O determined/O to/O provide/O clinically/O valuable/O genotyping/O information/O for/O a/O historically/O underserved/O population/O and/O to/O utilize/O factor/O VIII/O (/O FVIII/O )/O structural/O information/O to/O analyse/O the/O effects/O of/O haemophilic/O missense/O substitutions/O ./O
DNA/O samples/O were/O analysed/O to/O detect/O intron/O 22/O and/O intron/O 1/O inversions/O followed/O by/O heteroduplex/O analysis/O of/O PCR/O -/O amplified/O fragments/O containing/O all/O exonic/O sequences/O ./O
Missense/O sites/O identified/O by/O DNA/O sequencing/O were/O visualized/O in/O the/O recently/O described/O crystal/O structures/O of/O human/O FVIII/O ./O
Of/O the/O 26/O different/O point/O mutations/O ,/O 12/O were/O novel/O ./O
Gel/O electrophoresis/O identified/O samples/O with/O a/O second/O major/O DNA/O band/O that/O migrated/O abnormally/O ;/O these/O amplified/O products/O were/O sequenced/O ./O
Thirteen/O intron/O 22/O inversions/O and/O one/O intron/O 1/O inversion/O were/O found/O ./O
Two/O patients/O had/O large/O ,/O partial/O gene/O deletions/O and/O there/O were/O six/O frameshift/O ,/O two/O non/O -/O sense/O ,/O two/O splicing/O and/O 16/O missense/O genotypes/O ./O
Two/O subjects/O with/O an/O intron/O 22/O inversion/O and/O one/O with/O a/O large/O ,/O partial/O gene/O deletion/O developed/O an/O alloimmune/O inhibitor/O ./O
Their/O localization/O suggests/O intra-/O and/O possibly/O inter/O -/O molecular/O interactions/O that/O are/O important/O for/O the/O structural/O integrity/O and/or/O procoagulant/O function/O of/O FVIII/O ./O
Investigation/O of/O C5a/O receptor/O gene/O 450/O C/O //O T/O polymorphism/O in/O Turkish/O patients/O with/O familial/O Mediterranean/O fever/O ./O
Familial/B-Disease Mediterranean/I-Disease fever/I-Disease (/O FMF/O )/O is/O a/O genetic/O disorder/O with/O acute/O inflammatory/O serosal/O attacks/O due/B-Reg to/I-Reg MEFV/B-Gene gene/O mutations/B-Var which/O resides/O in/O chromosome/O 16/O ./O
Lack/O of/O a/O C5a/O inhibitor/O activity/O in/O the/O peritoneum/O has/O previously/O been/O proposed/O in/O part/O to/O contribute/O in/O propagation/O of/O the/O serosal/O inflammation/O in/O FMF/O attacks/O ./O
The/O aim/O of/O this/O study/O is/O to/O investigate/O C5a/O receptor/O (/O C5aR/O )/O gene/O polymorphism/O in/O patients/O with/O FMF/O and/O its/O relation/O to/O the/O main/O features/O of/O the/O disease/O ./O
A/O polymorphism/O in/O the/O coding/O region/O of/O C5aR/O gene/O leading/O to/O C/O to/O T/O transition/O at/O nucleotide/O position/O 450/O has/O been/O investigated/O in/O 85/O non/O -/O related/O Turkish/O FMF/O patients/O and/O 160/O non/O -/O related/O healthy/O controls/O by/O using/O PCR/O -/O RFLP/O ./O
The/O frequencies/O of/O C5aR/O gene/O 450/O CT/O genotype/O and/O T/O allele/O were/O not/O significantly/O different/O between/O Turkish/O FMF/O patients/O and/O healthy/O subjects/O (/O 14.12/O and/O 8.24/O %/O for/O FMF/O vs./O 10/O and/O 5/O %/O for/O controls/O ,/O respectively/O )/O ./O
C5aR/O gene/O 450/O CT/O genotype/O tended/O to/O associate/O with/O the/O presence/O Henoch/O -/O Schonlein/O purpura/O (/O OR/O :/O 1.25/O ,/O 95/O %/O CI/O :/O 0.917/O -/O 1.704/O ,/O P/O =/O 0.017/O )/O but/O with/O no/O other/O clinical/O findings/O of/O the/O disease/O ./O
C5aR/O polymorphism/O might/O be/O searched/O in/O populations/O having/O high/O prevalence/O of/O FMF/O ./O
Expression/O of/O the/O familial/O Mediterranean/O fever/O gene/O is/O regulated/O by/O nonsense/O -/O mediated/O decay/O ./O
Mutations/B-Var in/O the/O MEditerranean/O FeVer/O (/B-Gene MEFV/I-Gene )/I-Gene gene/O are/O responsible/B-Reg for/O familial/B-Disease Mediterranean/I-Disease fever/I-Disease (/O FMF/O )/O ,/O a/O recessively/O inherited/O auto/O -/O inflammatory/O disease/O ./O
Cases/O of/O dominant/O inheritance/O and/O phenotype/O -/O genotype/O heterogeneity/O have/O been/O reported/O ;/O however/O ,/O the/O underlying/O molecular/O mechanism/O is/O not/O currently/O understood/O ./O
The/O FMF/O protein/O named/O pyrin/O or/O marenostrin/O (/O P/O //O M/O )/O is/O thought/O to/O be/O involved/O in/O regulating/O innate/O immunity/O but/O its/O function/O remains/O subject/O to/O controversy/O ./O
Recent/O studies/O postulate/O that/O a/O defect/O in/O MEFV/O expression/O regulation/O may/O play/O a/O role/O in/O FMF/O physiopathology/O ./O
Our/O group/O ,/O along/O with/O others/O ,/O has/O identified/O several/O alternatively/O spliced/O MEFV/O transcripts/O in/O leukocytes/O ./O
Since/O alternative/O splicing/O and/O nonsense/O -/O mediated/O decay/O (/O NMD/O )/O pathways/O are/O usually/O coupled/O in/O the/O post/O -/O transcriptional/O regulation/O of/O gene/O expression/O ,/O we/O hypothesized/O that/O NMD/O could/O contribute/O to/O the/O regulation/O of/O the/O MEFV/O gene/O ./O
To/O address/O this/O issue/O ,/O we/O examined/O the/O effect/O of/O indirect/O and/O direct/O inhibition/O of/O NMD/O on/O expression/O of/O the/O MEFV/O transcripts/O in/O THP1/O ,/O monocyte/O and/O neutrophil/O cells/O ./O
We/O showed/O that/O MEFV/O is/O the/O first/O auto/O -/O inflammatory/O gene/O regulated/O by/O NMD/O in/O both/O a/O cell-/O and/O transcript/O -/O specific/O manner/O ./O
These/O results/O and/O preliminary/O western/O -/O blot/O analyses/O suggest/O the/O possible/O translation/O of/O alternatively/O spliced/O MEFV/O transcripts/O into/O several/O P/O //O M/O variants/O according/O to/O cell/O type/O and/O inflammatory/O state/O ./O
Our/O results/O introduce/O the/O novel/O hypothesis/O that/O variation/O of/O NMD/O efficiency/O could/O play/O an/O important/O role/O in/O FMF/O physiopathology/O as/O a/O potent/O phenotypic/O modifier/O ./O
Novel/O PORCN/B-Gene mutations/B-Var in/B-Reg focal/B-Disease dermal/I-Disease hypoplasia/I-Disease ./O
Focal/O dermal/O hypoplasia/O (/O FDH/O )/O ,/O Goltz/O or/O Goltz/O -/O Gorlin/O syndrome/O ,/O is/O an/O X/O -/O linked/O dominant/O multisystem/O disorder/O characterized/O primarily/O by/O involvement/O of/O the/O skin/O ,/O skeletal/O system/O and/O eyes/O ./O
We/O screened/O for/O mutations/B-Var in/O the/O PORCN/B-Gene gene/O in/B-Reg eight/O patients/O of/O Belgian/O and/O Finnish/O origin/O with/O firm/O clinical/O suspicion/O of/O FDH/B-Disease ./O
First/O ,/O we/O performed/O quantitative/O PCR/O (/O qPCR/O )/O analysis/O to/O define/O the/O copy/O number/O at/O this/O locus/O ./O
Next/O ,/O we/O sequenced/O the/O coding/O regions/O and/O flanking/O intronic/O sequences/O of/O the/O PORCN/O gene/O ./O
Three/O de/O novo/O mutations/O were/O identified/O in/O our/O patients/O with/O FDH/O :/O a/O 150-kb/O deletion/O removing/O six/O genes/O including/O PORCN/O ,/O as/O defined/O by/O qPCR/O and/O X/O -/O array/O -/O CGH/O ,/O and/O two/O heterozygous/O missense/O mutations/O ;/O c.992T/O >/O G/O (/O p/O ./O L331R/O )/O in/O exon/O 11/O and/O c.1094G/O >/O A/O (/O p/O ./O R365Q/O )/O in/O exon/O 13/O of/O the/O gene/O ./O
Both/O point/O mutations/O changed/O highly/O conserved/O amino/O acids/O and/O were/O not/O found/O in/O 300/O control/O X/O chromosomes/O ./O
The/O three/O patients/O in/O whom/O mutations/O were/O identified/O all/O present/O with/O characteristic/O dermal/O findings/O together/O with/O limb/O manifestations/O ,/O which/O were/O not/O seen/O in/O our/O mutation/O -/O negative/O patients/O ./O
The/O clinical/O characteristics/O of/O our/O patients/O with/O PORCN/O mutations/O were/O compared/O with/O the/O previously/O reported/O mutation/O -/O positive/O cases/O ./O
In/O this/O report/O ,/O we/O summarize/O the/O literature/O on/O PORCN/O mutations/O and/O associated/O phenotypes/O ./O
Longitudinal/O course/O of/O cognitive/O ,/O adaptive/O ,/O and/O behavioral/O characteristics/O in/O Costello/O syndrome/O ./O
Costello/B-Disease syndrome/I-Disease is/O a/O rare/O rasopathy/O caused/B-Reg by/I-Reg germline/O mutations/B-Var in/O the/O oncogene/O HRAS/B-Gene resulting/O in/O increased/B-PosReg signal/B-MPA transduction/I-MPA through/O the/O Ras/B-Pathway //I-Pathway mitogen/I-Pathway -/I-Pathway activated/I-Pathway protein/I-Pathway kinase/I-Pathway pathway/I-Pathway ./O
In/O contrast/O to/O the/O more/O common/O rasopathies/O ,/O such/O as/O neurofibromatosis/O type/O 1/O and/O Noonan/O syndrome/O ,/O limited/O information/O is/O available/O on/O standardized/O cognitive/O testing/O in/O this/O cohort/O ./O
Past/O research/O indicated/O a/O mean/O average/O IQ/O in/O the/O mild/O mental/O retardation/O range/O ,/O with/O strengths/O in/O fluid/O reasoning/O (/O FR/O )/O and/O weakness/O in/O expressive/O language/O ,/O as/O well/O as/O static/O skills/O over/O time/O ./O
Here/O we/O report/O on/O standardized/O IQ/O and/O adaptive/O functioning/O in/O 18/O individuals/O with/O Costello/O syndrome/O ,/O nine/O males/O and/O nine/O females/O ,/O and/O longitudinal/O development/O for/O 11/O who/O had/O previous/O testing/O ./O
The/O overall/O IQ/O ,/O ranging/O from/O severe/O mental/O retardation/O to/O the/O average/O range/O ,/O with/O a/O mean/O in/O the/O mildly/O mentally/O retarded/O range/O ,/O was/O again/O found/O to/O be/O stable/O ,/O but/O an/O interesting/O pattern/O in/O the/O development/O of/O nonverbal/O FR/O was/O identified/O ./O
Participants/O showed/O an/O improvement/O in/O nonverbal/O FR/O ,/O followed/O by/O stable/O skills/O thereafter/O ,/O suggesting/O a/O "/O late/O bloomer/O "/O effect/O in/O late/O childhood/O //O early/O adolescence/O ./O
Overall/O adaptive/O functioning/O fell/O into/O the/O range/O of/O Intellectual/O Disability/O for/O 70/O %/O of/O subjects/O ,/O with/O Socialization/O as/O a/O relative/O strength/O and/O Daily/O Living/O Skills/O an/O area/O of/O relative/O difficulty/O ./O
Interestingly/O ,/O females/O were/O found/O to/O be/O higher/O functioning/O than/O males/O in/O all/O domains/O ,/O including/O Communication/O ,/O Daily/O Living/O Skills/O and/O Socialization/O ./O
Caregivers/O reported/O significantly/O more/O behavioral/O concerns/O in/O males/O ,/O including/O internalizing/O ,/O externalizing/O ,/O and/O other/O maladaptive/O behaviors/O ./O
In/O contrast/O ,/O no/O gender/O differences/O were/O found/O in/O cognitive/O or/O visuomotor/O functioning/O ./O
Molecular/O analysis/O of/O 42/O patients/O with/B-Reg congenital/B-Disease dyserythropoietic/I-Disease anemia/I-Disease type/I-Disease II/I-Disease :/I-Disease new/O mutations/B-Var in/O the/O SEC23B/B-Gene gene/O and/O a/O search/O for/O a/O genotype/O -/O phenotype/O relationship/O ./O
BACKGROUND/O :/O The/O most/O frequent/O form/O of/O congenital/O dyserythropoietic/O anemia/O is/O the/O type/O II/O form/O ./O
Recently/O it/O was/O shown/O that/O the/O vast/O majority/O of/O patients/O with/O congenital/B-Disease dyserythropoietic/I-Disease anemia/I-Disease type/I-Disease II/I-Disease carry/B-Reg mutations/B-Var in/O the/O SEC23B/B-Gene gene/O ./O
Here/O we/O established/O the/O molecular/O basis/O of/O 42/O cases/O of/O congenital/O dyserythropoietic/O anemia/O type/O II/O and/O attempted/O to/O define/O a/O genotype/O -/O phenotype/O relationship/O ./O
DESIGN/O AND/O METHODS/O :/O SEC23B/O gene/O sequencing/O analysis/O was/O performed/O to/O assess/O the/O diversity/O and/O incidence/O of/O each/O mutation/O in/O 42/O patients/O with/O congenital/O dyserythropoietic/O anemia/O type/O II/O (/O 25/O described/O exclusively/O in/O this/O work/O )/O ,/O from/O the/O Italian/O and/O the/O French/O Registries/O ,/O and/O the/O relationship/O of/O these/O mutations/O with/O the/O clinical/O presentation/O ./O
To/O this/O purpose/O ,/O we/O divided/O the/O patients/O into/O two/O groups/O :/O (/O i/O )/O patients/O with/O two/O missense/O mutations/O and/O (/O ii/O )/O patients/O with/O one/O nonsense/O and/O one/O missense/O mutation/O ./O
RESULTS/O :/O We/O found/O 22/O mutations/O of/O uneven/O frequency/O ,/O including/O seven/O novel/O mutations/O ./O
Compound/O heterozygosity/O for/O a/O missense/O and/O a/O nonsense/O mutation/O tended/O to/O produce/O a/O more/O severe/O clinical/O presentation/O ,/O a/O lower/O reticulocyte/O count/O ,/O a/O higher/O serum/O ferritin/O level/O ,/O and/O ,/O in/O some/O cases/O ,/O more/O pronounced/O transfusion/O needs/O ,/O than/O homozygosity/O or/O compound/O heterozygosity/O for/O two/O missense/O mutations/O ./O
Homozygosity/O or/O compound/O heterozygosity/O for/O two/O nonsense/O mutations/O was/O never/O found/O ./O
CONCLUSIONS/O :/O This/O study/O allowed/O us/O to/O determine/O the/O most/O frequent/O mutations/O in/O patients/O with/O congenital/O dyserythropoietic/O anemia/O type/O II/O ./O
Correlations/O between/O the/O mutations/O and/O various/O biological/O parameters/O suggested/O that/O the/O association/O of/O one/O missense/O mutation/O and/O one/O nonsense/O mutation/O was/O significantly/O more/O deleterious/O that/O the/O association/O of/O two/O missense/O mutations/O ./O
However/O ,/O there/O was/O an/O overlap/O between/O the/O two/O categories/O ./O
Identification/O and/O characterization/O of/O novel/O sequence/O variations/O in/O MECP2/O gene/O in/O Rett/O syndrome/O patients/O ./O
Rett/B-Disease syndrome/I-Disease (/O RS/O )/O is/O a/O neurodevelopmental/O disorder/O caused/B-Reg by/I-Reg mutations/B-Var in/O MECP2/B-Gene gene/O ./O
Exons/O 2/O ,/O 3/O ,/O and/O 4/O ,/O in/O addition/O to/O intronic/O and/O 3'UTR/O adjacent/O regions/O ,/O were/O sequenced/O in/O 80/O patients/O with/O RS/O ./O
Twenty/O -/O nine/O sequence/O variations/O were/O detected/O in/O 49/O patients/O ,/O 34/O (/O 69.4/O %/O )/O patients/O with/O the/O classic/O form/O of/O RS/O ,/O and/O 15/O (/O 30.6/O %/O )/O patients/O with/O atypical/O forms/O of/O RS/O ./O
Thirteen/O of/O the/O 29/O detected/O mutations/O represent/O novel/O sequence/O variations/O ./O
Missense/O mutation/O T158/O M/O was/O the/O most/O commonly/O observed/O mutation/O ,/O detected/O in/O nine/O patients/O (/O 11.2/O %/O )/O ./O
Six/O hotspot/O pathogenic/O mutations/O (/O R133C/O ,/O T158/O M/O ,/O R168X/O ,/O R255X/O ,/O R270X/O ,/O and/O R294X/O )/O were/O responsible/O for/O the/O phenotype/O in/O 26/80/O patients/O (/O 32.5/O %/O )/O ./O
Ribosomal/O protein/O genes/O RPS10/B-Gene and/O RPS26/B-Gene are/O commonly/O mutated/B-Var in/B-Reg Diamond/B-Disease -/I-Disease Blackfan/I-Disease anemia/I-Disease ./O
Diamond/O -/O Blackfan/O anemia/O (/O DBA/O )/O ,/O an/O inherited/O bone/O marrow/O failure/O syndrome/O characterized/O by/O anemia/O that/O usually/O presents/O before/O the/O first/O birthday/O or/O in/O early/O childhood/O ,/O is/O associated/O with/O birth/O defects/O and/O an/O increased/O risk/O of/O cancer/O ./O
Although/O anemia/O is/O the/O most/O prominent/O feature/O of/O DBA/O ,/O the/O disease/O is/O also/O characterized/O by/O growth/O retardation/O and/O congenital/O malformations/O ,/O in/O particular/O craniofacial/O ,/O upper/O limb/O ,/O heart/O ,/O and/O urinary/O system/O defects/O that/O are/O present/O in/O approximately/O 30%-50/O %/O of/O patients/O ./O
DBA/O has/O been/O associated/O with/O mutations/O in/O seven/O ribosomal/O protein/O (/O RP/O )/O genes/O ,/O RPS19/O ,/O RPS24/O ,/O RPS17/O ,/O RPL35A/O ,/O RPL5/O ,/O RPL11/O ,/O and/O RPS7/O ,/O in/O about/O 43/O %/O of/O patients/O ./O
To/O continue/O our/O large/O -/O scale/O screen/O of/O RP/O genes/O in/O a/O DBA/O population/O ,/O we/O sequenced/O 35/O ribosomal/O protein/O genes/O ,/O RPL15/O ,/O RPL24/O ,/O RPL29/O ,/O RPL32/O ,/O RPL34/O ,/O RPL9/O ,/O RPL37/O ,/O RPS14/O ,/O RPS23/O ,/O RPL10A/O ,/O RPS10/O ,/O RPS12/O ,/O RPS18/O ,/O RPL30/O ,/O RPS20/O ,/O RPL12/O ,/O RPL7A/O ,/O RPS6/O ,/O RPL27A/O ,/O RPLP2/O ,/O RPS25/O ,/O RPS3/O ,/O RPL41/O ,/O RPL6/O ,/O RPLP0/O ,/O RPS26/O ,/O RPL21/O ,/O RPL36AL/O ,/O RPS29/O ,/O RPL4/O ,/O RPLP1/O ,/O RPL13/O ,/O RPS15A/O ,/O RPS2/O ,/O and/O RPL38/O ,/O in/O our/O DBA/O patient/O cohort/O of/O 117/O probands/O ./O
We/O identified/O three/O distinct/O mutations/O of/O RPS10/O in/O five/O probands/O and/O nine/O distinct/O mutations/O of/O RPS26/O in/O 12/O probands/O ./O
Pre/O -/O rRNA/O analysis/O in/O lymphoblastoid/O cells/O from/O patients/O bearing/O mutations/B-Var in/O RPS10/B-Gene and/O RPS26/B-Gene showed/O elevated/B-PosReg levels/B-MPA of/I-MPA 18S/I-MPA -/I-MPA E/I-MPA pre/I-MPA -/I-MPA rRNA/I-MPA ./O
This/O accumulation/O is/O consistent/O with/O the/O phenotype/O observed/O in/O HeLa/O cells/O after/O knockdown/O of/O RPS10/O or/O RPS26/O expression/O with/O siRNAs/O ,/O which/O indicates/O that/O mutations/B-Var in/O the/O RPS10/B-Gene and/O RPS26/B-Gene genes/O in/O DBA/O patients/O affect/B-Reg the/O function/B-MPA of/I-MPA the/I-MPA proteins/I-MPA in/I-MPA rRNA/I-MPA processing/O ./O
Clinical/O and/O molecular/O aspects/O of/O aniridia/O ./O
Aniridia/O is/O a/O severe/O ,/O congenital/O ocular/O malformation/O inherited/O in/O an/O autosomal/O -/O dominant/O fashion/O with/O high/O penetrance/O and/O variable/O expression/O ./O
Eye/O morphogenesis/O in/O humans/O involves/O a/O molecular/O genetic/O cascade/O in/O which/O a/O number/O of/O developmental/O genes/O interact/O in/O a/O highly/O organized/O process/O during/O the/O embryonic/O period/O to/O produce/O functional/O ocular/O structures/O ./O
Among/O these/O genes/O ,/O paired/O box/O gene/O 6/O (/O PAX6/O )/O has/O an/O essential/O role/O as/O it/O encodes/O a/O phylogenetically/O conserved/O transcription/O factor/O almost/O universally/O employed/O for/O eye/O formation/O in/O animals/O with/O bilateral/O symmetry/O ,/O despite/O widely/O different/O embryological/O origins/O ./O
To/O direct/O eye/O development/O ,/O PAX6/O regulates/O the/O tissue/O -/O specific/O expression/O of/O diverse/O molecules/O ,/O hormones/O ,/O and/O structural/O proteins/O ./O
In/O humans/O ,/O PAX6/B-Gene is/O located/O in/O chromosome/O 11p13/O ,/O and/O its/O mutations/B-Var lead/B-Reg to/I-Reg a/O variety/O of/O hereditary/B-CPA ocular/I-CPA malformations/I-CPA of/O the/O anterior/O and/O posterior/O segment/O ,/O among/O which/O aniridia/O and/O most/O probably/O foveal/O hypoplasia/O are/O the/O major/O signs/O ./O
Aniridia/B-Disease occurs/O due/B-Reg to/I-Reg decreased/B-NegReg dosage/B-MPA of/O the/O PAX6/B-Gene gene/O and/O exists/O in/O both/O sporadic/O and/O familial/O forms/O ./O
The/O mutations/O are/O scattered/O throughout/O the/O gene/O and/O the/O vast/O majority/O of/O those/O reported/O so/O far/O are/O nonsense/B-Var mutations/I-Var ,/O frameshift/B-Var mutations/I-Var ,/O or/O splicing/B-Var errors/I-Var that/O are/O predicted/O to/O cause/B-Reg pre/B-MPA -/I-MPA mature/I-MPA truncation/I-MPA of/O the/O PAX6/B-Gene protein/B-Protein ,/O causing/B-Reg haploinsufficiency/B-MPA ./O
Here/O we/O review/O the/O data/O regarding/O the/O mechanisms/O and/O the/O mutations/O that/O relate/O to/O aniridia/B-Disease ./O
GARS/O axonopathy/O :/O not/O every/O neuron/O 's/O cup/O of/O tRNA/O ./O
Charcot/B-Disease -/I-Disease Marie/I-Disease -/I-Disease Tooth/I-Disease disease/I-Disease type/I-Disease 2D/I-Disease ,/O a/O hereditary/O axonal/O neuropathy/O ,/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O glycyl/O -/O tRNA/O synthetase/O (/B-Gene GARS/I-Gene )/I-Gene ./O
The/O mutations/O are/O distributed/O throughout/O the/O protein/O in/O multiple/O functional/O domains/O ./O
In/O biochemical/O and/O cell/O culture/O experiments/O ,/O some/O mutant/O forms/O of/O GARS/O have/O been/O indistinguishable/O from/O wild/O -/O type/O protein/O ,/O suggesting/O that/O these/O in/O vitro/O tests/O might/O not/O adequately/O assess/O the/O aberrant/O activity/O responsible/O for/O axonal/O degeneration/O ./O
Recently/O ,/O mouse/O and/O fly/O models/O have/O offered/O new/O insights/O into/O the/O disease/O mechanism/O ./O
There/O are/O still/O gaps/O in/O our/O understanding/O of/O how/O mutations/O in/O a/O ubiquitously/O expressed/O component/O of/O the/O translation/O machinery/O result/O in/O axonal/O neuropathy/O ./O
Here/O ,/O we/O review/O recent/O reports/O ,/O weigh/O the/O evidence/O for/O and/O against/O possible/O mechanisms/O and/O suggest/O areas/O of/O focus/O for/O future/O work/O ./O
Genotype/O -/O phenotype/O correlation/O in/O a/O large/O population/O of/O muscular/B-Disease dystrophy/I-Disease patients/O with/B-Reg LAMA2/B-Gene mutations/B-Var ./O
Merosin/B-Disease deficient/I-Disease congenital/I-Disease muscular/I-Disease dystrophy/I-Disease 1A/I-Disease (/O MDC1A/O )/O results/B-Reg from/I-Reg mutations/B-Var in/O the/O LAMA2/B-Gene gene/O ./O
We/O report/O 51/O patients/O with/O MDC1A/O and/O examine/O the/O relationship/O between/O degree/O of/O merosin/O expression/O ,/O genotype/O and/O clinical/O features/O ./O
Thirty/O -/O three/O patients/O had/O absence/O of/O merosin/O and/O 13/O showed/O some/O residual/O merosin/O ./O
Compared/O to/O the/O residual/O merosin/O group/O ,/O patients/O with/O absent/O merosin/O had/O an/O earlier/O presentation/O (/O </O 7days/O )/O (/O P=0.0073/O )/O ,/O were/O more/O likely/O to/O lack/O independent/O ambulation/O (/O P=0.0215/O )/O ,/O or/O require/O enteral/O feeding/O (/O P=0.0099/O )/O and/O ventilatory/O support/O (/O P=0.0354/O )/O ./O
We/O identified/O 33/O novel/O LAMA2/O mutations/O ;/O these/O were/O distributed/O throughout/O the/O gene/O in/O patients/O with/O absent/O merosin/O ,/O with/O minor/O clusters/O in/O exon/O 27/O ,/O 14/O ,/O 25/O and/O 26/O (/O 55/O %/O of/O mutations/O )/O ./O
Patients/O with/O residual/O merosin/O often/O carried/O at/O least/O one/O splice/O site/O mutation/O and/O less/O frequently/O frameshift/O mutations/O ./O
This/O large/O study/O identified/O novel/O LAMA2/O mutations/O and/O highlights/O the/O role/O of/O immunohistochemical/O studies/O for/O merosin/O status/O in/O predicting/O clinical/O severity/O of/O MDC1A./O Novel/O and/O recurrent/O mutations/O in/O the/O filaggrin/O gene/O in/O Chinese/O patients/O with/O ichthyosis/O vulgaris/O ./O
BACKGROUND/O :/O Ichthyosis/B-Disease vulgaris/I-Disease (/O IV/O )/O is/O a/O common/O inherited/O skin/O disorder/O ,/O and/O the/O filament/O aggregating/O protein/O (/O filaggrin/O )/O is/O a/O key/O protein/O involved/O in/O skin/O barrier/O function/O ./O
Mutations/B-Var in/O the/O filaggrin/O gene/O (/B-Gene FLG/I-Gene )/I-Gene have/O recently/O been/O identified/O as/O the/O cause/B-Reg of/O IV/B-Disease ./O
However/O ,/O there/O have/O been/O no/O reports/O of/O FLG/O mutations/O in/O mainland/O Chinese/O families/O with/O IV/O ./O
OBJECTIVES/O :/O To/O identify/O FLG/O mutations/O in/O Chinese/O patients/O with/O IV/O ./O
METHODS/O :/O Eleven/O unrelated/O Chinese/O families/O with/O IV/O were/O examined/O for/O FLG/O mutations/O with/O denaturing/O high/O -/O performance/O liquid/O chromatography/O prescreening/O and/O sequencing/O ./O
SNaPShot/O was/O employed/O to/O obtain/O a/O high/O -/O throughput/O screening/O for/O the/O identified/O mutations/O ./O
RESULTS/O :/O Three/O mutations/O -/O one/O novel/O mutation/O (/O Q1256X/O )/O and/O two/O known/O mutations/O (/O 3321delA/O and/O E2422X/O )/O -/O were/O identified/O in/O these/O families/O ./O
The/O novel/O mutation/O ,/O Q1256X/O ,/O found/O in/O a/O Chinese/O family/O with/O IV/O ,/O was/O located/O in/O filaggrin/O repeat/O 3/O ./O
Mutation/O 3321delA/O ,/O previously/O found/O in/O Japanese/O patients/O ,/O was/O present/O in/O eight/O Chinese/O families/O with/O IV/O ./O
Mutation/O E2422X/O ,/O previously/O found/O in/O a/O Dutch/O patient/O of/O Chinese/O origin/O ,/O was/O present/O in/O two/O Chinese/O families/O with/O IV/O ./O
Neither/O of/O the/O null/O mutations/O ,/O Q1256X/O and/O E2422X/O ,/O were/O found/O in/O 100/O unrelated/O control/O cases/O from/O the/O Chinese/O population/O ;/O however/O ,/O the/O mutation/O ratio/O for/O 3321delA/O was/O 3/O %/O in/O these/O controls/O ./O
CONCLUSIONS/O :/O Our/O study/O suggests/O that/O each/O population/O may/O have/O a/O unique/O and/O prevalent/O set/O of/O FLG/O mutations/O ./O
Genetic/O analysis/O of/O haemophilia/O A/O in/O Taiwan/O ./O
Haemophilia/B-Disease A/I-Disease (/O HA/O )/O is/O an/O X/O -/O linked/O bleeding/O disorder/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O factor/O VIII/O (/B-Gene FVIII/I-Gene )/I-Gene gene/O ./O
Identification/O of/O these/O mutations/O is/O becoming/O increasingly/O important/O in/O a/O variety/O of/O clinical/O settings/O ./O
The/O purpose/O of/O this/O report/O is/O to/O describe/O our/O experience/O of/O FVIII/O gene/O mutation/O analysis/O in/O the/O largest/O cohort/O of/O patients/O in/O Taiwan/O including/O the/O discovery/O of/O 21/O novel/O mutations/O ./O
We/O tested/O 115/O HA/O patients/O from/O 91/O unrelated/O families/O ,/O including/O 79/O severe/O ,/O 15/O moderate/O and/O 21/O mild/O types/O starting/O with/O an/O assay/O for/O the/O intron/O 22/O inversion/O by/O long/O range/O -/O PCR/O followed/O if/O necessary/O by/O additional/O genetic/O studies/O ./O
Intron/O 22/O inversion/O accounted/O for/O 27.8/O %/O of/O the/O total/O and/O 36.7/O %/O of/O severe/O HA/O patients/O respectively/O while/O intron/O 1/O inversion/O comprised/O 7.6/O %/O of/O severe/O patients/O ./O
These/O were/O clearly/O different/O from/O the/O known/O data/O in/O caucasian/O populations/O ./O
Of/O 75/O patients/O without/O intron/O 22/O or/O 1/O inversion/O ,/O 70/O from/O 62/O unrelated/O families/O revealed/O 56/O different/O mutations/O by/O denaturing/O high/O -/O performance/O liquid/O chromatography/O (/O DHPLC/O )/O ,/O of/O which/O 21/O were/O novel/O ./O
Also/O ,/O the/O only/O female/O patient/O with/O severe/O HA/O was/O found/O to/O have/O heterozygous/O non/O -/O sense/O mutation/O (/O c.6683G/O >/O A/O )/O of/O exon/O 24/O ./O
Seven/O patients/O ,/O including/O five/O without/O amplified/O PCR/O product/O and/O two/O without/O encoded/O DNA/O defect/O turned/O out/O to/O have/O exon(s/O )/O deletion/O or/O insertion/O by/O reverse/O transcript/O PCR/O (/O RT/O -/O PCR/O )/O ./O
In/O our/O study/O ,/O the/O combination/O of/O various/O molecular/O techniques/O including/O LR/O -/O PCR/O ,/O multiplex/O PCR/O ,/O DHPLC/O and/O RT/O -/O PCR/O analysis/O enabled/O definitive/O detection/O of/O the/O causative/O FVIII/O gene/O defects/O in/O 112/O of/O 113/O (/O 99/O %/O )/O HA/O patients/O ./O
Mutation/O spectra/O in/O autosomal/O dominant/O and/O recessive/O retinitis/O pigmentosa/O in/O northern/O Sweden/O ./O
Retinal/O degenerations/O represent/O a/O heterogeneous/O group/O of/O disorders/O affecting/O the/O function/O of/O the/O retina/O ./O
The/O frequency/O of/O retinitis/O pigmentosa/O (/O RP/O )/O is/O 1/3500/O worldwide/O ,/O however/O ,/O in/O northern/O Sweden/O it/O is/O 1/2000/O due/O to/O limited/O migration/O and/O a/O '/O founder/O '/O effect/O ./O
In/O this/O study/O we/O identified/O genetic/O mechanisms/O underlying/O autosomal/O dominant/O and/O recessive/O RP/O present/O in/O northern/O Sweden/O ./O
Several/O novel/O mutations/O unique/O for/O this/O region/O were/O found/O ./O
In/O an/O autosomal/O recessive/O form/O of/O RP/O ,/O Bothnia/B-Disease dystrophy/I-Disease caused/B-Reg by/I-Reg mutations/B-Var in/O the/O RLBP1/B-Gene gene/O ,/O bi/O -/O allelic/O mutations/O R234W/O ,/O M226/O K/O and/O compound/O heterozygosity/O ,/O M226K+R234W/O was/O detected/O ./O
In/O dominant/O form/O of/O RP/O mapped/O to/O 19q13.42/O a/O 59/O kb/O genomic/O deletion/O including/O the/O PRPF31/O and/O three/O other/O genes/O was/O found/O ./O
These/O data/O provide/O additional/O information/O on/O the/O molecular/O mechanisms/O of/O RP/O evolvement/O and/O in/O the/O future/O might/O be/O useful/O in/O development/O of/O therapeutic/O strategies/O ./O
Identification/O of/O the/O disease/O -/O causing/O mutations/O allowed/O introducing/O molecular/O genetic/O testing/O of/O the/O patients/O and/O their/O families/O into/O the/O clinical/O practice/O ./O
Sequence/O variants/B-Var of/O the/O DFNB31/B-Gene gene/O among/B-Reg Usher/B-Disease syndrome/I-Disease patients/O of/O diverse/O origin/O ./O
PURPOSE/O :/O It/O has/O been/O demonstrated/O that/O mutations/B-Var in/O deafness/O ,/O autosomal/O recessive/O 31/O (/B-Gene DFNB31/I-Gene )/I-Gene ,/O the/O gene/O encoding/O whirlin/O ,/O is/O responsible/B-Reg for/O nonsyndromic/B-Disease hearing/I-Disease loss/I-Disease (/O NSHL/O ;/O DFNB31/O )/O and/O Usher/B-Disease syndrome/I-Disease type/I-Disease II/I-Disease (/O USH2D/O )/O ./O
We/O screened/O DFNB31/O in/O a/O large/O cohort/O of/O patients/O with/O different/O clinical/O subtypes/O of/O Usher/O syndrome/O (/O USH/O )/O to/O determine/O the/O prevalence/O of/O DFNB31/O mutations/O among/O USH/O patients/O ./O
METHODS/O :/O DFNB31/O was/O screened/O in/O 149/O USH2/O ,/O 29/O USH1/O ,/O six/O atypical/O USH/O ,/O and/O 11/O unclassified/O USH/O patients/O from/O diverse/O ethnic/O backgrounds/O ./O
Mutation/O detection/O was/O performed/O by/O direct/O sequencing/O of/O all/O coding/O exons/O ./O
RESULTS/O :/O We/O identified/O 38/O different/O variants/O among/O 195/O patients/O ./O
Most/O variants/O were/O clearly/O polymorphic/O ,/O but/O at/O least/O two/O out/O of/O the/O 15/O nonsynonymous/O variants/O (/B-Var p/I-Var ./I-Var R350W/I-Var and/O p/B-Var ./I-Var R882S/I-Var )/I-Var are/O predicted/O to/O impair/B-NegReg whirlin/B-Protein structure/B-MPA and/O function/B-MPA ,/O suggesting/O eventual/O pathogenicity/O ./O
No/O putatively/O pathogenic/O mutation/O was/O found/O in/O the/O second/O allele/O of/O patients/O with/O these/O mutations/O ./O
CONCLUSIONS/O :/O DFNB31/O is/O not/O a/O major/O cause/O of/O USH/O ./O
Partial/O depletion/O of/O CREB/O -/O binding/O protein/O reduces/O life/O expectancy/O in/O a/O mouse/O model/O of/O Huntington/O disease/O ./O
Previous/O studies/O have/O reported/O that/O mutant/B-Var huntingtin/B-Gene (/O htt/O )/O interferes/B-Reg with/O cyclic/B-Protein AMP/I-Protein response/I-Protein element/I-Protein binding/I-Protein protein/I-Protein binding/B-Interaction protein/B-Protein (/O CBP)-mediated/O transcription/B-MPA ,/O possibly/O by/O inhibiting/B-NegReg the/O acetylation/B-MPA of/O histones/B-Protein ./O
In/O Drosophila/O models/O that/O express/O fragments/O of/O mutant/O htt/O ,/O histone/O deacetylase/O inhibitors/O reverse/O deficits/O in/O histone/O acetylation/O ,/O rescue/O photoreceptor/O degeneration/O ,/O and/O prolong/O their/O survival/O ./O
These/O compounds/O also/O improve/O motor/O deficits/O in/O a/O transgenic/O mouse/O model/O of/O Huntington/O disease/O (/O HD/O )/O ./O
To/O determine/O whether/O endogenous/O CBP/O depletion/O contributes/O to/O HD/O pathogenesis/O ,/O we/O crossed/O HD/O -/O N171/O -/O 82Q/O transgenic/O mice/O with/O mice/O harboring/O a/O disrupted/O CBP/O gene/O and/O produced/O mice/O with/O partial/O (/O 50/O %/O )/O depletion/O of/O CBP/O ./O
This/O reduction/O of/O CBP/O levels/O decreased/O the/O life/O expectancy/O of/O the/O HD/O -/O N171/O -/O 82Q/O Line/O 6/O mouse/O model/O ./O
The/O loss/O of/O CBP/O had/O no/O obvious/O impact/O on/O the/O severity/O of/O motor/O impairment/O ,/O degeneration/O of/O the/O striatum/O ,/O mutant/O htt/O inclusion/O formation/O ,/O or/O global/O levels/O of/O acetylated/O histones/O H3/O or/O H4/O in/O brain/O ./O
In/O cell/O models/O ,/O we/O confirmed/O that/O mutant/O htt/O inclusions/O recruit/O human/O CBP/O but/O found/O no/O evidence/O for/O interactions/O between/O soluble/O forms/O of/O mutant/O htt/O and/O CBP/O ./O
Although/O we/O identified/O no/O neurological/O explanation/O for/O the/O decreased/O life/O expectancy/O of/O HD/O -/O N171/O -/O 82Q/O mice/O with/O partial/O depletion/O of/O CBP/O ,/O the/O data/O are/O consistent/O with/O the/O notion/O that/O CBP/O function/O mitigates/O mutant/O htt/O toxicity/O by/O a/O currently/O unidentified/O mechanism/O ./O
Type/O I/O hyperprolinemia/O :/O genotype/O //O phenotype/O correlations/O ./O
Type/B-Disease I/I-Disease hyperprolinemia/I-Disease (/O HPI/O )/O is/O an/O autosomal/O recessive/O disorder/O associated/O with/O cognitive/O and/O psychiatric/O troubles/O ,/O caused/O by/O alterations/O of/O the/O Proline/O Dehydrogenase/O gene/O (/O PRODH/O )/O at/O 22q11/O ./O
HPI/B-Disease results/B-Reg from/I-Reg PRODH/B-Gene deletion/B-Var and/or/O missense/B-Var mutations/I-Var reducing/B-NegReg proline/B-Enzyme oxidase/I-Enzyme (/O POX/O )/O activity/B-MPA ./O
The/O goals/O of/O this/O study/O were/O first/O to/O measure/O in/O controls/O the/O frequency/O of/O PRODH/O variations/O described/O in/O HPI/O patients/O ,/O second/O to/O assess/O the/O functional/O effect/O of/O PRODH/O mutations/O on/O POX/O activity/O ,/O and/O finally/O to/O establish/O genotype/O //O enzymatic/O activity/O correlations/O in/O a/O new/O series/O of/O HPI/O patients/O ./O
Eight/O of/O 14/O variants/O occurred/O at/O polymorphic/O frequency/O in/O 114/O controls/O ./O
POX/O activity/O was/O determined/O for/O six/O novel/O mutations/O and/O two/O haplotypes/O ./O
The/O c.1331G/O >/O A/O ,/O p/O ./O G444D/O allele/O has/O a/O drastic/O effect/O ,/O whereas/O the/O c.23C/B-Var >/I-Var T/I-Var ,/O p/B-Var ./I-Var P8L/I-Var allele/O and/O the/O c.[56C/B-Var >/I-Var A/I-Var ;/I-Var 172G/I-Var >/I-Var A/I-Var ]/I-Var ,/O p.[Q19P/B-Var ;/I-Var A58/I-Var T/I-Var ]/I-Var haplotype/O result/O in/O a/O moderate/O decrease/B-NegReg in/O activity/B-MPA ./O
Among/O the/O 19/O HPI/O patients/O ,/O 10/O had/O a/O predicted/O residual/O activity/O </O 50/O %/O ./O
Eight/O out/O of/O nine/O subjects/O with/O a/O predicted/O residual/O activity/O >/O or/O =/O 50/O %/O bore/O at/O least/O one/O c.824C/O >/O A/O ,/O p/O ./O T275N/O allele/O ,/O which/O has/O no/O detrimental/O effect/O on/O activity/O but/O whose/O frequency/O in/O controls/O is/O only/O 3/O %/O ./O
Our/O results/O suggest/O that/O PRODH/B-Gene mutations/B-Var lead/O to/O a/O decreased/B-NegReg POX/B-Enzyme activity/B-MPA or/O affect/B-Reg other/B-MPA biological/I-MPA parameters/I-MPA causing/B-Reg hyperprolinemia/B-Disease ./O
Dihydropyrimidine/B-Disease dehydrogenase/I-Disease deficiency/I-Disease caused/B-Reg by/I-Reg a/O novel/O genomic/O deletion/O c.505_513del/B-Var of/O DPYD/B-Gene ./O
Dihydropyrimidine/O dehydrogenase/O (/O DPD/O )/O deficiency/O is/O an/O autosomal/O recessive/O disorder/O of/O the/O pyrimidine/O degradation/O pathway/O ./O
In/O a/O patient/O presenting/O with/O convulsions/O ,/O psychomotor/O retardation/O and/O Reye/O like/O syndrome/O ,/O strongly/O elevated/O levels/O of/O uracil/O and/O thymine/O were/O detected/O in/O urine/O ./O
No/O DPD/O activity/O could/O be/O detected/O in/O peripheral/O blood/O mononuclear/O cells/O ./O
Analysis/O of/O the/O gene/O encoding/O DPD/O (/O DPYD/O )/O showed/O that/O the/O patient/O was/O homozygous/O for/O a/O novel/O c.505_513del/O (/O p.169_171del/O )/O mutation/O in/O exon/O 6/O of/O DPYD/O ./O
Analysis/O of/O mutations/B-Var causing/B-Reg biotinidase/B-Disease deficiency/I-Disease ./O
Biotinidase/O deficiency/O is/O an/O inherited/O disorder/O in/O which/O the/O vitamin/O ,/O biotin/O ,/O is/O not/O recycled/O ./O
Individuals/O with/O biotinidase/O deficiency/O can/O develop/O neurological/O and/O cutaneous/O symptoms/O if/O they/O are/O not/O treated/O with/O biotin/O ./O
Biotinidase/O deficiency/O screening/O has/O been/O incorporated/O into/O essentially/O all/O newborn/O screening/O programs/O in/O the/O United/O States/O and/O in/O many/O countries/O ./O
We/O now/O report/O 140/O known/O mutations/B-Var in/O the/O biotinidase/O gene/O (/B-Gene BTD/I-Gene )/I-Gene that/O cause/B-Reg biotinidase/B-Disease deficiency/I-Disease ./O
All/O types/O of/O mutations/B-Var have/O been/O found/O to/O cause/B-Reg biotinidase/B-Disease deficiency/I-Disease ./O
Variants/O have/O been/O identified/O throughout/O the/O coding/O sequence/O ./O
Essentially/O all/O the/O variants/B-Var result/O in/O enzymatic/B-Enzyme activities/B-MPA with/O less/B-NegReg than/O 10/O %/O of/O mean/O normal/O enzyme/O activity/O (/O profound/O biotinidase/O deficiency/O )/O with/O the/O exception/O of/O the/O c.1330G/B-Var >/I-Var C/I-Var (/O p/O ./O D444H/O )/O mutation/O ,/O which/O results/O in/O an/O enzyme/B-Enzyme having/O 50/B-NegReg %/I-NegReg of/O mean/O normal/O serum/B-MPA activity/I-MPA ./O
The/O putative/O three/O -/O dimensional/O structure/O of/O biotinidase/O has/O been/O predicted/O by/O homology/O to/O that/O of/O nitrilases/O //O amidases/O ./O
The/O effect/O of/O the/O various/O missense/O mutations/O can/O be/O predicted/O to/O affect/O various/O important/O sites/O within/O the/O structure/O of/O the/O enzyme/O ./O
This/O compilation/O of/O variants/O causing/O biotinidase/O deficiency/O will/O be/O useful/O to/O clinical/O laboratories/O that/O are/O performing/O mutation/O analysis/O for/O confirmational/O testing/O when/O the/O enzymatic/O results/O are/O equivocal/O for/O children/O identified/O through/O newborn/O screening/O ./O
N88S/B-Var mutation/O in/O the/O BSCL2/B-Gene gene/O in/B-Reg a/O Serbian/O family/O with/O distal/B-Disease hereditary/I-Disease motor/I-Disease neuropathy/I-Disease type/I-Disease V/I-Disease or/O Silver/B-Disease syndrome/I-Disease ./O
BACKGROUND/O :/O Distal/B-Disease hereditary/I-Disease motor/I-Disease neuropathy/I-Disease type/I-Disease V/I-Disease (/O dHMN/O -/O V/O )/O and/O Silver/B-Disease syndrome/I-Disease are/O rare/O phenotypically/O overlapping/O diseases/O which/O can/O be/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O Berardinelli/O -/O Seip/O Congenital/O Lipodystrophy/O 2/O (/B-Gene BSCL2/I-Gene )/I-Gene gene/O or/O Seipin/B-Gene ./O
AIM/O :/O To/O report/O the/O first/O Serbian/O family/O with/O a/O BSCL2/O mutation/O showing/O variable/O expression/O within/O the/O family/O ./O
PATIENTS/O AND/O METHODS/O :/O A/O 55-year/O -/O old/O woman/O presented/O with/O weakness/O of/O both/O hands/O at/O the/O age/O of/O 45/O ./O
At/O age/O 47/O ,/O she/O noticed/O distal/O muscle/O weakness/O and/O atrophy/O in/O her/O legs/O ./O
Physical/O examination/O revealed/O atrophy/O and/O weakness/O of/O small/O hand/O muscles/O and/O mild/O atrophy/O and/O weakness/O of/O the/O lower/O limbs/O ./O
There/O was/O generalized/O hyperreflexia/O with/O the/O exception/O of/O ankle/O reflexes/O which/O were/O diminished/O ./O
Her/O 25year/O -/O old/O son/O had/O only/O stiffness/O of/O both/O legs/O at/O the/O age/O of/O 22/O ./O
Physical/O examination/O revealed/O only/O generalized/O hyporeflexia/O ./O
The/O third/O affected/O member/O in/O this/O family/O was/O her/O 55year/O -/O old/O cousin/O who/O showed/O a/O more/O prominent/O involvement/O of/O leg/O muscles/O with/O mild/O asymmetrical/O weakness/O of/O hand/O muscles/O and/O no/O pyramidal/O tract/O features/O ./O
RESULTS/O :/O In/O all/O three/O patients/O sensory/O nerve/O conduction/O velocities/O (/O NCV/O )/O were/O normal/O in/O all/O extremities/O ./O
Compound/O muscle/O action/O potential/O (/O CMAP/O )/O amplitudes/O were/O markedly/O reduced/O in/O all/O patients/O ./O
Concentric/O needle/O EMG/O showed/O evidence/O of/O chronic/O denervation/O in/O distal/O muscles/O ./O
DNA/O sequencing/O of/O BSCL2/O was/O performed/O and/O a/O heterozygous/O N88S/O missense/O mutation/O in/O BSCL2/O gene/O was/O detected/O in/O all/O three/O patients/O ./O
CONCLUSION/O :/O This/O report/O is/O further/O confirmation/O of/O phenotypic/O heterogenity/O due/O to/O the/O N88S/O mutation/O of/O BSCL2/O gene/O in/O the/O same/O family/O ./O
DOK7/B-Gene mutations/B-Var presenting/B-Reg as/I-Reg a/O proximal/B-Disease myopathy/I-Disease in/O French/O Canadians/O ./O
DOK7/B-Gene mutations/B-Var cause/B-Reg a/O congenital/B-Disease myasthenic/I-Disease syndrome/I-Disease (/O OMIM/O 254300/O )/O characterized/O by/O a/O "/O limb/O -/O girdle/O "/O phenotype/O ./O
We/O identified/O 7/O French/O -/O Canadian/O patients/O with/O a/O previously/O undiagnosed/O proximal/O myopathy/O ./O
A/O genome/O wide/O scan/O was/O performed/O ./O
Homozygosity/O mapping/O identified/O a/O locus/O on/O chromosome/O 4p16.2/O containing/O DOK7/O ./O
Sequencing/O of/O DOK7/O revealed/O homozygous/O 1124_1127dupTGCC/O mutations/O in/O all/O individuals/O ./O
SNP/O genotyping/O of/O 42/O kb/O surrounding/O DOK7/O in/O our/O cohort/O and/O in/O 9/O patients/O of/O various/O European/O origins/O demonstrated/O a/O shared/O haplotype/O suggesting/O a/O common/O ancestral/O European/O mutation/O ./O
In/O our/O cohort/O ,/O fatigability/O was/O not/O prominent/O ;/O rather/O patients/O reported/O prolonged/O periods/O of/O increased/O weakness/O ./O
Abnormalities/O on/O repetitive/O nerve/O stimulation/O and/O single/O fiber/O EMG/O were/O not/O invariably/O present/O ./O
There/O was/O considerable/O intra/O -/O familial/O phenotypic/O variability/O ,/O and/O we/O report/O an/O asymptomatic/O individual/O ./O
DOK7/O mutations/O should/O be/O considered/O in/O patients/O with/O early/O -/O onset/O myopathy/O ,/O even/O in/O the/O absence/O of/O symptoms/O suggesting/O a/O possible/O myasthenia/O ./O
Identification/O of/O known/O and/O novel/O PTCH/B-Gene mutations/B-Var in/B-Reg both/O syndromic/O and/O non/O -/O syndromic/O keratocystic/B-Disease odontogenic/I-Disease tumors/I-Disease ./O
AIM/O :/O To/O clarify/O the/O role/O of/O PTCH/O in/O patients/O with/O NBCCS/O -/O related/O and/O non/O -/O sydromic/O keratocystic/O odontogenic/O tumors/O ./O
METHODOLOGY/O :/O Mutation/O analysis/O was/O undertaken/O in/O 8/O sporadic/O and/O 4/O NBCCS/O -/O associated/O KCOTs/O ./O
RESULTS/O :/O Four/O novel/O and/O two/O known/O mutations/O were/O identified/O in/O 2/O sporadic/O and/O 3/O syndromic/O cases/O ,/O two/O of/O which/O being/O germline/O mutations/O (/O c.2179delT/O ,/O c.2824delC/O )/O and/O 4/O somatic/O mutations/O (/O c.3162dupG/O ,/O c.1362/O -/O 1374dup/O ,/O c.1012/O C/O >/O T/O ,/O c.403C/O >/O T/O )/O ./O
CONCLUSION/O :/O Our/O findings/O suggest/O that/O defects/O of/O PTCH/O are/O associated/O with/O the/O pathogenesis/O of/O syndromic/O as/O well/O as/O a/O subset/O of/O non/O -/O syndromic/O KCOTs/O ./O
NOTCH3/B-Gene mutations/B-Var and/O clinical/O features/O in/O 33/O mainland/O Chinese/O families/O with/B-Reg CADASIL/B-Disease ./O
BACKGROUND/O :/O Cerebral/B-Disease autosomal/I-Disease dominant/I-Disease arteriopathy/I-Disease with/I-Disease subcortical/I-Disease infarcts/I-Disease and/I-Disease leucoencephalopathy/I-Disease (/O CADASIL/O )/O is/O an/O inherited/O small/O -/O vessel/O disease/O caused/B-Reg by/I-Reg mutations/B-Var in/O NOTCH3/B-Gene ./O
Although/O CADASIL/O cases/O have/O been/O identified/O worldwide/O ,/O the/O data/O from/O mainland/O China/O are/O still/O limited/O ./O
OBJECTIVE/O :/O To/O identify/O NOTCH3/O mutations/O and/O analyse/O the/O clinical/O and/O MRI/O findings/O in/O a/O large/O series/O of/O CADASIL/O patients/O from/O mainland/O China/O ./O
METHODS/O :/O Direct/O sequencing/O of/O NOTCH3/O and/or/O skin/O or/O sural/O nerve/O biopsies/O were/O performed/O on/O 48/O unrelated/O suspected/O CADASIL/O cases/O of/O Chinese/O descent/O ./O
The/O clinical/O manifestations/O and/O MRI/O features/O were/O retrospectively/O collected/O and/O analysed/O in/O the/O 33/O index/O patients/O with/O confirmed/O diagnosis/O and/O their/O available/O affected/O family/O members/O ./O
RESULTS/O :/O 20/O different/O NOTCH3/O mutations/O were/O identified/O in/O 33/O families/O ,/O including/O seven/O novel/O mutations/O ./O
The/O highest/O mutation/O frequency/O was/O in/O exons/O 4/O (/O 55/O %/O )/O and/O 3/O (/O 30/O %/O )/O ./O
Granular/O osmiophilic/O material/O in/O smooth/O muscle/O cells/O was/O found/O in/O 30/O cases/O who/O were/O biopsied/O ./O
Clinical/O presentation/O included/O TIA/O //O stroke/O in/O 82/O %/O ,/O cognitive/O decline/O in/O 60/O %/O ,/O and/O migraine/O with/O aura/O in/O only/O 5/O %/O of/O 57/O symptomatic/O cases/O ./O
MRI/O detected/O multiple/O lacunar/O infarcts/O and/O leucoaraiosis/O in/O all/O symptomatic/O cases/O ,/O brainstem/O lesions/O in/O 64/O %/O of/O symptomatic/O cases/O and/O white/O -/O matter/O lesions/O in/O the/O temporal/O pole/O in/O 46/O %/O of/O affected/O members/O ./O
CONCLUSIONS/O :/O The/O mutational/O spectrum/O and/O primary/O clinical/O features/O of/O patients/O with/O CADASIL/O from/O mainland/O China/O are/O similar/O to/O those/O in/O Caucasians/O ./O
However/O ,/O migraine/O with/O aura/O and/O abnormal/O white/O matter/O in/O the/O temporal/O pole/O are/O less/O common/O than/O among/O Caucasians/O ,/O while/O brainstem/O involvement/O is/O more/O common/O than/O among/O Caucasians/O ./O
Prevalence/O ,/O mutation/O spectrum/O and/O phenotypic/O variability/O in/O Norwegian/O patients/O with/O Limb/O Girdle/O Muscular/O Dystrophy/O 2I./O Mutations/B-Var in/O the/O FKRP/B-Gene (/O Fukutin/O Related/O Protein/O )/O gene/O produce/B-Reg a/O range/O of/O phenotypes/O including/O Limb/B-Disease Girdle/I-Disease Muscular/I-Disease Dystrophy/I-Disease Type/I-Disease 2I/I-Disease (/O LGMD2I/O )/O ./O
In/O order/O to/O investigate/O the/O prevalence/O ,/O the/O mutation/O spectrum/O and/O possible/O genotype/O -/O phenotype/O correlation/O ,/O we/O studied/O a/O cohort/O of/O Norwegian/O patients/O with/O LGMD2I/O ,/O ascertained/O in/O a/O 4-year/O period/O ./O
In/O this/O retrospective/O study/O of/O genetically/O tested/O patients/O ,/O we/O identified/O 88/O patients/O from/O 69/O families/O ,/O who/O were/O either/O homozygous/O or/O compound/O heterozygous/O for/O FKRP/O mutations/O ./O
This/O gives/O a/O minimum/O prevalence/O of/O 1/54,000/O and/O a/O corresponding/O carrier/O frequency/O of/O 1/116/O in/O the/O Norwegian/O population/O ./O
Seven/O different/O FKRP/O mutations/O ,/O including/O three/O novel/O changes/O ,/O were/O detected/O ./O
Seventy/O -/O six/O patients/O were/O homozygous/O for/O the/O common/O c.826C/O >/O A/O mutation/O ./O
These/O patients/O had/O later/O disease/O onset/O than/O patients/O who/O were/O compound/O heterozygous/O -/O 14.0/O vs./O 6.1/O years/O ./O
We/O detected/O substantial/O variability/O in/O disease/O severity/O among/O homozygous/O patients/O ./O
Novel/O and/O recurrent/O connexin/O 30.3/O and/O connexin/O 31/O mutations/O associated/O with/O erythrokeratoderma/O variabilis/O ./O
Erythrokeratoderma/B-Disease variabilis/I-Disease (/O EKV/O )/O is/O characterized/O by/O fixed/O hyperkeratotic/O plaques/O and/O transient/O erythema/O ./O
Mutations/B-Var in/O the/O genes/O GJB3/B-Gene and/O GJB4/B-Gene ,/O which/O encode/O connexin/O (/O Cx)31/O and/O Cx30.3/O ,/O are/O associated/B-Reg with/O EKV/B-Disease ./O
We/O report/O one/O novel/O mutation/O in/O Cx31/O and/O one/O recurrent/O mutation/O in/O Cx30.3/O in/O two/O different/O families/O ./O
One/O novel/O rare/O sequence/O variant/O of/O unknown/O clinical/O significance/O was/O also/O identified/O ./O
This/O finding/O extends/O the/O spectrum/O of/O known/O EKV/O -/O associated/O mutations/O ./O
Thyroid/O pathology/O in/O PTEN/O -/O hamartoma/O tumor/O syndrome/O :/O characteristic/O findings/O of/O a/O distinct/O entity/O ./O
BACKGROUND/O :/O Phosphatase/O and/O tensin/O homolog/O deleted/O on/O chromosome/O ten/O (/B-Disease PTEN)-hamartoma/I-Disease tumor/I-Disease syndrome/I-Disease (/O PHTS/O )/O is/O a/O complex/O disorder/O caused/O by/O germline/O inactivating/B-NegReg mutations/B-Var of/O the/O PTEN/B-Gene tumor/O suppressor/O gene/O ./O
PHTS/O includes/O Cowden/O syndrome/O (/O CS/O )/O ,/O Bannayan/O -/O Riley/O -/O Ruvalcaba/O syndrome/O (/O BRRS/O )/O ,/O and/O Proteus/O -/O like/O syndromes/O ./O
Affected/O individuals/O develop/O both/O benign/O and/O malignant/O tumors/O in/O a/O variety/O of/O tissues/O ,/O including/O the/O thyroid/O ./O
This/O study/O is/O to/O better/O characterize/O and/O describe/O the/O thyroid/O pathology/O within/O the/O different/O entities/O of/O this/O syndrome/O ,/O and/O examine/O whether/O there/O is/O an/O association/O between/O specific/O thyroid/O findings/O and/O different/O PTEN/O mutations/O ./O
METHODS/O :/O Twenty/O patients/O with/O known/O PTEN/O mutations/O ,/O and/or/O clinical/O diagnosis/O of/O PHTS/O ,/O and/O thyroid/O pathology/O were/O identified/O :/O 14/O with/O CS/O and/O 6/O with/O BRRS/O ./O
RESULTS/O :/O Thyroid/O pathology/O findings/O were/O as/O follows/O :/O multiple/O adenomatous/O nodules/O in/O a/O background/O of/O lymphocytic/O thyroiditis/O (/O LT/O )/O in/O 75/O %/O ,/O papillary/O carcinoma/O in/O 60/O %/O ,/O LT/O alone/O in/O 55/O %/O ,/O follicular/O carcinoma/O in/O 45/O %/O ,/O C/O -/O cell/O hyperplasia/O in/O 55/O %/O ,/O and/O follicular/O adenomas/O in/O 25/O %/O ./O
Within/O the/O papillary/O carcinoma/O group/O ,/O there/O were/O 6/O microcarcinomas/O ,/O 5/O follicular/O variants/O ,/O and/O 1/O classical/O type/O ./O
CONCLUSIONS/O :/O There/O were/O no/O morphologic/O differences/O between/O the/O thyroid/O findings/O in/O CS/O and/O BRRS/O ./O
Also/O ,/O there/O was/O no/O correlation/O between/O specific/O PTEN/O germline/O mutations/O (/O exons/O 5/O ,/O 6/O ,/O and/O 8)/O and/O pathologic/O findings/O ./O
Distinctive/O and/O characteristic/O findings/O in/O PHTS/O include/O multiple/O unique/O adenomatous/O nodules/O in/O a/O background/O of/O LT/O ,/O and/O C/O -/O cell/O hyperplasia/O ;/O it/O is/O vital/O that/O pathologists/O recognize/O the/O classical/O histologic/O features/O of/O this/O syndrome/O to/O alert/O clinicians/O to/O the/O possibility/O of/O this/O syndrome/O in/O their/O patients/O ./O
Variable/O phenotypes/O are/O associated/O with/O PMP22/O missense/O mutations/O ./O
Charcot/B-Disease -/I-Disease Marie/I-Disease -/I-Disease Tooth/I-Disease disease/I-Disease (/O CMT/O )/O is/O the/O commonest/O hereditary/O neuropathy/O encompassing/O a/O large/O group/O of/O clinically/O and/O genetically/O heterogeneous/O disorders/O ./O
The/O commonest/O form/O of/O CMT/B-Disease ,/O CMT1A/B-Disease ,/O is/O usually/O caused/B-Reg by/I-Reg a/O 1.4/O megabase/O duplication/B-Var of/O chromosome/O 17/O containing/O the/O PMP22/B-Gene gene/O ./O
Mutations/B-Var of/O PMP22/B-Gene are/O a/O less/O common/O cause/B-Reg of/O CMT/B-Disease ./O
We/O describe/O clinical/O ,/O electrophysiological/O and/O molecular/O findings/O of/O 10/O patients/O carrying/O PMP22/O missense/O mutations/O ./O
The/O phenotype/O varied/O from/O mild/O hereditary/O neuropathy/O with/O liability/O to/O pressure/O palsies/O (/O HNPP/O )/O to/O severe/O CMT1/O ./O
We/O identified/O six/O different/O point/O mutations/O ,/O including/O two/O novel/O mutations/O ./O
Three/O families/O were/O also/O found/O to/O harbour/O a/O Thr118Met/O mutation/O ./O
Although/O PMP22/O point/O mutations/O are/O not/O common/O ,/O our/O findings/O highlight/O the/O importance/O of/O sequencing/O the/O PMP22/O gene/O in/O patients/O with/O variable/O CMT/O phenotypes/O and/O also/O confirm/O that/O the/O PMP22/B-Gene Thr118Met/B-Var mutation/O is/O associated/B-Reg with/I-Reg a/O neuropathy/B-CPA albeit/O with/O reduced/O penetrance/O ./O
Genotype/O -/O phenotype/O analysis/O of/O the/O branchio/O -/O oculo/O -/O facial/O syndrome/O ./O
Branchio/B-Disease -/I-Disease oculo/I-Disease -/I-Disease facial/I-Disease syndrome/I-Disease (/O BOFS/O ;/O OMIM#113620/O )/O is/O a/O rare/O autosomal/O dominant/O craniofacial/O disorder/O with/O variable/O expression/O ./O
Major/O features/O include/O cutaneous/O and/O ocular/O abnormalities/O ,/O characteristic/O facies/O ,/O renal/O ,/O ectodermal/O ,/O and/O temporal/O bone/O anomalies/O ./O
Having/O determined/O that/O mutations/B-Var involving/O TFAP2A/B-Gene result/B-Reg in/I-Reg BOFS/B-Disease ,/O we/O studied/O a/O total/O of/O 30/O families/O (/O 41/O affected/O individuals/O )/O ;/O 26/30/O (/O 87/O %/O )/O fulfilled/O our/O cardinal/O diagnostic/O criteria/O ./O
The/O original/O family/O with/O the/O 3.2/O Mb/O deletion/O including/O the/O TFAP2A/O gene/O remains/O the/O only/O BOFS/O family/O without/O the/O typical/O CL/O //O P/O and/O the/O only/O family/O with/O a/O deletion/O ./O
We/O have/O identified/O a/O hotspot/O region/O in/O the/O highly/O conserved/O exons/O 4/O and/O 5/O of/O TFAP2A/O that/O harbors/O missense/O mutations/O in/O 27/30/O (/O 90/O %/O )/O families/O ./O
Several/O of/O these/O mutations/O are/O recurrent/O ./O
Mosaicism/O was/O detected/O in/O one/O family/O ./O
To/O date/O ,/O genetic/O heterogeneity/O has/O not/O been/O observed/O ./O
Although/O the/O cardinal/O criteria/O for/O BOFS/O have/O been/O based/O on/O the/O presence/O of/O each/O of/O the/O core/O defects/O ,/O an/O affected/O family/O member/O or/O thymic/O remnant/O ,/O we/O documented/O TFAP2A/O mutations/O in/O three/O (/O 10/O %/O )/O probands/O in/O our/O series/O without/O a/O classic/O cervical/O cutaneous/O defect/O or/O ectopic/O thymus/O ./O
Temporal/O bone/O anomalies/O were/O identified/O in/O 3/5/O patients/O investigated/O ./O
The/O occurrence/O of/O CL/O //O P/O ,/O premature/O graying/O ,/O coloboma/O ,/O heterochromia/O irides/O ,/O and/O ectopic/O thymus/O ,/O are/O evidence/O for/O BOFS/O as/O a/O neurocristopathy/O ./O
Intrafamilial/O clinical/O variability/O can/O be/O marked/O ./O
Although/O there/O does/O not/O appear/O to/O be/O mutation/O -/O specific/O genotype/O -/O phenotype/O correlations/O at/O this/O time/O ,/O more/O patients/O need/O to/O be/O studied/O ./O
Clinical/O testing/O for/O TFAP2A/O mutations/O is/O now/O available/O and/O will/O assist/O geneticists/O in/O confirming/O the/O typical/O cases/O or/O excluding/O the/O diagnosis/O in/O atypical/O cases/O ./O
Twenty/O -/O five/O novel/O mutations/O including/O duplications/O in/O the/O ATP7A/O gene/O ./O
Twenty/O -/O five/O novel/O mutations/O including/O duplications/O in/O the/O ATP7A/O gene/O ./O
Menkes/B-Disease disease/I-Disease (/O MD/O )/O and/O occipital/B-Disease horn/I-Disease syndrome/I-Disease (/O OHS/O )/O are/O allelic/O X/O -/O linked/O recessive/O copper/O deficiency/O disorders/O resulting/B-Reg from/I-Reg ATP7A/B-Gene gene/O mutations/B-Var ./O
MD/O is/O a/O severe/O condition/O leading/O to/O progressive/O neurological/O degeneration/O and/O death/O in/O early/O childhood/O ,/O whereas/O OHS/O has/O a/O milder/O phenotype/O with/O mainly/O connective/O tissue/O abnormalities/O ./O
Until/O now/O ,/O molecular/O analyses/O have/O revealed/O only/O deletions/O and/O point/O mutations/O in/O both/O diseases/O ./O
This/O study/O reports/O new/O molecular/O data/O in/O a/O series/O of/O 40/O patients/O referred/O for/O either/O MD/O or/O OHS/O ./O
We/O describe/O 23/O point/O mutations/O (/O 9/O missense/O mutations/O ,/O 7/O splice/O site/O variants/O ,/O 4/O nonsense/O mutations/O ,/O and/O 3/O small/O insertions/O or/O deletions/O )/O and/O 7/O intragenic/O deletions/O ./O
Of/O these/O ,/O 18/O point/O mutations/O and/O 3/O deletions/O are/O novel/O ./O
Furthermore/O ,/O our/O finding/O of/O four/O whole/O exon/O duplications/O enlarges/O the/O mutation/O spectrum/O in/O the/O ATP7A/O gene/O ./O
ATP7A/O alterations/O were/O found/O in/O 85/O %/O of/O cases/O ./O
Of/O these/O alterations/O ,/O two/O thirds/O were/O point/O mutations/O and/O the/O remaining/O one/O third/O consisted/O of/O large/O rearrangements/O ./O
We/O found/O that/O 66.6/O %/O of/O point/O mutations/B-Var resulted/O in/O impaired/B-NegReg ATP7A/B-Gene transcript/B-MPA splicing/I-MPA ,/O a/O phenomenon/O more/O frequent/O than/O expected/O ./O
This/O finding/O enabled/O us/O to/O confirm/O the/O pathogenic/O role/O of/O ATP7A/O mutations/O ,/O particularly/O in/O missense/O and/O splice/O site/O variants/O ./O
Phenotypic/O heterogeneity/O in/O a/O large/O Thai/O slow/O -/O channel/O congenital/O myasthenic/O syndrome/O kinship/O ./O
The/O slow/B-Disease -/I-Disease channel/I-Disease congenital/I-Disease myasthenic/I-Disease syndrome/I-Disease (/O SCCMS/O )/O is/O an/O autosomal/O dominant/O neuromuscular/O disorder/O caused/B-Reg by/I-Reg mutations/B-Var in/O different/O subunits/O of/O the/O acetylcholine/O receptor/O (/B-Gene AChR/I-Gene )/I-Gene ./O
We/O here/O report/O our/O clinical/O findings/O in/O three/O generations/O of/O a/O large/O Thai/O kinship/O suffering/O from/O SCCMS/O and/O trace/O the/O disease/O to/O the/O p/O ./O Gly153Ser/O mutation/O in/O the/O AChR/O α/O subunit/O ./O
The/O same/O mutation/O had/O previously/O been/O reported/O only/O in/O Caucasian/O but/O not/O in/O Asian/O patients/O ./O
The/O clinical/O features/O include/O ptosis/O ,/O ophthalmoparesis/O ,/O and/O weakness/O of/O the/O cervical/O and/O finger/O extensor/O muscles/O as/O well/O as/O marked/O phenotypic/O heterogeneity/O ./O
[/O Anaemia/O caused/O by/O a/O congenital/O haemoglobin/O defect/O can/O also/O occur/O in/O native/O Dutch/O patients/O ]/O ./O
Anemie/O door/O aangeboren/O afwijkingen/O van/O het/O hemoglobine/O ,/O ook/O bij/O autochtone/O Nederlanders/O ./O
An/O 11-year/O -/O old/O boy/O of/O Dutch/O descent/O had/O suffered/O from/O tiredness/O ,/O pallor/O and/O poor/O appetite/O for/O many/O years/O ./O
There/O was/O no/O indication/O of/O chronic/O infection/O ./O
Iron/O supplements/O did/O not/O produce/O sufficient/O improvement/O in/O the/O symptoms/O ./O
Following/O analysis/O using/O fast/O protein/O liquid/O chromatography/O and/O DNA/O sequencing/O analysis/O ,/O it/O appeared/O that/O this/O was/O a/O case/O of/O β/B-Disease -/I-Disease thalassaemia/I-Disease intermedia/I-Disease ,/O caused/B-Reg by/I-Reg a/O point/B-Var mutation/I-Var in/O the/O promotor/O region/O of/O the/O β/B-Gene -/I-Gene globulin/I-Gene gene/O ./O
The/O boy/O 's/O parents/O both/O proved/O to/O be/O heterozygotes/O for/O this/O point/O mutation/O ./O
A/O second/O patient/O ,/O a/O 5-year/O -/O old/O girl/O of/O Dutch/O descent/O ,/O suffered/O from/O an/O icterus/O following/O a/O respiratory/O tract/O infection/O ./O
Splenomegaly/O ,/O hyperbilirubinaemia/O and/O microcytic/O anaemia/O with/O raised/O reticulocyte/O values/O were/O observed/O ./O
Because/O of/O the/O presence/O of/O spherocytes/O ,/O hereditary/O spherocytosis/O was/O initially/O suspected/O ./O
On/O further/O analysis/O Heinz/O bodies/O were/O also/O seen/O ,/O following/O which/O DNA/O sequencing/O analysis/O showed/O a/O de/O novo/O Hb/O Köln/O mutation/O ./O
Congenital/O haemoglobin/O defects/O are/O usually/O associated/O with/O people/O originating/O from/O Africa/O ,/O the/O Mediterranean/O ,/O the/O Middle/O -/O East/O or/O South/O -/O East/O Asia/O ./O
That/O such/O abnormalities/O can/O also/O occur/O in/O children/O of/O Dutch/O descent/O is/O demonstrated/O by/O these/O two/O cases/O ./O
Mild/O recessive/O dystrophic/B-Disease epidermolysis/I-Disease bullosa/I-Disease associated/B-Reg with/I-Reg two/O compound/O heterozygous/O COL7A1/B-Gene mutations/B-Var ./O
Dystrophic/B-Disease epidermolysis/I-Disease bullosa/I-Disease is/O a/O group/O of/O inherited/O skin/O blistering/O disorders/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O COL7A1/B-Gene gene/O coding/O for/O type/O VII/O collagen/O ./O
More/O than/O 500/O different/O COL7A1/B-Gene mutations/B-Var have/O been/O detected/B-Reg in/O dystrophic/B-Disease epidermolysis/I-Disease bullosa/I-Disease to/O date/O ./O
Clarification/O of/O genotype/O -/O phenotype/O correlations/O is/O of/O particular/O importance/O for/O the/O development/O of/O novel/O therapeutic/O approaches/O ./O
Here/O we/O report/O a/O female/O patient/O with/O mild/O dystrophic/O epidermolysis/O bullosa/O harbouring/O two/O compound/O heterozygous/O COL7A1/O mutations/O ,/O namely/O the/O intronic/O splice/O site/O mutation/O c.3832/O -/O 2A/O >/O G/O and/O the/O glycine/O substitution/O p/O ./O G1347W./O Our/O data/O extend/O the/O current/O knowledge/O on/O genotype/O -/O phenotype/O correlations/O in/O dystrophic/O epidermolysis/O bullosa/O ./O
[/O Association/O of/O mutation/O types/O and/O distribution/O characteristics/O of/O dystrophin/O gene/O with/O clinical/O symptoms/O in/O Chinese/O population/O ]/O ./O
Duchenne/O muscular/O dystrophy/O (/O DMD/O )/O is/O X/O -/O linked/O disorder/O caused/O by/O mutations/O in/O the/O dystrophin/O gene/O ./O
To/O investigate/O mutation/O types/O and/O distribution/O characteristics/O of/O dystrophin/O gene/O in/O Chinese/O DMD/O patients/O ,/O we/O used/O Multiplex/O Ligation/O -/O Dependent/O Probe/O Amplification/O (/O MLPA/O )/O to/O analyze/O the/O dystrophin/O gene/O in/O 720/O DMD/O patients/O ,/O their/O mothers/O ,/O and/O 20/O normal/O adult/O males/O ./O
Results/O showed/O that/O detection/O rate/O was/O 64.9/O %/O (/O 467/720/O )/O in/O all/O the/O patients/O ,/O gene/O deletion/O rate/O was/O 54.3/O %/O (/O 391/720/O )/O ,/O and/O gene/O duplication/O rate/O was/O 10.6/O %/O (/O 76/720/O )/O ./O
The/O rate/O of/O deletion/O mutant/O occurred/O in/O Exon/O 45/O -/O 54/O was/O 71.9/O %/O (/O 281/391/O )/O in/O all/O gene/O deletion/O patients/O ;/O meanwhile/O ,/O the/O rate/O of/O gene/O duplication/O occurred/O in/O Exon/O 1/O -/O 40/O was/O 82.9/O %/O (/O 63/76/O )/O in/O all/O gene/O duplication/O ones/O ./O
In/O all/O the/O patients/O with/O gene/O deletion/O and/O duplication/O ,/O the/O rate/O of/O DMD/O and/O IMD/O was/O 90.6/O %/O (/O 423/467/O )/O ,/O and/O BMD/O ,/O 9.4/O %/O (/O 44/467/O )/O ./O
This/O indicates/O that/O the/O main/O reason/B-Reg of/O duchenne/B-Disease muscular/I-Disease dystrophy/I-Disease is/O dystrophin/B-Gene gene/I-Gene deletion/B-Var mutation/O ,/O which/O would/O occur/O in/O any/O gene/O unevenly/O with/O hot/O spots/O of/O mutation/O ./O
The/O location/O and/O fragment/O length/O of/O gene/O deletion/O and/O duplication/O can/O not/O decide/O the/O severity/O of/O clinical/O symptoms/O directly/O ./O
AXIN2-associated/O autosomal/O dominant/O ectodermal/O dysplasia/O and/O neoplastic/O syndrome/O ./O
We/O describe/O a/O family/O with/O a/O novel/O ,/O inherited/O AXIN2/O mutation/O (/O c.1989G/O >/O A/O )/O segregating/O in/O an/O autosomal/O dominant/O pattern/O with/O oligodontia/O and/O variable/O other/O findings/O including/O colonic/O polyposis/O ,/O gastric/O polyps/O ,/O a/O mild/O ectodermal/O dysplasia/O phenotype/O with/O sparse/O hair/O and/O eyebrows/O ,/O and/O early/O onset/O colorectal/O and/O breast/O cancers/O ./O
This/O novel/O mutation/O predicts/O p/O ./O Trp663X/O ,/O which/O is/O a/O truncated/O protein/O that/O is/O missing/O the/O last/O three/O exons/O ,/O including/O the/O DIX/O (/O Disheveled/O and/O AXIN/O interacting/O )/O domain/O ./O
This/O nonsense/O mutation/B-Var is/O predicted/O to/O destroy/B-NegReg the/O inhibitory/B-MPA action/I-MPA of/O AXIN2/B-Gene on/O WNT/B-Pathway signaling/I-Pathway ./O
Previous/O authors/O have/O described/O an/O unrelated/O family/O with/O autosomal/O dominant/O oligodontia/O and/O a/O variable/O colorectal/O phenotype/O segregating/O with/O a/O nonsense/O mutation/O of/O AXIN2/O ,/O as/O well/O as/O a/O frameshift/O AXIN2/O mutation/O in/O an/O unrelated/O individual/O with/O oligodontia/O ./O
Our/O report/O provides/O additional/O evidence/O supporting/O an/O autosomal/B-Var dominant/I-Var AXIN2-associated/B-Reg ectodermal/B-Disease dysplasia/I-Disease and/O neoplastic/B-Disease syndrome/I-Disease ./O
The/O Down/O syndrome/O critical/O region/O regulates/O retinogeniculate/O refinement/O ./O
Down/B-Disease syndrome/I-Disease (/O DS/O )/O is/O a/O developmental/O disorder/O caused/B-Reg by/I-Reg a/O third/O chromosome/O 21/O in/O humans/O (/B-Var Trisomy/I-Var 21/I-Var )/I-Var ,/O leading/O to/O neurological/O deficits/O and/O cognitive/O impairment/O ./O
Studies/O in/O mouse/O models/O of/O DS/O suggest/O that/O cognitive/O deficits/O in/O the/O adult/O are/O associated/O with/O deficits/O in/O synaptic/O learning/O and/O memory/O mechanisms/O ,/O but/O it/O is/O unclear/O whether/O alterations/O in/O the/O early/O wiring/O and/O refinement/O of/O neuronal/O circuits/O contribute/O to/O these/O deficits/O ./O
Here/O ,/O we/O show/O that/O early/O developmental/O refinement/O of/O visual/O circuits/O is/O perturbed/O in/O mouse/O models/O of/O Down/O syndrome/O ./O
Specifically/O ,/O we/O find/O excessive/O eye/O -/O specific/O segregation/O of/O retinal/O axons/O in/O the/O dorsal/O lateral/O geniculate/O nucleus/O ./O
Indeed/O ,/O the/O degree/O of/O refinement/O scales/O with/O defects/O in/O the/O "/O Down/O syndrome/O critical/O region/O "/O (/O DSCR/O )/O in/O a/O dose/O -/O dependent/O manner/O ./O
We/O further/O identify/O Dscam/O (/O Down/O syndrome/O cell/O adhesion/O molecule/O )/O ,/O a/O gene/O within/O the/O DSCR/O ,/O as/O a/O regulator/O of/O eye/O -/O specific/O segregation/O of/O retinogeniculate/O projections/O ./O
Although/O Dscam/O is/O not/O the/O sole/O gene/O in/O the/O DSCR/O contributing/O to/O enhanced/O refinement/O in/O trisomy/O ,/O Dscam/O dosage/O clearly/O regulates/O cell/O spacing/O and/O dendritic/O fasciculation/O in/O a/O specific/O class/O of/O retinal/O ganglion/O cells/O ./O
Thus/O ,/O altered/O developmental/O refinement/O of/O visual/O circuits/O that/O occurs/O before/O sensory/O experience/O is/O likely/O to/O contribute/O to/O visual/O impairment/O in/O individuals/O with/O Down/O syndrome/O ./O
Identification/O and/O functional/O consequences/O of/O a/O recurrent/O NLRP12/B-Gene missense/B-Var mutation/I-Var in/B-Reg periodic/B-Disease fever/I-Disease syndromes/I-Disease ./O
OBJECTIVE/O :/O To/O gain/O insight/O into/O the/O molecular/O bases/O of/O genetically/O unexplained/O periodic/O fever/O syndromes/O (/O PFS/O )/O by/O screening/O NLRP12/O ,/O a/O gene/O in/O which/O only/O a/O nonsense/O and/O a/O splice/O site/O mutation/O have/O so/O far/O been/O identified/O ,/O and/O to/O assess/O the/O functional/O consequences/O of/O the/O identified/O missense/O variation/O ./O
METHODS/O :/O NLRP12/O was/O screened/O for/O mutations/O by/O direct/O sequencing/O ./O
Functional/O assays/O were/O performed/O in/O HEK/O 293/O T/O cells/O stably/O expressing/O the/O proapoptotic/O protein/O ASC/O and/O procaspase/O 1/O ,/O in/O order/O to/O determine/O the/O effects/O of/O normal/O and/O mutated/O NLRP12/O proteins/O on/O speck/O formation/O ,/O caspase/O 1/O signaling/O ,/O and/O NF/O -/O κB/O activation/O ./O
RESULTS/O :/O A/O heterozygous/O NLRP12/B-Gene missense/O mutation/O involving/O a/O CpG/O site/O (/B-Var c.1054C/I-Var >/I-Var T/I-Var ;/I-Var p/O ./O Arg352Cys/O )/O was/O identified/O in/O exon/O 3/O ,/O which/O encodes/B-Reg the/O nucleotide/B-Interaction -/I-Interaction binding/I-Interaction site/O (/O NBS/O )/O of/O the/O protein/B-Protein ,/O in/O 2/O patients/O from/O different/O countries/O and/O carrying/O different/O NLRP12/O haplotypes/O ./O
The/O mutation/B-Var ,/O which/O does/O not/O alter/O the/O inhibitory/O effect/O of/O NLRP12/O on/O NF/O -/O κB/O activation/O ,/O increases/B-PosReg speck/B-MPA formation/I-MPA and/O activates/B-PosReg caspase/B-MPA 1/I-MPA signaling/I-MPA ./O
To/O define/O this/O new/O class/O of/O PFS/O ,/O we/O propose/O the/O term/O NLRP12-associated/O disorders/O (/O NLRP12AD/O )/O ./O
CONCLUSION/O :/O Given/O the/O rarity/O of/O known/O NLRP12-associated/O disorders/O ,/O the/O identification/O of/O this/O NLRP12/O molecular/O defect/O contributes/O to/O the/O delineation/O of/O the/O clinical/O spectrum/O associated/O with/O mutations/O in/O this/O gene/O and/O highlights/O the/O importance/O of/O screening/O NLRP12/O in/O patients/O presenting/O with/O unexplained/O PFS/O ./O
This/O study/O also/O demonstrates/O ,/O by/O means/O of/O functional/O assays/O ,/O the/O deleterious/O effect/O of/O this/O recurrent/O missense/O mutation/O ;/O the/O gain/B-PosReg of/I-PosReg function/I-PosReg for/O speck/B-MPA formation/I-MPA and/O caspase/B-MPA 1/I-MPA signaling/I-MPA associated/O with/O this/O NBS/O mutation/B-Var is/O consistent/O with/O the/O inflammatory/O phenotype/O of/O PFS/O ./O
New/O homozygous/O SPINK5/O mutation/O ,/O p/O ./O Gln333X/O ,/O in/O a/O Turkish/O pedigree/O with/O Netherton/O syndrome/O ./O
Netherton/B-Disease syndrome/I-Disease (/O NS/O )/O is/O a/O rare/O autosomal/O recessive/O genodermatosis/O caused/O by/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O the/O SPINK5/B-Gene gene/O ./O
The/O clinical/O features/O include/O congenital/O ichthyosis/O ,/O trichorrhexis/O invaginata/O and/O atopy/O ./O
In/O this/O study/O ,/O we/O report/O a/O new/O homozygous/O SPINK5/B-Gene mutation/O ,/O p/B-Var ./I-Var Gln333X/I-Var ,/O responsible/B-Reg for/O NS/B-Disease in/O affected/O members/O of/O two/O closely/O related/O Turkish/O families/O ,/O and/O provide/O an/O overview/O of/O the/O genotype/O -/O phenotype/O correlation/O in/O this/O condition/O ./O
Severer/O phenotype/O in/O Unverricht/B-Disease -/I-Disease Lundborg/I-Disease disease/I-Disease (/O EPM1/O )/O patients/O compound/O heterozygous/O for/B-Reg the/O dodecamer/O repeat/O expansion/O and/O the/O c.202C/B-Var >/I-Var T/I-Var mutation/O in/O the/O CSTB/B-Gene gene/O ./O
BACKGROUND/O //O AIMS/O :/O Unverricht/B-Disease -/I-Disease Lundborg/I-Disease disease/I-Disease (/O EPM1/O )/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O cystatin/O B/O (/B-Gene CSTB/I-Gene )/I-Gene gene/O ./O
Most/O patients/O are/O homozygous/O for/O the/O expanded/O dodecamer/O repeat/O mutation/O alleles/O ,/O but/O 9/O other/O EPM1-associated/O mutations/O have/O also/O been/O identified/O ./O
We/O describe/O the/O clinical/O ,/O cognitive/O and/O imaging/O characteristics/O of/O 5/O Finnish/O EPM1/O patients/O who/O are/O compound/O heterozygous/O for/O the/O dodecamer/O repeat/O expansion/O and/O the/O c.202C/O >/O T/O mutations/O ./O
METHODS/O :/O Five/O compound/O heterozygous/O patients/O and/O 21/O patients/O homozygous/O for/O the/O expansion/O mutation/O ,/O participating/O in/O an/O ongoing/O nationwide/O clinical/O and/O molecular/O genetics/O study/O ,/O were/O evaluated/O using/O the/O Unified/O Myoclonus/O Rating/O Scale/O test/O and/O comprehensive/O neuropsychological/O testing/O ./O
All/O patients/O underwent/O MR/O imaging/O ./O
The/O MR/O data/O were/O also/O compared/O with/O those/O of/O 24/O healthy/O control/O subjects/O ./O
RESULTS/O :/O Age/O at/O onset/O of/O symptoms/O was/O significantly/O lower/O in/O the/O compound/O heterozygotes/O than/O in/O the/O homozygous/O EPM1/O patients/O ./O
They/O also/O had/O severer/O myoclonus/O and/O drug/O -/O resistant/O tonic/O -/O clonic/O seizures/O ./O
Moreover/O ,/O they/O had/O lower/O cognitive/O performance/O ./O
In/O MRI/O a/O voxel/O -/O based/O morphometry/O analysis/O of/O primary/O and/O premotor/O cortex/O ,/O supplementary/O motor/O cortex/O and/O thalami/O revealed/O gray/O matter/O volume/O loss/O when/O compared/O with/O the/O healthy/O controls/O ,/O similar/O to/O patients/O homozygous/O for/O the/O expansion/O mutation/O ./O
CONCLUSION/O :/O Patients/O compound/O heterozygous/O for/O the/O dodecamer/O repeat/O expansion/O and/O the/O c.202C/O >/O T/O mutations/O seem/O to/O have/O a/O severer/O form/O of/O EPM1/O than/O patients/O homozygous/O for/O the/O expansion/O mutation/O ./O
These/O findings/O have/O implications/O for/O counseling/O of/O EPM1/O patients/O with/O different/O genetic/O defects/O ./O
Acquisition/O of/O steady/O -/O state/O operant/O behavior/O in/O long/O -/O living/O Ames/O Dwarf/O mice/O ./O
Ames/O dwarf/O mice/O have/O a/O Prop-1/B-Gene mutation/B-Var that/O has/O been/O identified/O with/O increased/B-PosReg levels/B-MPA of/I-MPA IGF/I-MPA -/I-MPA I/I-MPA in/O the/O central/O nervous/O system/O ,/O upregulation/B-PosReg of/O neuroprotective/B-CPA systems/I-CPA ,/O and/O increased/O lifespan/O ./O
To/O elucidate/O the/O behavioral/O effects/O of/O the/O Prop-1/O mutation/O ,/O 8/O Ames/O dwarf/O and/O 7/O normal/O mice/O (/O all/O of/O whom/O were/O 8/O months/O of/O age/O or/O younger/O )/O were/O compared/O on/O a/O differential/O -/O reinforcement/O -/O of/O -/O low/O -/O rate/O -/O of/O -/O responding/O schedule/O of/O reinforcement/O and/O a/O matching/O -/O to/O -/O sample/O task/O ./O
On/O both/O tasks/O ,/O nosepokes/O were/O reinforced/O with/O access/O to/O a/O saccharin/O solution/O ./O
Comparisons/O were/O based/O on/O several/O measures/O of/O behavioral/O efficiency/O :/O pause/O durations/O ,/O intertrial/O intervals/O ,/O and/O numbers/O of/O responses/O ./O
Ames/O dwarf/O mice/O were/O generally/O less/O efficient/O than/O normal/O mice/O ./O
One/O possible/O cause/O of/O this/O outcome/O is/O that/O relatively/O young/O Ames/O dwarf/O mice/O show/O less/O cognitive/O development/O than/O age/O -/O matched/O normal/O mice/O ./O
[/B-Gene GNE/I-Gene gene/O mutation/B-Var analysis/O in/O 5/O patients/O with/B-Reg distal/B-Disease myopathy/I-Disease with/I-Disease rimmed/I-Disease vacuoles/I-Disease ]/I-Disease ./O
OBJECTIVE/O :/O To/O investigate/O GNE/O gene/O mutations/O in/O 5/O Chinese/O patients/O with/O distal/O myopathy/O with/O rimmed/O vacuoles/O (/O DMRV/O )/O ./O
METHODS/O :/O Five/O patients/O with/O typical/O clinical/O and/O pathological/O features/O of/O DMRV/O were/O studied/O ./O
All/O the/O 11/O coding/O exons/O and/O the/O flanking/O intron/O sequences/O of/O GNE/O gene/O were/O amplified/O by/O PCR/O and/O sequenced/O ./O
Four/O family/O members/O of/O case/O 5/O were/O also/O examined/O for/O GNE/O gene/O mutations/O ./O
RESULTS/O :/O All/O the/O patients/O were/O identified/O to/O have/O different/O GNE/O gene/O mutations/O :/O Cases/O 1/O -/O 4/O had/O complex/O heterozygous/O mutations/O and/O case/O 5/O had/O homozygous/O mutation/O ./O
Six/O reported/O mutations/O had/O been/O identified/O ,/O including/O 1/O nonsense/O mutation/O (/O p/O ./O R8X/O )/O and/O 5/O missense/O mutations/O (/O p/O ./O D176V/O ,/O p/O ./O I298/O T/O ,/O p/O ./O A591/O T/O ,/O P.A631V/O ,/O and/O p/O ./O V696/O M/O )/O ./O
A/O novel/O mutation/O (/O c.317T/O >/O C/O ,/O p/O ./O I106/O T/O )/O was/O identified/O in/O case/O 2/O ./O
CONCLUSION/O :/O This/O is/O the/O first/O report/O of/O p/B-Var ./I-Var R8X/I-Var ,/O p/B-Var ./I-Var I298/I-Var T/I-Var ,/O p/B-Var ./I-Var A591/I-Var T/I-Var and/O p/B-Var ./I-Var V696/I-Var M/I-Var mutations/O in/O GNE/B-Gene gene/O in/O Chinese/O population/O ,/O and/O a/O novel/O mutation/O p/B-Var ./I-Var I106/I-Var T/I-Var was/O identified/O ./O
These/O findings/O further/O expand/O the/O clinical/O and/O genetic/O spectrum/O of/B-Reg DMRV/B-Disease in/O China/O ./O
Congenital/O variant/O of/O Rett/O syndrome/O due/O to/O an/O intragenic/O large/O deletion/O in/O MECP2/O ./O
Rett/B-Disease syndrome/I-Disease (/O RTT/O )/O is/O a/O neurodevelopmental/O disorder/O that/O is/O one/O of/O the/O most/O common/O causes/O of/O mental/O retardation/O in/O females/O ./O
RTT/O diagnosis/O is/O based/O on/O distinct/O clinical/O criteria/O ./O
We/O describe/O here/O a/O female/O patient/O with/O severe/O phenotype/O of/O congenital/O variant/O RTT/O ./O
The/O patient/O originally/O presented/O with/O severe/O developmental/O delay/O prior/O to/O the/O age/O of/O 6/O months/O and/O later/O exhibited/O characteristic/O features/O of/O RTT/O that/O included/O air/O swallowing/O ,/O bruxism/O ,/O and/O hand/O stereotypies/O ./O
Results/O of/O an/O array/O -/O based/O comparative/O genomic/O hybridization/O analysis/O indicated/O there/O was/O a/O very/O small/O microdeletion/O in/O Xq28/O ./O
Multiplex/O ligation/O -/O dependent/O probe/O amplification/O analysis/O further/O confirmed/O there/O were/O heterozygous/O deletions/O of/O intron/O 2/O ,/O exon/O 3/O ,/O intron/O 3/O ,/O and/O part/O of/O exon/O 4/O in/O MECP2/O ./O
Findings/O in/O the/O present/O patient/O confirm/O the/O view/O that/O large/O MECP2/B-Gene deletions/B-Var are/O an/O important/O cause/B-Reg of/O severe/O congenital/O variant/O RTT/B-Disease ./O
To/O ensure/O an/O accurate/O diagnosis/O of/O congenital/O variant/O RTT/O ,/O a/O multiplex/O ligation/O -/O dependent/O probe/O amplification/O analysis/O of/O MECP2/O should/O be/O performed/O in/O patients/O suspected/O of/O having/O this/O disorder/O ./O
A/O new/O frame/B-Var -/I-Var shifting/I-Var mutation/O of/O UGT1A1/B-Gene gene/O causes/B-Reg type/B-Disease I/I-Disease Crigler/I-Disease -/I-Disease Najjar/I-Disease syndrome/I-Disease ./O
We/O present/O a/O case/O of/O severe/O persisting/O unconjugated/O hyperbilirubinemia/O in/O a/O Uigur/O infant/O boy/O ,/O eventually/O diagnosed/O as/O Crigler/O -/O Najjar/O syndrome/O type/O I./O DNA/O analysis/O of/O his/O blood/O of/O the/O UGT1A1/O gene/O sequence/O demonstrated/O that/O he/O was/O homozygous/O for/O an/O insertion/O mutation/O causing/O a/O change/O of/O the/O coding/O exons/O with/O a/O frame/O -/O shift/O ,/O resulting/O in/O the/O substitution/O of/O 27/O abnormal/O amino/O acid/O residues/O in/O his/O hepatic/O bilirubin/O uridine/O diphosphoglucuronyl/O transferase/O enzyme/O ./O
Both/O of/O his/O parents/O were/O heterozygous/O for/O the/O same/O mutation/O ./O
A/O novel/O frame/O -/O shifting/O mutation/O of/O the/O UGT1A1/O gene/O was/O found/O ,/O confirming/O the/O diagnosis/O of/O Crigler/O -/O Najjar/O syndrome/O type/O I/O for/O this/O patient/O ./O
X/O inactivation/O in/O females/O with/O X/O -/O linked/O Charcot/O -/O Marie/O -/O Tooth/O disease/O ./O
X/B-Disease -/I-Disease linked/I-Disease Charcot/I-Disease -/I-Disease Marie/I-Disease -/I-Disease Tooth/I-Disease disease/I-Disease (/O CMT1X/O )/O is/O the/O second/O most/O common/O inherited/O neuropathy/O ,/O caused/B-Reg by/I-Reg mutations/B-Var in/O gap/O junction/O beta-1/O (/B-Gene GJB1/I-Gene )/I-Gene ./O
Males/O have/O a/O uniformly/O moderately/O severe/O phenotype/O while/O females/O have/O a/O variable/O phenotype/O ,/O suggested/O to/O be/O due/O to/O X/O inactivation/O ./O
We/O aimed/O to/O assess/O X/O inactivation/O pattern/O in/O females/O with/O CMT1X/O and/O correlate/O this/O with/O phenotype/O using/O the/O CMT/O examination/O score/O to/O determine/O whether/O the/O X/O inactivation/O pattern/O accounted/O for/O the/O variable/O phenotype/O in/O females/O with/O CMT1X./O We/O determined/O X/O inactivation/O pattern/O in/O 67/O females/O with/O CMT1X/O and/O 24/O controls/O using/O the/O androgen/O receptor/O assay/O ./O
We/O were/O able/O to/O determine/O which/O X/O chromosome/O carried/O the/O GJB1/O mutation/O in/O 30/O females/O ./O
There/O was/O no/O difference/O in/O X/O inactivation/O pattern/O between/O patients/O and/O controls/O ./O
In/O addition/O ,/O there/O was/O no/O correlation/O between/O X/O inactivation/O pattern/O in/O blood/O and/O phenotype/O ./O
A/O possible/O explanation/O for/O these/O findings/O is/O that/O the/O X/O inactivation/O pattern/O in/O Schwann/O cells/O rather/O than/O in/O blood/O may/O explain/O the/O variable/O phenotype/O in/O females/O with/O CMT1X./O Autosomal/B-Disease dominant/I-Disease polycystic/I-Disease kidney/I-Disease disease/I-Disease :/I-Disease comprehensive/O mutation/B-Var analysis/O of/O PKD1/B-Gene and/O PKD2/B-Gene in/B-Reg 700/O unrelated/O patients/O ./O
Autosomal/B-Disease dominant/I-Disease polycystic/I-Disease kidney/I-Disease disease/I-Disease (/O ADPKD/O )/O ,/O the/O most/O common/O inherited/O kidney/O disorder/O ,/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O PKD1/B-Gene or/O PKD2/B-Gene ./O
The/O molecular/O diagnosis/O of/O ADPKD/O is/O complicated/O by/O extensive/O allelic/O heterogeneity/O and/O particularly/O by/O the/O presence/O of/O six/O highly/O homologous/O sequences/O of/O PKD1/O exons/O 1/O -/O 33/O ./O
Here/O ,/O we/O screened/O PKD1/O and/O PKD2/O for/O both/O conventional/O mutations/O and/O gross/O genomic/O rearrangements/O in/O up/O to/O 700/O unrelated/O ADPKD/O patients/O --/O the/O largest/O patient/O cohort/O to/O date/O --/O by/O means/O of/O direct/O sequencing/O ,/O followed/O by/O quantitative/O fluorescent/O multiplex/O polymerase/O chain/O reaction/O or/O array/O -/O comparative/O genomic/O hybridization/O ./O
This/O resulted/O in/O the/O identification/O of/O the/O largest/O number/O of/O new/O pathogenic/O mutations/O (/O n/O =/O 351/O )/O in/O a/O single/O publication/O ,/O expanded/O the/O spectrum/O of/O known/O ADPKD/O pathogenic/O mutations/O by/O 41.8/O %/O for/O PKD1/O and/O by/O 23.8/O %/O for/O PKD2/O ,/O and/O provided/O new/O insights/O into/O several/O issues/O ,/O such/O as/O the/O population/O -/O dependent/O distribution/O of/O recurrent/O mutations/O compared/O with/O founder/O mutations/O and/O the/O relative/O paucity/O of/O pathogenic/O missense/O mutations/O in/O the/O PKD2/O gene/O ./O
Our/O study/O ,/O together/O with/O others/O ,/O highlights/O the/O importance/O of/O developing/O novel/O approaches/O for/O both/O mutation/O detection/O and/O functional/O validation/O of/O nondefinite/O pathogenic/O mutations/O to/O increase/O the/O diagnostic/O value/O of/O molecular/O testing/O for/O ADPKD/O ./O
A/O novel/O classification/O system/O to/O predict/O the/O pathogenic/O effects/O of/O CHD7/B-Gene missense/B-Var variants/I-Var in/B-Reg CHARGE/B-Disease syndrome/I-Disease ./O
CHARGE/B-Disease syndrome/I-Disease is/O characterized/O by/O the/O variable/O occurrence/O of/O multisensory/O impairment/O ,/O congenital/O anomalies/O ,/O and/O developmental/O delay/O ,/O and/O is/O caused/B-Reg by/I-Reg heterozygous/B-Var mutations/I-Var in/O the/O CHD7/B-Gene gene/O ./O
Correct/O interpretation/O of/O CHD7/O variants/O is/O essential/O for/O genetic/O counseling/O ./O
This/O is/O particularly/O difficult/O for/O missense/O variants/O because/O most/O variants/O in/O the/O CHD7/O gene/O are/O private/O and/O a/O functional/O assay/O is/O not/O yet/O available/O ./O
We/O have/O therefore/O developed/O a/O novel/O classification/O system/O to/O predict/O the/O pathogenic/O effects/O of/O CHD7/O missense/O variants/O that/O can/O be/O used/O in/O a/O diagnostic/O setting/O ./O
Our/O classification/O system/O combines/O the/O results/O from/O two/O computational/O algorithms/O (/O PolyPhen-2/O and/O Align/O -/O GVGD/O )/O and/O the/O prediction/O of/O a/O newly/O developed/O structural/O model/O of/O the/O chromo-/O and/O helicase/O domains/O of/O CHD7/O with/O segregation/O and/O phenotypic/O data/O ./O
The/O combination/O of/O different/O variables/O will/O lead/O to/O a/O more/O confident/O prediction/O of/O pathogenicity/O than/O was/O previously/O possible/O ./O
We/O have/O used/O our/O system/O to/O classify/O 145/O CHD7/O missense/O variants/O ./O
Our/O data/O show/O that/O pathogenic/O missense/O mutations/O are/O mainly/O present/O in/O the/O middle/O of/O the/O CHD7/O gene/O ,/O whereas/O benign/O variants/O are/O mainly/O clustered/O in/O the/O 5/O '/O and/O 3/O '/O regions/O ./O
Finally/O ,/O we/O show/O that/O CHD7/O missense/O mutations/O are/O ,/O in/O general/O ,/O associated/O with/O a/O milder/O phenotype/O than/O truncating/O mutations/O ./O
Novel/O mutation/O in/O SLC9A6/O gene/O in/O a/O patient/O with/O Christianson/O syndrome/O and/O retinitis/O pigmentosum/O ./O
Mutations/B-Var in/O the/O SLC9A6/B-Gene gene/O cause/B-Reg Christianson/B-Disease syndrome/I-Disease in/O boys/O ./O
This/O X/O -/O linked/O syndrome/O is/O characterized/O by/O profound/O mental/O retardation/O with/O autistic/O behavior/O ,/O microcephaly/O ,/O epilepsy/O ,/O ophthalmoplegia/O ,/O and/O ataxia/O ./O
Progressive/O cerebellar/O atrophy/O with/O motor/O regression/O is/O a/O remarkable/O feature/O in/O some/O patients/O ./O
We/O report/O on/O a/O 22year/O -/O old/O male/O patient/O with/O Christianson/O syndrome/O carrying/O the/O novel/O p/O ./O Gln306X/O mutation/O ./O
The/O infantile/O phenotype/O suggested/O pervasive/O developmental/O disorder/O ,/O then/O profound/O mental/O retardation/O ensued/O ./O
In/O later/O childhood/O ,/O progressive/O cerebellar/O atrophy/O was/O diagnosed/O on/O serial/O brain/O MRIs/O and/O motor/O regression/O occurred/O ./O
Furthermore/O ,/O ophthalmological/O evaluations/O showed/O a/O retinitis/O pigmentosum/O previously/O unreported/O in/O this/O condition/O ./O
We/O conclude/O that/O the/O natural/O history/O of/O the/O disease/O in/O this/O patient/O tends/O to/O confirm/O the/O degenerative/O nature/O of/O Christianson/O syndrome/O ,/O and/O that/O retinal/O degeneration/O may/O be/O part/O of/O the/O condition/O ./O
Before/O the/O onset/O of/O degeneration/O ,/O the/O syndromic/O association/O of/O severe/O mental/O retardation/O ,/O autistic/O behavior/O ,/O external/O ophthalmoplegia/O ,/O and/O facial/O dysmorphism/O in/O male/O patients/O is/O a/O clue/O to/O the/O diagnosis/O ./O
Mutation/B-Var analysis/O in/O two/O Chinese/O families/O with/B-Reg multiple/B-Disease endocrine/I-Disease neoplasia/I-Disease type/I-Disease 1/I-Disease ./O
OBJECTIVE/O :/O This/O study/O aimed/O at/O identifing/O mutations/O in/O two/O Chinese/O genealogies/O with/O MEN1/B-Gene ./O
SUBJECTS/O AND/O METHODS/O :/O Three/O members/O of/O two/O Chinese/O families/O with/O MEN1/O were/O enrolled/O in/O this/O study/O ,/O and/O all/O of/O the/O coding/O regions/O and/O adjacent/O sequences/O of/O the/O MEN1/O gene/O were/O amplified/O and/O sequenced/O ./O
RESULTS/O :/O A/O recurrent/O mutation/O of/O heterozygous/O change/O T/O >/O A/O at/O IVS/O 4/O +/O 1/O was/O found/O in/O family/O I/O ,/O and/O a/O novel/O insGAGGTGG/O mutation/O (/O c.703/O -/O 709dup7bp/O )/O resulted/O in/O a/O frameshift/O (/O p/O ./O A237Gfsx13/O )/O in/O family/O II/O ./O
CONCLUSION/O :/O We/O are/O able/O to/O add/O a/O new/O mutation/O of/O MEN1/O gene/O in/O Chinese/O patients/O with/O MEN1/O that/O will/O be/O useful/O for/O the/O diagnosis/O and/O treatment/O of/O the/O disease/O ./O
Two/O novel/O mutations/O in/O the/O lactase/O gene/O in/O a/O Japanese/O infant/O with/O congenital/O lactase/O deficiency/O ./O
Intestinal/O lactase/O is/O required/O for/O the/O hydrolysis/O of/O lactose/O that/O is/O the/O most/O essential/O carbohydrate/O in/O milk/O and/O the/O primary/O diet/O source/O of/O newborn/O ./O
Congenital/B-Disease lactase/I-Disease deficiency/I-Disease [/O CLD/O (/O MIM/O 223000/O )/O ]/O is/O a/O severe/O gastrointestinal/O disorder/O and/O is/O characterized/O by/O watery/O diarrhea/O due/O to/O an/O extremely/O low/O or/O the/O lack/O of/O lactase/O activity/O in/O the/O intestinal/O wall/O from/O birth/O ./O
CLD/O is/O a/O rare/O disease/O and/O occurs/O more/O frequently/O in/O Finland/O ./O
Recent/O studies/O have/O shown/O that/O mutations/B-Var in/O the/O coding/O region/O of/O the/O lactase/O (/B-Gene LCT/I-Gene )/I-Gene gene/O underlie/B-Reg CLD/B-Disease in/O patients/O from/O Finland/O and/O other/O European/O countries/O ./O
Here/O ,/O we/O report/O two/O novel/O mutations/O in/O the/O LCT/O gene/O in/O a/O Japanese/O female/O infant/O with/O clinical/O features/O consistent/O with/O those/O of/O CLD/O ./O
She/O suffered/O from/O severe/O watery/O diarrhea/O from/O the/O age/O of/O 2/O days/O on/O breast/O milk/O //O lactose/O containing/O cow/O 's/O milk/O formula/O ./O
With/O the/O lactose/O -/O free/O hydrolyzed/O cow/O 's/O milk/O formula/O ,/O diarrhea/O was/O stopped/O ,/O and/O she/O has/O now/O developed/O well/O on/O a/O lactose/O -/O free/O diet/O ./O
She/O shows/O a/O lactose/O -/O intolerance/O pattern/O on/O the/O lactose/O challenge/O test/O ./O
Sequence/O analysis/O revealed/O the/O two/O mutations/O in/O her/O LCT/B-Gene gene/O :/O c.4419C/B-Var >/I-Var G/I-Var (/O p/O ./O Y1473X/O )/O in/O exon/O 10/O transmitted/O from/O her/O mother/O and/O c.5387delA/B-Var (/O p/O ./O D1796fs/O )/O in/O exon/O 16/O transmitted/O from/O her/O father/O ./O
Both/O mutations/O cause/B-Reg premature/B-MPA truncation/I-MPA of/O lactase/B-Protein polypeptide/I-Protein and/O are/O supposed/O to/O be/B-Reg responsible/I-Reg for/I-Reg CLD/B-Disease ./O
To/O our/O knowledge/O ,/O this/O is/O the/O first/O report/O on/O mutations/O in/O the/O LCT/O gene/O in/O Japan/O ./O
We/O suggest/O that/O an/O increased/O awareness/O is/O required/O regarding/O CLD/O ./O
Analysis/O of/O gene/O mutations/O in/O Chinese/O patients/O with/O maple/O syrup/O urine/O disease/O ./O
OBJECTIVE/O :/O Maple/B-Disease syrup/I-Disease urine/I-Disease disease/I-Disease (/O MSUD/O )/O is/O predominantly/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O BCKDHA/B-Gene ,/O BCKDHB/B-Gene and/O DBT/B-Gene genes/O ,/O which/O encode/O for/O the/O E1α/O ,/O E1β/O and/O E2/O subunits/O of/O the/O branched/O -/O chain/O α/O -/O keto/O acid/O dehydrogenase/O complex/O ,/O respectively/O ./O
The/O aim/O of/O this/O study/O was/O to/O screen/O DNA/O samples/O from/O 16/O Chinese/O MSUD/O patients/O and/O assess/O a/O potential/O correlation/O between/O genotype/O and/O phenotype/O ./O
METHODS/O :/O BCKDHA/O ,/O BCKDHB/O and/O DBT/O genes/O were/O analyzed/O by/O polymerase/O chain/O reaction/O (/O PCR/O )/O and/O direct/O sequencing/O ./O
Segments/O bearing/O novel/O mutations/O were/O identified/O by/O PCR/O -/O restriction/O fragment/O length/O polymorphism/O (/O PCR/O -/O RFLP/O )/O analysis/O ./O
RESULTS/O :/O Within/O the/O variant/O alleles/O ,/O 28/O mutations/O (/O 28/32/O ,/O 87.5/O %/O )/O ,/O were/O detected/O in/O 15/O patients/O ,/O while/O one/O patient/O displayed/O no/O mutations/O ./O
Mutations/O were/O comprised/O of/O 20/O different/O :/O 6/O BCKDHA/O gene/O mutations/O in/O 4/O cases/O ,/O 10/O BCKDHB/O gene/O mutations/O in/O 8/O cases/O and/O 4/O DBT/O gene/O mutations/O in/O 3/O cases/O ./O
From/O these/O ,/O 14/O were/O novel/O ,/O which/O included/O 3/O mutations/O in/O the/O BCKDHA/O gene/O ,/O 7/O in/O the/O BCKDHB/O gene/O and/O 4/O in/O the/O DBT/O gene/O ./O
Only/O two/O patients/O with/O mutations/O in/O the/O BCKDHB/O and/O DBT/O genes/O were/O thiamine/O -/O responsive/O and/O presented/O a/O better/O clinical/O outcome/O ./O
CONCLUSION/O :/O We/O identified/O 20/O different/O mutations/O within/O the/O BCKDHA/O ,/O BCKDHB/O and/O DBT/O genes/O among/O 16/O Chinese/O MSUD/O patients/O ,/O including/O 14/O novel/O mutations/O ./O
The/O majority/O were/O non/O -/O responsive/O to/O thiamine/O ,/O associating/O with/O a/O worse/O clinical/O outcome/O ./O
Our/O data/O provide/O the/O basis/O for/O further/O genotype/O -/O phenotype/O correlation/O studies/O in/O these/O patients/O ,/O which/O will/O be/O beneficial/O for/O early/O diagnosis/O and/O in/O directing/O the/O approach/O to/O clinical/O intervention/O ./O
Cell/O models/O for/O McArdle/O disease/O and/O aminoglycoside/O -/O induced/O read/O -/O through/O of/O a/O premature/O termination/O codon/O ./O
McArdle/B-Disease disease/I-Disease results/B-Reg from/I-Reg mutations/O in/O the/O gene/O encoding/O muscle/O glycogen/O phosphorylase/O (/B-Gene PYGM/I-Gene )/I-Gene protein/O and/O the/O two/O most/O common/O mutations/O are/O a/O premature/O termination/O codon/O (/B-Var R50X/I-Var )/I-Var and/O a/O missense/O mutation/O (/B-Var G205S/I-Var )/I-Var ./O
Myoblasts/O from/O patients/O can/O not/O be/O used/O to/O create/O a/O cell/O model/O of/O McArdle/O disease/O because/O even/O normal/O myoblasts/O produce/O little/O or/O no/O PYGM/O protein/O in/O cell/O culture/O ./O
We/O therefore/O created/O cell/O models/O by/O expressing/O wild/O -/O type/O or/O mutant/O (/O R50X/O or/O G205S/O )/O PYGM/O from/O cDNA/O integrated/O into/O the/O genome/O of/O Chinese/O hamster/O ovary/O cells/O ./O
These/O cell/O lines/O enable/O the/O study/O of/O McArdle/O mutations/O in/O the/O absence/O of/O nonsense/O -/O mediated/O decay/O of/O mRNA/O transcripts/O ./O
Although/O all/O cell/O lines/O produced/O stable/O mRNA/O ,/O only/O wild/O -/O type/O produced/O detectable/O PYGM/O protein/O ./O
Our/O data/O suggest/O that/O the/O G205S/B-Var mutation/O affects/O PYGM/B-Gene by/O causing/B-Reg misfolding/B-MPA and/O accelerated/B-Reg protein/B-Protein turnover/B-MPA ./O
Using/O the/O N/O -/O terminal/O region/O of/O PYGM/O containing/O the/O R50X/O mutation/O fused/O to/O green/O fluorescent/O protein/O ,/O we/O were/O able/O to/O demonstrate/O both/O small/O amounts/O of/O truncated/O protein/O production/O and/O read/O -/O through/O of/O the/O R50X/O premature/O termination/O codon/O induced/O by/O the/O aminoglycoside/O ,/O G418/O ./O
Origins/O of/O albino/O and/O hooded/O rats/O :/O implications/O from/O molecular/O genetic/O analysis/O across/O modern/O laboratory/O rat/O strains/O ./O
Albino/O and/O hooded/O (/O or/O piebald/O )/O rats/O are/O one/O of/O the/O most/O frequently/O used/O laboratory/O animals/O for/O the/O past/O 150/O years/O ./O
Despite/O this/O fact/O ,/O the/O origin/O of/O the/O albino/O mutation/O as/O well/O as/O the/O genetic/O basis/O of/O the/O hooded/O phenotype/O remained/O unclear/O ./O
Recently/O ,/O the/O albino/B-CPA mutation/O has/O been/O identified/O as/B-Reg the/O Arg299His/B-Var missense/I-Var mutation/I-Var in/O the/O Tyrosinase/B-Gene gene/I-Gene and/O the/O hooded/O (/O H/O )/O locus/O has/O been/O mapped/O to/O the/O ∼460-kb/O region/O in/O which/O only/O the/O Kit/O gene/O exists/O ./O
Here/O ,/O we/O surveyed/O 172/O laboratory/O rat/O strains/O for/O the/O albino/O mutation/O and/O the/O hooded/O (/O h/O )/O mutation/O that/O we/O identified/O by/O positional/O cloning/O approach/O to/O investigate/O possible/O genetic/O roots/O and/O relationships/O of/O albino/O and/O hooded/O rats/O ./O
All/O of/O 117/O existing/O laboratory/O albino/O rats/O shared/O the/O same/O albino/O missense/O mutation/O ,/O indicating/O they/O had/O only/O one/O single/O ancestor/O ./O
Genetic/O fine/O mapping/O followed/O by/O de/O novo/O sequencing/O of/O BAC/O inserts/O covering/O the/O H/O locus/O revealed/O that/O an/O endogenous/O retrovirus/O (/O ERV/O )/O element/O was/O inserted/O into/O the/O first/O intron/O of/O the/O Kit/O gene/O where/O the/O hooded/O allele/O maps/O ./O
A/O solitary/O long/O terminal/O repeat/O (/O LTR/O )/O was/O found/O at/O the/O same/O position/O to/O the/O ERV/O insertion/O in/O another/O allele/O of/O the/O H/O locus/O ,/O which/O causes/O the/O so/O called/O Irish/O (/O h(i/O )/O )/O phenotype/O ./O
The/O ERV/O and/O the/O solitary/O LTR/O insertions/O were/O completely/O associated/O with/O the/O hooded/O and/O Irish/O coat/O patterns/O ,/O respectively/O ,/O across/O all/O colored/O rat/O strains/O examined/O ./O
Interestingly/O ,/O all/O 117/O albino/O rat/O strains/O shared/O the/O ERV/O insertion/O without/O any/O exception/O ,/O which/O strongly/O suggests/O that/O the/O albino/O mutation/O had/O originally/O occurred/O in/O hooded/O rats/O ./O
Identification/O of/O a/O novel/O arylsulfatase/B-Gene B/I-Gene gene/I-Gene mutation/B-Var in/B-Reg three/O unrelated/O Iranian/O mucopolysaccharidosis/B-Disease type/I-Disease -/I-Disease VI/I-Disease patients/O with/O different/O phenotype/O severity/O ./O
BACKGROUND/O :/O Mucopolysaccharidosis/B-Disease type/I-Disease -/I-Disease VI/I-Disease (/O MPS/O -/O VI/O )/O ,/O which/O is/O inherited/O as/O an/O autosomal/O recessive/O trait/O ,/O results/B-Reg from/I-Reg the/O deficiency/B-NegReg of/O N/B-Enzyme -/I-Enzyme acetylgalactosamine/I-Enzyme 4-sulfatase/I-Enzyme (/O arylsulfatase/O B/O )/O activity/B-MPA and/O the/O lysosomal/B-MPA accumulation/B-PosReg of/O dermatan/O sulfate/O ./O
In/O this/O study/O ,/O ARSB/O mutation/O analysis/O was/O performed/O on/O three/O unrelated/O patients/O who/O were/O originally/O from/O the/O West/O Azerbaijan/O province/O of/O Iran/O ./O
METHODS/O :/O After/O PCR/O and/O direct/O DNA/O sequencing/O ,/O DNA/O extraction/O was/O performed/O ./O
RESULTS/O :/O Sequencing/O analysis/O revealed/O a/O novel/O homozygous/O missense/O mutation/O in/O the/O ARSB/O gene/O at/O c.1457A/O </O G/O [/O p./O D486V/O ]/O in/O three/O unrelated/O Iranian/O MPS/O -/O VI/O patients/O with/O different/O phenotype/O severity/O ./O
CONCLUSION/O :/O The/O mutation/O type/O in/O three/O patients/O was/O the/O same/O ;/O probably/O ,/O because/O of/O a/O foundation/O effect/O on/O their/O population/O ./O
C.428_451/O dup(24bp/O )/O mutation/O of/O the/O ARX/O gene/O detected/O in/O a/O Turkish/O family/O ./O
ARX/B-Gene mutations/B-Var give/B-Reg rise/I-Reg to/I-Reg both/O syndromic/O and/O nonsyndromic/O forms/O of/O mental/B-Disease retardation/I-Disease (/O MR/O )/O ./O
We/O investigated/O the/O most/O common/O ARX/O mutations/O ,/O c.428_451/O dup(24bp/O )/O and/O c.333ins/O (/O GCG)7/O in/O a/O series/O of/O 370/O mentally/O retarded/O FMR1/O (/O CGG)n/O expansion/O mutation/O negative/O Turkish/O patients/O using/O PCR/O amplification/O and/O high/O resolution/O MetaPhor/O agarose/O gel/O electrophoresis/O ./O
Sequence/O analysis/O was/O also/O performed/O for/O confirmation/O and/O discrimination/O of/O the/O mutations/O ./O
One/O patient/O representing/O non/O -/O syndromic/O X/O -/O linked/O MR/B-Disease showed/B-Reg an/O abnormal/O band/O pattern/O on/O agarose/O gel/O and/O sequence/O analysis/O of/O exon/O 2/O of/O the/O ARX/B-Gene gene/O revealed/O that/O the/O patient/O had/O the/O c.428_451/B-Var dup(24bp/I-Var )/I-Var mutation/O ./O
When/O we/O screened/O the/O family/O members/O ,/O we/O found/O that/O his/O sister/O and/O mother/O were/O also/O carrier/O for/O the/O same/O mutation/O ./O
The/O proband/O showed/O mild/O MR/O and/O subtle/O clinical/O findings/O like/O dysarthria/O and/O lack/O of/O fine/O motor/O functions/O ./O
In/O conclusion/O ,/O the/O patients/O with/O weak/O fine/O motor/O skills/O and/O positive/O family/O history/O for/O X/O -/O linked/O MR/O should/O be/O screened/O for/O the/O most/O common/O ARX/O gene/O mutations/O ./O
Analysis/O of/O a/O Chinese/O pedigree/O with/O Zellweger/B-Disease syndrome/I-Disease reveals/B-Reg a/O novel/O PEX1/B-Gene mutation/B-Var by/O next/O -/O generation/O sequencing/O ./O
BACKGROUND/O :/O Autosomal/O recessive/O Zellweger/B-Disease spectrum/I-Disease disorder/I-Disease (/O ZSD/O )/O ,/O the/O main/O subgroup/O of/O the/O peroxisome/O biogenesis/O disorders/O (/O PBDs/O )/O ,/O can/O be/O caused/B-Reg by/I-Reg mutations/B-Var in/O any/O of/O the/O 13/O PEX/B-Gene genes/O ./O
Zellweger/O syndrome/O (/O ZS/O )/O is/O the/O most/O common/O and/O severe/O phenotype/O in/O the/O heterogeneous/O ZSD/O ./O
For/O the/O large/O number/O genes/O involved/O ,/O it/O is/O difficult/O to/O make/O a/O precise/O genetic/O diagnosis/O by/O traditional/O methods/O at/O a/O time/O ./O
A/O combination/O of/O enrichment/O of/O targeted/O genes/O and/O next/O -/O generation/O sequencing/O (/O NGS/O )/O would/O result/O in/O both/O high/O efficiency/O and/O low/O cost/O for/O targeted/O sequencing/O of/O genes/O of/O interest/O ./O
METHODS/O :/O To/O identify/O potential/O mutations/O in/O a/O Chinese/O family/O associated/O with/O Zellweger/O syndrome/O ,/O 1930/O kb/O of/O all/O the/O targeted/O region/O of/O PEX/O genes/O were/O captured/O and/O sequenced/O using/O NGS/O ./O
We/O also/O performed/O Sanger/O sequencing/O to/O validate/O the/O NGS/O results/O ./O
RESULTS/O :/O Here/O ,/O we/O reported/O a/O Chinese/O patient/O diagnosed/O as/O a/O severe/O classic/O type/O of/O PBD/O based/O on/O a/O clinical/O investigation/O ./O
We/O then/O performed/O microarray/O -/O based/O NGS/O to/O detect/O the/O variants/O in/O PEX/O genes/O of/O the/O whole/O family/O ./O
One/O reported/O heterozygosis/O mutation/O (/O c.782_783delAA/O )/O was/O identified/O in/O the/O patient/O 's/O father/O and/O one/O novel/O heterozygosis/O missense/O mutation/O (/O c.475G/O >/O C/O )/O was/O found/O in/O the/O patient/O 's/O mother/O ,/O the/O patient/O inherited/O both/O mutations/O ./O
CONCLUSIONS/O :/O The/O results/O proved/O that/O the/O application/O of/O target/O sequence/O capture/O using/O chip/O and/O high/O -/O throughput/O NGS/O is/O a/O valuable/O tool/O for/O the/O molecular/O diagnosis/O of/O peroxisome/O biogenesis/O disorders/O ./O
The/O accuracy/O ,/O high/O -/O throughput/O and/O speed/O of/O the/O method/O make/O it/O suitable/O for/O clinical/O application/O ./O
Aspartylglucosaminuria/B-Disease :/I-Disease unusual/O neonatal/O presentation/O in/O Qatari/O twins/O with/B-Reg a/O novel/O aspartylglucosaminidase/B-Gene gene/I-Gene mutation/B-Var and/O 3/O new/O cases/O in/O a/O Turkish/O family/O ./O
Aspartylglucosaminuria/O is/O a/O rare/O autosomal/O recessive/O lysosomal/O storage/O disorder/O leading/O early/O to/O a/O progressive/O intellectual/O disability/O ./O
Monozygous/O Qatari/O twins/O presented/O with/O an/O unusual/O perinatal/O manifestation/O characterized/O by/O severe/O muscular/O hypotonia/O ,/O scarce/O spontaneous/O movements/O ,/O multiple/O contractures/O ,/O and/O respiratory/O insufficiency/O ./O
Biochemical/O investigations/O suggested/B-Reg aspartylglucosaminuria/B-Disease ,/O and/O a/O novel/O homozygous/O mutation/O c.439T/B-Var >/I-Var C/I-Var (/O p/O ./O S147P/O )/O was/O found/O in/O the/O aspartylglucosaminidase/B-Gene gene/I-Gene ./O
However/O ,/O it/O can/O not/O be/O excluded/O that/O the/O unusual/O neonatal/O presentation/O is/O due/O to/O an/O additional/O autosomal/O recessive/O disease/O in/O this/O multiply/O consanguineous/O family/O ./O
The/O classical/O aspartylglucosaminuria/O phenotype/O (/O progressive/O speech/O delay/O ,/O psychomotor/O retardation/O ,/O and/O behavioral/O abnormalities/O )/O was/O observed/O in/O 3/O Turkish/O siblings/O ./O
Although/O aspartylglucosaminuria/O was/O suspected/O early/O ,/O the/O definite/O diagnosis/O was/O not/O confirmed/O until/O the/O age/O of/O 18/O years/O ./O
A/O novel/O homozygous/O mutation/O c.346C/O >/O T/O (/O p/O ./O R116W/O )/O was/O found/O ./O
These/O 5/O cases/O emphasize/O that/O aspartylglucosaminuria/O is/O panethnic/O and/O may/O possibly/O present/O with/O prenatal/O manifestation/O ./O
Screening/O for/O aspartylglucosaminuria/O should/O be/O done/O in/O all/O patients/O with/O unexplained/O psychomotor/O retardation/O ./O
Mutations/O of/O the/O thyroid/O peroxidase/O gene/O in/O Chinese/O siblings/O with/O congenital/O goitrous/O hypothyroidism/O ./O
OBJECTIVES/O :/O To/O investigate/O thyroid/O peroxidase/O gene/O (/B-Gene TPO/I-Gene )/I-Gene mutations/B-Var in/B-Reg a/O Chinese/O siblings/O with/O congenital/B-Disease goitrous/I-Disease hypothyroidism/I-Disease (/O CGH/O )/O ./O
SUBJECTS/O AND/O METHODS/O :/O The/O proband/O ,/O his/O sister/O ,/O and/O their/O parents/O were/O enrolled/O ./O
All/O subjects/O underwent/O clinical/O examination/O and/O laboratory/O tests/O ./O
Mutation/O screening/O of/O the/O TPO/O gene/O was/O performed/O by/O sequencing/O fragments/O amplified/O from/O extracted/O genomic/O DNA/O ./O
RESULTS/O :/O The/O siblings/O were/O diagnosed/O as/O CGH/O with/O neurodevelopmental/O deficits/O ./O
Two/O compound/O heterozygous/O inactivating/O mutations/O were/O found/O in/O the/O two/O patients/O :/O a/O frameshift/O mutation/O between/O positions/O 2268/O and/O 2269/O (/O c.2268/O -/O 2269/O insT/O )/O and/O a/O missense/O mutation/O at/O c.2089/O G/O >/O A/O (/O p/O ./O G667S/O )/O of/O the/O TPO/O gene/O ./O
Their/O parents/O ,/O with/O normal/O thyroid/O hormone/O levels/O ,/O were/O heterozygous/O for/O mutations/O c.2268/O -/O 2269/O insT/O and/O c.2089/O G/O >/O A/O ,/O respectively/O ./O
The/O polymorphisms/O of/O c.1207/O G/O >/O T/O ,/O c.1283/O G/O >/O C/O ,/O and/O c.2088/O C/O >/O T/O were/O detected/O in/O the/O family/O ./O
CONCLUSIONS/O :/O CGH/B-Disease of/O the/O Chinese/O siblings/O was/O due/B-Reg to/I-Reg the/O TPO/B-Gene gene/O mutations/O (/B-Var c.2268/I-Var -/I-Var 2269/I-Var insT/I-Var and/O c.2089/B-Var G/I-Var >/I-Var A/I-Var )/I-Var ./O
Nebulin/O (/O NEB/O )/O mutations/O in/O a/O childhood/O onset/O distal/O myopathy/O with/O rods/O and/O cores/O uncovered/O by/O next/O generation/O sequencing/O ./O
Recessive/O nebulin/O (/B-Gene NEB/I-Gene )/I-Gene mutations/B-Var are/O a/O common/O cause/B-Reg of/O nemaline/B-Disease myopathy/I-Disease (/O NM/O )/O ,/O typically/O characterized/O by/O generalized/O weakness/O of/O early/O -/O onset/O and/O nemaline/O rods/O on/O muscle/O biopsy/O ./O
Exceptional/O adult/O cases/O with/O additional/O cores/O and/O an/O isolated/O distal/O weakness/O have/O been/O reported/O ./O
The/O large/O NEB/O gene/O with/O 183/O exons/O has/O been/O an/O obstacle/O for/O the/O genetic/O work/O -/O up/O ./O
Here/O we/O report/O a/O childhood/O -/O onset/O case/O with/O distal/O weakness/O and/O a/O core/O -/O rod/O myopathy/O ,/O associated/O with/O recessive/O NEB/O mutations/O identified/O by/O next/O generation/O sequencing/O (/O NGS/O )/O ./O
This/O 6-year/O -/O old/O boy/O presented/O with/O a/O history/O of/O gross/O -/O motor/O difficulties/O following/O a/O normal/O early/O development/O ./O
He/O had/O distal/O leg/O weakness/O with/O bilateral/O foot/O drop/O ,/O as/O well/O as/O axial/O muscle/O weakness/O ,/O scoliosis/O and/O spinal/O rigidity/O ;/O additionally/O he/O required/O nocturnal/O respiratory/O support/O ./O
Muscle/O magnetic/O resonance/O (/O MR/O )/O imaging/O showed/O distal/O involvement/O in/O the/O medial/O and/O anterior/O compartment/O of/O the/O lower/O leg/O ./O
A/O muscle/O biopsy/O featured/O both/O rods/O and/O cores/O ./O
Initial/O targeted/O testing/O identified/O a/O heterozygous/O Nebulin/O exon/O 55/O deletion/O ./O
Further/O analysis/O using/O NGS/O revealed/O a/O frameshifting/O 4/O bp/O duplication/O ,/O c.24372_24375dup/O (/O P.Val8126fs/O )/O ,/O on/O the/O opposite/O allele/O ./O
This/O case/O illustrates/O that/O NEB/B-Gene mutations/B-Var can/O cause/B-Reg childhood/O onset/O distal/O NM/B-Disease ,/O with/O additional/O cores/O on/O muscle/O biopsy/O and/O proves/O the/O diagnostic/O utility/O of/O NGS/O for/O myopathies/O ,/O particularly/O when/O large/O genes/O are/O implicated/O ./O
EDM1/O :/O a/O novel/O point/B-Var mutation/I-Var in/O cartilage/O oligomeric/O matrix/O protein/O gene/O in/O a/O Chinese/O family/O with/B-Reg multiple/B-Disease epiphyseal/I-Disease dysplasia/I-Disease ./O
BACKGROUND/O :/O Multiple/B-Disease epiphysis/I-Disease dysplasia/I-Disease (/O MED/O )/O is/O a/O common/O skeletal/O dysplasia/O with/O a/O significant/O locus/O heterogeneity/O ./O
In/B-Reg the/O majority/O of/O clinically/O defined/O cases/O ,/O mutations/B-Var have/O been/O identified/O in/O the/O gene/O encoding/O cartilage/O algometric/O matrix/O protein/O (/B-Gene COMP/I-Gene )/I-Gene ./O
METHODS/O :/O Five/O patients/O were/O included/O in/O the/O study/O ./O
Linkage/O analysis/O and/O mutation/O analysis/O of/O the/O COMP/O gene/O were/O conducted/O in/O the/O patients/O and/O their/O family/O members/O ./O
RESULTS/O :/O We/O have/O identified/O a/O novel/O mutation/O in/O axon/O 14/O of/O COMP/O gene/O in/O the/O family/O ./O
CONCLUSIONS/O :/O This/O mutation/O produced/O a/O severe/O MED/O phenotype/O with/O marked/O short/O stature/O ,/O early/O onset/O osteoarthritis/O ,/O and/O remarkable/O radiographic/O changes/O ./O
Our/O results/O extended/O the/O range/O of/O disease/O -/O causing/O mutations/O in/O COMP/O gene/O and/O contributed/O more/O information/O about/O relationship/O between/O mutations/O and/O phenotype/O ./O
A/O patient/O with/O limb/B-Disease girdle/I-Disease muscular/I-Disease dystrophy/I-Disease carries/B-Reg a/O TRIM32/B-Gene deletion/B-Var ,/O detected/O by/O a/O novel/O CGH/O array/O ,/O in/O compound/O heterozygosis/O with/O a/O nonsense/O mutation/O ./O
Limb/B-Disease girdle/I-Disease muscular/I-Disease dystrophy/I-Disease 2H/I-Disease is/O a/O rare/O autosomal/O recessive/O muscular/O dystrophy/O ,/O clinically/O highly/O variable/O ,/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O TRIM32/B-Gene gene/O ./O
Here/O we/O describe/O a/O 35-years/O -/O old/O who/O experienced/O progressive/O muscle/O weakness/O ./O
The/O muscle/O biopsy/O revealed/O an/O unspecific/O pattern/O of/O atrophic/O and/O hypertrophic/O fibers/O ;/O the/O immunohistochemistry/O for/O several/O proteins/O was/O normal/O ./O
Comparative/O genomic/O hybridization/O (/O CGH/O )/O analysis/O showed/O a/O heterozygous/O deletion/O of/O the/O entire/O TRIM32/O gene/O ./O
On/O the/O other/O allele/O we/O identified/O the/O R316X/O nonsense/O mutation/O ./O
The/O genetic/O diagnosis/O of/O LGMD2H/O in/O this/O case/O was/O reached/O by/O using/O a/O novel/O high/O throughput/O diagnostic/O tool/O ./O
Epigenetic/O and/O genetic/O alterations/O of/O the/O imprinting/O disorder/O Beckwith/O -/O Wiedemann/O syndrome/O and/O related/O disorders/O ./O
Genomic/O imprinting/O is/O an/O epigenetic/O phenomenon/O that/O leads/O to/O parent/O -/O specific/O differential/O expression/O of/O a/O subset/O of/O genes/O ./O
Most/O imprinted/O genes/O form/O clusters/O ,/O or/O imprinting/O domains/O ,/O and/O are/O regulated/O by/O imprinting/O control/O regions/O ./O
As/O imprinted/O genes/O have/O an/O important/O role/O in/O growth/O and/O development/O ,/O aberrant/O expression/O of/O imprinted/O genes/O due/O to/O genetic/O or/O epigenetic/O abnormalities/O is/O involved/O in/O the/O pathogenesis/O of/O human/O disorders/O ,/O or/O imprinting/O disorders/O ./O
Beckwith/B-Disease -/I-Disease Wiedemann/I-Disease syndrome/I-Disease (/O BWS/O )/O is/O a/O representative/O imprinting/O disorder/O characterized/O by/O macrosomia/O ,/O macroglossia/O and/O abdominal/O wall/O defects/O ,/O and/O exhibits/O a/O predisposition/O to/O tumorigenesis/O ./O
The/O relevant/O imprinted/O chromosomal/O region/O in/O BWS/O is/O 11p15.5/O ,/O which/O consists/O of/O two/O imprinting/O domains/O ,/O IGF2/O //O H19/O and/O CDKN1C/O //O KCNQ1OT1/O ./O
BWS/O has/O five/O known/O causative/O epigenetic/O and/O genetic/O alterations/O :/O loss/O of/O methylation/O (/O LOM/O )/O at/O KvDMR1/O ,/O gain/O of/O methylation/O (/O GOM/O )/O at/O H19DMR/O ,/O paternal/O uniparental/O disomy/O ,/O CDKN1C/O mutations/O and/O chromosomal/O rearrangements/O ./O
Opposite/O methylation/O defects/O ,/O GOM/O and/O LOM/O ,/O at/O H19DMR/O are/O known/O to/O cause/O clinically/O opposite/O disorders/O :/O BWS/O and/O Silver/O -/O Russell/O syndrome/O ,/O respectively/O ./O
Interestingly/O ,/O a/O recent/O study/O discovered/O that/O loss/B-NegReg of/I-NegReg function/I-NegReg or/O gain/B-PosReg of/I-PosReg function/I-PosReg of/O CDKN1C/B-Gene also/O causes/O clinically/O opposite/O disorders/O ,/O BWS/B-Disease and/O IMAGe/B-Disease (/I-Disease intrauterine/I-Disease growth/I-Disease restriction/I-Disease ,/O metaphyseal/I-Disease dysplasia/I-Disease ,/O adrenal/I-Disease hypoplasia/I-Disease congenita/I-Disease ,/O and/I-Disease genital/I-Disease anomalies/I-Disease )/I-Disease syndrome/I-Disease ,/O respectively/O ./O
Furthermore/O ,/O several/O clinical/O studies/O have/O suggested/O a/O relationship/O between/O assisted/O reproductive/O technology/O (/O ART/O )/O and/O the/O risk/O of/O imprinting/O disorders/O ,/O along/O with/O the/O existence/O of/O trans/O -/O acting/O factors/O that/O regulate/O multiple/O imprinted/O differentially/O methylated/O regions/O ./O
In/O this/O review/O ,/O we/O describe/O the/O latest/O knowledge/O surrounding/O the/O imprinting/O mechanism/O of/O 11p15.5/O ,/O in/O addition/O to/O epigenetic/O and/O genetic/O etiologies/O of/O BWS/O ,/O associated/O childhood/O tumors/O ,/O the/O effects/O of/O ART/O and/O multilocus/O hypomethylation/O disorders/O ./O
Characterization/O of/O seizure/O -/O like/O events/O recorded/O in/O vivo/O in/O a/O mouse/O model/O of/O Rett/O syndrome/O ./O
Rett/B-Disease syndrome/I-Disease is/O a/O neurodevelopmental/O disorder/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O X/O -/O linked/O gene/O encoding/O methyl/O -/O CpG/O -/O binding/O protein/O 2/O (/B-Gene MECP2/I-Gene )/I-Gene ./O
Spontaneous/O recurrent/O discharge/O episodes/O are/O displayed/O in/O Rett/O -/O related/O seizures/O as/O in/O other/O types/O of/O epilepsies/O ./O
The/O aim/O of/O this/O paper/O is/O to/O investigate/O the/O seizure/O -/O like/O event/O (/O SLE/O )/O and/O inter/O -/O SLE/O states/O in/O a/O female/O MeCP2-deficient/O mouse/O model/O of/O Rett/O syndrome/O and/O compare/O them/O to/O those/O found/O in/O other/O spontaneous/O recurrent/O epilepsy/O models/O ./O
The/O study/O was/O performed/O on/O a/O small/O population/O of/O female/O MeCP2-deficient/O mice/O using/O telemetric/O local/O field/O potential/O (/O LFP/O )/O recordings/O over/O a/O 24/O h/O period/O ./O
Durations/O of/O SLEs/O and/O inter/O -/O SLEs/O were/O extracted/O using/O a/O rule/O -/O based/O automated/O SLE/O detection/O system/O for/O both/O daytime/O and/O nighttime/O ,/O as/O well/O as/O high/O and/O low/O power/O levels/O of/O the/O delta/O frequency/O range/O (/O 0.5/O -/O 4/O Hz/O )/O of/O the/O recorded/O LFPs/O ./O
The/O results/O suggest/O SLE/O occurrences/O are/O not/O influenced/O by/O circadian/O rhythms/O ,/O but/O had/O a/O significantly/O greater/O association/O with/O delta/O power/O ./O
Investigating/O inter/O -/O SLE/O and/O SLE/O states/O by/O fitting/O duration/O histograms/O to/O the/O gamma/O distribution/O showed/O that/O SLE/O initiation/O and/O termination/O were/O associated/O with/O random/O and/O deterministic/O mechanisms/O ,/O respectively/O ./O
These/O findings/O when/O compared/O to/O reported/O studies/O on/O epilepsy/O suggest/O that/O Rett/O -/O related/O seizures/O share/O many/O similarities/O with/O absence/O epilepsy/O ./O
Familial/B-Disease lipoprotein/I-Disease lipase/I-Disease deficiency/I-Disease :/I-Disease a/O case/O of/O compound/O heterozygosity/O of/O a/O novel/O duplication/O (/O R44Kfs*4/O )/O and/O a/O common/O mutation/O (/B-Var N291S/I-Var )/I-Var in/B-Reg the/O lipoprotein/B-Gene lipase/I-Gene gene/I-Gene ./O
Familial/B-Disease lipoprotein/I-Disease lipase/I-Disease (/I-Disease LPL/I-Disease )/I-Disease deficiency/I-Disease (/O FLLD/O )/O is/O a/O rare/O autosomal/O recessive/O genetic/O disorder/O caused/B-Reg by/I-Reg homozygous/O or/O compound/O heterozygous/O mutations/B-Var in/O the/O LPL/B-Gene gene/O ./O
FLLD/O individuals/O usually/O express/O an/O impaired/O or/O non/O -/O functional/O LPL/O enzyme/O with/O low/O or/O absent/O triglyceride/O (/O TG/O )/O hydrolysis/O activity/O causing/O severe/O hypertriglyceridaemia/O ./O
Here/O we/O report/O a/O case/O of/O FLLD/O in/O a/O 29-year/O -/O old/O man/O ,/O who/O initially/O presented/O with/O eruptive/O cutaneous/O xanthomata/O ,/O elevated/O plasma/O TG/O concentration/O but/O no/O other/O co/O -/O morbidities/O ./O
Subsequent/O genetic/O testing/O of/O the/O patient/O revealed/O compound/O heterozygosity/O of/O a/O novel/O duplication/O (/B-Var p/I-Var ./I-Var R44Kfs*4/I-Var )/I-Var leading/B-Reg to/I-Reg a/O premature/B-MPA stop/I-MPA codon/O in/O exon/O 2/O and/O a/O known/O mutation/O (/B-Var N291S/I-Var )/I-Var in/O exon/O 5/O of/O the/O LPL/B-Gene gene/O ./O
Further/O biochemical/O analysis/O of/O the/O patient/O 's/O postheparin/O plasma/O confirmed/O a/O reduction/B-NegReg of/O total/O lipase/B-Enzyme activity/B-MPA compared/O with/O his/O heterozygous/O father/O carrying/O the/O common/O N291S/B-Var mutation/O and/O to/O a/O healthy/O control/O ./O
Also/O the/O patient/O showed/O increased/B-PosReg (/O 1.85-fold/O )/O activity/B-MPA of/O hepatic/B-Enzyme lipase/I-Enzyme (/O HL/O )/O ,/O indicating/O a/O functional/O link/O between/O HL/O and/O LPL/O ./O
In/O summary/O ,/O we/O report/O a/O case/O of/O FLLD/B-Disease caused/B-Reg by/I-Reg compound/O heterozygosity/O of/O a/O new/O duplication/B-Var and/O a/O common/O mutation/B-Var in/O the/O LPL/B-Gene gene/O ,/O resulting/O in/O residual/B-NegReg LPL/B-Enzyme activity/B-MPA ./O
With/O such/O mutations/O ,/O individuals/O may/O not/O receive/O a/O diagnosis/O before/O classical/O FLLD/O symptoms/O appear/O later/O in/O adulthood/O ./O
Nevertheless/O ,/O early/O diagnosis/O and/O lipid/O -/O lowering/O treatment/O may/O favour/O a/O reduced/O risk/O of/O premature/O cardiovascular/O disease/O or/O acute/O pancreatitis/O in/O such/O individuals/O ./O
Microarray/O analysis/O of/O unbalanced/O translocation/O in/O Wolf/O -/O Hirschhorn/O syndrome/O ./O
Wolf/B-Disease -/I-Disease Hirschhorn/I-Disease syndrome/I-Disease (/O WHS/O )/O is/O caused/B-Reg by/I-Reg deletions/B-Var involving/O chromosome/O region/O 4p16.3/B-Gene ,/O which/O is/O characterized/O by/O growth/O delay/O ,/O mild/O -/O to/O -/O severe/O mental/O retardation/O ,/O hypotonia/O ,/O facial/O dysmorphisms/O and/O shows/O extensive/O phenotypic/O variability/O include/O feeding/O difficulties/O ,/O epilepsy/O and/O congenital/O anomalies/O ./O
Variation/O in/O the/O size/O of/O the/O deletion/O involving/O chromosome/O region/O 4p16.3/O may/O explain/O the/O clinical/O variation/O ./O
However/O ,/O previous/O studies/O indicate/O that/O duplication/O for/O another/O chromosome/O region/O due/O to/O an/O unbalanced/O translocation/O elucidate/O approximately/O 40/O -/O 45/O %/O WHS/O patients/O ./O
Therefore/O ,/O we/O used/O whole/O genomic/O cytogenetics/O array/O to/O analyze/O the/O entire/O genome/O at/O a/O significantly/O higher/O resolution/O over/O conventional/O cytogenetics/O to/O characterize/O the/O exact/O subtelomeric/O aberration/O region/O of/O one/O patient/O with/O developmental/O delay/O and/O several/O facial/O characteristics/O reminiscent/O Wolf/O -/O Hirschhorn/O syndrome/O ./O
Here/O we/O report/O that/O our/O patient/O had/O 3.7/O Mb/O deletion/O at/O the/O 4p16.2/O and/O 6.8/O Mb/O duplication/O at/O 8p23.1/O resulted/O from/O the/O unbalanced/O translocations/O der(4)t(4;8)(p16.2;p23.1/O )/O ./O
We/O confirmed/O that/O our/O patient/O with/O monosomy/O 4p16.2/O which/O is/O consistent/O with/O Wolf/O -/O Hirschhorn/O syndrome/O and/O trisomy/O 8p23.1/O ./O
The/O combination/O of/O the/O 4p/O deletion/O with/O 8p/O partial/O trisomy/O explains/O the/O complex/O phenotype/O presented/O by/O our/O patient/O ./O
Novel/O ALPL/O genetic/O alteration/O associated/O with/O an/O odontohypophosphatasia/O phenotype/O ./O
Hypophosphatasia/B-Disease (/O HPP/O )/O is/O an/O inherited/O disorder/O of/O mineral/O metabolism/O caused/B-Reg by/I-Reg mutations/B-Var in/O ALPL/B-Gene ,/O encoding/O tissue/O non/O -/O specific/O alkaline/O phosphatase/O (/O TNAP/O )/O ./O
Here/O ,/O we/O report/O the/O molecular/O findings/O from/O monozygotic/O twins/O ,/O clinically/O diagnosed/O with/O tooth/O -/O specific/O odontohypophosphatasia/O (/O odonto/O -/O HPP/O )/O ./O
Sequencing/O of/O ALPL/O identified/O two/O genetic/O alterations/O in/O the/O probands/O ,/O including/O a/O heterozygous/O missense/O mutation/O c.454C/B-Var >/I-Var T/I-Var ,/O leading/B-Reg to/I-Reg change/O of/O arginine/O 152/O to/O cysteine/O (/B-Var p/I-Var ./I-Var R152C/I-Var )/I-Var ,/O and/O a/O novel/O heterozygous/O gene/O deletion/O c.1318_1320delAAC/B-Var ,/O leading/B-Reg to/I-Reg the/O loss/O of/O an/O asparagine/O residue/O at/O codon/O 440/O (/B-Var p/I-Var ./I-Var N440del/I-Var )/I-Var ./O
Clinical/O identification/O of/O low/O serum/O TNAP/O activity/O ,/O dental/O abnormalities/O ,/O and/O pedigree/O data/O strongly/O suggests/O a/O genotype/O -/O phenotype/O correlation/O between/O p/O ./O N440del/O and/O odonto/O -/O HPP/O in/O this/O family/O ./O
Computational/O analysis/O of/O the/O p/B-Var ./I-Var N440del/I-Var protein/O structure/O revealed/O an/O alteration/B-Reg in/O the/O tertiary/B-MPA structure/I-MPA affecting/B-Reg the/O collagen/B-Interaction -/I-Interaction binding/I-Interaction site/I-Interaction (/O loop/O 422/O -/O 452/O )/O ,/O which/O could/O potentially/O impair/B-NegReg the/O mineralization/B-MPA process/I-MPA ./O
Nevertheless/O ,/O the/O probands/O (/O compound/O heterozygous/O :/O p.[N440del];[R152C/O ]/O )/O feature/O early/O -/O onset/O and/O severe/O odonto/O -/O HPP/O phenotype/O ,/O whereas/O the/O father/O (/O p.[N440del];[=/O ]/O )/O has/O only/O moderate/O symptoms/O ,/O suggesting/O p/O ./O R152C/O may/O contribute/O or/O predispose/O to/O a/O more/O severe/O dental/O phenotype/O in/O combination/O with/O the/O deletion/O ./O
These/O results/O assist/O in/O defining/O the/O genotype/O -/O phenotype/O associations/O for/O odonto/O -/O HPP/O ,/O and/O further/O identify/O the/O collagen/O -/O binding/O site/O as/O a/O region/O of/O potential/O structural/O importance/O for/O TNAP/O function/O in/O the/O biomineralization/O ./O
Analysis/O of/O STK11/O gene/O variant/O in/O five/O Chinese/O patients/O with/O Peutz/O -/O Jeghers/O syndrome/O ./O
BACKGROUND/O :/O Peutz/B-Disease -/I-Disease Jeghers/I-Disease syndrome/I-Disease (/O PJS/O )/O is/O a/O rare/O autosomal/O dominant/O inherited/O disorder/O characterized/O by/O gastrointestinal/O hamartomatous/O polyps/O and/O mucocutaneous/O pigmentation/O ./O
Germline/O mutation/B-Var of/O a/O serine/O //O threonine/O kinase/O 11(STK11/B-Gene )/I-Gene gene/O has/O been/O identified/O as/O a/O cause/B-Reg of/O PJS/O ./O
In/O this/O study/O ,/O we/O investigated/O the/O molecular/O basis/O of/O five/O Chinese/O PJS/O patients/O ./O
METHODS/O :/O Blood/O samples/O were/O collected/O from/O five/O unrelated/O Chinese/O PJS/O patients/O and/O their/O parents/O ./O
The/O entire/O coding/O region/O of/O the/O STK11/O gene/O was/O amplified/O by/O polymerase/O chain/O reaction/O and/O analyzed/O by/O direct/O sequencing/O ./O
RESULTS/O :/O Three/O different/O frameshift/O mutations/O (/O c.519insTGTG/O ,/O c.792_793insT/O ,/O and/O c.334_335insC/O )/O ,/O all/O of/O which/O would/O cause/O truncation/O of/O the/O gene/O product/O ,/O were/O found/O in/O three/O patients/O ./O
One/O missense/O mutation/O (/O p/O ./O Ser307Thr/O )/O and/O one/O 3bp/O deletion/O mutation/O (/O c.228/O -/O 230del/O CGT/O )/O were/O identified/O in/O the/O remaining/O two/O patients/O ./O
All/O of/O the/O five/O investigated/O patients/O carried/O de/O novo/O mutations/O ./O
CONCLUSIONS/O :/O The/O results/O support/O that/O mutation/B-Var of/O the/O LKB1/B-Gene gene/O is/O a/O cause/B-Reg of/O PJS/B-Disease ,/O and/O expand/O the/O spectrum/O of/O the/O STK11/O gene/O mutations/O ./O
Recurrent/O de/O novo/O c.316G/O >/O A/O mutation/O in/O NIPA1/O hotspot/O ./O
Mutations/B-Var in/O the/O NIPA1/B-Gene cause/B-Reg autosomal/O dominant/O form/O of/O hereditary/B-Disease spastic/I-Disease paraplegia/I-Disease ./O
Allelic/O heterogeneity/O of/O known/O NIPA1/B-Gene mutations/O is/O quite/O limited/O and/O the/O most/O common/O mutation/O is/O c.316G/B-Var >/I-Var A/I-Var resulting/B-Reg in/I-Reg p/B-Protein ./I-Protein G106R/I-Protein protein/O change/B-MPA ./O
Here/O we/O report/O the/O first/O direct/O evidence/O of/O de/O novo/O c.316G/O >/O A/O mutation/O in/O the/O same/O hotspot/O of/O the/O gene/O in/O two/O unrelated/O patients/O who/O had/O otherwise/O a/O prototypical/O NIPA1-associated/O phenotype/O with/O a/O severe/O form/O of/O uncomplicated/O spastic/O paraplegia/O ./O
De/O novo/O nature/O of/O these/O mutations/O was/O confirmed/O by/O sequencing/O both/O sets/O of/O clinically/O unaffected/O parents/O and/O confirmation/O of/O paternity/O ./O
We/O also/O discuss/O likely/O molecular/O mechanisms/O accounting/O for/O recurrent/O mutations/O in/O this/O segment/O of/O the/O gene/O ./O
Apparently/O sporadic/O patients/O without/O a/O positive/O family/O history/O of/O hereditary/O spastic/O paraplegia/O need/O to/O be/O also/O evaluated/O for/O possible/O disease/O -/O causing/O mutations/O in/O genes/O that/O are/O inherited/O in/O an/O autosomal/O dominant/O fashion/O ./O
Late/O adult/O -/O onset/O of/O X/O -/O linked/O myopathy/O with/O excessive/O autophagy/O ./O
INTRODUCTION/O :/O X/B-Disease -/I-Disease linked/I-Disease myopathy/I-Disease with/I-Disease excessive/I-Disease autophagy/I-Disease (/O XMEA/O )/O is/O characterized/O by/O autophagic/O vacuoles/O with/O sarcolemmal/O features/O ./O
Mutations/B-Var in/O VMA21/B-Gene result/O in/O insufficient/B-NegReg lysosome/B-MPA acidification/I-MPA ,/O causing/B-Reg progressive/B-CPA proximal/I-CPA weakness/I-CPA with/O onset/O before/O age/O 20/O years/O and/O loss/O of/O ambulation/O by/O middle/O age/O ./O
METHODS/O :/O We/O describe/O a/O patient/O with/O onset/O of/O slowly/O progressive/O proximal/O weakness/O of/O the/O lower/O limbs/O after/O age/O 50/O ,/O who/O maintains/O ambulation/O with/O the/O assistance/O of/O a/O cane/O at/O age/O 71/O ./O
RESULTS/O :/O Muscle/O biopsy/O at/O age/O 66/O showed/O complex/O muscle/O fiber/O splitting/O ,/O internalized/O capillaries/O ,/O and/O vacuolar/O changes/O characteristic/O of/O autophagic/O vacuolar/O myopathy/O ./O
Vacuoles/O stained/O positive/O for/O sarcolemmal/O proteins/O ,/O LAMP2/O ,/O and/O complement/O C5b-9/O ./O
Ultrastructural/O evaluation/O further/O revealed/O basal/O lamina/O reduplication/O and/O extensive/O autophagosome/O extrusion/O ./O
Sanger/O sequencing/O identified/O a/O known/O pathologic/O splice/O site/O mutation/O in/O VMA21/O (/O c.164/O -/O 7T/O >/O G/O )/O ./O
CONCLUSIONS/O :/O This/O case/O expands/O the/O clinical/O phenotype/O of/O XMEA/O and/O suggests/O VMA21/O sequencing/O be/O considered/O in/O evaluating/O men/O with/O LAMP2-positive/O autophagic/O vacuolar/O myopathy/O ./O
Novel/O homozygous/O PANK2/B-Gene mutation/B-Var causing/B-Reg atypical/O pantothenate/B-Disease kinase/I-Disease -/I-Disease associated/I-Disease neurodegeneration/I-Disease (/O PKAN/O )/O in/O a/O Cypriot/O family/O ./O
Pantothenate/B-Disease kinase/I-Disease -/I-Disease associated/I-Disease neurodegeneration/I-Disease (/O PKAN/O )/O is/O the/O commonest/O ,/O recessively/O inherited/O form/O of/O neurodegeneration/O with/O brain/O iron/O accumulation/O (/O NBIA/O )/O resulting/B-Reg from/I-Reg mutations/B-Var in/O the/O pantothenate/O kinase/O 2/O (/B-Gene PANK2/I-Gene )/I-Gene gene/O on/O chromosome/O 20/O ./O
PKAN/O is/O usually/O rapidly/O progressive/O ,/O presenting/O in/O the/O vast/O majority/O in/O the/O first/O decade/O of/O life/O (/O classic/O form/O )/O ./O
A/O rarer/O ,/O later/O onset/O and/O slowly/O progressive/O (/O atypical/O )/O PKAN/O form/O also/O exists/O ./O
We/O present/O two/O siblings/O of/O Cypriot/O descent/O ,/O a/O 27-year/O -/O old/O man/O and/O his/O clinically/O asymptomatic/O younger/O sister/O ,/O both/O of/O whom/O were/O found/O to/O be/O homozygous/O for/O a/O novel/O c.695A/O >/O G/O (/O p/O ./O Asp232Gly/O )/O missense/O mutation/O in/O exon/O 2/O of/O the/O PANK2/O gene/O ./O
The/O index/O patient/O presented/O with/O a/O 5-year/O history/O of/O slowly/O progressive/O gait/O disturbance/O ,/O dysarthria/O ,/O mild/O axial/O rigidity/O and/O bradykinesia/O ./O
His/O brain/O MRI/O scan/O revealed/O the/O characteristic/O "/O eye/O -/O of/O -/O the/O -/O tiger/O "/O sign/O ./O
Atypical/O genetically/O confirmed/O PKAN/O cases/O are/O sparsely/O reported/O and/O should/O be/O considered/O in/O the/O differential/O diagnosis/O of/O patients/O presenting/O with/O a/O progressive/O extrapyramidal/O syndrome/O particularly/O if/O the/O radiographic/O findings/O are/O suggestive/O of/O iron/O accumulation/O ./O
Effective/O treatment/O strategies/O for/O PKAN/O are/O not/O currently/O available/O and/O symptomatic/O therapy/O is/O often/O unsatisfactory/O ./O
However/O ,/O early/O diagnosis/O including/O the/O presymptomatic/O stage/O is/O important/O for/O genetic/O counseling/O and/O will/O be/O crucial/O for/O testing/O novel/O therapeutics/O in/O the/O future/O ./O
A/O novel/O SUCLA2/B-Gene mutation/B-Var in/O a/O Portuguese/O child/O associated/O with/B-Reg "/O mild/O "/O methylmalonic/B-Disease aciduria/I-Disease ./O
Succinyl/O -/O coenzyme/O A/O synthase/O is/O a/O mitochondrial/O matrix/O enzyme/O that/O catalyzes/O the/O reversible/O synthesis/O of/O succinate/O and/O adenosine/O triphosphate/O (/O ATP/O )/O from/O succinyl/O -/O coenzyme/O A/O and/O adenosine/O diphosphate/O (/O ADP/O )/O in/O the/O tricarboxylic/O acid/O cycle/O ./O
This/O enzyme/O is/O made/O up/O of/O α/O and/O β/O subunits/O encoded/O by/O SUCLG1/O and/O SUCLA2/O ,/O respectively/O ./O
We/O present/O a/O child/O with/O severe/O muscular/O hypotonia/O ,/O dystonia/O ,/O failure/O to/O thrive/O ,/O sensorineural/O deafness/O ,/O and/O dysmorphism/O ./O
Metabolic/O investigations/O disclosed/O hyperlactacidemia/O ,/O moderate/O urinary/O excretion/O of/O methylmalonic/O acid/O ,/O and/O elevated/O levels/O of/O C4-dicarboxylic/O carnitine/O in/O blood/O ./O
We/O identified/O a/O novel/O homozygous/O p/O ./O M329V/O in/O SUCLA2/B-Gene ./O
In/O cultured/O cells/O ,/O the/O p/B-Var ./I-Var M329V/I-Var resulted/O in/O a/O reduced/B-NegReg amount/B-MPA of/O the/O SUCLA2/B-Gene protein/B-Protein ,/O impaired/B-NegReg production/B-CPA of/I-CPA mitochondrial/I-CPA ATP/I-CPA ,/O and/O enhanced/B-PosReg production/B-CPA of/I-CPA reactive/I-CPA oxygen/I-CPA species/I-CPA ,/O which/O was/O partially/O reduced/O by/O using/O 5-aminoimidazole-4-carboxamide/O ribonucleotide/O in/O the/O culture/O medium/O ./O
Expanding/O the/O array/O of/O SUCLA2/O mutations/O ,/O we/O suggested/O that/O reactive/O oxygen/O species/O scavengers/O are/O likely/O to/O impact/O on/O disease/O prognosis/O ./O
Molecular/O profiling/O of/O complete/O congenital/O stationary/O night/O blindness/O :/O a/O pilot/O study/O on/O an/O Indian/O cohort/O ./O
PURPOSE/O :/O Congenital/B-Disease stationary/I-Disease night/I-Disease blindness/I-Disease (/O CSNB/O )/O is/O a/O non/O -/O progressive/O retinal/O disorder/O that/O shows/O genetic/O and/O clinical/O heterogeneity/O ./O
CSNB/O is/O inherited/O as/O an/O autosomal/O recessive/O ,/O autosomal/O dominant/O ,/O or/O X/O -/O linked/O recessive/O trait/O and/O shows/O a/O good/O genotype/O -/O phenotype/O correlation/O ./O
Clinically/O ,/O CSNB/O is/O classified/O as/O the/O Riggs/O type/O and/O the/O Schubert/O -/O Bornschein/O type/O ./O
The/O latter/O form/O is/O further/O sub/O -/O classified/O into/O complete/O and/O incomplete/O forms/O based/O on/O specific/O waveforms/O on/O the/O electroretinogram/O (/O ERG/O )/O ./O
There/O are/O no/O molecular/O genetic/O data/O for/O CSNB/O in/O the/O Indian/O population/O ./O
Therefore/O ,/O we/O present/O for/O the/O first/O time/O molecular/O profiling/O of/O eight/O families/O with/O complete/O CSNB/O (/O cCSNB/O )/O ./O
METHODS/O :/O The/O index/O patients/O and/O their/O other/O affected/O family/O members/O were/O comprehensively/O evaluated/O for/O the/O phenotype/O ,/O including/O complete/O ophthalmic/O evaluation/O ,/O ERG/O ,/O fundus/O autofluorescence/O ,/O optical/O coherence/O tomography/O ,/O and/O color/O vision/O test/O ./O
The/O known/O gene/O defects/O for/O cCSNB/O ,/O LRIT3/O ,/O TRPM1/O ,/O GRM6/O ,/O GPR179/O ,/O and/O NYX/O ,/O were/O screened/O by/O PCR/O direct/O sequencing/O ./O
Bioinformatic/O analyses/O were/O performed/O using/O SIFT/O and/O PolyPhen/O for/O the/O identified/O missense/O mutations/O ./O
RESULTS/O :/O All/O eight/O affected/O index/O patients/O and/O affected/O family/O members/O were/O identified/O as/O having/B-Reg cCSNB/B-Disease based/O on/O their/O ERG/O waveforms/O ./O
Mutations/B-Var in/O the/O TRPM1/B-Gene gene/O were/O identified/O in/O six/O index/O patients/O ./O
The/O two/O remaining/O index/O patients/O each/O carried/O a/O GPR179/B-Gene and/O GRM6/B-Gene mutation/B-Var ./O
Seven/O of/O the/O patients/O revealed/O homozygous/O mutations/O ,/O while/O one/O patient/O showed/O a/O compound/O heterozygous/O mutation/O ./O
Six/O of/O the/O eight/O mutations/O identified/O are/O novel/O ./O
CONCLUSIONS/O :/O This/O is/O the/O first/O report/O on/O molecular/O profiling/O of/O candidate/O genes/O in/O CSNB/O in/O an/O Indian/O cohort/O ./O
As/O shown/O for/O other/O cohorts/O ,/O TRPM1/B-Gene seems/O to/O be/O a/O major/O gene/O defect/B-Var in/O patients/O with/B-Reg cCSNB/B-Disease in/O India/O ./O
UBQLN2/B-Gene mutation/B-Var causing/B-Reg heterogeneous/B-Disease X/I-Disease -/I-Disease linked/I-Disease dominant/I-Disease neurodegeneration/I-Disease ./O
We/O report/O a/O 5-generation/O family/O with/O phenotypically/O diverse/O neurodegenerative/O disease/O including/O relentlessly/O progressive/O choreoathetoid/O movements/O ,/O dysarthria/O ,/O dysphagia/O ,/O spastic/O paralysis/O ,/O and/O behavioral/O dementia/O in/O descendants/O of/O a/O 67-year/O -/O old/O woman/O with/O amyotrophic/O lateral/O sclerosis/O ./O
Disease/O onset/O varied/O with/O gender/O ,/O occurring/O in/O male/O children/O and/O adult/O women/O ./O
Exome/O sequence/O analyses/O revealed/O a/O novel/O mutation/O (/O c.1490C/O >/O T/O ,/O p/O ./O P497L/O )/O in/O the/O ubiquilin-2/O gene/O (/O UBQLN2/O )/O with/O X/O -/O linked/O inheritance/O in/O all/O studied/O affected/O individuals/O ./O
As/O ubiquilin-2-positive/O inclusions/O were/O identified/O in/O brain/O ,/O we/O suggest/O that/O mutant/B-Var peptide/O predisposes/B-Reg to/I-Reg protein/B-Protein misfolding/B-MPA and/O accumulation/B-PosReg ./O
Our/O findings/O expand/O the/O spectrum/O of/O neurodegenerative/O phenotypes/O caused/O by/O UBQLN2/O mutations/O ./O
Splicing/B-Var mutation/I-Var in/O MVK/B-Gene is/O a/O cause/B-Reg of/O porokeratosis/B-Disease of/I-Disease Mibelli/I-Disease ./O
Porokeratosis/O is/O a/O chronic/O skin/O disorder/O characterized/O by/O the/O presence/O of/O patches/O with/O elevated/O ,/O thick/O ,/O keratotic/O borders/O ,/O with/O histological/O cornoid/O lamella/O ./O
Classic/O porokeratosis/O of/O Mibelli/O (/O PM/O )/O frequently/O appears/O in/O childhood/O with/O a/O risk/O of/O malignant/O transformation/O ./O
Disseminated/O superficial/O actinic/O porokeratosis/O (/O DSAP/O )/O is/O the/O most/O common/O subtype/O of/O porokeratosis/O with/O genetic/O heterogeneities/O ,/O and/O mevalonate/O kinase/O gene/O (/O MVK/O )/O mutations/O have/O been/O identified/O in/O minor/O portion/O of/O DSAP/O families/O of/O Chinese/O origin/O ./O
To/O confirm/O the/O previous/O findings/O about/O MVK/O mutations/O in/O DSAP/O patients/O and/O test/O MVK/O 's/O role(s/O )/O in/O PM/O development/O ,/O we/O performed/O genomic/O sequence/O analysis/O for/O 3/O DSAP/O families/O and/O 1/O PM/O family/O of/O Chinese/O origin/O ./O
We/O identified/O a/O splicing/O mutation/O of/O MVK/O gene/O ,/O designated/O as/O c.1039/O +/O 1G/O >/O A/O ,/O in/O the/O PM/O family/O ./O
No/O MVK/O mutations/O were/O found/O in/O three/O DSAP/O families/O ./O
Sequence/O analysis/O for/O complementary/O DNA/O templates/O from/O PM/O lesions/O of/O all/O patients/O revealed/O a/O mutation/O at/O splice/O donor/O site/O of/O intron/O 10/O ,/O designated/O as/O c.1039/B-Var +/I-Var 1G/I-Var >/I-Var A/I-Var ,/O leading/B-Reg to/I-Reg the/O splicing/B-MPA defect/I-MPA and/O termination/B-MPA codon/I-MPA 52/O amino/O acids/O after/O exon/O 10/O ./O
Although/O no/O MVK/O mutations/O in/O DSAP/O patients/O were/O found/O as/O reported/O previously/O ,/O we/O identified/O MVK/O simultaneously/O responsible/O for/O PM/O development/O ./O
Whole/O exome/O sequencing/O reveals/O concomitant/O mutations/B-Var of/O multiple/O FA/B-Gene genes/O in/B-Reg individual/O Fanconi/B-Disease anemia/I-Disease patients/O ./O
BACKGROUND/O :/O Fanconi/O anemia/O (/O FA/O )/O is/O a/O rare/O inherited/O genetic/O syndrome/O with/O highly/O variable/O clinical/O manifestations/O ./O
Fifteen/O genetic/O subtypes/O of/O FA/O have/O been/O identified/O ./O
Traditional/O complementation/O tests/O for/O grouping/O studies/O have/O been/O used/O generally/O in/O FA/O patients/O and/O in/O stepwise/O methods/O to/O identify/O the/O FA/O type/O ,/O which/O can/O result/O in/O incomplete/O genetic/O information/O from/O FA/O patients/O ./O
METHODS/O :/O We/O diagnosed/O five/O pediatric/O patients/O with/O FA/O based/O on/O clinical/O manifestations/O ,/O and/O we/O performed/O exome/O sequencing/O of/O peripheral/O blood/O specimens/O from/O these/O patients/O and/O their/O family/O members/O ./O
The/O related/O sequencing/O data/O were/O then/O analyzed/O by/O bioinformatics/O ,/O and/O the/O FANC/O gene/O mutations/O identified/O by/O exome/O sequencing/O were/O confirmed/O by/O PCR/O re/O -/O sequencing/O ./O
RESULTS/O :/O Homozygous/O and/O compound/O heterozygous/O mutations/O of/O FANC/O genes/O were/O identified/O in/O all/O of/O the/O patients/O ./O
The/O FA/O subtypes/O of/O the/O patients/O included/O FANCA/O ,/O FANCM/O and/O FANCD2/O ./O
Interestingly/O ,/O four/O FA/O patients/O harbored/O multiple/O mutations/O in/O at/O least/O two/O FA/O genes/O ,/O and/O some/O of/O these/O mutations/O have/O not/O been/O previously/O reported/O ./O
These/O patients/O '/O clinical/O manifestations/O were/O vastly/O different/O from/O each/O other/O ,/O as/O were/O their/O treatment/O responses/O to/O androstanazol/O and/O prednisone/O ./O
This/O finding/O suggests/O that/O heterozygous/O mutation(s/O )/O in/O FA/O genes/O could/O also/O have/O diverse/O biological/O and/or/O pathophysiological/O effects/O on/O FA/O patients/O or/O FA/O gene/O carriers/O ./O
Interestingly/O ,/O we/O were/O not/O able/O to/O identify/O de/O novo/O mutations/O in/O the/O genes/O implicated/O in/O DNA/O repair/O pathways/O when/O the/O sequencing/O data/O of/O patients/O were/O compared/O with/O those/O of/O their/O parents/O ./O
CONCLUSIONS/O :/O Our/O results/O indicate/O that/O Chinese/O FA/O patients/O and/O carriers/O might/O have/O higher/O and/O more/O complex/O mutation/O rates/O in/O FANC/O genes/O than/O have/O been/O conventionally/O recognized/O ./O
Testing/O of/O the/O fifteen/O FANC/O genes/O in/O FA/O patients/O and/O their/O family/O members/O should/O be/O a/O regular/O clinical/O practice/O to/O determine/O the/O optimal/O care/O for/O the/O individual/O patient/O ,/O to/O counsel/O the/O family/O and/O to/O obtain/O a/O better/O understanding/O of/O FA/O pathophysiology/O ./O
Mutations/B-Var in/O SMARCAD1/B-Gene cause/B-Reg autosomal/B-Disease dominant/I-Disease adermatoglyphia/I-Disease and/O perturb/B-Reg the/O expression/B-MPA of/O epidermal/O differentiation/O -/O associated/O genes/O ./O
BACKGROUND/O :/O Autosomal/O dominant/O adermatoglyphia/O (/O ADG/O )/O is/O characterized/O by/O lack/O of/O palmoplantar/O epidermal/O ridges/O ./O
Recently/O ,/O ADG/O was/O found/O to/O be/O caused/O in/O one/O family/O by/O a/O mutation/O in/O SMARCAD1/O ,/O a/O member/O of/O the/O SNF/O subfamily/O of/O the/O helicase/O protein/O superfamily/O ./O
OBJECTIVES/O :/O To/O investigate/O the/O genetic/O basis/O of/O ADG/O ./O
METHODS/O :/O We/O used/O direct/O sequencing/O and/O global/O gene/O expression/O analysis/O ./O
RESULTS/O :/O We/O identified/O three/O novel/O heterozygous/O mutations/O in/O SMARCAD1/O (/O c.378/O +/O 2/O T/O >/O C/O ,/O c.378/O +/O 5/O G/O >/O C/O and/O c.378/O +/O 1/O G/O >/O A/O )/O in/O a/O total/O of/O six/O patients/O ./O
Surprisingly/O ,/O all/O four/O ADG/O -/O causing/O mutations/B-Var identified/O to/O date/O disrupt/B-NegReg a/O single/B-MPA conserved/I-MPA donor/I-MPA splice/I-MPA site/I-MPA adjacent/O to/O the/O 3/O '/O end/O of/O a/O noncoding/O exon/O and/O are/O predicted/O to/O result/O in/O haploinsufficiency/B-NegReg for/O a/O skin/B-MPA -/I-MPA specific/I-MPA isoform/I-MPA of/O SMARCAD1/B-Gene ./O
These/O data/O indicate/O a/O pivotal/O role/O for/O the/O SMARCAD1-skin/O specific/O isoform/O in/O dermatoglyph/O formation/O ./O
In/O order/O to/O better/O understand/O the/O consequences/O of/O ADG/O -/O associated/O mutations/O ,/O we/O ascertained/O the/O global/O transcription/O profiles/O of/O primary/O keratinocytes/O downregulated/O for/O SMARCAD1/O and/O of/O patient/O -/O derived/O keratinocytes/O ./O
A/O total/O of/O eight/O genes/O were/O found/O to/O be/O differentially/O expressed/O in/O both/O patient/O -/O derived/O and/O knocked/O down/O keratinocytes/O ./O
Of/O interest/O ,/O these/O differentially/O expressed/O genes/O have/O been/O implicated/O in/O epidermal/O ontogenesis/O and/O differentiation/O ,/O and/O in/O psoriasis/O ,/O which/O is/O characterized/O by/O abnormal/O finger/O ridge/O patterns/O ./O
CONCLUSIONS/O :/O The/O present/O data/O suggest/O that/O ADG/O is/O genetically/O homogeneous/O and/O result/O from/O perturbed/O expression/O of/O epidermal/O differentiation/O -/O associated/O genes/O ./O
Genetics/O and/O pathophysiology/O of/O primary/O dystonia/O with/O special/O emphasis/O on/O DYT1/O and/O DYT5/O ./O
DYT1/O and/O DYT5/O are/O early/O -/O onset/O dominant/O inherited/O dystonias/O ./O
DYT1/B-Disease is/O caused/B-Reg by/I-Reg mutations/B-Var of/O the/O TOR1A/B-Gene gene/O ,/O located/O on/O 9q34/O ,/O which/O causes/O dysfunction/B-NegReg of/O the/O D1/B-Pathway direct/I-Pathway pathway/I-Pathway or/O the/O indirect/B-Pathway pathway/I-Pathway ./O
Dysfunction/O of/O the/O former/O causes/O postural/B-Disease -/I-Disease type/I-Disease and/I-Disease segmental/I-Disease dystonia/I-Disease ;/I-Disease the/O latter/O causes/O action/B-Disease -/I-Disease type/I-Disease dystonia/I-Disease ./O
In/O families/O with/O action/O -/O type/O dystonia/O ,/O there/O are/O cases/O with/O focal/O and/O segmental/O dystonia/O ./O
Ages/O of/O onset/O of/O postural/O -/O type/O dystonia/O are/O around/O 6/O years/O ,/O and/O 8/O to/O 10/O years/O in/O cases/O of/O action/O -/O type/O dystonia/O ./O
Focal/O and/O segmental/O dystonia/O develops/O in/O the/O teens/O ./O
Mental/O and/O psychological/O functions/O are/O preserved/O ./O
DYT5/B-Disease is/O caused/B-Reg by/I-Reg heterozygous/O mutations/B-Var of/O the/O GCH1/B-Gene gene/O ,/O located/O on/O 14q22.1-q22.2/O ./O
Again/O ,/O mental/O and/O psychological/O functions/O are/O preserved/O ./O
Clinically/O ,/O there/O are/O two/O types/O :/O postural/O and/O action/O ./O
Postural/O -/O type/O dystonia/O occurs/O around/O 6/O years/O of/O age/O ,/O with/O postural/O dystonia/O of/O one/O leg/O ,/O and/O all/O extremities/O and/O trunk/O muscles/O are/O involved/O by/O the/O late/O teens/O ./O
Action/O -/O type/O dystonia/O shows/O dystonic/O movements/O from/O around/O 8/O to/O 10/O years/O of/O age/O ./O
In/O both/O types/O ,/O all/O symptoms/O show/O diurnal/O fluctuations/O that/O diminish/O with/O age/O and/O are/O no/O longer/O apparent/O in/O the/O late/O teens/O ./O
L/O -/O dopa/O produces/O dramatic/O effects/O ,/O which/O continue/O throughout/O the/O course/O of/O the/O illness/O ./O
In/O both/O postural/O and/O action/O types/O ,/O each/O family/O or/O sporadic/O case/O has/O a/O particular/O mutation/O ./O
It/O remains/O unclear/O why/O specific/O mutations/O cause/O certain/O age-/O and/O gender/O -/O specific/O symptoms/O ./O
First/O report/O of/O a/O deletion/O encompassing/O an/O entire/O exon/O in/O the/O homogentisate/O 1,2-dioxygenase/O gene/O causing/O alkaptonuria/O ./O
Alkaptonuria/B-Disease is/O often/O diagnosed/O clinically/O with/O episodes/O of/O dark/O urine/O ,/O biochemically/O by/O the/O accumulation/O of/O peripheral/O homogentisic/O acid/O and/O molecularly/O by/B-Reg the/I-Reg presence/I-Reg of/I-Reg mutations/B-Var in/O the/O homogentisate/O 1,2-dioxygenase/O gene/O (/B-Gene HGD/I-Gene )/I-Gene ./O
Alkaptonuria/B-Disease is/O invariably/O associated/B-Reg with/I-Reg HGD/B-Gene mutations/B-Var ,/O which/O consist/O of/O single/B-Var nucleotide/I-Var variants/I-Var and/O small/B-Var insertions/I-Var //I-Var deletions/I-Var ./O
Surprisingly/O ,/O the/O presence/O of/O deletions/O beyond/O a/O few/O nucleotides/O among/O over/O 150/O reported/O deleterious/O mutations/O has/O not/O been/O described/O ,/O raising/O the/O suspicion/O that/O this/O gene/O might/O be/O protected/O against/O the/O detrimental/O mechanisms/O of/O gene/O rearrangements/O ./O
The/O quest/O for/O an/O HGD/O mutation/O in/O a/O proband/O with/O AKU/O revealed/O with/O a/O SNP/O array/O five/O large/O regions/O of/O homozygosity/O (/O 5/O -/O 16/O Mb/O )/O ,/O one/O of/O which/O includes/O the/O HGD/O gene/O ./O
A/O homozygous/O deletion/O of/O 649/O bp/O deletion/O that/O encompasses/O the/O 72/O nucleotides/O of/O exon/O 2/O and/O surrounding/O DNA/O sequences/O in/O flanking/O introns/O of/O the/O HGD/O gene/O was/O unveiled/O in/O a/O proband/O with/O AKU/O ./O
The/O nature/O of/O this/O deletion/O suggests/O that/O this/O in/O -/O frame/O deletion/O could/O generate/O a/O protein/O without/O exon/O 2/O ./O
Thus/O ,/O we/O modeled/O the/O tertiary/O structure/O of/O the/O mutant/O protein/O structure/O to/O determine/O the/O effect/O of/O exon/O 2/O deletion/O ./O
While/O the/O two/O β/O -/O pleated/O sheets/O encoded/O by/O exon/O 2/O were/O missing/O in/O the/O mutant/O structure/O ,/O other/O β/O -/O pleated/O sheets/O are/O largely/O unaffected/O by/O the/O deletion/O ./O
However/O ,/O nine/O novel/O α/O -/O helical/O coils/O substituted/O the/O eight/O coils/O present/O in/O the/O native/O HGD/O crystal/O structure/O ./O
Thus/O ,/O this/O deletion/B-Var results/B-Reg in/I-Reg a/O deleterious/O enzyme/B-Enzyme ,/O which/O is/O consistent/O with/O the/O proband/O 's/O phenotype/O ./O
Screening/O for/O mutations/O in/O the/O HGD/O gene/O ,/O particularly/O in/O the/O Middle/O East/O ,/O ought/O to/O include/O this/O exon/O 2/O deletion/O in/O order/O to/O determine/O its/O frequency/O and/O uncover/O its/O origin/O ./O
Identification/O of/O two/O novel/O mutations/O in/O patients/O with/O X/O -/O linked/O primary/O immunodeficiencies/O ./O
Primary/B-Disease immunodeficiency/I-Disease diseases/I-Disease (/O PID/O )/O are/O a/O heterogeneous/O group/O of/O inherited/O disorders/O with/O defects/O in/O one/O or/O more/O component/O of/O the/O immune/O system/O ./O
In/O this/O study/O ,/O we/O analyzed/O gene/O mutations/O in/O four/O X/O -/O linked/O PID/O pedigrees/O ,/O which/O include/O one/O X-/O linked/O agammaglobulinemia/O (/O XLA/O )/O pedigree/O ,/O one/O X/O -/O linked/O chronic/O granulomatous/O disease/O (/O XCGD/O )/O pedigree/O ,/O and/O two/O X/O -/O linked/O Hyper/O IgM/O syndrome/O (/O XHIGM/O )/O pedigrees/O ./O
Sequence/O analysis/O of/O the/O BTK/B-Gene gene/O revealed/O a/O novel/O mutation/O (/B-Var c.1802_1803delinsGCC/I-Var ,/O p/O ./O Phe601CysfsX3/O )/O which/O results/B-Reg in/O the/O developmental/B-CPA arrest/I-CPA of/I-CPA B/I-CPA cells/I-CPA in/O the/O bone/O marrow/O ./O
Sequence/O analysis/O of/O the/O CYBB/B-Gene gene/O revealed/O a/O recurrent/O frameshift/O mutation/O (/B-Var c.1313_1314delinsT/I-Var )/I-Var in/O exon/O 10/O ,/O which/O generates/B-Reg a/O premature/B-MPA stop/I-MPA codon/O (/O p/O ./O Lys438IlefsX63/O )/O ./O
One/O novel/O frameshift/O mutation/O (/B-Var c.114delG/I-Var ,/O p/O ./O Ser39GlnfsX14/O )/O and/O one/O recurrent/O missense/O mutation/O (/B-Var c.499G/I-Var >/I-Var C/I-Var ,/O p/O ./O Gly167Arg/O )/O were/O found/O in/O the/O CD40LG/B-Gene gene/O and/O cause/O defective/B-NegReg T/B-CPA cell/I-CPA functioning/I-CPA ./O
In/O conclusion/O ,/O our/O study/O identified/O two/O novel/O mutations/O on/O the/O BTK/O and/O CD40LG/O genes/O in/O Chinese/O patients/O and/O established/O accurate/O and/O simple/O genetic/O diagnostic/O methods/O for/O three/O X/O -/O linked/O PID/O ./O
Novel/O COL9A3/B-Gene mutation/B-Var in/O a/O family/O diagnosed/O with/B-Reg multiple/B-Disease epiphyseal/I-Disease dysplasia/I-Disease :/I-Disease a/O case/O report/O ./O
BACKGROUND/O :/O Multiple/O epiphyseal/O dysplasia/O is/O a/O common/O skeletal/O dysplasia/O characterized/O by/O mild/O short/O stature/O ,/O early/O -/O onset/O osteoarthritis/O mainly/O involving/O the/O hip/O and/O knee/O joints/O ,/O and/O abnormally/O small/O and/or/O irregular/O epiphyses/O ./O
Multiple/O epiphyseal/O dysplasia/O is/O clinically/O and/O genetically/O heterogeneous/O and/O six/O genes/O are/O associated/O with/O the/O phenotype/O of/O multiple/O epiphyseal/O dysplasia/O ./O
CASE/O PRESENTATION/O :/O A/O 12-year/O -/O old/O Korean/O boy/O presented/O with/O intermittent/O knee/O pain/O ./O
His/O height/O was/O 144.6/O cm/O (/O 20th/O percentile/O )/O and/O family/O history/O was/O notable/O for/O early/O -/O onset/O osteoarthritis/O in/O his/O father/O ./O
The/O proband/O 's/O x/O -/O rays/O revealed/O epiphyseal/O changes/O characteristic/O of/O multiple/O epiphyseal/O dysplasia/O associated/O with/O a/O collagen/O IX/O defect/O ,/O with/O manifestations/O primarily/O restricted/O to/O the/O knees/O ./O
Mutational/O analysis/O identified/O a/O novel/O c.104G/B-Var >/I-Var A/I-Var substitution/O in/O exon/O 2/O of/O COL9A3/B-Gene ,/O resulting/B-Reg in/I-Reg p/B-Var ./I-Var Gly35Asp/I-Var in/O the/O proband/O and/O his/O father/O ./O
In/O silico/O analyses/O predicted/O the/O p/O ./O Gly35Asp/O amino/O acid/O change/O to/O be/O detelerious/O ,/O and/O molecular/O dynamics/O simulation/O demonstrated/O a/O major/O structural/O change/O in/O the/O heterotrimeric/O collagen/O IX/O ./O
CONCLUSION/O :/O So/O far/O ,/O three/O COL9A3/O mutations/O ,/O have/O been/O reported/O ./O
These/O three/O mutations/B-Var are/O located/O at/O the/O splice/O donor/O or/O acceptor/O site/O of/O COL9A3/B-Gene and/O cause/B-Reg skipping/B-MPA of/I-MPA exon/I-MPA 3/I-MPA ,/O resulting/B-Reg in/I-Reg the/O deletion/B-Var of/O 12/O aminoacids/O in/O the/O COL3/O domain/O of/O COL9A3/B-Gene ./O
In/O contrast/O ,/O the/O novel/O missense/O mutation/O identified/O in/O this/O two/O -/O generation/O family/O with/O multiple/O epiphyseal/O dysplasia/O is/O a/O missense/O mutation/B-Var affecting/B-Reg the/O Gly/B-MPA residue/I-MPA of/O the/O Pro/O -/O Pro/O -/O Gly/O repeat/O sequence/O in/O the/O COL3/O domain/O of/O collage/O IX/O ,/O with/O accompanying/O major/O structural/B-MPA change/O of/O the/O collagen/B-Protein peptide/O ./O
Rett/O -/O like/O onset/O in/O late/B-Disease -/I-Disease infantile/I-Disease neuronal/I-Disease ceroid/I-Disease lipofuscinosis/I-Disease (/O CLN7/O )/O caused/B-Reg by/I-Reg compound/O heterozygous/O mutation/B-Var in/O the/O MFSD8/B-Gene gene/O and/O review/O of/O the/O literature/O data/O on/O clinical/O onset/O signs/O ./O
BACKGROUND/O :/O We/O present/O clinical/O and/O molecular/O findings/O of/O a/O patient/O with/O ceroid/O -/O lipofuscinosis/O CLN7/B-Disease ,/O with/B-Reg a/O compound/O heterozygous/O mutation/B-Var of/O the/O MFSD8/B-Gene gene/O ,/O with/O Rett/O syndrome/O clinical/O signs/O onset/O and/O a/O later/O development/O of/O full/O picture/O of/O vLINCL/O ./O
CASE/O PRESENTATION/O :/O A/O 7/O years/O -/O old/O female/O patient/O with/O normal/O development/O until/O the/O age/O 12/O months/O ,/O developed/O Rett/O like/O clinical/O picture/O (/O psychomotor/O regression/O ,/O microcephaly/O ,/O stereotypic/O hands/O movements/O in/O the/O midline/O ,/O hyperventilation/O episodes/O )/O present/O at/O the/O onset/O of/O her/O condition/O (/O age/O 18/O months/O )/O ,/O features/O still/O present/O at/O the/O initial/O evaluation/O in/O our/O clinic/O at/O age/O 5/O years/O ./O
RESULTS/O :/O MECP2/O (/O methyl/O CpG/O binding/O protein/O 2/O )/O gene/O mutation/O was/O negative/O ./O
At/O age/O 6/O years/O she/O was/O readmitted/O for/O severe/O ataxia/O and/O blindness/O ,/O seizures/O ,/O and/O severe/O developmental/O regression/O leading/O to/O NCL/O (/O neuronal/O ceroid/O lipofuscinosis/O )/O suspicion/O ./O
EEG/O showed/O slow/O background/O with/O IRDA/O (/O intermittent/O rhythmic/O delta/O activity/O )/O ./O
A/O conjunctive/O biopsy/O showed/O abnormal/O curvilinear/O and/O fingerprint/O lysosomal/O deposits/O ,/O and/O genetic/O analysis/O revealed/O two/O heterozygous/O mutations/O of/O MFSD8/O gene/O (/O c.881C/O >/O A/O p/O ./O Thr294Lys/O and/O c.754/O +/O 2/O T/O >/O A/O )/O each/O inherited/O from/O carrier/O parents/O and/O a/O heterozygous/O variant/O (/O c.470A/O >/O C/O p/O ./O Asp157Ala/O )/O of/O CLN5/O gene/O ./O
CONCLUSION/O :/O NCL/O should/O be/O suspected/O and/O MFSD8/O genetic/O testing/O should/O also/O be/O considered/O in/O patients/O with/O Rett/O like/O phenotype/O at/O onset/O and/O negative/O MECP2/O mutation/O ./O
Such/O cases/O should/O be/O carefully/O and/O frequently/O re/O -/O evaluated/O in/O order/O to/O avoid/O delayed/O diagnosis/O and/O offer/O proper/O genetic/O advice/O to/O the/O family/O ./O
In/O our/O knowledge/O ,/O this/O might/O be/O the/O first/O case/O of/O CLN7/O disease/O with/O Rett/O like/O onset/O described/O in/O the/O literature/O ,/O which/O developed/O typical/O vLINCL/O clinical/O phenotype/O after/O age/O 5.5/O years/O ./O
A/O short/O review/O of/O the/O literature/O showing/O NCL/O onset/O modalities/O is/O presented/O ./O
Novel/O homozygous/B-Var deletion/I-Var of/O segmental/O KAL1/B-Gene and/O entire/O STS/B-Gene cause/B-Reg Kallmann/B-Disease syndrome/I-Disease and/O X/B-Disease -/I-Disease linked/I-Disease ichthyosis/I-Disease in/O a/O Chinese/O family/O ./O
Kallmann/O syndrome/O (/O KS/O )/O is/O a/O genetically/O heterogeneous/O disease/O characterised/O by/O hypogonadotrophic/O hypogonadism/O in/O association/O with/O anosmia/O or/O hyposmia/O ./O
This/O condition/O affects/O 1/O in/O 10/O 000/O men/O and/O 1/O in/O 50/O 000/O women/O ./O
Defects/O in/O seventeen/O genes/O including/O KAL1/O gene/O contribute/O to/O the/O molecular/O basis/O of/O KS/O ./O
We/O report/O the/O clinical/O characteristics/O ,/O molecular/O causes/O and/O treatment/O outcome/O of/O two/O Chinese/O brothers/O with/O KS/O and/O X/O -/O linked/O ichthyosis/O ./O
The/O phenotypes/O of/O the/O patients/O were/O characterised/O by/O bilateral/O cryptorchidism/O ,/O unilateral/O renal/O agenesis/O in/O one/O patient/O but/O normal/O kidney/O development/O in/O another/O ./O
The/O patients/O had/O low/O serum/O testosterone/O ,/O follicle/O -/O stimulating/O hormone/O and/O luteinising/O hormone/O levels/O and/O a/O blunt/O response/O to/O the/O gonadotrophin/O -/O releasing/O hormone/O stimulation/O test/O ./O
After/O human/O chorionic/O gonadotrophin/O treatment/O ,/O the/O serum/O testosterone/O levels/O were/O normalized/O ,/O and/O the/O pubic/O hair/O ,/O penis/O length/O and/O testicular/O volumes/O were/O greatly/O improved/O in/O both/O of/O the/O patients/O ./O
The/O two/O affected/O siblings/O had/O the/O same/O novel/O deletion/O at/O Xp22.3/O including/O exons/O 9/O -/O 14/O of/O KAL1/O gene/O and/O entire/O STS/O gene/O ./O
Our/O study/O broadens/O the/O mutation/B-Var spectrum/O in/O the/O KAL1/B-Gene gene/O associated/B-Reg with/I-Reg KS/B-Disease and/O facilitates/O the/O genetic/O diagnosis/O and/O counselling/O for/O KS/O ./O
[/O Heterozygote/O forms/O of/O familial/O Mediterranean/O fever/O can/O be/O manifested/O in/O adults/O as/O myofacial/O pain/O syndrome/O ]/O ./O
Heterozygote/O Formen/O des/O familiären/O Mittelmeerfiebers/O können/O beim/O Erwachsenen/O als/O myofasziales/O Schmerzsyndrom/O imponieren/O ./O
BACKGROUND/O :/O Familial/B-Disease Mediterranean/I-Disease fever/I-Disease (/O FMF/O )/O is/O a/O disease/O characterized/O by/O recurrent/O fever/O ,/O serositis/O ,/O arthritis/O and/O unspecific/O myalgia/O ./O
It/O is/O prevalent/O among/O Mediterranean/O people/O and/O has/O been/O shown/O to/O be/O associated/B-Reg with/O mutations/B-Var in/O the/O Mediterranean/O fever/O (/B-Gene MEFV/I-Gene )/I-Gene gene/O which/O ,/O encodes/O pyrin/O a/O regulatory/O protein/O of/O the/O inflammasome/O ./O
As/O heterozygous/B-Var mutations/I-Var in/O MEFV/B-Gene can/O be/O associated/B-Reg with/O only/O mild/O inflammatory/O symptoms/O ,/O such/O as/O arthralgia/B-CPA or/O chronic/B-CPA fibromyalgic/I-CPA pain/I-CPA ,/O FMF/O may/O be/O underdiagnosed/O in/O the/O current/O diagnostic/O work/O -/O up/O of/O musculoskeletal/O diseases/O ./O
METHODS/O :/O The/O selection/O of/O patients/O was/O carried/O out/O according/O to/O the/O following/O criteria/O :/O myofacial/O pain/O syndrome/O ,/O seronegative/O oligoarthralgia/O ,/O a/O slight/O inflammatory/O constellation/O and/O ethnic/O origin/O from/O the/O Mediterranean/O area/O ./O
When/O these/O criteria/O were/O fulfilled/O a/O molecular/O genetic/O investigation/O was/O carried/O out/O RESULTS/O :/O This/O article/O presents/O evidence/O that/O 9/O out/O of/O 12/O Mediterranean/O patients/O with/O recurrent/O myofascial/B-Disease pain/I-Disease syndrome/I-Disease and/O mild/B-CPA inflammation/I-CPA revealed/B-Reg heterozygote/B-Var mutations/I-Var in/O the/O MEFV/B-Gene gene/O and/O 7/O of/O these/O patients/O benefitted/O from/O treatment/O with/O colchicine/O ./O
DISCUSSION/O :/O As/O colchicine/O treatment/O not/O only/O improved/O the/O myofascial/O pain/O but/O also/O prevented/O FMF/O -/O associated/O amyloidosis/O and/O nephropathy/O ,/O differential/O diagnosis/O of/O fibromyalgia/O in/O patients/O of/O Mediterranean/O origin/O should/O include/O FMF/O and/O a/O genetic/O screening/O of/O the/O MEFV/O locus/O ./O
In/O silico/O analyses/O of/O missense/O mutations/O in/O coagulation/O factor/O VIII/O :/O identification/O of/O severity/O determinants/O of/O haemophilia/O A./O Factor/O VIII/O (/B-Gene FVIII/I-Gene )/I-Gene mutations/B-Var cause/B-Reg haemophilia/B-Disease A/I-Disease (/O HA/O )/O ,/O an/O X/O -/O linked/O recessive/O coagulation/O disorder/O ./O
Over/O 1000/O missense/O mutations/O in/O FVIII/O are/O known/O and/O they/O lead/O to/O variable/O clinical/O phenotypes/O (/O severe/O ,/O moderate/O and/O mild/O )/O ./O
The/O exact/O molecular/O basis/O of/O this/O phenotypic/O heterogeneity/O by/O FVIII/O missense/O mutations/O is/O elusive/O to/O date/O ./O
In/O this/O study/O ,/O we/O aimed/O to/O identify/O the/O severity/O determinants/O that/O cause/O phenotypic/O heterogeneity/O of/O HA/O ./O
We/O compiled/O and/O curated/O a/O data/O set/O of/O 766/O missense/O mutations/O from/O the/O repertoire/O of/O missense/O mutations/O in/O FVIII/O ./O
We/O analysed/O these/O mutations/O by/O computational/O programs/O (/O e.g./O Swiss/O -/O PdbViewer/O )/O and/O different/O mutation/O analysis/O servers/O (/O e.g./O SIFT/O ,/O PROVEAN/O ,/O CUPSAT/O ,/O PolyPhen2/O ,/O MutPred/O )/O ;/O and/O various/O sequence-/O and/O structure/O -/O based/O parameters/O were/O assessed/O for/O any/O significant/O distribution/O bias/O among/O different/O HA/O phenotypes/O ./O
Our/O analyses/O suggest/O that/O '/O mutations/O in/O evolutionary/O conserved/O residues/O '/O ,/O '/O mutations/O in/O buried/O residues/O '/O ,/O mutation/B-Reg -/I-Reg induced/I-Reg '/O steric/O clash/O '/O and/O '/B-MPA surface/I-MPA electrostatic/I-MPA potential/I-MPA alteration/I-MPA '/I-MPA act/O as/O risk/O factors/B-Reg towards/O severe/O HA/B-Disease ./O
We/O have/O developed/O a/O grading/O system/O for/O FVIII/O mutations/O combining/O the/O severity/O determinants/O ,/O and/O the/O grading/O pattern/O correlates/O with/O HA/O phenotype/O ./O
This/O study/O will/O help/O to/O correctly/O associate/O the/O HA/O phenotype/O with/O a/O mutation/O and/O aid/O early/O characterization/O of/O novel/O variants/O ./O
X/B-Disease -/I-Disease linked/I-Disease adrenal/I-Disease hypoplasia/I-Disease congenita/I-Disease :/I-Disease clinical/O and/O follow/O -/O up/O findings/O of/O two/O kindreds/O ,/O one/O with/B-Reg a/O novel/O NR0B1/B-Gene mutation/B-Var ./O
X/B-Disease -/I-Disease linked/I-Disease adrenal/I-Disease hypoplasia/I-Disease congenita/I-Disease typically/O manifests/O as/O primary/O adrenal/B-Disease insufficiency/I-Disease in/O the/O newborn/O age/O and/O hypogonadotropic/B-Disease hypogonadism/I-Disease in/O males/O ,/O being/O caused/B-Reg by/I-Reg mutations/B-Var in/O NR0B1/B-Gene gene/O ./O
We/O present/O the/O clinical/O and/O follow/O -/O up/O findings/O of/O two/O kindreds/O with/O NR0B1/O mutations/O ./O
The/O proband/O of/O kindred/O A/O had/O a/O diagnosis/O of/O primary/O adrenal/O insufficiency/O when/O he/O was/O a/O newborn/O ./O
Family/O history/O was/O relevant/O for/O a/O maternal/O uncle/O death/O at/O the/O newborn/O age/O ./O
Beyond/O 2/O year/O -/O old/O steroid/O measurements/O rendered/O undetectable/O and/O delayed/O bone/O age/O was/O noticed/O ./O
Molecular/O analysis/O of/O NR0B1/B-Gene gene/O revealed/O a/O previously/O unreported/O mutation/O (/B-Var c.1084A/I-Var >/I-Var T/I-Var )/I-Var ,/O leading/B-Reg to/I-Reg a/O premature/O stop/O codon/O ,/O p/B-MPA ./I-MPA Lys362/I-MPA */I-MPA ,/O in/O exon/O 1/O ./O
His/O mother/O and/O sister/O were/O asymptomatic/O carriers/O ./O
At/O 14/O year/O -/O old/O he/O had/O 3/O mL/O of/O testicular/O volume/O and/O biochemical/O surveys/O (/O LH/O </O 0.1/O UI/O //O L/O ,/O total/O testosterone/O </O 10/O ng/O //O dL/O )/O concordant/O with/O hypogonadotrophic/O hypogonadism/O ./O
Kindred/O B/O had/O two/O males/O diagnosed/O with/O adrenal/O insufficiency/O at/O the/O newborn/O age/O ./O
By/O 3/O year/O -/O old/O both/O siblings/O had/O undetectable/O androgen/O levels/O and/O delayed/O bone/O age/O ./O
NR0B1/O molecular/O analysis/O identified/O a/O nonsense/O mutation/O in/O both/O cases/O ,/O c.243C/O >/O G/O ;/O p/O ./O Tyr81/O */O ,/O in/O exon/O 1/O ./O
Their/O mother/O and/O sister/O were/O asymptomatic/O carriers/O ./O
At/O 14/O year/O -/O old/O (/O Tanner/O stage/O 1/O )/O hypothalamic/O -/O pituitary/O -/O gonadal/O axis/O evaluation/O in/O both/O males/O (/O LH/O </O 0.1UI/O //O L/O ,/O total/O testosterone/O </O 10/O ng/O //O dL/O )/O confirmed/O hypogonadotropic/O hypogonadism/O ./O
In/O conclusion/O ,/O biochemical/O profiles/O ,/O bone/O age/O and/O an/O X/O -/O linked/O inheritance/O led/O to/O suspicion/O of/O NR0B1/O mutations/O ./O
Two/O nonsense/O mutations/O were/O detected/O in/O both/O kindreds/O ,/O one/O previously/O unreported/O (/O c.1084A/O >/O T/O ;/O p/O ./O Lys362/O */O )/O ./O
Mutation/O identification/O allowed/O the/O timely/O institution/O of/O testosterone/O in/O patients/O at/O puberty/O and/O an/O appropriate/O genetic/O counselling/O for/O relatives/O ./O
Phenotypic/O Variability/O and/O Newly/O Identified/O Mutations/B-Var of/O the/O IVD/B-Gene Gene/O in/O Japanese/O Patients/O with/B-Reg Isovaleric/B-Disease Acidemia/I-Disease ./O
Isovaleric/O acidemia/O (/O IVA/O )/O is/O an/O autosomal/O recessive/O inborn/O error/O affecting/O leucine/O metabolism/O ./O
It/O is/O caused/O by/O a/O deficiency/O in/O isovaleryl/O -/O CoA/O dehydrogenase/O (/O IVD/O )/O ,/O a/O mitochondrial/O matrix/O enzyme/O that/O catalyzes/O the/O oxidation/O of/O isovaleryl/O -/O CoA/O to/O 3-methylcrotonyl/O -/O CoA./O IVD/O is/O a/O FAD/O -/O containing/O enzyme/O ,/O consisting/O of/O four/O identical/O subunits/O ./O
Clinical/O features/O of/O IVA/O include/O poor/O feeding/O ,/O vomiting/O ,/O lethargy/O ,/O developmental/O delay/O ,/O metabolic/O acidosis/O ,/O and/O a/O characteristic/O "/O sweaty/O foot/O "/O odor/O ./O
IVA/O is/O one/O of/O the/O target/O disorders/O for/O newborn/O screening/O by/O tandem/O mass/O spectrometry/O (/O MS/O //O MS/O )/O ./O
The/O human/O IVD/O gene/O is/O located/O on/O chromosome/O 15q/O ./O
To/O date/O ,/O over/O 50/O disease/O -/O causing/O mutations/O have/O been/O reported/O worldwide/O ./O
In/O this/O study/O ,/O we/O searched/O for/O IVD/O mutations/O in/O five/O Japanese/O patients/O with/O IVA/O (/O neonatal/O type/O ,/O two/O patients/O ;/O chronic/O intermittent/O type/O ,/O two/O patients/O ;/O and/O mild/O biochemical/O type/O ,/O one/O patient/O )/O ./O
The/O diagnosis/O of/O IVA/O was/O confirmed/O by/O urinary/O organic/O acid/O analysis/O using/O gas/O chromatography/O and/O mass/O spectrometry/O ./O
All/O coding/O exons/O and/O the/O flanking/O introns/O in/O the/O IVD/O gene/O were/O amplified/O by/O PCR/O and/O were/O directly/O sequenced/O ./O
We/O thus/O identified/O six/O hitherto/O unknown/O mutations/O (/O p/O ./O G94D/O ,/O p/O ./O E116/O K/O ,/O p/O ./O M167/O T/O ,/O p/O ./O L243P/O ,/O p/O ./O L246P/O ,/O and/O c.696/O +/O 1G/O >/O T/O )/O and/O four/O previously/O reported/O (/O p/O ./O R53P/O ,/O p/O ./O R395C/O ,/O p/O ./O Y403C/O ,/O and/O p/O ./O E411/O K/O )/O pathogenic/O mutations/O ./O
All/O patients/O were/O compound/O heterozygotes/O ,/O and/O each/O mutation/O was/O identified/O in/O a/O single/O patient/O ./O
Pathogenicity/O of/O newly/O identified/O mutations/O was/O validated/O using/O computational/O programs/O ./O
Among/O them/O ,/O the/O p/B-Var ./I-Var M167/I-Var T/I-Var is/O believed/O to/O influence/B-Reg FAD/B-Interaction binding/I-Interaction ,/O as/O the/O position/O 167/O is/O present/O in/O one/O of/O the/O FAD/O -/O binding/O sites/O ./O
Our/O results/O have/O illustrated/O the/O heterogeneous/O mutation/O spectrum/O and/O clinical/O presentation/O of/O IVA/O in/O the/O Japanese/O patients/O ./O
Molecular/O and/O clinical/O features/O of/O inherited/O neuropathies/O due/O to/O PMP22/O duplication/O ./O
PMP22/O is/O a/O transmembrane/O glycoprotein/O component/O of/O myelin/O ,/O important/O for/O myelin/O functioning/O ./O
Mutation/B-Var of/O PMP22/B-Gene gene/O which/O encodes/O for/O the/O production/O of/O PMP22/O glycoprotein/O is/O associated/B-Reg with/I-Reg a/O variety/O of/O inherited/O neuropathies/B-Disease ./O
This/O literature/O review/O sought/O to/O review/O the/O molecular/O mechanism/O and/O clinical/O features/O of/O inherited/O neuropathies/O caused/O by/O PMP22/O duplication/O ./O
PMP22/O duplication/O causes/O CMT1A/O which/O accounts/O for/O more/O than/O half/O of/O all/O CMT/O cases/O and/O about/O 70/O %/O of/O CMT1/O cases/O ./O
It/O manifests/O with/O muscle/O weakness/O ,/O depressed/O reflexes/O ,/O impaired/O distal/O sensation/O ,/O hand/O and/O foot/O deformities/O ,/O slowing/O of/O NCV/O and/O onion/O bulbs/O ./O
With/O no/O specific/O treatment/O available/O ,/O it/O is/O managed/O conservatively/O ./O
Future/O treatment/O may/O be/O based/O on/O the/O molecular/O genetics/O of/O the/O disease/O ./O
A/O novel/O gene/O insertion/B-Var combined/O with/O a/O missense/O mutation/O causing/B-Reg factor/B-Disease VII/I-Disease deficiency/I-Disease in/O two/O unrelated/O Chinese/O families/O ./O
Hereditary/O coagulation/O factor/O VII/O (/O FVII/O )/O deficiency/O is/O a/O rare/O bleeding/O disorder/O characterized/O by/O reduced/O FVII/O activity/O (/O FVII/O :/O C/O )/O and/O inconsistent/O FVII/O antigen/O (/O FVII/O :/O Ag/O )/O ./O
In/O our/O study/O ,/O two/O pregnant/O probands/O were/O diagnosed/O with/O FVII/O deficiency/O ,/O based/O on/O the/O tests/O that/O FVII/O :/O C/O were/O both/O 3/O %/O and/O FVII/O :/O Ag/O were/O less/O than/O 7.5/O %/O ./O
Gene/O sequencing/O revealed/O the/O same/O compound/O mutations/O ,/O a/O recurrent/O missense/O mutation/O p/O ./O Arg277Cys/O and/O a/O novel/O insertion/O mutation/O g.11520/O -/O 11521insT./O What/O is/O more/O ,/O haplotype/O analysis/O of/O SNPs/O excluded/O the/O possibility/O of/O consanguinity/O between/O the/O two/O families/O ./O
According/O to/O the/O model/O ,/O we/O speculated/O that/O although/O the/O insertion/B-Var mutation/O was/O close/O to/O the/O carboxy/O -/O terminal/O ,/O it/O induced/B-PosReg the/O protein/B-MPA extension/I-MPA and/O affected/B-Reg the/B-MPA 3/I-MPA '/I-MPA untranslated/I-MPA region/I-MPA of/O F7/B-Gene gene/O ,/O which/O is/O significant/O to/O posttranscriptional/O regulation/O ./O
Hypothetically/O ,/O the/O stability/O or/O translational/O efficiency/O of/O mRNA/O may/O be/O influenced/O ,/O resulting/O in/O reducing/O FVII/O :/O C./O Hereditary/O spastic/O paraplegia/O SPG4/O :/O what/O is/O known/O and/O not/O known/O about/O the/O disease/O ./O
Mutations/O in/O more/O than/O 70/O distinct/O loci/O and/O more/O than/O 50/O mutated/O gene/O products/O have/O been/O identified/O in/O patients/O with/O hereditary/B-Disease spastic/I-Disease paraplegias/I-Disease ,/O a/O diverse/O group/O of/O neurological/O disorders/O characterized/O predominantly/O ,/O but/O not/O exclusively/O ,/O by/O progressive/O lower/O limb/O spasticity/O and/O weakness/O resulting/O from/O distal/O degeneration/O of/O corticospinal/O tract/O axons/O ./O
Mutations/B-Var in/O the/O SPAST/B-Gene (/O previously/O known/O as/O SPG4/B-Gene )/I-Gene gene/O that/O encodes/O the/O microtubule/O -/O severing/O protein/O called/O spastin/O ,/O are/O the/O most/O common/O cause/B-Reg of/O the/O disease/B-Disease ./O
The/O aetiology/O of/O the/O disease/O is/O poorly/O understood/O ,/O but/O partial/O loss/B-NegReg of/O microtubule/B-CPA -/I-CPA severing/I-CPA activity/I-CPA resulting/O from/O inactivating/B-Var mutations/I-Var in/O one/O SPAST/B-Gene allele/O is/O the/O most/O postulated/O explanation/O ./O
Microtubule/O severing/O is/O important/O for/O regulating/O various/O aspects/O of/O the/O microtubule/O array/O ,/O including/O microtubule/O number/O ,/O length/O ,/O and/O mobility/O ./O
In/O addition/O ,/O higher/O numbers/O of/O dynamic/O plus/O -/O ends/O of/O microtubules/O ,/O resulting/O from/O microtubule/O -/O severing/O events/O ,/O may/O play/O a/O role/O in/O endosomal/O tubulation/O and/O fission/O ./O
Even/O so/O ,/O there/O is/O growing/O evidence/O that/O decreased/O severing/O of/O microtubules/O does/O not/O fully/O explain/O HSP/O -/O SPG4/O ./O
The/O presence/O of/O two/O translation/O initiation/O codons/O in/O SPAST/O allows/O synthesis/O of/O two/O spastin/O isoforms/O :/O a/O full/O -/O length/O isoform/O called/O M1/O and/O a/O slightly/O shorter/O isoform/O called/O M87/O ./O
M87/O is/O more/O abundant/O in/O both/O neuronal/O and/O non/O -/O neuronal/O tissues/O ./O
Studies/O on/O rodents/O suggest/O that/O M1/O is/O only/O readily/O detected/O in/O adult/O spinal/O cord/O ,/O which/O is/O where/O nerve/O degeneration/O mainly/O occurs/O in/O humans/O with/O HSP/O -/O SPG4/O ./O
M1/O ,/O due/O to/O its/O hydrophobic/O N/O -/O terminal/O domain/O not/O shared/O by/O M87/O ,/O may/O insert/O into/O endoplasmic/O reticulum/O membrane/O ,/O and/O together/O with/O reticulons/O ,/O atlastin/O and/O REEP1/O ,/O may/O play/O a/O role/O in/O the/O morphogenesis/O of/O this/O organelle/O ./O
Some/B-Var mutated/I-Var spastins/B-Protein may/O act/O in/O dominant/O -/O negative/O fashion/O to/O lower/B-NegReg microtubule/B-CPA -/I-CPA severing/I-CPA activity/I-CPA ,/O but/O others/B-Var have/O detrimental/B-NegReg effects/I-NegReg on/O neurons/B-CPA without/O further/O lowering/O microtubule/O severing/O ./O
The/O observed/O adverse/B-NegReg effects/I-NegReg on/O microtubule/B-CPA dynamics/I-CPA ,/O axonal/B-CPA transport/I-CPA ,/O endoplasmic/B-CPA reticulum/I-CPA ,/O and/O endosomal/B-CPA trafficking/I-CPA are/O likely/O caused/O not/O only/O by/O diminished/B-NegReg severing/B-CPA of/I-CPA microtubules/I-CPA ,/O but/O also/O by/O neurotoxicity/B-CPA of/B-Reg mutant/B-Var spastin/B-Protein proteins/I-Protein ,/O chiefly/O M1/B-Protein ./O
Some/O large/O deletions/O in/O SPAST/O might/O also/O affect/O the/O function/O of/O adjacent/O genes/O ,/O further/O complicating/O the/O aetiology/O of/O the/O disease/O ./O
Clinical/O phenotype/O in/O genetically/O confirmed/O von/O Willebrand/O disease/O type/O 2N/O patients/O reflects/O a/O haemophilia/O A/O phenotype/O ./O
INTRODUCTION/O :/O Von/B-Disease Willebrand/I-Disease disease/I-Disease (/I-Disease VWD/I-Disease )/I-Disease type/I-Disease 2N/I-Disease is/O characterized/O by/O a/O defective/B-NegReg binding/B-Interaction of/O factor/B-Protein VIII/I-Protein (/O FVIII/O )/O to/O von/B-Protein Willebrand/I-Protein factor/I-Protein (/O VWF/O )/O resulting/O in/O diminished/B-NegReg plasma/B-CPA FVIII/I-CPA levels/I-CPA and/O a/O clinical/O phenotype/O mimicking/O mild/O haemophilia/O A./O Several/O mutations/B-Var in/O the/O FVIII/O binding/O site/O of/O VWF/B-Gene have/O been/O reported/O ./O
AIM/O :/O This/O study/O aims/O to/O examine/O the/O effect/O of/O genotype/O on/O clinical/O phenotype/O in/O a/O cohort/O of/O VWD/O 2N/O patients/O ./O
METHODS/O :/O Patients/O with/O at/O least/O one/O genetically/O confirmed/O 2N/O mutation/O were/O selected/O retrospectively/O from/O a/O cohort/O of/O patients/O with/O suspected/O VWD/O ./O
Clinical/O and/O laboratory/O phenotypes/O including/O bleeding/O scores/O (/O BS/O )/O were/O obtained/O and/O analysed/O ./O
RESULTS/O :/O Forty/O -/O two/O VWD/O 2N/O patients/O with/O a/O mean/O age/O of/O 44/O years/O were/O included/O ./O
Eleven/O patients/O were/O homozygous/O or/O compound/O heterozygous/O (/O genetically/O confirmed/O group/O )/O and/O 31/O patients/O were/O heterozygously/O affected/O (/O carriers/O group/O )/O ./O
Statistically/O significant/O differences/O between/O genetically/O confirmed/O VWD/O 2N/O patients/O and/O carriers/O were/O found/O in/O FVIII/O activity/O ,/O VWF/O antigen/O levels/O ,/O VWF/O -/O FVIII/O binding/O capacity/O ,/O FVIII/O //O VWF/O antigen/O ratio/O (/O all/O P<0.001/O )/O ,/O VWF/O -/O ristocetin/O activity/O (/O p=0.001/O )/O and/O VWF/O collagen/O binding/O (/O P/O =/O 0.002/O )/O ./O
Median/O BS/O was/O 6/O in/O genetically/O confirmed/O VWD/O 2N/O patients/O compared/O with/O 3/O in/O carriers/O (/O P/O =/O 0.047/O )/O ./O
Haemarthrosis/O ,/O muscle/O haematomas/O and/O postpartum/O haemorrhage/O were/O only/O reported/O in/O genetically/O confirmed/O 2N/O patients/O ./O
CONCLUSION/O :/O Phenotypic/O analysis/O showed/O that/O all/O laboratory/O parameters/O are/O lower/O in/O genetically/O confirmed/O VWD/O 2N/O patients/O compared/O with/O heterozygous/O 2N/O carriers/O ./O
The/O clinical/O phenotype/O in/O genetically/O confirmed/O VWD/O 2N/O patients/O is/O comparable/O to/O mild/O haemophilia/O A/O patients/O and/O more/O severe/O than/O heterozygous/O 2N/O carriers/O ./O
A/O novel/O SLC12A3/B-Gene gene/O homozygous/O mutation/B-Var of/B-Reg Gitelman/B-Disease syndrome/I-Disease in/O an/O Asian/O pedigree/O and/O literature/O review/O ./O
OBJECTIVES/O :/O Gitelman/B-Disease syndrome/I-Disease (/O GS/O )/O is/O an/O autosomal/O recessive/O disease/O characterized/O by/O hypokalemic/O metabolic/O alkalosis/O in/O combination/O with/O significant/O hypomagnesemia/O and/O hypocalciuria/O which/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O SLC12A3/B-Gene gene/O ./O
In/O this/O study/O ,/O we/O reported/O a/O case/O of/O GS/O pedigree/O and/O reviewed/O pertinent/O literature/O so/O as/O to/O explore/O the/O relationship/O between/O clinical/O characteristics/O and/O genotype/O meanwhile/O provide/O recommendations/O for/O the/O diagnosis/O and/O treatment/O of/O GS/O ./O
DESIGN/O AND/O METHODS/O :/O This/O is/O a/O pedigree/O -/O based/O genetic/O study/O of/O GS/O and/O 11/O members/O from/O one/O family/O were/O included/O ./O
We/O summarized/O their/O clinical/O features/O ,/O analyzed/O laboratory/O parameters/O related/O to/O GS/O and/O SLC12A3/O gene/O ./O
RESULTS/O :/O The/O proband/O experienced/O intermittent/O severe/O symptoms/O of/O weakness/O accompanied/O by/O significant/O hypokalemia/O ,/O hypomagnesemia/O and/O hypocalciuria/O in/O laboratory/O test/O with/O poor/O treatments/O ./O
His/O mother/O had/O more/O slight/O symptoms/O of/O weakness/O than/O him/O with/O mild/O hypokalemia/O and/O hypocalciuria/O ./O
Mild/O hypomagnesemia/O was/O also/O observed/O in/O his/O sister/O with/O occasional/O weakness/O ./O
All/O other/O pedigree/O members/O had/O normal/O laboratory/O test/O with/O no/O GS/O -/O related/O symptoms/O ./O
A/O homozygous/O mutation/O of/O SLC12A3/O gene/O (/O c.488C/O >/O T/O )/O was/O detected/O by/O genetic/O testing/O in/O three/O members/O ,/O and/O six/O were/O carriers/O of/O this/O mutation/O ./O
CONCLUSIONS/O :/O Genotype/O and/O phenotype/O vary/O significantly/O among/O GS/O patients/O ./O
Male/O patients/O tend/O to/O experience/O more/O severe/O symptoms/O and/O poor/O treatment/O effect/O ./O
Further/O large/O -/O scale/O population/O ,/O animal/O ,/O and/O molecular/O biology/O experiments/O are/O required/O to/O investigate/O the/O complexity/O of/O GS/O and/O to/O find/O a/O better/O treatment/O regimen/O for/O this/O disease/O ./O
Darier/O disease/O in/O israel/O :/O combined/O evaluation/O of/O genetic/O and/O neuropsychiatric/O aspects/O ./O
BACKGROUND/O :/O Darier/B-Disease disease/I-Disease (/O DD/O )/O is/O a/O rare/O genodermatose/O caused/B-Reg by/I-Reg heterozygous/O mutations/B-Var in/O the/O ATP2A2/B-Gene gene/O and/O has/O been/O associated/O with/O neuropsychiatric/O manifestations/O ./O
OBJECTIVES/O :/O To/O investigate/O the/O genetic/O basis/O of/O Israeli/O patients/O with/O DD/O ,/O and/O its/O association/O with/O neuropsychiatric/O phenotype/O ./O
METHODS/O :/O A/O cohort/O of/O 32/O families/O comprising/O 74/O affected/O individuals/O and/O 13/O unaffected/O family/O members/O recruited/O from/O the/O Haemek/O Dermatology/O Department/O and/O other/O dermatology/O clinics/O in/O Israel/O were/O evaluated/O by/O detailed/O questionnaires/O ,/O physical/O examination/O ,/O and/O genetic/O analysis/O ./O
Main/O outcome/O measures/O were/O genetic/O mutations/O ,/O psychiatric/O profile/O ,/O and/O their/O association/O ./O
RESULTS/O :/O 23/O mutations/O in/O ATP2A2/O gene/O were/O scattered/O over/O the/O entire/O gene/O ,/O 14/O of/O them/O novel/O ./O
Two/O families/O shared/O the/O same/O mutation/O ./O
Twenty/O -/O one/O patients/O (/O 28.3/O %/O )/O had/O a/O history/O of/O psychiatric/O disorder/O ,/O most/O of/O them/O mood/O disorders/O ;/O another/O 7/O (/O 9.4/O %/O )/O patients/O were/O highly/O suspected/O of/O having/O a/O psychiatric/O disorder/O ;/O 21/O (/O 27.6/O %/O )/O reported/O suicidal/O thoughts/O ;/O and/O 5/O (/O 6.6/O %/O )/O had/O attempted/O suicide/O ./O
Psychiatric/O phenotype/O demonstrated/O inter-/O and/O intra/O -/O familial/O variability/O ,/O and/O was/O not/O associated/O with/O disease/O severity/O ,/O family/O history/O of/O psychiatric/O disease/O ,/O or/O mutation/O location/O ./O
CONCLUSIONS/O :/O The/O cohort/O demonstrated/O genetic/O heterogeneity/O with/O no/O mutation/O cluster/O along/O the/O gene/O ,/O and/O high/O prevalence/O of/O psychiatric/O disorders/O ./O
Although/O no/O clear/O genotype/O -/O phenotype/O correlation/O was/O found/O ,/O the/O results/O point/O to/O a/O major/O effect/O of/O genetic/O background/O on/O psychiatric/O phenotype/O ,/O together/O with/O other/O modifiers/O ./O
This/O article/O is/O protected/O by/O copyright/O ./O
All/O rights/O reserved/O ./O
A/O recurrent/B-Var germline/I-Var mutation/I-Var in/O the/O PIGA/B-Gene gene/O causes/B-Reg Simpson/B-Disease -/I-Disease Golabi/I-Disease -/I-Disease Behmel/I-Disease syndrome/I-Disease type/I-Disease 2/I-Disease ./O
Hypomorphic/O germline/O mutations/O in/O the/O PIGA/O (/O phosphatidylinositol/O glycan/O class/O A/O )/O gene/O recently/O were/O recognized/O as/O the/O cause/O of/O a/O clinically/O heterogeneous/O spectrum/O of/O X/O -/O linked/O disorders/O including/O (/O i/O )/O early/O onset/O epileptic/O encephalopathy/O with/O severe/O muscular/O hypotonia/O ,/O dysmorphism/O ,/O multiple/O congenital/O anomalies/O ,/O and/O early/O death/O (/O "/O MCAHS2/O "/O )/O ,/O (/O ii/O )/O neurodegenerative/O encephalopathy/O with/O systemic/O iron/O overload/O (/O ferro/O -/O cerebro/O -/O cutaneous/O syndrome/O ,/O "/O FCCS/O "/O )/O ,/O and/O (/O iii/O )/O intellectual/O disability/O and/O seizures/O without/O dysmorphism/O ./O
Previous/O studies/O showed/O that/O the/O recurrent/O PIGA/O germline/O mutation/O c.1234C/O >/O T/O (/O p/O ./O Arg412/O */O )/O leads/O to/O a/O clinical/O phenotype/O at/O the/O most/O severe/O end/O of/O the/O spectrum/O associated/O with/O early/O infantile/O lethality/O ./O
We/O identified/O three/O additional/O individuals/O from/O two/O unrelated/O families/O with/O the/O same/O PIGA/O mutation/O ./O
Major/O clinical/O findings/O include/O early/O onset/O intractable/O epileptic/O encephalopathy/O with/O a/O burst/O -/O suppression/O pattern/O on/O EEG/O ,/O generalized/O muscular/O hypotonia/O ,/O structural/O brain/O abnormalities/O ,/O macrocephaly/O and/O increased/O birth/O weight/O ,/O joint/O contractures/O ,/O coarse/O facial/O features/O ,/O widely/O spaced/O eyes/O ,/O a/O short/O nose/O with/O anteverted/O nares/O ,/O gingival/O overgrowth/O ,/O a/O wide/O mouth/O ,/O short/O limbs/O with/O short/O distal/O phalanges/O ,/O and/O a/O small/O penis/O ./O
Based/O on/O the/O phenotypic/O overlap/O with/O Simpson/O -/O Golabi/O -/O Behmel/O syndrome/O type/O 2/O (/O SGBS2/O )/O ,/O we/O hypothesized/O that/O both/O disorders/O might/O have/O the/O same/O underlying/O cause/O ./O
We/O were/O able/O to/O confirm/O the/O same/O c.1234C/O >/O T/O (/O p/O ./O Arg412/O */O )/O mutation/O in/O the/O DNA/O sample/O from/O an/O affected/O fetus/O of/O the/O original/O family/O affected/O with/O SGBS2/O ./O
We/O conclude/O that/O the/O recurrent/O PIGA/B-Gene germline/O mutation/O c.1234C/B-Var >/I-Var T/I-Var leads/B-Reg to/I-Reg a/O recognizable/B-CPA clinical/I-CPA phenotype/I-CPA with/O a/O poor/O prognosis/O and/O is/O the/O cause/B-Reg of/O SGBS2/B-Disease ./O
©/O 2015/O Wiley/O Periodicals/O ,/O Inc./O Incontinentia/O pigmenti/O (/O Bloch/O -/O Sulzberger/O syndrome/O )/O ./O
Incontinentia/B-Disease pigmenti/I-Disease (/O IP/O ;/O Bloch/O -/O Sulzberger/O syndrome/O ;/O OMIM/O #/O 308300/O )/O is/O an/O X/O -/O linked/O dominant/O neurocutaneous/O disorder/O with/O presumed/O male/O lethality/O ./O
It/O is/O usually/O diagnosed/O in/O female/O newborns/O based/O on/O skin/O features/O (/O erythematous/O ,/O vesicular/O ,/O or/O bullous/O eruption/O in/O linear/O streaks/O )/O ./O
The/O skin/O lesions/O evolve/O into/O a/O verrucous/O stage/O ,/O followed/O by/O atrophy/O and/O scarring/O ,/O leaving/O linear/O areas/O of/O hypopigmentation/O and/O hyperpigmented/O macules/O in/O bizarre/O patterns/O following/O Blaschko/O 's/O lines/O ./O
Systemic/O and/O neurologic/O complications/O include/O focal/O seizures/O and/O hemorrhagic/O cerebral/O infarction/O in/O infants/O ,/O and/O retinal/O vasculopathy/O leading/O to/O blindness/O ./O
Hypodontia/O ,/O conical/O or/O pegged/O teeth/O ,/O and/O linear/O areas/O of/O alopecia/O persist/O into/O adulthood/O ./O
IP/B-Disease is/O caused/B-Reg by/I-Reg mutation/B-Var of/O the/O IKBKG/B-Gene //I-Gene NEMO/I-Gene gene/O on/O Xq28/O ./O
Deletion/O of/O exons/O 4/O to/O 10/O (/O NEMOΔ4/O -/O 10/O )/O accounts/O for/O about/O 80/O %/O of/O cases/O (/O familial/O and/O sporadic/O )/O ./O
NEMO/B-Gene mutation/B-Var leads/O to/O loss/B-NegReg of/I-NegReg function/I-NegReg of/O NF/B-MPA -/I-MPA κB/I-MPA ,/O a/O critical/O protein/O that/O modulates/O cellular/O proliferation/O ,/O apoptosis/O ,/O and/O response/O to/O proinflammatory/O factors/O ,/O leading/B-Reg to/I-Reg the/O characteristic/O features/O of/O IP/B-Disease ./O
In/O female/O carriers/O ,/O selective/O loss/O of/O cells/O expressing/O the/O mutant/O X/O -/O chromosome/O results/O in/O completely/O skewed/O X/O -/O inactivation/O in/O the/O majority/O of/O cases/O ./O
Study/O of/O mouse/O models/O in/O which/O various/O components/O of/O the/O NF/O -/O κB/O pathway/O (/O including/O NEMO/O )/O have/O been/O knocked/O out/O has/O contributed/O significantly/O to/O our/O understanding/O of/O disease/O pathogenesis/O ./O
Lipoid/O proteinosis/O ./O
Lipoid/B-Disease proteinosis/I-Disease is/O a/O rare/O autosomal/O recessive/O disorder/O caused/B-Reg by/I-Reg mutations/B-Var in/O ECM1/B-Gene ,/O encoding/O extracellular/O matrix/O protein/O 1/O ,/O a/O glycoprotein/O expressed/O in/O many/O organs/O and/O which/O has/O important/O protein/O -/O protein/O interactions/O in/O tissue/O homeostasis/O ./O
Although/O the/O disease/O usually/O presents/O clinically/O with/O warty/O infiltration/O of/O the/O skin/O and/O mucous/O membranes/O and/O a/O hoarse/O voice/O ,/O neuropsychological/O and/O neuropsychiatric/O abnormalities/O are/O often/O prominent/O features/O ./O
There/O may/O be/O bean-/O or/O comma/O -/O shaped/O intracranial/O calcifications/O ,/O often/O selectively/O affecting/O the/O amygdala/O ./O
Patients/O with/O lipoid/O proteinosis/O therefore/O have/O been/O used/O as/O models/O for/O demonstrating/O physiologic/O and/O pathologic/O abnormalities/O of/O the/O amygdala/O with/O respect/O to/O fear/O processing/O ,/O affect/O and/O cognition/O ,/O anxiety/O and/O memory/O ./O
Clinically/O ,/O patients/O may/O also/O have/O epilepsy/O ,/O especially/O involving/O the/O temporal/O lobes/O ./O
Less/O common/O or/O rare/O disease/O associations/O are/O headache/O (/O including/O migraine/O )/O ,/O ataxia/O ,/O dizziness/O ,/O schizophrenia/O ,/O generalized/O dystonia/O ,/O transient/O brachiofacial/O paralysis/O ,/O and/O intracerebral/O hemorrhage/O ./O
Beyond/O the/O foci/O of/O calcification/O ,/O the/O cause/O of/O the/O neurologic/O abnormalities/O in/O lipoid/O proteinosis/O is/O unknown/O ,/O although/O the/O ECM1/O protein/O can/O normally/O bind/O to/O various/O extracellular/O matrix/O proteins/O and/O glycosaminoglycans/O as/O well/O as/O certain/O enzymes/O ,/O including/O matrix/O metalloproteinase/O 9/O ./O
Loss/O of/O key/O protein/O -/O protein/O interactions/O may/O underscore/O some/O of/O the/O disease/O pathophysiology/O ./O
There/O is/O currently/O no/O effective/O treatment/O for/O lipoid/O proteinosis/O and/O clinical/O care/O is/O largely/O supportive/O ./O
Paternal/O uniparental/O disomy/O 11p15.5/O in/O the/O pancreatic/O nodule/O of/O an/O infant/O with/O Costello/O syndrome/O :/O Shared/O mechanism/O for/O hyperinsulinemic/O hypoglycemia/O in/O neonates/O with/O Costello/O and/O Beckwith/O -/O Wiedemann/O syndrome/O and/O somatic/O loss/O of/O heterozygosity/O in/O Costello/O syndrome/O driving/O clonal/O expansion/O ./O
Costello/B-Disease syndrome/I-Disease (/O CS/O )/O entails/O a/O cancer/O predisposition/O and/O is/O caused/O by/O activating/B-PosReg HRAS/B-Gene mutations/B-Var ,/O typically/O arising/O de/O novo/O in/O the/O paternal/O germline/O ./O
Hypoglycemia/O is/O common/O in/O CS/O neonates/O ./O
A/O previously/O reported/O individual/O with/O the/O rare/O HRAS/O p/O ./O Gln22Lys/O had/O hyperinsulinemic/O hypoglycemia/O ./O
Autopsy/O showed/O a/O discrete/O pancreatic/O nodule/O ./O
The/O morphologic/O and/O immunohistochemistry/O findings/O ,/O including/O loss/O of/O p57(Kip2/O )/O protein/O ,/O were/O identical/O to/O a/O focal/O lesion/O of/O congenital/O hyperinsulinism/O ,/O however/O ,/O no/O KCNJ11/O or/O ABCC8/O mutation/O was/O identified/O and/O germline/O derived/O DNA/O showed/O no/O alternation/O of/O the/O maternal/O or/O paternal/O 11p15/O alleles/O ./O
Here/O we/O report/O paternal/O uniparental/O disomy/O (/O pUPD/O )/O within/O the/O lesion/O ,/O similar/O to/O the/O pUPD11p15.5/O in/O Beckwith/O -/O Wiedemann/O syndrome/O (/O BWS/O )/O ./O
The/O similar/O extent/O of/O the/O pUPD/O suggests/O a/O similar/O mechanism/O driving/O hyperinsulinemia/O in/O both/O conditions/O ./O
After/O coincidental/O somatic/O LOH/O and/O pUPD/O ,/O the/O growth/O promoting/O effects/O of/O the/O paternally/O derived/O HRAS/O mutation/O ,/O in/O combination/O with/O the/O increased/O function/O of/O the/O adjacent/O paternally/O expressed/O IGF2/O ,/O may/O together/O result/O in/O clonal/O expansion/O ./O
Although/O this/O somatic/O LOH/O within/O pancreatic/O tissue/O resulted/O in/O hyperinsulinism/O ,/O similar/O LOH/O in/O mesenchymal/O cells/O may/O drive/O embryonal/O rhabdomyosarcoma/O (/O ERMS/O )/O ./O
Interestingly/O ,/O biallelic/O IGF2/O expression/O has/O been/O linked/O to/O rhabdomyosarcoma/O tumorigenesis/O and/O pUPD11/O occurred/O in/O all/O 8/O ERMS/O samples/O from/O CS/O individuals/O ./O
Somatic/O KRAS/O and/O HRAS/O mutations/O occur/O with/O comparable/O frequency/O in/O isolated/O malignancies/O ./O
Yet/O ,/O the/O malignancy/O risk/O in/O CS/O is/O notably/O higher/O than/O in/O Noonan/O syndrome/O with/O a/O KRAS/O mutation/O ./O
It/O is/O conceivable/O that/O HRAS/O co/O -/O localization/O with/O IGF2/O and/O the/O combined/O effect/O of/O pUPD/O 11p15.5/O on/O both/O genes/O contributes/O to/O the/O oncogenic/O potential/O ./O
©/O 2015/O Wiley/O Periodicals/O ,/O Inc./O Progranulin/O deficiency/O induces/O overactivation/O of/O WNT5A/O expression/O via/O TNF/O -/O α/O //O NF/O -/O κB/O pathway/O in/O peripheral/O cells/O from/O frontotemporal/O dementia/O -/O linked/O granulin/O mutation/O carriers/O ./O
BACKGROUND/O :/O Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg progranulin/O gene/O (/B-Gene GRN/I-Gene )/I-Gene mutations/B-Var have/O been/O identified/O as/O the/O major/O cause/O of/O frontotemporal/B-Disease lobar/I-Disease degeneration/I-Disease with/O transactive/O response/O (/O TAR/O )/O DNA/O -/O binding/O protein/O 43/O (/O TDP-43/O )/O pathology/O (/O frontotemporal/O lobar/O degeneration/O [/O FTLD]-TDP/O )/O ;/O however/O ,/O little/O is/O known/O about/O the/O association/O between/O progranulin/O (/O PGRN/O )/O deficiency/O and/O neuronal/O loss/O in/O individuals/O with/O FTLD/O -/O TDP/O ./O
Previously/O we/O reported/O enhanced/O proliferative/O activity/O associated/O with/O the/O activation/O of/O WNT5A/O //O CDK6/O //O pRb/O signalling/O in/O PGRN/O -/O deficient/O cells/O ./O
The/O objective/O of/O this/O work/O was/O to/O elucidate/O the/O association/O between/O PGRN/O deficiency/O ,/O WNT5A/O signalling/O and/O cell/O proliferation/O in/O immortalized/O lymphoblasts/O from/O carriers/O of/O the/O c.709/O -/O 1/O G/O >/O A/O GRN/O mutation/O (/O asymptomatic/O and/O FTLD/O -/O TDP/O )/O ./O
METHODS/O :/O We/O assessed/O cell/O proliferation/O in/O carriers/O of/O the/O c.709/O -/O 1/O G/O >/O A/O GRN/O gene/O mutation/O and/O controls/O without/O GRN/O mutation/O and/O without/O sign/O of/O neurologic/O degeneration/O by/O cell/O counting/O or/O using/O an/O MTT/O assay/O ./O
We/O used/O a/O luciferase/O assay/O to/O measure/O the/O nuclear/O factor/O -/O κ/O (/O NF/O -/O κ/O )/O activity/O ./O
We/O evaluated/O messenger/O RNA/O levels/O using/O quantitative/O real/O -/O time/O polymerase/O chain/O reaction/O and/O protein/O levels/O by/O immunoblotting/O ./O
Co/O -/O immunoprecipitation/O was/O used/O to/O analyze/O the/O interaction/O between/O PGRN/O and/O its/O receptors/O ./O
RESULTS/O :/O We/O enrolled/O 19/O carriers/O of/O the/O GRN/O gene/O mutation/O and/O 10/O controls/O in/O this/O study/O ./O
The/O PGRN/B-Var -/I-Var deficient/I-Var cells/O showed/O increased/B-PosReg expression/B-MPA of/O WNT5A/B-Gene due/O to/O NF/B-Pathway -/I-Pathway κB/I-Pathway signalling/I-Pathway overactivation/B-PosReg ./O
We/O observed/O a/O competition/O between/O PGRN/O and/O tumour/O necrosis/O factor/O -/O α/O (/O TNF/O -/O α/O )/O for/O binding/O both/O TNF/O receptors/O (/O TNFR/O )/O I/O and/O II/O ./O
Blocking/O NF/O -/O κB/O signalling/O using/O wedelolactone/O or/O specific/O antibodies/O against/O TNFRs/O inhibited/O WNT5A/O overexpression/O and/O proliferation/O of/O PGRN/O -/O deficient/O cells/O ./O
Conversely/O ,/O the/O activation/O of/O NF/O -/O κB/O signalling/O by/O TNF/O -/O α/O increased/O WNT5A/O -/O dependent/O proliferation/O of/O control/O cells/O ./O
LIMITATIONS/O :/O All/O cell/O lines/O were/O derived/O from/O individuals/O harboring/O the/O same/O splicing/O GRN/O mutation/O ./O
Nevertheless/O ,/O most/O of/O the/O known/O GRN/B-Gene mutations/B-Var lead/B-Reg to/I-Reg haploinsufficiency/B-Var of/O the/O protein/B-Protein ./O
CONCLUSION/O :/O Our/O results/O revealed/O an/O important/O role/O of/O NF/O -/O κB/O signalling/O in/O PGRN/O -/O associated/O FTLD/O -/O TDP/O and/O confirm/O that/O PGRN/O can/O bind/O to/O TNF/O -/O a/O receptors/O regulating/O the/O expression/O of/O WNT5A/O ,/O suggesting/O novel/O targets/O for/O treatment/O of/O FTLD/O -/O TDP/O linked/O to/O GRN/O mutations/O ./O
ADIPOR1/B-Gene is/O Mutated/B-Var in/B-Reg Syndromic/O Retinitis/B-Disease Pigmentosa/I-Disease ./O
Retinitis/O pigmentosa/O (/O RP/O )/O is/O a/O genetically/O heterogeneous/O retinal/O disorder/O ./O
Despite/O the/O numerous/O genes/O associated/O with/O RP/O already/O identified/O ,/O the/O genetic/O basis/O remains/O unknown/O in/O a/O substantial/O number/O of/O patients/O and/O families/O ./O
In/O this/O study/O ,/O we/O performed/O whole/O exome/O sequencing/O to/O investigate/O the/O molecular/O basis/O of/O a/O syndromic/O RP/O case/O which/O can/O not/O be/O solved/O by/O mutations/O in/O known/O disease/O -/O causing/O genes/O ./O
After/O applying/O a/O series/O of/O variant/O filtering/O strategies/O ,/O we/O identified/O an/O apparently/O homozygous/O frameshift/O mutation/O ,/O c.31delC/O (/O p/O ./O Q11Rfs*24/O )/O in/O the/O ADIPOR1/O gene/O ./O
The/O reported/O phenotypes/O of/O Adipor1-null/O mice/O contain/O retinal/O dystrophy/O ,/O obesity/O and/O behavioral/O abnormalities/O ,/O which/O highly/O mimic/O those/O in/O the/O syndromic/O RP/O patient/O ./O
We/O further/O confirmed/O ADIPOR1/O retina/O expression/O by/O immunohistochemistry/O ./O
Our/O results/O established/O ADIPOR1/O as/O a/O novel/O disease/O -/O causing/O gene/O for/O syndromic/O RP/O and/O highlight/O the/O importance/O of/O fatty/O acid/O transport/O in/O the/O retina/O ./O
This/O article/O is/O protected/O by/O copyright/O ./O
All/O rights/O reserved/O ./O
Dysferlinopathy/O in/O Iran/O :/O Clinical/O and/O genetic/O report/O ./O
BACKGROUND/O :/O Dysferlinopathy/B-Disease is/O caused/B-Reg by/I-Reg a/O very/O wide/O range/O of/O autosomal/O recessively/O inherited/O mutations/B-Var of/O the/O Dysferlin/B-Gene gene/I-Gene ./O
It/O causes/B-Reg a/O spectrum/O of/O muscle/O diseases/O including/O limb/B-Disease -/I-Disease girdle/I-Disease muscular/I-Disease dystrophy/I-Disease (/O LGMD/O )/O 2B/O and/O Miyoshi/B-Disease myopathy/I-Disease (/O MM/O )/O ./O
We/O describe/O the/O clinical/O course/O and/O mutational/O analyses/O of/O 15/O Iranian/O patients/O with/O dysferlinopathy/O from/O 9/O different/O families/O ./O
METHODS/O :/O Genomic/O DNA/O was/O extracted/O from/O peripheral/O blood/O and/O 55/O exons/O and/O flanking/O intronic/O boundaries/O of/O the/O dysferlin/O gene/O (/O DYSF/O ;/O NM_003494.2/O )/O were/O screened/O for/O mutations/O and/O analyzed/O ./O
RESULTS/O :/O From/O 15/O studied/O patients/O in/O 9/O families/O ,/O 5/O patients/O were/O male/O ./O
Seven/O families/O had/O consanguineous/O marriage/O ./O
Median/O age/O of/O onset/O was/O 16.8/O ;/O and/O the/O median/O age/O of/O diagnosis/O was/O 26.6/O ./O
The/O onset/O was/O clearly/O distal/O in/O 7/O patients/O ,/O and/O proximal/O in/O 6/O patients/O ./O
Three/O patients/O had/O partial/O biceps/O atrophy/O and/O 13/O showed/O prominent/O calf/O muscle/O wasting/O ./O
Foot/O plantar/O flexors/O ,/O deep/O finger/O flexors/O and/O hip/O adductors/O were/O predominantly/O involved/O ./O
Genetic/O testing/O showed/O homozygous/O mutation/O of/O dysferlin/O gene/O in/O 9/O probands/O ,/O 5/O of/O which/O were/O not/O previously/O reported/O ./O
CONCLUSION/O :/O This/O work/O ,/O in/O fact/O ,/O may/O help/O shed/O some/O light/O on/O the/O pattern/O of/O this/O morbidity/O in/O Iran/O ,/O an/O effort/O that/O may/O have/O not/O been/O attempted/O so/O far/O ./O
Limb/O -/O girdle/O muscular/O dystrophy/O type/O 2A/O in/O Brazilian/O children/O ./O
Calpainopathy/O is/O an/O autosomal/B-Disease recessive/I-Disease limb/I-Disease girdle/I-Disease muscular/I-Disease dystrophy/I-Disease (/O LGMD2A/O )/O caused/B-Reg by/I-Reg mutations/B-Var in/O CAPN3/B-Gene gene/O ./O
Objective/O To/O present/O clinical/O and/O histological/O findings/O in/O six/O children/O with/O a/O molecular/O diagnosis/O of/O LGMD2A/O and/O additionally/O the/O MRI/O findings/O in/O two/O of/O them/O ./O
Method/O We/O retrospectively/O assessed/O medical/O records/O of/O 6/O patients/O with/O mutation/O on/O CAPN3/O gene/O ./O
Results/O All/O patients/O were/O female/O (/O three/O to/O 12/O years/O )/O ./O
The/O mean/O of/O age/O of/O disease/O onset/O was/O 9/O years/O ./O
All/O of/O them/O showed/O progressive/O weakness/O with/O predominance/O in/O lower/O limbs/O ./O
Other/O findings/O were/O scapular/O winging/O ,/O joint/O contractures/O and/O calf/O hypertrophy/O ./O
One/O female/O had/O a/O more/O severe/O phenotype/O than/O her/O dizygotic/O twin/O sister/O that/O was/O confirmed/O by/O muscle/O MRI/O ./O
Muscle/O biopsies/O showed/O a/O dystrophic/O pattern/O in/O all/O patients/O ./O
Conclusion/O In/O this/O cohort/O of/O children/O with/O LGMD2A/O ,/O the/O clinical/O aspects/O were/O similar/O to/O adults/O with/O the/O same/O disorder/O ./O
Frequency/O of/O mutations/O in/O Mediterranean/O fever/O gene/O ,/O with/O gender/O and/O genotype/O -/O phenotype/O correlations/O in/O a/O Turkish/O population/O ./O
Familial/B-Disease Mediterranean/I-Disease fever/I-Disease (/O FMF/O )/O is/O the/O most/O common/O hereditary/O inflammatory/O periodic/O disease/O ,/O characterized/O by/O recurrent/O episodes/O of/O fever/O ,/O abdominal/O pain/O ,/O synovitis/O and/O pleurisy/O ./O
The/O aim/O of/O this/O study/O was/O to/O determine/O the/O frequency/O and/O distribution/O of/O Mediterranean/O fever/O (/B-Gene MEFV/I-Gene )/I-Gene gene/O mutations/B-Var and/O to/O investigate/O the/O clinical/O characteristics/O and/O genotype/O -/O phenotype/O correlation/O in/B-Reg patients/O with/O FMF/B-Disease in/O Aydin/O ,/O a/O province/O in/O western/O Anatolia/O ,/O Turkey/O ./O
Therefore/O ,/O we/O retrospectively/O analysed/O MEFV/O gene/O mutations/O in/O 383/O patients/O with/O suspected/O FMF/O and/O the/O clinical/O features/O of/O 327/O among/O them/O ./O
The/O MEFV/O gene/O mutations/O were/O investigated/O using/O the/O reverse/O dot/O -/O blot/O hybridization/O technique/O ./O
We/O detected/O 26/O different/O genotypes/O and/O 11/O different/O mutations/O ./O
The/O most/O common/O mutations/O in/O our/O cohort/O were/O p/O ./O M694V/O (/O 41.15/O %/O )/O ,/O p/O ./O E148Q/O (/O 20.35/O %/O )/O ,/O p/O ./O M680I(G/O //O C/O )/O (/O 12.39/O %/O )/O and/O p/O ./O R761H/O (/O 9.73/O %/O )/O ./O
Abdominal/O pain/O (/O 86.2/O %/O )/O ,/O fever/O (/O 80.7/O %/O )/O ,/O arthralgia/O (/O 57.2/O %/O )/O ,/O vomiting/O (/O 36.1/O %/O )/O ,/O arthritis/O (/O 34.6/O %/O )/O ,/O fatigue/O (/O 31.5/O %/O )/O ,/O anorexia/O (/O 22.9/O %/O )/O and/O chest/O pain/O (/O 19.0/O %/O )/O were/O the/O most/O prevalent/O clinical/O features/O in/O our/O patients/O ./O
This/O is/O the/O first/O study/O from/O Aydin/O in/O which/O the/O distribution/O of/O MEFV/B-Gene gene/O mutations/B-Var and/O clinical/O features/O were/O evaluated/O in/B-Reg patients/O with/O FMF/B-Disease ./O
We/O found/O that/O the/O most/O common/O mutation/O was/O p/O ./O M694V/O in/O our/O region/O ,/O while/O the/O frequency/O of/O the/O p/O ./O R761H/O mutation/O was/O higher/O compared/O to/O other/O regions/O of/O Turkey/O with/O respect/O to/O extracted/O data/O from/O previous/O similar/O studies/O ./O
Presented/O results/O supported/O the/O clinical/O findings/O in/O the/O literature/O that/O the/O homozygous/O p/O ./O M694V/O and/O compound/O heterozygous/O genotype/O were/O associated/O with/O more/O severe/O courses/O in/O FMF/O patients/O ./O
Delayed/O hemoglobin/O switching/O and/O perinatal/O neocytolysis/O in/O mice/O with/O gain/O -/O of/O -/O function/O erythropoietin/O receptor/O ./O
Mutations/B-Var of/O the/O truncated/O cytoplasmic/O domain/O of/O human/O erythropoietin/O receptor/O (/B-Gene EPOR/I-Gene )/I-Gene result/B-Reg in/I-Reg gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg of/O erythropoietin/B-Pathway (/I-Pathway EPO/I-Pathway )/I-Pathway signaling/I-Pathway and/O a/O dominantly/B-Disease inherited/I-Disease polycythemia/I-Disease ,/O primary/B-Disease familial/I-Disease and/I-Disease congenital/I-Disease polycythemia/I-Disease (/O PFCP/O )/O ./O
We/O interrogated/O the/O unexplained/O transient/O absence/O of/O perinatal/O polycythemia/O observed/O in/O PFCP/O patients/O using/O an/O animal/O model/O of/O PFCP/O to/O examine/O its/O erythropoiesis/O during/O embryonic/O ,/O perinatal/O ,/O and/O early/O postnatal/O periods/O ./O
In/O this/O model/O ,/O we/O replaced/O the/O murine/O EpoR/O gene/O (/O mEpoR/O )/O with/O the/O wild/O -/O type/O human/O EPOR/O (/O wtHEPOR/O )/O or/O mutant/O human/O EPOR/O gene/O (/O mtHEPOR/O )/O and/O previously/O reported/O that/O the/O gain/O -/O of/O -/O function/O mtHEPOR/O mice/O become/O polycythemic/O at/O 3~6/O weeks/O of/O age/O ,/O but/O not/O at/O birth/O ,/O similar/O to/O the/O phenotype/O of/O PFCP/O patients/O ./O
In/O contrast/O ,/O wtHEPOR/O mice/O had/O sustained/O anemia/O ./O
We/O report/O that/O the/O mtHEPOR/O fetuses/O are/O polycythemic/O ,/O but/O their/O polycythemia/O is/O abrogated/O in/O the/O perinatal/O period/O and/O reappears/O again/O at/O 3/O weeks/O after/O birth/O ./O
mtHEPOR/O fetuses/O have/O a/O delayed/O switch/O from/O primitive/O to/O definitive/O erythropoiesis/O ,/O augmented/O erythropoietin/O signaling/O ,/O and/O prolonged/O Stat5/O phosphorylation/O while/O the/O wtHEPOR/O fetuses/O are/O anemic/O ./O
Our/O study/O demonstrates/O the/O in/O vivo/O effect/O of/O excessive/O EPO/O //O EPOR/O signaling/O on/O developmental/O erythropoiesis/O switch/O and/O describes/O that/O fetal/O polycythemia/O in/O this/O PFCP/O model/O is/O followed/O by/O transient/O correction/O of/O polycythemia/O in/O perinatal/O life/O associated/O with/O low/O Epo/O levels/O and/O increased/O exposure/O of/O erythrocytes/O '/O phosphatidylserine/O ./O
We/O suggest/O that/O neocytolysis/O contributes/O to/O the/O observed/O perinatal/O correction/O of/O polycythemia/O in/O mtHEPOR/O newborns/O as/O embryos/O leaving/O the/O hypoxic/O uterus/O are/O exposed/O to/O normoxia/O at/O birth/O ./O
KEY/O MESSAGE/O :/O Human/O gain/O -/O of/O -/O function/O EPOR/B-Gene (/O mtHEPOR/O )/O causes/B-Reg fetal/B-Disease polycythemia/I-Disease in/O knock/B-Var -/I-Var in/I-Var mice/O ./O
Wild/O -/O type/O human/O EPOR/O causes/O fetal/O anemia/O in/O knock/O -/O in/O mouse/O model/O ./O
mtHEPOR/O mice/O have/O delayed/O switch/O from/O primitive/O to/O definitive/O erythropoiesis/O ./O
Polycythemia/O of/O mtHEPOR/O mice/O is/O transiently/O corrected/O in/O perinatal/O life/O ./O
mtHEPOR/O newborns/O have/O low/O Epo/O and/O increased/O exposure/O of/O erythrocytes/O '/O phosphatidylserine/O ./O
Renal/O Cell/O Carcinoma/O Programmed/O Death/O -/O ligand/O 1/O ,/O a/O New/O Direct/O Target/O of/O Hypoxia/O -/O inducible/O Factor-2/O Alpha/O ,/O is/O Regulated/O by/O von/O Hippel/O -/O Lindau/O Gene/O Mutation/O Status/O ./O
BACKGROUND/O :/O Clear/O cell/O renal/O cell/O carcinomas/O (/O ccRCC/O )/O frequently/O display/O a/O loss/O of/O function/O of/O the/O von/O Hippel/O -/O Lindau/O (/O VHL/O )/O gene/O ./O
OBJECTIVE/O :/O To/O elucidate/O the/O putative/O relationship/O between/O VHL/O mutation/O status/O and/O immune/O checkpoint/O ligand/O programmed/O death/O -/O ligand/O 1/O (/O PD/O -/O L1/O )/O expression/O ./O
DESIGN/O ,/O SETTING/O ,/O AND/O PARTICIPANTS/O :/O A/O series/O of/O 32/O renal/O tumors/O composed/O of/O 11/O VHL/O tumor/O -/O associated/O and/O 21/O sporadic/O RCCs/O were/O used/O to/O evaluate/O PD/O -/O L1/O expression/O levels/O after/O sequencing/O of/O the/O three/O exons/O and/O exon/O -/O intron/O junctions/O of/O the/O VHL/O gene/O ./O
The/O 786-O/O ,/O A498/O ,/O and/O RCC4/O cell/O lines/O were/O used/O to/O investigate/O the/O mechanisms/O of/O PD/O -/O L1/O regulation/O ./O
OUTCOME/O MEASUREMENTS/O AND/O STATISTICAL/O ANALYSIS/O :/O Fisher/O 's/O exact/O test/O was/O used/O for/O VHL/O mutation/O and/O Kruskal/O -/O Wallis/O test/O for/O PD/O -/O L1/O expression/O ./O
If/O no/O covariate/O accounted/O for/O the/O association/O of/O VHL/O and/O PD/O -/O L1/O ,/O then/O a/O Kruskal/O -/O Wallis/O test/O was/O used/O ;/O otherwise/O Cochran/O -/O Mantel/O -/O Haenzsel/O test/O was/O used/O ./O
We/O also/O used/O the/O Fligner/O -/O Policello/O test/O to/O compare/O two/O medians/O when/O the/O distributions/O had/O different/O dispersions/O ./O
RESULTS/O AND/O LIMITATIONS/O :/O We/O demonstrated/O that/O tumors/O from/O ccRCC/O patients/O with/O VHL/B-Gene biallelic/O inactivation/B-Var (/O ie/O ,/O loss/O of/O function/O )/O display/O a/O significant/O increase/B-PosReg in/O PD/B-Protein -/I-Protein L1/I-Protein expression/B-MPA compared/O with/O ccRCC/O tumors/O carrying/O one/O VHL/O wild/O -/O type/O allele/O ./O
Using/O the/O inducible/O VHL/O 786-O/O -/O derived/O cell/O lines/O with/O varying/O hypoxia/O -/O inducible/O factor-2/O alpha/O (/O HIF-2α/O )/O stabilization/O levels/O ,/O we/O showed/O that/O PD/B-Protein -/I-Protein L1/I-Protein expression/B-MPA levels/I-MPA positively/O correlate/B-Reg with/O VHL/B-Gene mutation/B-Var and/O HIF-2α/O expression/O ./O
Targeting/O HIF-2α/O decreased/O PD/O -/O L1/O ,/O while/O HIF-2α/O overexpression/O increased/O PD/O -/O L1/O mRNA/O and/O protein/O levels/O in/O ccRCC/O cells/O ./O
Interestingly/O ,/O chromatin/O immunoprecipitation/O and/O luciferase/O assays/O revealed/O a/O direct/O binding/O of/O HIF-2α/O to/O a/O transcriptionally/O active/O hypoxia/O -/O response/O element/O in/O the/O human/O PD/O -/O L1/O proximal/O promoter/O in/O 786-O/O cells/O ./O
CONCLUSIONS/O :/O Our/O work/O provides/O the/O first/O evidence/O that/O VHL/B-Gene mutations/B-Var positively/O correlate/B-Reg with/O PD/B-Protein -/I-Protein L1/I-Protein expression/B-MPA in/O ccRCC/O and/O may/O influence/B-Reg the/O response/B-MPA to/I-MPA ccRCC/I-MPA anti/I-MPA -/I-MPA PD/I-MPA -/I-MPA L1/I-MPA //I-MPA PD-1/I-MPA immunotherapy/I-MPA ./O
PATIENT/O SUMMARY/O :/O We/O investigated/O the/O relationship/O between/O von/O Hippel/O -/O Lindau/O mutations/O and/O programmed/O death/O -/O ligand/O 1/O expression/O ./O
We/O demonstrated/O that/O von/B-Gene Hippel/I-Gene -/I-Gene Lindau/I-Gene mutation/B-Var status/O significantly/O correlated/B-Reg with/O programmed/B-MPA death/I-MPA -/I-MPA ligand/I-MPA 1/I-MPA expression/I-MPA in/O clear/O cell/O renal/O cell/O carcinomas/O ./O
Huntington/O 's/O Disease/O :/O Relationship/O Between/O Phenotype/O and/O Genotype/O ./O
Huntington/B-Disease 's/I-Disease disease/I-Disease (/O HD/O )/O is/O an/O autosomal/O dominant/O inherited/O neurodegenerative/O disease/O with/O the/O typical/O manifestations/O of/O involuntary/O movements/O ,/O psychiatric/O and/O behavior/O disorders/O ,/O and/O cognitive/O impairment/O ./O
It/O is/O caused/B-Reg by/I-Reg the/O dynamic/B-Var mutation/I-Var in/I-Var CAG/I-Var triplet/I-Var repeat/I-Var number/I-Var in/I-Var exon/I-Var 1/I-Var of/O huntingtin/O (/B-Gene HTT/I-Gene )/I-Gene gene/O ./O
The/O symptoms/O of/O HD/O especially/O the/O age/O at/O onset/O are/O related/O to/O the/O genetic/O characteristics/O ,/O both/O the/O CAG/O triplet/O repeat/O and/O the/O modified/O factors/O ./O
Here/O ,/O we/O reviewed/O the/O recent/O advancement/O on/O the/O genotype/O -/O phenotype/O relationship/O of/O HD/O ,/O mainly/O focus/O on/O the/O characteristics/O of/O different/O expanded/O CAG/O repeat/O number/O ,/O genetic/O modifiers/O ,/O and/O CCG/O repeat/O number/O in/O the/O 3/O '/O end/O of/O CAG/O triplet/O repeat/O and/O their/O effects/O on/O the/O phenotype/O ./O
We/O also/O reviewed/O the/O special/O forms/O of/O HD/O (/O juvenile/O HD/O ,/O atypical/O onset/O HD/O ,/O and/O homozygous/O HD/O )/O and/O their/O phenotype/O -/O genotype/O correlations/O ./O
The/O review/O will/O aid/O clinicians/O to/O predict/O the/O onset/O age/O and/O disease/O course/O of/O HD/O ,/O give/O the/O genetic/O counseling/O ,/O and/O accelerate/O research/O into/O the/O HD/O mechanism/O ./O
Polyamine/B-Enzyme oxidase/I-Enzyme 5/I-Enzyme loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O Arabidopsis/O thaliana/O trigger/B-Reg metabolic/B-MPA and/I-MPA transcriptional/I-MPA reprogramming/I-MPA and/O promote/B-PosReg salt/B-MPA stress/I-MPA tolerance/I-MPA ./O
The/O family/O of/O polyamine/O oxidases/O (/O PAO/O )/O in/O Arabidopsis/O (/O AtPAO1/O -/O 5/O )/O mediates/O polyamine/O (/O PA/O )/O back/O -/O conversion/O ,/O which/O reverses/O the/O PA/O biosynthetic/O pathway/O from/O spermine/O and/O its/O structural/O isomer/O thermospermine/O (/O tSpm/O )/O into/O spermidine/O and/O then/O putrescine/O ./O
Here/O ,/O we/O have/O studied/O the/O involvement/O of/O PA/O back/O -/O conversion/O in/O Arabidopsis/O salinity/O tolerance/O ./O
AtPAO5/O is/O the/O Arabidopsis/O PAO/O gene/O member/O most/O transcriptionally/O induced/O by/O salt/O stress/O ./O
Two/O independent/O loss/O -/O of/O -/O function/O mutants/B-Var (/O atpao5/O -/O 2/O and/O atpao5/O -/O 3/O )/O were/O found/O to/O exhibit/O constitutively/O higher/B-PosReg tSpm/B-MPA levels/I-MPA ,/O with/O associated/O increased/O salt/O tolerance/O ./O
Using/O global/O transcriptional/O and/O metabolomic/O analyses/O ,/O the/O underlying/O mechanisms/O were/O studied/O ./O
Stimulation/B-PosReg of/O abscisic/B-MPA acid/I-MPA and/I-MPA jasmonate/I-MPA (/I-MPA JA/I-MPA )/I-MPA biosynthesis/I-MPA and/O accumulation/B-MPA of/I-MPA important/I-MPA compatible/I-MPA solutes/I-MPA ,/O such/O as/O sugars/O ,/O polyols/O and/O proline/O ,/O as/O well/O as/O TCA/B-MPA cycle/I-MPA intermediates/I-MPA were/O observed/O in/O atpao5/O mutants/B-Var under/O salt/O stress/O ./O
Expression/O analyses/O indicate/O that/O tSpm/O modulates/O the/O transcript/O levels/O of/O several/O target/O genes/O ,/O including/O many/O involved/O in/O the/O biosynthesis/O and/O signalling/O of/O JA/O ,/O some/O of/O which/O are/O already/O known/O to/O promote/O salinity/O tolerance/O ./O
Transcriptional/O modulation/O by/O tSpm/O is/O isomer/O -/O dependent/O ,/O thus/O demonstrating/O the/O specificity/O of/O this/O response/O ./O
Overall/O ,/O we/O conclude/O that/O tSpm/O triggers/O metabolic/O and/O transcriptional/O reprogramming/O that/O promotes/O salt/O stress/O tolerance/O in/O Arabidopsis/O ./O
Recessive/B-Disease dystrophic/I-Disease epidermolysis/I-Disease bullosa/I-Disease caused/B-Reg by/I-Reg a/O de/B-CPA novo/I-CPA interstitial/I-CPA deletion/B-NegReg spanning/O COL7A1/B-Gene and/O a/O hemizygous/O splicing/B-Var mutation/I-Var in/I-Var trans/I-Var ./O
BACKGROUND/O :/O Recessive/B-Disease dystrophic/I-Disease epidermolysis/I-Disease bullosa/I-Disease (/O RDEB/O )/O is/O a/O rare/O heritable/O blistering/O skin/O condition/O caused/O by/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O the/O COL7A1/B-Gene gene/O ./O
Incongruent/O gene/O transmission/O is/O occasionally/O reported/O in/O recessive/O diseases/O ,/O and/O its/O underlying/O mechanism/O is/O often/O uniparental/O disomy/O (/O UPD/O )/O ./O
AIM/O :/O To/O understand/O the/O genetic/O basis/O of/O incongruent/O gene/O transmission/O in/O a/O Chinese/O family/O with/O RDEB/O ,/O in/O which/O a/O discrepancy/O of/O COL7A1/O genotyping/O was/O encountered/O during/O our/O mutation/O analysis/O ./O
METHODS/O :/O We/O used/O a/O pCAS2/O minigene/O -/O based/O in/O vitro/O splicing/O assay/O to/O confirm/O the/O pathogenicity/O of/O the/O splicing/O variant/O we/O identified/O in/O the/O proband/O ./O
Next/O ,/O a/O combination/O of/O genetic/O tools/O ,/O including/O whole/O -/O genome/O SNP/O array/O analysis/O and/O multiplex/O ligation/O -/O dependent/O probe/O amplification/O copy/O number/O analysis/O ,/O was/O used/O to/O unravel/O the/O cause/O of/O the/O discrepancy/O in/O the/O COL7A1/O genotyping/O ./O
RESULTS/O :/O Sanger/O sequencing/O identified/O a/O novel/O ,/O single/O -/O peak/O mutation/O ,/O c.4980/O +/O 5G/O >/O C/O ,/O in/O COL7A1/O in/O the/O proband/O ,/O which/O was/O heterozygous/O in/O his/O father/O and/O wild/O type/O in/O his/O mother/O ./O
In/O vitro/O splicing/O assay/O showed/O that/O c.4980/O +/O 5G/O >/O C/O was/O pathogenic/O and/O led/O to/O skipping/O of/O COL7A1/O exon/O 53/O ./O
SNP/O array/O analysis/O and/O multiplex/O ligation/O -/O dependent/O probe/O amplification/O of/O the/O proband/O 's/O DNA/O revealed/O a/O maternally/O derived/O ,/O de/O novo/O ,/O interstitial/O deletion/O on/O chromosome/O 3p21.31/O ,/O which/O removed/O COL7A1/O and/O 15/O flanking/O genes/O ,/O excluding/O the/O possibility/O of/O UPD/O ./O
CONCLUSION/O :/O Our/O findings/O favour/O an/O exceptionally/O rare/O event/O ,/O namely/O a/O de/O novo/O COL7A1/O microdeletion/O in/O concurrence/O with/O an/O inherited/O mutation/O in/O trans/O ./O
This/O study/O should/O aid/O molecular/O diagnosis/O and/O genetic/O counselling/O of/O RDEB/O and/O possibly/O other/O recessive/O diseases/O in/O which/O genotyping/O discrepancy/O is/O encountered/O ./O
A/O novel/O frameshift/O mutation/O leading/O to/O inherited/O type/O I/O antithrombin/O deficiency/O ./O
Inherited/B-Disease antithrombin/I-Disease (/I-Disease AT/I-Disease )/I-Disease deficiency/I-Disease is/O an/O autosomal/O dominant/O thrombotic/O disorder/O ./O
We/O encountered/O a/O case/O of/O inherited/O type/O I/O AT/B-Disease deficiency/I-Disease and/O identified/B-Reg the/O mutation/O responsible/O ;/O a/O novel/O 5406delA/B-Var mutation/I-Var in/O the/O SERPINC1/B-Gene gene/O appeared/O to/O have/O caused/B-Reg a/O frameshift/B-MPA with/I-MPA premature/I-MPA termination/I-MPA at/I-MPA amino/I-MPA acid/I-MPA +283/I-MPA ./O
The/O recombinant/O AT/O protein/O including/O 5406delA/O was/O not/O detected/O in/O cell/O lysates/O or/O culture/O supernatants/O ./O
These/O results/O will/O contribute/O to/O the/O creation/O of/O an/O accurate/O database/O and/O define/O the/O molecular/O basis/O for/O AT/O deficiency/O ./O
Increase/O in/O NRAS/O mutant/O allele/O percentage/O during/O metastatic/O melanoma/O progression/O ./O
One/O -/O fifth/O of/O cutaneous/B-Disease melanomas/I-Disease have/O dominant/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var of/O the/O NRAS/B-Gene oncogene/O ./O
We/O report/O the/O first/O two/O cases/O of/O increasing/O NRAS/O mutant/O allele/O frequency/O in/O melanoma/O metastases/O and/O show/O that/O the/O chromosomal/O mechanism/O of/O this/O homozygosity/O is/O an/O increased/O polysomy/O of/O chromosome/O 1/O ./O
We/O observed/O an/O increase/O in/O NRAS/O mutant/O allele/O percentage/O (/O NRAS/O -/O MA%/O )/O in/O the/O metastatic/O melanoma/O progression/O from/O 2/O patients/O with/O melanomas/O harbouring/O a/O NRAS/O mutation/O (/O p/O ./O Q61/O K/O in/O case/O 1/O and/O p/O ./O Q61R/O in/O case/O 2/O )/O ./O
In/O case/O 1/O ,/O we/O observed/O a/O NRAS/O -/O MA%/O increase/O from/O 18/O %/O within/O the/O first/O metastatic/O node/O to/O 81/O %/O ,/O 92/O %/O and/O 85/O %/O respectively/O in/O the/O three/O subsequent/O metastases/O :/O lymph/O node/O ,/O brain/O and/O subcutaneous/O metastases/O biopsied/O 1/O ,/O 6/O and/O 17/O months/O ,/O respectively/O ,/O after/O the/O initial/O lymph/O node/O biopsy/O ./O
In/O case/O 2/O ,/O we/O observed/O an/O increase/O in/O NRAS/O -/O MA%/O from/O 40/O %/O within/O the/O primary/O melanoma/O to/O 63/O %/O within/O the/O metastatic/O lymph/O node/O ./O
FISH/O analysis/O showed/O the/O same/O results/O in/O both/O cases/O :/O a/O frequent/O polysomy/O of/O chromosome/O 1/O in/O metastasis/O samples/O with/O NRAS/O mutant/O allele/O percentage/O >/O 60/O %/O ,/O while/O most/O cells/O were/O disomic/O in/O the/O samples/O with/O well/O -/O balanced/O heterozygous/O mutations/O ./O
The/O percentage/O of/O NRAS/O mutant/O allele/O may/O increase/O during/O metastatic/O progression/O and/O may/O be/O associated/O with/O chromosomal/O instability/O ./O
Further/O studies/O are/O needed/O to/O evaluate/O the/O prognostic/O impact/O of/O the/O NRAS/O homozygous/O status/O and/or/O polyploidy/O in/O metastatic/O cutaneous/O melanomas/O ./O
A/O Comprehensive/O Analysis/O of/O Choroideremia/O :/O From/O Genetic/O Characterization/O to/O Clinical/O Practice/O ./O
Choroideremia/B-Disease (/O CHM/O )/O is/O a/O rare/O X/O -/O linked/O disease/O leading/O to/O progressive/O retinal/O degeneration/O resulting/O in/O blindness/O ./O
The/O disorder/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O CHM/B-Gene gene/O encoding/O REP-1/O protein/O ,/O an/O essential/O component/O of/O the/O Rab/O geranylgeranyltransferase/O (/O GGTase/O )/O complex/O ./O
In/O the/O present/O study/O ,/O we/O evaluated/O a/O multi/O -/O technique/O analysis/O algorithm/O to/O describe/O the/O mutational/O spectrum/O identified/O in/O a/O large/O cohort/O of/O cases/O and/O further/O correlate/O CHM/O variants/O with/O phenotypic/O characteristics/O and/O biochemical/O defects/O of/O choroideremia/O patients/O ./O
Molecular/O genetic/O testing/O led/O to/O the/O characterization/O of/O 36/O out/O of/O 45/O unrelated/O CHM/O families/O (/O 80/O %/O )/O ,/O allowing/O the/O clinical/O reclassification/O of/O four/O CHM/O families/O ./O
Haplotype/O reconstruction/O showed/O independent/O origins/O for/O the/O recurrent/O p/O ./O Arg293/O */O and/O p/O ./O Lys178Argfs*5/O mutations/O ,/O suggesting/O the/O presence/O of/O hotspots/O in/O CHM/O ,/O as/O well/O as/O the/O identification/O of/O two/O different/O unrelated/O events/O involving/O exon/O 9/O deletion/O ./O
No/O certain/O genotype/O -/O phenotype/O correlation/O could/O be/O established/O ./O
Furthermore/O ,/O all/O the/O patients/O ´/O fibroblasts/O analyzed/O presented/O significantly/O increased/O levels/O of/O unprenylated/O Rabs/O proteins/O compared/O to/O control/O cells/O ;/O however/O ,/O this/O was/O not/O related/O to/O the/O genotype/O ./O
This/O research/O demonstrates/O the/O major/O potential/O of/O the/O algorithm/O proposed/O for/O diagnosis/O ./O
Our/O data/O enhance/O the/O importance/O of/O establish/O a/O differential/O diagnosis/O with/O other/O retinal/O dystrophies/O ,/O supporting/O the/O idea/O of/O an/O underestimated/O prevalence/O of/O choroideremia/O ./O
Moreover/O ,/O they/O suggested/O that/O the/O severity/O of/O the/O disorder/O can/O not/O be/O exclusively/O explained/O by/O the/O genotype/O ./O
Four/O novel/O ATP2C1/B-Gene mutations/B-Var in/O Chinese/O patients/O with/B-Reg Hailey/B-Disease -/I-Disease Hailey/I-Disease disease/I-Disease ./O
Hailey/O -/O Hailey/O disease/O (/O HHD/O )/O is/O a/O kind/O of/O autosomal/O dominant/O dermatosis/O ./O
The/O ATP2C1/O gene/O has/O been/O identified/O as/O the/O pathogenic/O gene/O of/O HHD/O since/O 2000/O ./O
In/O this/O study/O ,/O direct/O DNA/O sequencing/O was/O used/O to/O identify/O ATP2C1/O gene/O mutations/O in/O four/O Chinese/O families/O and/O two/O sporadic/O cases/O with/O HHD/O ./O
The/O entire/O coding/O and/O flanking/O intronic/O sequences/O of/O ATP2C1/O were/O screened/O for/O mutations/O and/O five/O heterozygous/O mutations/O of/O the/O ATP2C1/O gene/O were/O detected/O in/O the/O four/O pedigrees/O and/O two/O sporadic/O cases/O with/O HHD/O ./O
Four/O of/O them/O were/O novel/O ,/O including/O three/O frame/O -/O shift/O mutations/O (/O c.1330delC/O ,/O c.888_889insT/O ,/O c.478_479insA/O )/O and/O one/O nonsense/O mutation/O (/O c.1720C/O >/O T/O )/O ./O
These/O data/O added/O new/O variants/O to/O the/O database/O of/O ATP2C1/B-Gene mutations/B-Var associated/B-Reg with/I-Reg HHD/B-Disease ./O
Glycogen/O storage/O disease/O type/O III/O :/O diagnosis/O ,/O genotype/O ,/O management/O ,/O clinical/O course/O and/O outcome/O ./O
Glycogen/B-Disease storage/I-Disease disease/I-Disease type/I-Disease III/I-Disease (/O GSDIII/O )/O is/O a/O rare/O disorder/O of/O glycogenolysis/O due/B-Reg to/I-Reg AGL/B-Gene gene/O mutations/B-Var ,/O causing/O glycogen/O debranching/O enzyme/O deficiency/O and/O storage/O of/O limited/O dextrin/O ./O
Patients/O with/O GSDIIIa/O show/O involvement/O of/O liver/O and/O cardiac/O //O skeletal/O muscle/O ,/O whereas/O GSDIIIb/O patients/O display/O only/O liver/O symptoms/O and/O signs/O ./O
The/O International/O Study/O on/O Glycogen/O Storage/O Disease/O (/O ISGSDIII/O )/O is/O a/O descriptive/O retrospective/O ,/O international/O ,/O multi/O -/O centre/O cohort/O study/O of/O diagnosis/O ,/O genotype/O ,/O management/O ,/O clinical/O course/O and/O outcome/O of/O 175/O patients/O from/O 147/O families/O (/O 86/O %/O GSDIIIa/O ;/O 14/O %/O GSDIIIb/O )/O ,/O with/O follow/O -/O up/O into/O adulthood/O in/O 91/O patients/O ./O
In/O total/O 58/O AGL/O mutations/O (/O non/O -/O missense/O mutations/O were/O overrepresented/O and/O 21/O novel/O mutations/O were/O observed/O )/O were/O identified/O in/O 76/O families/O ./O
GSDIII/O patients/O first/O presented/O before/O the/O age/O of/O 1.5/O years/O ,/O hepatomegaly/O was/O the/O most/O common/O presenting/O clinical/O sign/O ./O
Dietary/O management/O was/O very/O diverse/O and/O included/O frequent/O meals/O ,/O uncooked/O cornstarch/O and/O continuous/O gastric/O drip/O feeding/O ./O
Chronic/O complications/O involved/O the/O liver/O (/O hepatic/O cirrhosis/O ,/O adenoma(s/O )/O ,/O and/or/O hepatocellular/O carcinoma/O in/O 11/O %/O )/O ,/O heart/O (/O cardiac/O involvement/O and/O cardiomyopathy/O ,/O in/O 58/O %/O and/O 15/O %/O ,/O respectively/O ,/O generally/O presenting/O in/O early/O childhood/O )/O ,/O and/O muscle/O (/O pain/O in/O 34/O %/O )/O ./O
Type/O 2/O diabetes/O mellitus/O was/O diagnosed/O in/O eight/O out/O of/O 91/O adult/O patients/O (/O 9/O %/O )/O ./O
In/O adult/O patients/O no/O significant/O correlation/O was/O detected/O between/O (/O non-/O )/O missense/O AGL/O genotypes/O and/O hepatic/O ,/O cardiac/O or/O muscular/O complications/O ./O
This/O study/O demonstrates/O heterogeneity/O in/O a/O large/O cohort/O of/O ageing/O GSDIII/O patients/O ./O
An/O international/O GSD/O patient/O registry/O is/O warranted/O to/O prospectively/O define/O the/O clinical/O course/O ,/O heterogeneity/O and/O the/O effect/O of/O different/O dietary/O interventions/O in/O patients/O with/O GSDIII/O ./O
Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg Function/I-PosReg Mutations/B-Var in/O RARB/B-Gene Cause/B-Reg Intellectual/B-MPA Disability/I-MPA with/O Progressive/B-MPA Motor/I-MPA Impairment/I-MPA ./O
Retinoic/O acid/O (/O RA/O )/O signaling/O plays/O a/O key/O role/O in/O the/O development/O and/O function/O of/O several/O systems/O in/O mammals/O ./O
We/O previously/O discovered/O that/O the/O de/O novo/O mutations/O c.1159C/B-Var >/I-Var T/I-Var (/O p/O ./O Arg387Cys/O )/O and/O c.1159C/B-Var >/I-Var A/I-Var (/O p/O ./O Arg387Ser/O )/O in/O the/O RA/O Receptor/O Beta/O (/B-Gene RARB/I-Gene )/I-Gene gene/O cause/B-Reg microphthalmia/B-Disease and/O diaphragmatic/B-Disease hernia/I-Disease ./O
However/O ,/O the/O natural/O history/O of/O affected/O subjects/O beyond/O the/O prenatal/O or/O neonatal/O period/O was/O unknown/O ./O
Here/O ,/O we/O describe/O nine/O additional/O subjects/O with/O microphthalmia/O who/O have/O de/O novo/O mutations/O in/O RARB/O ,/O including/O the/O previously/O described/O p/O ./O Arg387Cys/O as/O well/O as/O the/O novel/O c.887G/O >/O C/O (/O p/O ./O Gly296Ala/O )/O and/O c.638T/O >/O C/O (/O p/O ./O Leu213Pro/O )/O ./O
Moreover/O ,/O we/O review/O the/O information/O on/O four/O previously/O reported/O cases/O ./O
All/O subjects/O who/O survived/O the/O neonatal/O period/O (/O n/O =/O 10/O )/O displayed/O severe/O global/O developmental/O delay/O with/O progressive/O motor/O impairment/O due/O to/O spasticity/O and/or/O dystonia/O (/O with/O or/O without/O chorea/O )/O ./O
The/O majority/O of/O subjects/O also/O showed/O Chiari/O type/O I/O malformation/O and/O severe/O feeding/O difficulties/O ./O
We/O previously/O found/O that/O p/O ./O Arg387Cys/O and/O p/O ./O Arg387Ser/O induce/O a/O gain/O -/O of/O -/O function/O ./O
We/O show/O here/O that/O the/O p/B-Var ./I-Var Gly296Ala/I-Var and/O p/B-Var ./I-Var Leu213Pro/I-Var RARB/B-Gene mutations/O further/O promote/B-PosReg the/O RA/B-MPA ligand/I-MPA -/I-MPA induced/I-MPA transcriptional/I-MPA activity/I-MPA by/O twofold/O to/O threefold/O over/O the/O wild/O -/O type/O receptor/O ,/O also/O indicating/O a/O gain/O -/O of/O -/O function/O mechanism/O ./O
These/O observations/O suggest/O that/O precise/O regulation/O of/O RA/O signaling/O is/O required/O for/O brain/O development/O and/or/O function/O in/O humans/O ./O
Long/O -/O term/O vemurafenib/O treatment/O drives/B-Reg inhibitor/B-MPA resistance/I-MPA through/O a/O spontaneous/O KRAS/B-Gene G12D/B-Var mutation/O in/O a/O BRAF/O V600E/O papillary/O thyroid/O carcinoma/O model/O ./O
The/O BRAF/O V600E/O mutation/O is/O commonly/O observed/O in/O papillary/O thyroid/O cancer/O (/O PTC/O )/O and/O predominantly/O activates/O the/O MAPK/O pathway/O ./O
Presence/O of/O BRAF/O V600E/O predicts/O increasing/O risk/O of/O recurrence/O and/O higher/O mortality/O rate/O ,/O and/O treatment/O options/O for/O such/O patients/O are/O limited/O ./O
Vemurafenib/O ,/O a/O BRAF/O V600E/O inhibitor/O ,/O is/O initially/O effective/O ,/O but/O cells/O inevitably/O develop/O alternative/O mechanisms/O of/O pathway/O activation/O ./O
Mechanisms/O of/O primary/O resistance/O have/O been/O described/O in/O short/O -/O term/O cultures/O of/O PTC/O cells/O ;/O however/O ,/O mechanisms/O of/O acquired/O resistance/O have/O not/O ./O
In/O the/O present/O study/O ,/O we/O investigated/O possible/O adaptive/O mechanisms/O of/O BRAF/O V600E/O inhibitor/O resistance/O in/O KTC1/O thyroid/O cancer/O cells/O following/O long/O -/O term/O vemurafenib/O exposure/O ./O
We/O found/O that/O a/O subpopulation/O of/O KTC1/O cells/O acquired/O resistance/O to/O vemurafenib/O following/O 5/O months/O of/O treatment/O with/O the/O inhibitor/O ./O
Resistance/O coincided/O with/O the/O spontaneous/O acquisition/O of/O a/O KRAS/O G12D/O activating/O mutation/O ./O
Increases/O in/O activated/O AKT/O ,/O ERK1/2/O ,/O and/O EGFR/O were/O observed/O in/O these/O cells/O ./O
In/O addition/O ,/O the/O resistant/O cells/O were/O less/O sensitive/O to/O combinations/O of/O vemurafenib/O and/O MEK1/O inhibitor/O or/O AKT/O inhibitor/O ./O
These/O results/O support/O the/O KRAS/B-Gene G12D/B-Var mutation/O as/O a/O genetic/O mechanism/O of/O spontaneously/O acquired/B-Reg secondary/B-MPA BRAF/I-MPA inhibitor/I-MPA resistance/I-MPA in/O BRAF/O V600E/O thyroid/O cancer/O cells/O ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O the/O APX1/B-Gene gene/O result/O in/O enhanced/B-PosReg selenium/B-MPA tolerance/I-MPA in/O Arabidopsis/O thaliana/O ./O
It/O is/O generally/O recognized/O that/O excess/O selenium/O (/O Se/O )/O has/O a/O negative/O effect/O on/O the/O growth/O and/O development/O of/O plants/O ./O
Numerous/O studies/O have/O identified/O key/O genes/O involved/O in/O selenium/O tolerance/O in/O plants/O ;/O however/O ,/O our/O understanding/O of/O its/O molecular/O mechanisms/O is/O far/O from/O complete/O ./O
In/O this/O study/O ,/O we/O isolated/O an/O Arabidopsis/O selenium/O -/O resistant/O mutant/B-Var from/O the/O mutant/O XVE/O pool/O lines/O because/O of/O its/O increased/B-PosReg root/B-MPA growth/I-MPA and/O fresh/B-MPA weight/I-MPA in/O Se/O stress/O ,/O and/O cloned/O the/O gene/O ,/O which/O encodes/O the/O cytosolic/O ascorbate/O peroxidase/O (/O APX1/O )/O ./O
Two/O other/O APX1/O gene/O knockout/O allelic/O lines/O were/O also/O selenium/O resistant/O ,/O and/O the/O APX1-complementary/O COM1/O restored/O the/O growth/O state/O of/O wild/O type/O under/O Se/O stress/O ./O
In/O addition/O ,/O these/O APX1/O allelic/O lines/O accumulated/O more/O Se/O than/O did/O wild/O -/O type/O plants/O when/O subjected/O to/O Se/O stress/O ./O
Further/O analysis/O revealed/O that/O the/O APX1-mediated/O Se/O tolerance/O was/O associated/O ,/O at/O least/O in/O part/O ,/O with/O the/O enhanced/O activities/O of/O antioxidant/O enzymes/O catalase/O ,/O glutathione/O peroxidase/O and/O glutathione/O reductase/O ./O
Moreover/O ,/O enhanced/B-PosReg Se/B-MPA resistance/I-MPA of/O the/O mutants/B-Var was/O associated/B-Reg with/O glutathione/B-MPA (/O GSH/O )/O ,/O which/O had/O the/O higher/O expression/O level/O of/O GSH1/O gene/O involved/O in/O GSH/O synthesis/O and/O consequently/O increased/O GSH/O content/O ./O
Our/O results/O provide/O genetic/O evidence/O indicating/O that/O loss/O -/O of/O -/O function/O of/O APX1/O results/O in/O tolerance/O to/O Se/O stress/O ./O
Coexistence/O of/O Mosaic/O Uniparental/O Isodisomy/O and/O a/O KCNJ11/O Mutation/O Presenting/O as/O Diffuse/O Congenital/O Hyperinsulinism/O and/O Hemihypertrophy/O ./O
BACKGROUND/O :/O Isolated/O hyperinsulinaemic/B-Disease hypoglycaemia/I-Disease (/O HH/O )/O commonly/O results/B-Reg from/I-Reg recessively/B-Var inherited/I-Var mutations/I-Var in/O the/O ABCC8/B-Gene and/O KCNJ11/B-Gene genes/O that/O are/O located/O on/O chromosome/O 11p15.1/O ./O
More/O rarely/O ,/O HH/O can/O feature/O in/O patients/O with/O Beckwith/O -/O Wiedemann/O syndrome/O (/O BWS/O )/O ,/O a/O congenital/O overgrowth/O disorder/O ,/O resulting/O from/O defects/O at/O a/O differentially/O methylated/O region/O telomeric/O to/O the/O K/O -/O ATP/O channel/O genes/O at/O chromosome/O 11p15.5/O ./O
SUBJECT/O :/O We/O undertook/O genetic/O testing/O in/O a/O patient/O with/O diazoxide/O -/O unresponsive/O HH/O diagnosed/O at/O birth/O ./O
Physical/O examination/O later/O revealed/O hemihypertrophy/O of/O the/O right/O arm/O ,/O a/O feature/O of/O BWS/O ./O
RESULTS/O :/O We/O identified/O a/O novel/O mosaic/O ,/O paternally/O -/O inherited/O KCNJ11/O mutation(s/O )/O in/O the/O patient/O ./O
Further/O analysis/O confirmed/O uniparental/O disomy/O (/O UPD/O )/O of/O chromosome/O 11/O ,/O which/O extended/O across/O the/O KCNJ11/O gene/O at/O 11p15.1/O and/O the/O BWS/O locus/O at/O 11p15.5/O ./O
CONCLUSION/O :/O These/O results/O highlight/O the/O importance/O of/O considering/O UPD/O as/O a/O mechanism/O of/O disease/O in/O patients/O with/O HH/O and/O a/O paternally/O inherited/O K/O -/O ATP/O channel/O mutation/O ,/O especially/O when/O additional/O syndromic/O features/O are/O present/O ./O
Loss/O of/O T/O -/O cell/O quiescence/O by/O targeting/O Slfn2/O prevents/O the/O development/O and/O progression/O of/O T/O -/O ALL/O ./O
T/O -/O cell/O acute/O lymphoblastic/O leukemia/O (/O T/O -/O ALL/O )/O is/O an/O aggressive/O malignancy/O of/O thymocytes/O ./O
Despite/O significant/O improvement/O in/O the/O treatment/O of/O T/O -/O ALL/O ,/O approximately/O 20/O %/O of/O children/O and/O most/O adults/O undergo/O relapse/O ./O
Previous/O findings/O demonstrated/O that/O loss/B-NegReg of/O T/B-CPA -/I-CPA cell/I-CPA quiescence/I-CPA due/O to/O a/O mutation/B-Var in/O the/O Slfn2/B-Gene gene/O (/O elektra/O )/O leads/B-Reg to/I-Reg acquisition/O of/O an/O aberrant/B-CPA developmental/I-CPA program/I-CPA by/O which/O T/O -/O cells/O lose/B-NegReg their/O renewal/B-CPA capabilities/I-CPA and/O undergo/B-CPA apoptosis/I-CPA ./O
Here/O we/O show/O that/O the/O elektra/O mutation/O in/O Slfn2/O completely/O prevents/O a/O severe/O lymphoproliferative/O disease/O caused/O by/O overexpression/O of/O BCL2/O in/O combination/O with/O Fas/O deficiency/O in/O mice/O ./O
Moreover/O ,/O Slfn2/O impaired/O -/O function/O protects/O mice/O from/O experimental/O disease/O similar/O to/O human/O T/O -/O ALL/O by/O severely/O impairing/O the/O proliferation/O potential/O and/O survival/O of/O leukemic/O T/O -/O cells/O ,/O partially/O by/O activation/O of/O the/O p53/O tumor/O suppressor/O protein/O ./O
Our/O study/O suggest/O that/O in/O certain/O malignancies/O ,/O such/O as/O T/O -/O ALL/O ,/O a/O novel/O therapeutic/O strategy/O may/O be/O applied/O by/O imposing/O aberrant/O development/O of/O leukemic/O cells/O ./O
Furthermore/O ,/O as/O the/O elektra/O mutation/B-Var in/O Slfn2/B-Gene seems/O to/O impair/B-Reg only/O T/B-CPA -/I-CPA cells/I-CPA and/O monocytes/B-CPA ,/O targeting/O Slfn2/O is/O expected/O to/O be/O harmless/O to/O other/O cell/O types/O ,/O and/O thereby/O could/O be/O a/O promising/O target/O for/O treating/O malignancies/O ./O
Together/O our/O results/O demonstrate/O the/O potential/O of/O targeting/O Slfn2/O and/O its/O human/O paralog/O for/O T/O -/O ALL/O treatment/O ./O
Mutational/B-Var Spectrum/O of/O the/O MEFV/B-Gene Gene/O in/O AA/O Amyloidosis/O Associated/B-Reg With/I-Reg Familial/B-Disease Mediterranean/I-Disease Fever/I-Disease ./O
INTRODUCTION/O :/O Familial/B-Disease Mediterranean/I-Disease fever/I-Disease (/O FMF/O )/O is/O a/O recessively/O inherited/O disease/O which/O is/O characterized/O by/O recurrent/O episodic/O fever/O ,/O abdominal/O pain/O ,/O and/O polyserositis/O ./O
It/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O MEFV/B-Gene gene/O ,/O encoding/O the/O pyrin/O protein/O ./O
The/O most/O important/O complication/O of/O FMF/O is/O secondary/O (/O AA/O )/O amyloidosis/O that/O leads/O to/O kidney/O failure/O ./O
This/O study/O aimed/O to/O identify/O the/O frequency/O and/O distribution/O of/O MEFV/O mutations/O in/O Turkish/O patients/O with/O FMF/O -/O associated/O AA/O amyloidosis/O ./O
MATERIALS/O AND/O METHODS/O :/O A/O total/O of/O 57/O patients/O with/O FMF/O -/O associated/O AA/O amyloidosis/O and/O 60/O healthy/O controls/O were/O included/O in/O this/O study/O ./O
We/O analyzed/O the/O MEFV/O gene/O for/O E148Q/O ,/O M694V/O ,/O M680I/O ,/O and/O V726A/O mutations/O and/O R202Q/O variant/O by/O polymerase/O chain/O reaction/O and/O restriction/O fragment/O length/O polymorphism/O methods/O ./O
Results/O ./O
The/O male/O -/O female/O ratio/O was/O 0.72/O ./O
The/O mean/O age/O of/O the/O patients/O was/O 29.8/O ±/O 12.8/O years/O ./O
Among/O the/O patients/O ,/O the/O rate/O of/O the/O MEFV/O mutations/O was/O found/O to/O be/O 77.2/O %/O ./O
The/O most/O frequently/O observed/O genotype/O was/O homozygous/O M694V/O mutation/O ,/O which/O was/O present/O in/O 17/O patients/O (/O 29.8/O %/O ,/O P/O </O .001/O )/O ,/O followed/O by/O compound/O heterozygous/O M680I/O //O M694V/O (/O 14.3/O %/O ,/O P/O =/O .01/O )/O ./O
The/O R202Q/O allele/O frequencies/O were/O significantly/O different/O between/O patients/O and/O control/O group/O (/O P/O =/O .02/O ;/O odds/O ratio/O ,/O 0.53/O ;/O 95/O %/O confidence/O interval/O ,/O 0.30/O to/O 0.94/O )/O ./O
CONCLUSIONS/O :/O In/O this/O study/O ,/O mutation/O analysis/O of/O MEFV/O gene/O confirmed/O that/O the/O most/O frequent/O mutation/O was/O homozygous/O M694V/O genotype/O ./O
R202Q/O may/O be/O important/O in/O patients/O with/O FMF/O -/O associated/O AA/O amyloidosis/O ./O
Thus/O ,/O it/O is/O suggested/O that/O investigation/O of/O R202Q/O should/O be/O considered/O as/O a/O genetic/O test/O for/O Turkish/O FMF/O patients/O ./O
Oncogenic/O Mutant/O p53/O Gain/O of/O Function/O Nourishes/O the/O Vicious/O Cycle/O of/O Tumor/O Development/O and/O Cancer/O Stem/O -/O Cell/O Formation/O ./O
More/O than/O half/O of/O human/O tumors/O harbor/O an/O inactivated/O p53/O tumor/O -/O suppressor/O gene/O ./O
It/O is/O well/O accepted/O that/O mutant/B-Var p53/B-Gene shows/O an/O oncogenic/O gain/O -/O of/O -/O function/O (/O GOF/O )/O activity/O that/O facilitates/B-PosReg the/O transformed/B-MPA phenotype/I-MPA of/I-MPA cancer/I-MPA cells/I-MPA ./O
In/O addition/O ,/O a/O growing/O body/O of/O evidence/O supports/O the/O notion/O that/O cancer/O stem/O cells/O comprise/O a/O seminal/O constituent/O in/O the/O initiation/O and/O progression/O of/O cancer/O development/O ./O
Here/O ,/O we/O elaborate/O on/O the/O mutant/B-Var p53/B-Gene oncogenic/O GOF/B-PosReg leading/O toward/O the/B-MPA acquisition/I-MPA of/I-MPA a/I-MPA transformed/I-MPA phenotype/I-MPA ,/O as/O well/O as/O placing/O mutant/O p53/O as/O a/O major/O component/O in/O the/O establishment/O of/O cancer/O stem/O cell/O entity/O ./O
Therefore/O ,/O therapy/O targeted/O toward/O cancer/O stem/O cells/O harboring/O mutant/O p53/O is/O expected/O to/O pave/O the/O way/O to/O eradicate/O tumor/O growth/O and/O recurrence/O ./O
N/O -/O glycan/O containing/O a/O core/O α1,3-fucose/O residue/O is/O required/O for/O basipetal/O auxin/O transport/O and/O gravitropic/O response/O in/O rice/O (/O Oryza/O sativa/O )/O ./O
In/O plants/O ,/O α1,3-fucosyltransferase/O (/O FucT/O )/O catalyzes/O the/O transfer/O of/O fucose/O from/O GDP/O -/O fucose/O to/O asparagine/O -/O linked/O GlcNAc/O of/O the/O N/O -/O glycan/O core/O in/O the/O medial/O Golgi/O ./O
To/O explore/O the/O physiological/O significance/O of/O this/O processing/O ,/O we/O isolated/O two/O Oryza/O sativa/O (/O rice/O )/O mutants/O (/O fuct-1/O and/O fuct-2/O )/O with/O loss/O of/O FucT/O function/O ./O
Biochemical/O analyses/O of/O the/O N/O -/O glycan/O structure/O confirmed/O that/O α1,3-fucose/O is/O missing/B-Var from/O the/O N/O -/O glycans/O of/O allelic/O fuct-1/B-Gene and/O fuct-2/B-Gene ./O
Compared/O with/O the/O wild/O -/O type/O cv/O Kitaake/O ,/O fuct-1/O displayed/O a/O larger/B-PosReg tiller/B-MPA angle/I-MPA ,/O shorter/B-NegReg internode/B-MPA and/O panicle/B-MPA lengths/O ,/O and/O decreased/B-NegReg grain/B-MPA filling/I-MPA as/O well/O as/O an/O increase/B-PosReg in/O chalky/B-MPA grains/I-MPA with/I-MPA abnormal/I-MPA shape/I-MPA ./O
The/O mutant/O allele/O fuct-2/O gave/O rise/O to/O similar/O developmental/O abnormalities/O ,/O although/O they/O were/O milder/O than/O those/O of/O fuct-1/O ./O
Restoration/O of/O a/O normal/O tiller/O angle/O in/O fuct-1/O by/O complementation/O demonstrated/O that/O the/O phenotype/O is/O caused/O by/O the/O loss/O of/O FucT/O function/O ./O
Both/O fuct-1/O and/O fuct-2/O plants/O exhibited/O reduced/O gravitropic/O responses/O ./O
Expression/O of/O the/O genes/O involved/O in/O tiller/O and/O leaf/O angle/O control/O was/O also/O affected/O in/O the/O mutants/O ./O
We/O demonstrate/O that/O reduced/O basipetal/O auxin/O transport/O and/O low/O auxin/O accumulation/O at/O the/O base/O of/O the/O shoot/O in/O fuct-1/O account/O for/O both/O the/O reduced/O gravitropic/O response/O and/O the/O increased/O tiller/O angle/O ./O
Hajdu/O -/O Cheney/O Syndrome/O ,/O a/O Disease/O Associated/O with/O NOTCH2/O Mutations/O ./O
Notch/O plays/O an/O important/O function/O in/O skeletal/O homeostasis/O ,/O osteoblastogenesis/O ,/O and/O osteoclastogenesis/O ./O
Hajdu/B-Disease -/I-Disease Cheney/I-Disease syndrome/I-Disease (/O HCS/O )/O is/O a/O rare/O disease/O associated/O with/O mutations/B-Var in/O NOTCH2/B-Gene leading/B-Reg to/I-Reg the/O translation/B-MPA of/I-MPA a/I-MPA truncated/I-MPA NOTCH2/B-Gene stable/O protein/B-Protein ./O
As/O a/O consequence/O ,/O a/O gain/O -/O of/O -/O NOTCH2/O function/O is/O manifested/O ./O
HCS/O is/O inherited/O as/O an/O autosomal/O dominant/O disease/O although/O sporadic/O cases/O exist/O ./O
HCS/O is/O characterized/O by/O craniofacial/O developmental/O defects/O ,/O including/O platybasia/O and/O wormian/O bones/O ,/O osteoporosis/O with/O fractures/O ,/O and/O acro/O -/O osteolysis/O ./O
Subjects/O may/O suffer/O severe/O neurological/O complications/O ,/O and/O HCS/O presents/O with/O cardiovascular/O defects/O and/O polycystic/O kidneys/O ./O
An/O experimental/O mouse/O model/O harboring/O a/O HCSNotch2/O mutation/O exhibits/O osteopenia/O secondary/O to/O enhanced/O bone/O resorption/O suggesting/O this/O as/O a/O possible/O mechanism/O for/O the/O skeletal/O disease/O ./O
If/O the/O same/O mechanisms/O were/O operational/O in/O humans/O ,/O anti/O -/O resorptive/O therapy/O could/O correct/O the/O bone/O loss/O ,/O but/O not/O necessarily/O the/O acro/O -/O osteolysis/O ./O
In/O conclusion/O ,/O HCS/O is/O a/O devastating/O disease/O associated/O with/O a/O gain/O -/O of/O -/O NOTCH2/O function/O resulting/O in/O diverse/O clinical/O manifestations/O ./O
Phenotypes/O and/O Genotypes/O in/O Five/O Children/O with/O Congenital/O Insensitivity/O to/O Pain/O with/O Anhidrosis/O ./O
BACKGROUND/O :/O Congenital/B-Disease insensitivity/I-Disease to/I-Disease pain/I-Disease with/I-Disease anhidrosis/I-Disease is/O an/O extremely/O rare/O hereditary/O disorder/O linked/B-Reg to/I-Reg variants/B-Var in/O NTRK1/B-Gene ./O
Our/O goal/O was/O to/O characterize/O the/O clinical/O features/O and/O the/O genetic/O basis/O of/O the/O disorder/O in/O Chinese/O patients/O ./O
METHODS/O :/O Patients/O were/O enrolled/O via/O social/O networking/O ./O
Clinical/O features/O were/O investigated/O by/O interview/O ,/O chart/O review/O ,/O and/O physical/O examination/O ./O
DNA/O was/O extracted/O from/O peripheral/O blood/O to/O genotype/O NTRK1/O in/O patients/O and/O their/O parents/O ./O
Variants/O identified/O were/O checked/O against/O a/O control/O cohort/O by/O high/O -/O throughput/O sequencing/O ,/O and/O the/O effects/O of/O these/O variants/O were/O assessed/O in/O silico/O ./O
RESULTS/O :/O Clinical/O features/O in/O five/O patients/O were/O cataloged/O ,/O and/O six/O loss/O -/O of/O -/O function/O NTRK1/O variants/O were/O identified/O ,/O including/O a/O frameshift/O variant/O c.963delG/O ,/O a/O nonsense/O variant/O c.1804C/O >/O T/O ,/O an/O intron/O variant/O c.851/O -/O 33T/O >/O A/O ,/O and/O three/O missense/O variants/O c.1802T/O >/O G/O ,/O c.2074C/O >/O T/O ,/O and/O c.2311C/O >/O T./O CONCLUSIONS/O :/O The/O results/O expand/O the/O spectrum/O of/O clinical/O and/O genetic/O features/O of/O congenital/O insensitivity/O to/O pain/O with/O anhidrosis/O and/O will/O help/O facilitate/O analysis/O of/O genotype/O -/O phenotype/O association/O in/O the/O future/O ./O
The/O impact/O of/O intermittent/O versus/O continuous/O exposure/O to/O EGFR/O tyrosine/O kinase/O inhibitor/O on/O selection/O of/O EGFR/O T790M/O -/O mutant/O drug/O -/O resistant/O clones/O in/O a/O lung/O cancer/O cell/O line/O carrying/O activating/O EGFR/O mutation/O ./O
Drug/O -/O resistant/O cell/O lines/O are/O essential/O tools/O for/O investigating/O the/O mechanisms/O of/O resistance/O to/O molecular/O -/O targeted/O anti/O -/O cancer/O drugs/O ./O
However/O ,/O little/O is/O known/O about/O how/O to/O establish/O clinically/O relevant/O drug/O -/O resistant/O cell/O lines/O ./O
Our/O study/O examined/O the/O impact/O of/O a/O drug/O -/O free/O period/O on/O the/O establishment/O of/O a/O cell/O line/O with/O clinically/O relevant/O resistance/O to/O molecular/O -/O targeted/O drugs/O ./O
We/O used/O PC9/O cells/O ,/O a/O lung/O cancer/O cell/O line/O carrying/O EGFR/O mutation/O ,/O because/O this/O is/O a/O validated/O target/O for/O EGFR/O tyrosine/O kinase/O inhibitors/O (/O TKI/O )/O ./O
PC9/O cells/O were/O intermittently/O or/O continuously/O exposed/O to/O increasing/O concentrations/O of/O gefitinib/O (/O 0.01/O μM/O to/O 1.0/O μM/O )/O and/O the/O emergence/O of/O the/O most/O common/O acquired/O resistance/O mutation/O in/O EGFR/O ,/O T790/O M/O ,/O was/O determined/O ./O
T790/O M/O was/O detected/O at/O a/O 25-fold/O lower/O drug/O concentration/O in/O cells/O continuously/O exposed/O to/O gefitinib/O (/O PC9/O //O GRc/O )/O than/O in/O cells/O intermittently/O exposed/O to/O gefitinib/O (/O PC9/O //O GRi/O )/O (/O 0.04/O μM/O vs/O 1.0/O μM/O ,/O respectively/O )/O ./O
The/O mutation/B-Var frequencies/O at/O those/O drug/O concentrations/O were/O 19.8/O %/O and/O 8.0/O %/O in/O PC9/O //O GRc/O and/O PC9/O //O GRi/O cells/O ,/O respectively/O ./O
After/O drug/O -/O free/O culture/O for/O 8/O weeks/O ,/O resistance/B-MPA to/I-MPA gefitinib/I-MPA decreased/B-NegReg in/O the/O PC9/O //O GRi/O cells/O but/O not/O in/O the/O PC9/O //O GRc/O cells/O ./O
In/O the/O PC9/O //O GRc/O cells/O ,/O the/O frequency/O of/O the/O T790/O M/O mutation/O was/O consistently/O about/O 20/O %/O from/O 0.04/O μM/O to/O 1.0/O μM/O of/O gefitinib/O ./O
In/O the/O PC9/O //O GRc/O cells/O ,/O the/O T790/O M/O mutation/O was/O detected/O in/O all/O single/O -/O cell/O clones/O ,/O at/O frequencies/O ranging/O from/O 7.0/O %/O to/O 37.0/O %/O ,/O with/O a/O median/O of/O 19.5/O %/O (/O 95/O %/O confidence/O interval/O ,/O 17.3%-20.9/O %/O )/O ./O
In/O conclusion/O ,/O compared/O with/O intermittent/O drug/O exposure/O ,/O continuous/O exposure/O might/O select/O better/O minor/O drug/O -/O resistant/O clones/O when/O creating/O cell/O lines/O resistant/O to/O molecular/O -/O targeted/O drugs/O ./O
Identification/O of/O mutations/B-Var in/O the/O F8/B-Gene and/O F9/B-Gene gene/O in/O families/O with/B-Reg haemophilia/B-Disease using/O targeted/O high/O -/O throughput/O sequencing/O ./O
INTRODUCTION/O :/O At/O present/O ,/O many/O methods/O are/O available/O for/O the/O genetic/O diagnosis/O of/O haemophilia/O ,/O including/O indirect/O linkage/O analysis/O ,/O direct/O sequencing/O ./O
However/O ,/O these/O methods/O are/O time/O -/O consuming/O ,/O labourious/O ,/O and/O limited/O in/O their/O application/O ./O
Therefore/O ,/O the/O development/O of/O new/O ,/O more/O effective/O techniques/O is/O necessary/O ./O
AIM/O :/O To/O detect/O the/O F8/B-Gene and/O F9/B-Gene gene/O mutations/B-Var in/O patients/O with/B-Reg haemophilia/B-Disease and/O their/O female/O relatives/O in/O 29/O haemophilia/O A/O (/O HA/O )/O and/O 11/O haemophilia/O B/O (/O HB/O )/O families/O ./O
METHODS/O :/O */O FVIII/O :/O C/O and/O FIX/O :/O C/O were/O analyzed/O using/O one/O -/O stage/O method/O ,/O and/O factor/O VIII/O and/O factor/O IX/O inhibitors/O were/O tested/O using/O the/O Bethesda/O method/O ./O
Intron/O 22/O and/O one/O inversions/O were/O identified/O using/O long/O -/O distance/O polymerase/O chain/O reaction/O (/O PCR/O )/O and/O standard/O PCR/O ./O
Non/O -/O inversion/O mutations/O of/O the/O F8/O and/O F9/O gene/O were/O identified/O by/O targeted/O high/O -/O throughput/O sequencing/O ./O
All/O mutations/O were/O verified/O by/O Sanger/O sequencing/O ./O
RESULTS/O :/O Intron/O 22/O inversion/O was/O detected/O in/O eight/O HA/O families/O and/O intron/O one/O inversion/O was/O detected/O in/O one/O HA/O family/O ./O
Apart/O from/O the/O inversion/O mutations/O ,/O 20/O mutations/O were/O identified/O in/O HA/O families/O ,/O including/O 17/O previously/O reported/O and/O three/O novel/O mutations/O :/O c.5724G/O >/O A/O (/O p/O ./O Trp1908/O */O )/O ,/O c.6116/O -/O 1_6120delGAGTGTinsTCC/O (/O p/O ./O Lys2039Ilefs*13/O )/O ,/O and/O c.5220/O -/O 2A/O >/O C./O We/O found/O a/O complex/O rearrangement/O in/O HA/O :/O intron/O one/O inversion/O concomitant/O with/O exon/O one/O deletion/O ./O
In/O HB/O ,/O eight/O recurrent/O mutations/O were/O detected/O ,/O including/O six/O missense/O mutations/O and/O two/O nonsense/O mutations/O ./O
CONCLUSION/O :/O Targeted/O high/O -/O throughput/O sequencing/O is/O an/O effective/O technique/O to/O detect/O the/O F8/O and/O F9/O gene/O mutations/O ,/O especially/O for/O the/O discovery/O of/O novel/O mutations/O ./O
The/O method/O is/O highly/O accurate/O ,/O time/O -/O saving/O and/O shows/O great/O advantage/O in/O uncovering/O large/O deletion/O mutations/O and/O also/O in/O distinguishing/O the/O wild/O -/O type/O genotype/O and/O heterozygous/O large/O deletions/O ./O
Loss/B-NegReg of/I-NegReg function/I-NegReg mutations/B-Var in/O RP1/B-Gene are/O responsible/O for/O retinitis/B-Disease pigmentosa/I-Disease in/O consanguineous/O familial/O cases/O ./O
PURPOSE/O :/O This/O study/O was/O undertaken/O to/O identify/O causal/O mutations/O responsible/O for/O autosomal/O recessive/O retinitis/O pigmentosa/O (/O arRP/O )/O in/O consanguineous/O families/O ./O
METHODS/O :/O Large/O consanguineous/O families/O were/O ascertained/O from/O the/O Punjab/O province/O of/O Pakistan/O ./O
An/O ophthalmic/O examination/O consisting/O of/O a/O fundus/O evaluation/O and/O electroretinography/O (/O ERG/O )/O was/O completed/O ,/O and/O small/O aliquots/O of/O blood/O were/O collected/O from/O all/O participating/O individuals/O ./O
Genomic/O DNA/O was/O extracted/O from/O white/O blood/O cells/O ,/O and/O a/O genome/O -/O wide/O linkage/O or/O a/O locus/O -/O specific/O exclusion/O analysis/O was/O completed/O with/O polymorphic/O short/O tandem/O repeats/O (/O STRs/O )/O ./O
Two/O -/O point/O logarithm/O of/O odds/O (/O LOD/O )/O scores/O were/O calculated/O ,/O and/O all/O coding/O exons/O and/O exon/O -/O intron/O boundaries/O of/O RP1/O were/O sequenced/O to/O identify/O the/O causal/O mutation/O ./O
RESULTS/O :/O The/O ophthalmic/O examination/O showed/O that/O affected/O individuals/O in/O all/O families/O manifest/O cardinal/O symptoms/O of/O RP/O ./O
Genome/O -/O wide/O scans/O localized/O the/O disease/O phenotype/O to/O chromosome/O 8q/O ,/O a/O region/O harboring/O RP1/O ,/O a/O gene/O previously/O implicated/O in/O the/O pathogenesis/O of/O RP/O ./O
Sanger/O sequencing/O identified/O a/O homozygous/O single/O base/O deletion/O in/O exon/O 4/O :/O c.3697delT/O (/O p/O ./O S1233Pfs22/O */O )/O ,/O a/O single/O base/O substitution/O in/O intron/O 3/O :/O c.787/O +/O 1G/O >/O A/O (/O p/O ./O I263Nfs8/O */O )/O ,/O a/O 2/O bp/O duplication/O in/O exon/O 2/O :/O c.551_552dupTA/O (/O p/O ./O Q185Yfs4/O */O )/O and/O an/O 11,117/O bp/O deletion/O that/O removes/O all/O three/O coding/O exons/O of/O RP1/O ./O
These/O variations/O segregated/O with/O the/O disease/O phenotype/O within/O the/O respective/O families/O and/O were/O not/O present/O in/O ethnically/O matched/O control/O samples/O ./O
CONCLUSIONS/O :/O These/O results/O strongly/O suggest/O that/O these/O mutations/O in/O RP1/O are/O responsible/O for/O the/O retinal/O phenotype/O in/O affected/O individuals/O of/O all/O four/O consanguineous/O families/O ./O
Ectrodactyly/B-Disease and/I-Disease Lethal/I-Disease Pulmonary/I-Disease Acinar/I-Disease Dysplasia/I-Disease Associated/B-Reg with/O Homozygous/O FGFR2/B-Gene Mutations/B-Var Identified/O by/O Exome/O Sequencing/O ./O
Ectrodactyly/O //O split/O hand/O -/O foot/O malformation/O is/O genetically/O heterogeneous/O with/O more/O than/O 100/O syndromic/O associations/O ./O
Acinar/O dysplasia/O is/O a/O rare/O congenital/O lung/O lesion/O of/O unknown/O etiology/O ,/O which/O is/O frequently/O lethal/O postnatally/O ./O
To/O date/O ,/O there/O have/O been/O no/O reports/O of/O combinations/O of/O these/O two/O phenotypes/O ./O
Here/O ,/O we/O present/O an/O infant/O from/O a/O consanguineous/O union/O with/O both/O ectrodactyly/O and/O autopsy/O confirmed/O acinar/O dysplasia/O ./O
SNP/O array/O and/O whole/O -/O exome/O sequencing/O analyses/O of/O the/O affected/O infant/O identified/O a/O novel/O homozygous/O Fibroblast/O Growth/O Factor/O Receptor/O 2/O (/O FGFR2/O )/O missense/O mutation/O (/O p/O ./O R255Q/O )/O in/O the/O IgIII/O domain/O (/O D3/O )/O ./O
Expression/O studies/O of/O Fgfr2/O in/O development/O show/O localization/O to/O the/O affected/O limbs/O and/O organs/O ./O
Molecular/O modeling/O and/O genetic/O and/O functional/O assays/O support/O that/O this/O mutation/O is/O at/O least/O a/O partial/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/B-Var ,/O and/O contributes/O to/O ectrodactyly/B-Disease and/I-Disease acinar/I-Disease dysplasia/I-Disease only/O in/O homozygosity/O ,/O unlike/O previously/O reported/O heterozygous/O activating/O FGFR2/B-Gene mutations/B-Var that/O cause/B-Reg Crouzon/B-Disease ,/O Apert/B-Disease ,/O and/O Pfeiffer/B-Disease syndromes/I-Disease ./O
This/O is/O the/O first/O report/O of/O mutations/O in/O a/O human/O disease/O with/O ectrodactyly/O with/O pulmonary/O acinar/O dysplasia/O and/O ,/O as/O such/O ,/O homozygous/O loss/O -/O of/O -/O function/O FGFR2/O mutations/O represent/O a/O unique/O syndrome/O ./O
X/B-Disease -/I-Disease linked/I-Disease Congenital/I-Disease Adrenal/I-Disease Hypoplasia/I-Disease with/B-Reg a/O Novel/O NR0B1/B-Gene //I-Gene DAX/I-Gene Gene/O Mutation/B-Var ./O
BACKGROUND/O :/O The/O etiology/O of/O primary/O adrenal/O insufficiency/O has/O implications/O for/O further/O management/O of/O the/O condition/O ./O
CASE/O CHARACTERISTICS/O :/O A/O 5-year/O -/O old/O boy/O presented/O in/O adrenal/O crisis/O with/O glucocorticoid/O and/O mineralocorticoid/O deficiency/O ./O
OBSERVATION/O :/O Investigations/O confirmed/O primary/O adrenal/B-CPA insufficiency/B-NegReg and/O ruled/O out/O the/O common/O etiologies/O ./O
Genetic/O testing/O identified/O a/O novel/O NR0B1/B-Gene //I-Gene DAX/I-Gene gene/O mutation/B-Var ./O
MESSAGE/O :/O A/O genetic/O diagnosis/O in/O children/O with/O primary/O adrenal/O insufficiency/O is/O useful/O to/O provide/O genetic/O counselling/O ./O
Severe/O Early/B-Disease -/I-Disease Onset/I-Disease Combined/I-Disease Immunodeficiency/I-Disease due/O to/O Heterozygous/O Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg Function/I-PosReg Mutations/B-Var in/O STAT1/B-Gene ./O
PURPOSE/O :/O Loss/O and/O gain/O -/O of/O -/O function/O (/O GOF/O )/O mutations/O in/O human/O signal/O transducer/O and/O activator/O of/O transcription/O 1/O (/O STAT1/O )/O lead/O to/O distinct/O phenotypes/O ./O
Although/O recurrent/O infections/O are/O common/O to/O both/O types/O of/O STAT1/O mutations/O ,/O GOF/B-PosReg mutations/B-Var are/O distinguished/O by/O chronic/B-Disease mucocutaneous/I-Disease candidiasis/I-Disease and/O autoimmunity/B-Disease ./O
However/O ,/O the/O clinical/O spectra/O of/O STAT1/O GOF/O mutations/O continue/O to/O expand/O ./O
We/O here/O describe/O two/O patients/O with/O STAT1/B-Gene GOF/B-PosReg mutations/B-Var presenting/O early/O in/O life/O with/O combined/B-Disease immunodeficiency/I-Disease (/O CID/O )/O ./O
METHODS/O :/O Clinical/O data/O and/O laboratory/O findings/O including/O immunophenotyping/O ,/O level/O of/O interferon/O (/O IFN)-γ/O //O IL-17(+/O )/O T/O cells/O ,/O interferon/O -/O induced/O STAT1/O phosphorylation/O ,/O and/O JAK/O inhibitor/O assays/O were/O evaluated/O ./O
Sequencing/O of/O STAT1/O gene/O was/O performed/O by/O Sanger/O sequencer/O ./O
RESULTS/O :/O Patient/O 1/O (/O P1/O )/O had/O persistent/O oral/O candidiasis/O and/O cytomegalovirus/O (/O CMV/O )/O infection/O since/O 2/O months/O of/O age/O and/O later/O developed/O cavitary/O lung/O lesions/O due/O to/O Mycobacterium/O tuberculosis/O ./O
Patient/O 2/O (/O P2/O )/O presented/O with/O oral/O candidiasis/O and/O recurrent/O pneumonia/O at/O 4/O months/O of/O age/O and/O subsequently/O developed/O CMV/O pneumonitis/O ./O
Both/O patients/O suffered/O heterozygous/O missense/B-Var mutations/I-Var in/O STAT1/B-Gene ,/O leading/B-Reg to/I-Reg deleterious/O amino/O acid/O substitutions/B-Var in/O the/O DNA/O binding/O domain/O (/O P1/O :/O c.1154C/B-Var >/I-Var T/I-Var ;/I-Var p/B-Var ./I-Var T385/I-Var M/I-Var ;/I-Var P2/O ./O
c.971/B-Var G/I-Var >/I-Var T/I-Var ;/I-Var p/B-Var ./I-Var C324F/I-Var )/I-Var ./O
Circulating/O CD4(+/O )/O T/O cells/O of/O both/O patients/O exhibited/O increased/B-PosReg interferon/B-MPA -/I-MPA γ/I-MPA and/O decreased/B-NegReg IL-17/B-MPA expression/I-MPA as/O compared/O to/O controls/O ./O
They/O also/O exhibited/O increased/B-PosReg IFN/B-MPA -/I-MPA β/I-MPA and/O -γ/B-MPA -/I-MPA induced/I-MPA STAT1/I-MPA phosphorylation/I-MPA that/O was/O reversed/O upon/O treatment/O with/O the/O JAK/O kinase/O inhibitor/O ruxolitinib/O ./O
CONCLUSION/O :/O STAT1/O GOF/O mutations/O may/O present/O early/O in/O life/O with/O CID/O ,/O consistent/O with/O the/O clinical/O heterogeneity/O of/O the/O disease/O ./O
JAK/O kinase/O inhibitors/O may/O potentially/O be/O useful/O in/O some/O patients/O as/O adjunct/O therapy/O pending/O definitive/O treatment/O with/O bone/O marrow/O transplantation/O ./O
Directed/O evolution/O of/O a/O sphingomyelin/O flippase/O reveals/O mechanism/O of/O substrate/O backbone/O discrimination/O by/O a/O P4-ATPase/O ./O
Phospholipid/O flippases/O in/O the/O type/O IV/O P/O -/O type/O ATPase/O (/O P4-ATPases/O )/O family/O establish/O membrane/O asymmetry/O and/O play/O critical/O roles/O in/O vesicular/O transport/O ,/O cell/O polarity/O ,/O signal/O transduction/O ,/O and/O neurologic/O development/O ./O
All/O characterized/O P4-ATPases/O flip/O glycerophospholipids/O across/O the/O bilayer/O to/O the/O cytosolic/O leaflet/O of/O the/O membrane/O ,/O but/O how/O these/O enzymes/O distinguish/O glycerophospholipids/O from/O sphingolipids/O is/O not/O known/O ./O
We/O used/O a/O directed/O evolution/O approach/O to/O examine/O the/O molecular/O mechanisms/O through/O which/O P4-ATPases/O discriminate/O substrate/O backbone/O ./O
A/O mutagenesis/O screen/O in/O the/O yeast/O Saccharomyces/O cerevisiae/O has/O identified/O several/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var in/O the/O P4-ATPase/B-Enzyme Dnf1/O that/O facilitate/B-PosReg the/O transport/B-MPA of/O a/O novel/O lipid/O substrate/O ,/O sphingomyelin/O ./O
We/O found/O that/O a/O highly/O conserved/O asparagine/O (/O N220/O )/O in/O the/O first/O transmembrane/O segment/O is/O a/O key/O enforcer/O of/O glycerophospholipid/O selection/O ,/O and/O specific/O substitutions/O at/O this/O site/O allow/O transport/O of/O sphingomyelin/O ./O
Loss/B-NegReg of/I-NegReg function/I-NegReg mutation/B-Var in/O LOX/B-Gene causes/O thoracic/B-Disease aortic/I-Disease aneurysm/I-Disease and/I-Disease dissection/I-Disease in/O humans/O ./O
Thoracic/O aortic/O aneurysms/O and/O dissections/O (/O TAAD/O )/O represent/O a/O substantial/O cause/O of/O morbidity/O and/O mortality/O worldwide/O ./O
Many/O individuals/O presenting/O with/O an/O inherited/O form/O of/O TAAD/O do/O not/O have/O causal/O mutations/O in/O the/O set/O of/O genes/O known/O to/O underlie/O disease/O ./O
Using/O whole/O -/O genome/O sequencing/O in/O two/O first/O cousins/O with/O TAAD/O ,/O we/O identified/O a/O missense/O mutation/O in/O the/O lysyl/O oxidase/O (/B-Gene LOX/I-Gene )/I-Gene gene/O (/B-Var c.893/I-Var T/I-Var >/I-Var G/I-Var encoding/O p/B-Var ./I-Var Met298Arg/I-Var )/I-Var that/O cosegregated/O with/O disease/O in/O the/O family/O ./O
Using/O clustered/O regularly/O interspaced/O short/O palindromic/O repeats/O (/O CRISPR)/clustered/O regularly/O interspaced/O short/O palindromic/O repeats/O -/O associated/O protein-9/O nuclease/O (/O Cas9/O )/O genome/O engineering/O tools/O ,/O we/O introduced/O the/O human/O mutation/O into/O the/O homologous/O position/O in/O the/O mouse/O genome/O ,/O creating/O mice/O that/O were/O heterozygous/O and/O homozygous/O for/O the/O human/O allele/O ./O
Mutant/O mice/O that/O were/O heterozygous/O for/O the/O human/O allele/O displayed/O disorganized/O ultrastructural/O properties/O of/O the/O aortic/O wall/O characterized/O by/O fragmented/O elastic/O lamellae/O ,/O whereas/O mice/O homozygous/O for/O the/O human/O allele/O died/O shortly/O after/O parturition/O from/O ascending/O aortic/O aneurysm/O and/O spontaneous/O hemorrhage/O ./O
These/O data/O suggest/O that/O a/O missense/B-Var mutation/I-Var in/O LOX/B-Gene is/O associated/B-Reg with/O aortic/B-Disease disease/I-Disease in/O humans/O ,/O likely/O through/O insufficient/B-NegReg cross/B-Interaction -/I-Interaction linking/I-Interaction of/O elastin/B-Protein and/O collagen/B-MPA in/O the/O aortic/O wall/O ./O
Mutation/B-Var carriers/O may/O be/O predisposed/B-Reg to/O vascular/B-Disease diseases/I-Disease because/O of/O weakened/B-NegReg vessel/B-CPA walls/I-CPA under/O stress/O conditions/O ./O
LOX/O sequencing/O for/O clinical/O TAAD/O may/O identify/O additional/O mutation/O carriers/O in/O the/O future/O ./O
Additional/O studies/O using/O our/O mouse/O model/O of/O LOX/O -/O associated/O TAAD/O have/O the/O potential/O to/O clarify/O the/O mechanism/O of/O disease/O and/O identify/O novel/O therapeutics/O specific/O to/O this/O genetic/O cause/O ./O
Fanconi/O -/O Bickel/O syndrome/O in/O two/O Palestinian/O children/O :/O marked/O phenotypic/O variability/O with/O identical/O mutation/O ./O
BACKGROUND/O :/O Fanconi/B-Disease -/I-Disease Bickel/I-Disease syndrome/I-Disease (/O FBS/O ,/O OMIM/O 227810/O )/O is/O a/O rare/O autosomal/O recessive/O disease/O caused/B-Reg by/I-Reg a/O deficiency/B-Var of/O glucose/O transporter/O 2/O (/B-Gene GLUT2/I-Gene )/I-Gene ,/O a/O member/O of/O the/O facilitative/O glucose/O transporter/O family/O (/O Santer/O et/O al/O ./O
J/O Inherit/O Metab/O Dis/O 21:191/O -/O 194/O ,/O 1998/O )/O ./O
The/O typical/O clinical/O picture/O is/O characterized/O by/O hepatorenal/O glycogen/O accumulation/O resulting/O in/O hepato-/O and/O nephromegaly/O ,/O impaired/O utilization/O of/O glucose/O and/O galactose/O ,/O proximal/O renal/O tubular/O dysfunction/O ,/O rickets/O and/O severe/O short/O stature/O ./O
CASE/O PRESENTATION/O :/O We/O report/O 2/O Palestinian/O patients/O from/O 2/O families/O who/O were/O homozygous/O for/O the/O mutation/O p/O ./O R301X/O (/O C/O >/O T/O )/O in/O exon/O 7of/O GLUT2/O gene/O ./O
Patient/O 1/O showed/O clinical/O and/O laboratory/O improvement/O with/O age/O characterized/O by/O normal/O growth/O and/O resolution/O of/O rickets/O ./O
Patient/O 2/O had/O severe/O phenotype/O characterized/O by/O progressive/O weight/O loss/O ,/O persistent/O metabolic/O acidosis/O ,/O marked/O polyuria/O and/O clinical/O and/O laboratory/O findings/O of/O rickets/O progressing/O to/O death/O at/O age/O 10/O months/O ./O
CONCLUSION/O :/O This/O report/O further/O expands/O the/O clinical/O spectrum/O of/O FBS/O even/O with/O identical/O mutations/O ./O
Other/O yet/O unknown/O genetic/O ,/O environmental/O or/O stochastic/O factors/O may/O be/O responsible/O for/O phenotypic/O variability/O ./O
Gli2/O gene/O -/O environment/O interactions/O contribute/O to/O the/O etiological/O complexity/O of/O holoprosencephaly/O :/O evidence/O from/O a/O mouse/O model/O ./O
Holoprosencephaly/B-Disease (/O HPE/O )/O is/O a/O common/O and/O severe/O human/O developmental/O abnormality/O marked/O by/O malformations/O of/O the/O forebrain/O and/O face/O ./O
Although/O several/O genetic/O mutations/O have/O been/O linked/O to/O HPE/O ,/O phenotypic/O outcomes/O range/O dramatically/O ,/O and/O most/O cases/O can/O not/O be/O attributed/O to/O a/O specific/O cause/O ./O
Gene/O -/O environment/O interaction/O has/O been/O invoked/O as/O a/O premise/O to/O explain/O the/O etiological/O complexity/O of/O HPE/O ,/O but/O identification/O of/O interacting/O factors/O has/O been/O extremely/O limited/O ./O
Here/O ,/O we/O demonstrate/O that/O mutations/B-Var in/O Gli2/B-Gene ,/O which/O encodes/O a/O Hedgehog/O pathway/O transcription/O factor/O ,/O can/O cause/B-Reg or/O predispose/O to/O HPE/B-Disease depending/O upon/O gene/O dosage/O ./O
On/O the/O C57BL/6J/O background/O ,/O homozygous/B-Var GLI2/B-Gene loss/B-NegReg of/I-NegReg function/I-NegReg results/O in/O the/O characteristic/O brain/O and/O facial/O features/O seen/O in/O severe/O human/O HPE/B-Disease ,/O including/O midfacial/O hypoplasia/O ,/O hypotelorism/O and/O medial/O forebrain/O deficiency/O with/O loss/O of/O ventral/O neurospecification/O ./O
Although/O normally/O indistinguishable/O from/O wild/O -/O type/O littermates/O ,/O we/O demonstrate/O that/O mice/O with/O single/O -/O allele/O Gli2/O mutations/O exhibit/O increased/O penetrance/O and/O severity/O of/O HPE/O in/O response/O to/O low/O -/O dose/O teratogen/O exposure/O ./O
This/O genetic/O predisposition/O is/O associated/O with/O a/O Gli2/O dosage/O -/O dependent/O attenuation/O of/O Hedgehog/O ligand/O responsiveness/O at/O the/O cellular/O level/O ./O
In/O addition/O to/O revealing/O a/O causative/O role/O for/O GLI2/O in/O HPE/O genesis/O ,/O these/O studies/O demonstrate/O a/O mechanism/O by/O which/O normally/O silent/O genetic/O and/O environmental/O factors/O can/O interact/O to/O produce/O severe/O outcomes/O ./O
Taken/O together/O ,/O these/O findings/O provide/O a/O framework/O for/O the/O understanding/O of/O the/O extreme/O phenotypic/O variability/O observed/O in/O humans/O carrying/O GLI2/O mutations/O and/O a/O paradigm/O for/O reducing/O the/O incidence/O of/O this/O morbid/O birth/O defect/O ./O
Identification/O of/O 15/O novel/O partial/O SHOX/O deletions/O and/O 13/O partial/O duplications/O ,/O and/O a/O review/O of/O the/O literature/O reveals/O intron/O 3/O to/O be/O a/O hotspot/O region/O ./O
Short/O stature/O homeobox/O gene/O (/O SHOX/O )/O is/O located/O in/O the/O pseudoautosomal/O region/O 1/O of/O the/O sex/O chromosomes/O ./O
It/O encodes/O a/O transcription/O factor/O implicated/O in/O the/O skeletal/O growth/O ./O
Point/B-Var mutations/I-Var ,/O deletions/B-Var or/O duplications/B-Var of/O SHOX/B-Gene or/O its/O transcriptional/O regulatory/O elements/O are/O associated/B-Reg with/O two/O skeletal/O dysplasias/O ,/O Léri/B-Disease -/I-Disease Weill/I-Disease dyschondrosteosis/I-Disease (/O LWD/O )/O and/O Langer/B-Disease mesomelic/I-Disease dysplasia/I-Disease (/O LMD/O )/O ,/O as/O well/O as/O in/O a/O small/O proportion/O of/O idiopathic/B-Disease short/I-Disease stature/I-Disease (/O ISS/O )/O individuals/O ./O
We/O have/O identified/O a/O total/O of/O 15/O partial/O SHOX/O deletions/O and/O 13/O partial/O SHOX/O duplications/O in/O LWD/O ,/O LMD/O and/O ISS/O patients/O referred/O for/O routine/O SHOX/O diagnostics/O during/O a/O 10/O year/O period/O (/O 2004/O -/O 2014/O )/O ./O
Subsequently/O ,/O we/O characterized/O these/O alterations/O using/O MLPA/O (/O multiplex/O ligation/O -/O dependent/O probe/O amplification/O assay/O )/O ,/O fine/O -/O tiling/O array/O CGH/O (/O comparative/O genomic/O hybridation/O )/O and/O breakpoint/O PCR/O ./O
Nearly/O half/O of/O the/O alterations/O have/O a/O distal/O or/O proximal/O breakpoint/O in/O intron/O 3/O ./O
Evaluation/O of/O our/O data/O and/O that/O in/O the/O literature/O reveals/O that/O although/O partial/O deletions/O and/O duplications/O only/O account/O for/O a/O small/O fraction/O of/O SHOX/O alterations/O ,/O intron/O 3/O appears/O to/O be/O a/O breakpoint/O hotspot/O ,/O with/O alterations/O arising/O by/O non/O -/O allelic/O homologous/O recombination/O ,/O non/O -/O homologous/O end/O joining/O or/O other/O complex/O mechanisms/O ./O
VHL/O Germline/O Mutations/O in/O Argentinian/O Patients/O with/O Clinical/O Diagnoses/O or/O Single/O Typical/O Manifestations/O of/O Type/O 1/O von/O Hippel/O -/O Lindau/O Disease/O ./O
AIMS/O :/O von/B-Disease Hippel/I-Disease -/I-Disease Lindau/I-Disease (/O VHL/O )/O disease/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O VHL/B-Gene tumor/O suppressor/O gene/O ./O
As/O tumors/O that/O develop/O in/O the/O context/O of/O VHL/O also/O occur/O in/O a/O sporadic/O context/O ,/O the/O frequency/O of/O this/O syndrome/O may/O be/O underestimated/O ./O
Our/O aim/O was/O to/O identify/O VHL/O gene/O mutations/O in/O Argentinian/O patients/O who/O fulfilled/O the/O clinical/O criteria/O for/O type/O 1/O VHL/O disease/O and/O in/O patients/O with/O VHL/O -/O associated/O manifestations/O that/O did/O not/O meet/O these/O criteria/O ./O
METHODS/O :/O We/O performed/O a/O retrospective/O cohort/O study/O ,/O including/O patients/O who/O met/O current/O diagnostic/O criteria/O for/O type/O 1/O VHL/O (/O Group/O 1/O ,/O n/O =/O 19/O )/O and/O patients/O with/O VHL/O -/O associated/O manifestations/O that/O did/O not/O meet/O these/O criteria/O (/O Group/O 2/O ,/O n/O =/O 21/O )/O ./O
Genomic/O DNA/O was/O extracted/O from/O peripheral/O blood/O leukocytes/O ./O
Mutation/O analysis/O involved/O DNA/O sequencing/O ,/O while/O large/O deletions/O were/O determined/O by/O universal/O primer/O quantitative/O fluorescent/O multiplex/O polymerase/O chain/O reaction/O (/O UPQFM/O -/O PCR/O )/O and/O multiplex/O ligation/O -/O dependent/O probe/O amplification/O (/O MLPA/O )/O analysis/O ./O
RESULTS/O :/O VHL/O mutations/O were/O detected/O in/O 16/19/O (/O 84.2/O %/O )/O patients/O in/O Group/O 1/O and/O included/O :/O gross/O deletions/O (/O 4/16/O )/O ;/O nonsense/O mutations/O (/O 6/16/O )/O ;/O frameshift/O mutations/O (/O 4/16/O )/O ;/O missense/O mutations/O (/O 1/16/O )/O ;/O and/O splicing/O mutations/O (/O 1/16/O )/O ./O
Three/O of/O these/O mutations/O were/O novel/O ./O
No/O alterations/O were/O found/O in/O 3/O of/O 19/O VHL/O patients/O ./O
In/O Group/O 2/O ,/O one/O nonsense/O VHL/O mutation/O was/O detected/O in/O a/O young/O patient/O with/O a/O solitary/O central/O nervous/O system/O hemangioblastoma/O without/O familial/O history/O ./O
A/O study/O of/O 30/O first/O -/O degree/O relatives/O revealed/O four/O carriers/O with/O VHL/O mutations/O ./O
CONCLUSIONS/O :/O We/O found/O three/O novel/O mutations/O in/O the/O VHL/O gene/O in/O our/O population/O ./O
Our/O results/O emphasize/O the/O importance/O of/O a/O complete/O genetic/O study/O of/O VHL/O to/O confirm/O type/O 1/O VHL/O disease/O ,/O not/O only/O in/O patients/O with/O clinical/O diagnostic/O criteria/O but/O also/O in/O those/O presenting/O a/O single/O typical/O manifestation/O ./O
Dysferlin/O Gene/O Mutation/O Spectrum/O in/O a/O Large/O Cohort/O of/O Chinese/O Patients/O with/O Dysferlinopathy/O ./O
BACKGROUND/O :/O Dysferlinopathy/B-Disease is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O dysferlin/O (/B-Gene DYSF/I-Gene )/I-Gene gene/O ./O
Here/O ,/O we/O described/O the/O genetic/O features/O of/O a/O large/O cohort/O of/O Chinese/O patients/O with/O this/O disease/O ./O
METHODS/O :/O Eighty/O -/O nine/O index/O patients/O were/O included/O in/O the/O study/O ./O
DYSF/O gene/O analysis/O was/O performed/O by/O Sanger/O sequencing/O in/O 41/O patients/O and/O targeted/O next/O generation/O sequencing/O (/O NGS/O )/O in/O 48/O patients/O ./O
Multiplex/O ligation/O -/O dependent/O probe/O amplification/O (/O MLPA/O )/O was/O performed/O to/O detect/O exon/O duplication/O //O deletion/O in/O patients/O with/O only/O one/O pathogenic/O mutation/O ./O
RESULTS/O :/O Among/O the/O 89/O index/O patients/O ,/O 79/O patients/O were/O demonstrated/O to/O carry/O two/O disease/O -/O causing/O (/O 73/O cases/O )/O or/O possibly/O disease/O -/O causing/O mutations/O (/O 6/O cases/O )/O ,/O including/O 26/O patients/O with/O homozygous/O mutations/O ./O
We/O identified/O 105/O different/O mutations/O ,/O including/O 59/O novel/O ones/O ./O
Notably/O ,/O in/O 13/O patients/O in/O whom/O only/O one/O pathogenic/O mutation/O was/O initially/O found/O by/O Sanger/O sequencing/O or/O NGS/O ,/O 3/O were/O further/O identified/O to/O carry/O exon/O deletions/O by/O MLPA/O ./O
The/O mutations/O identified/O in/O this/O study/O appeared/O to/O cluster/O in/O the/O N/O -/O terminal/O region/O ./O
Mutation/O types/O included/O missense/O mutations/O (/O 30.06/O %/O )/O ,/O nonsense/O mutations/O (/O 17.18/O %/O )/O ,/O frameshift/O mutations/O (/O 30.67/O %/O )/O ,/O in/O -/O frame/O deletions/O (/O 2.45/O %/O )/O ,/O intronic/O mutations/O (/O 17.79/O %/O )/O ,/O and/O exonic/O rearrangement/O (/O 1.84/O %/O )/O ./O
No/O genotype/O -/O phenotype/O correlation/O was/O identified/O ./O
CONCLUSIONS/O :/O DYSF/O mutations/O in/O Chinese/O patients/O clustered/O in/O the/O N/O -/O terminal/O region/O of/O the/O gene/O ./O
Exonic/O rearrangements/O were/O found/O in/O 23/O %/O of/O patients/O with/O only/O one/O pathogenic/O mutation/O identified/O by/O Sanger/O sequencing/O or/O NGS/O ./O
The/O novel/O mutations/O found/O in/O this/O study/O greatly/O expanded/O the/O mutational/O spectrum/O of/O dysferlinopathy/O ./O
Whole/O -/O exome/O sequencing/O identifies/O multiple/O loss/O -/O of/O -/O function/O mutations/O of/O NF/O -/O κB/O pathway/O regulators/O in/O nasopharyngeal/O carcinoma/O ./O
Nasopharyngeal/O carcinoma/O (/O NPC/O )/O is/O an/O epithelial/O malignancy/O with/O a/O unique/O geographical/O distribution/O ./O
The/O genomic/O abnormalities/O leading/O to/O NPC/O pathogenesis/O remain/O unclear/O ./O
In/O total/O ,/O 135/O NPC/O tumors/O were/O examined/O to/O characterize/O the/O mutational/O landscape/O using/O whole/O -/O exome/O sequencing/O and/O targeted/O resequencing/O ./O
An/O APOBEC/O cytidine/O deaminase/O mutagenesis/O signature/O was/O revealed/O in/O the/O somatic/O mutations/O ./O
Noticeably/O ,/O multiple/O loss/O -/O of/O -/O function/O mutations/O were/O identified/O in/O several/O NF/O -/O κB/O signaling/O negative/O regulators/O NFKBIA/O ,/O CYLD/O ,/O and/O TNFAIP3/O Functional/O studies/O confirmed/O that/O inhibition/O of/O NFKBIA/O had/O a/O significant/O impact/O on/O NF/O -/O κB/O activity/O and/O NPC/O cell/O growth/O ./O
The/O identified/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O NFKBIA/B-Gene leading/O to/O protein/B-MPA truncation/I-MPA contributed/O to/O the/O altered/B-Reg NF/B-Pathway -/I-Pathway κB/I-Pathway activity/B-MPA ,/O which/O is/O critical/O for/O NPC/O tumorigenesis/O ./O
In/O addition/O ,/O somatic/O mutations/O were/O found/O in/O several/O cancer/O -/O relevant/O pathways/O ,/O including/O cell/O cycle/O -/O phase/O transition/O ,/O cell/O death/O ,/O EBV/O infection/O ,/O and/O viral/O carcinogenesis/O ./O
These/O data/O provide/O an/O enhanced/O road/O map/O for/O understanding/O the/O molecular/O basis/O underlying/O NPC/O ./O
ACOX2/O deficiency/O :/O A/O disorder/O of/O bile/O acid/O synthesis/O with/O transaminase/O elevation/O ,/O liver/O fibrosis/O ,/O ataxia/O ,/O and/O cognitive/O impairment/O ./O
Acyl/O CoA/O Oxidase/O 2/O (/O ACOX2/O )/O encodes/O branched/O -/O chain/O acyl/O -/O CoA/O oxidase/O ,/O a/O peroxisomal/O enzyme/O believed/O to/O be/O involved/O in/O the/O metabolism/O of/O branched/O -/O chain/O fatty/O acids/O and/O bile/O acid/O intermediates/O ./O
Deficiency/O of/O this/O enzyme/O has/O not/O been/O described/O previously/O ./O
We/O report/O an/O 8-y/O -/O old/O male/O with/O intermittently/O elevated/O transaminase/O levels/O ,/O liver/O fibrosis/O ,/O mild/O ataxia/O ,/O and/O cognitive/O impairment/O ./O
Exome/O sequencing/O revealed/O a/O previously/O unidentified/O homozygous/O premature/O termination/O mutation/O (/B-Var p/I-Var ./I-Var Y69/I-Var */I-Var )/I-Var in/O ACOX2/B-Gene Immunohistochemistry/O confirmed/O the/O absence/B-NegReg of/O ACOX2/B-Gene expression/B-MPA in/O the/O patient/O 's/O liver/O ,/O and/O biochemical/O analysis/O showed/O marked/O elevation/B-PosReg of/O intermediate/B-MPA bile/I-MPA acids/I-MPA upstream/O of/O ACOX2/O ./O
These/O findings/O define/O a/O potentially/O treatable/O inborn/O error/O of/O bile/O acid/O biosynthesis/O caused/O by/O ACOX2/O deficiency/O ./O
Prevalence/O and/O phenotypic/O characterization/O of/O MC4R/O variants/O in/O a/O large/O pediatric/O cohort/O ./O
OBJECTIVE/O :/O We/O aimed/O to/O determine/O the/O prevalence/O of/O melanocortin-4/O receptor/O (/O MC4R/O )/O variants/O in/O a/O large/O German/O cohort/O of/O children/O with/O obesity/O in/O a/O pediatric/O outpatient/O clinic/O and/O to/O ascertain/O whether/O there/O is/O a/O specific/O phenotype/O associated/O with/O loss/O -/O of/O -/O function/O variants/O as/O previously/O reported/O ./O
STUDY/O DESIGN/O :/O Eight/O hundred/O and/O ninety/O -/O nine/O patients/O from/O our/O pediatric/O obesity/O clinic/O were/O screened/O for/O MC4R/O variants/O by/O DNA/O sequencing/O after/O PCR/O amplification/O ./O
Retrospective/O statistical/O analysis/O of/O anthropometric/O and/O metabolic/O characteristics/O was/O performed/O ,/O comparing/O patients/O with/O and/O without/O MC4R/O variants/O across/O the/O entire/O cohort/O (/O n=586/O )/O as/O well/O as/O in/O case/O -/O control/O analysis/O using/O patients/O with/O common/O sequence/O MC4R/O individually/O matched/O for/O age/O ,/O sex/O and/O body/O mass/O index/O standard/O deviation/O score/O (/O SDS/O )/O (/O n=11/O case/O -/O control/O pairs/O )/O ./O
RESULTS/O :/O We/O identified/O heterozygous/O variants/O within/O the/O coding/O region/O of/O the/O MC4R/B-Gene gene/O in/O n=22/O (/O 2.45/O %/O )/O patients/O ./O
Fourteen/O (/O 1.56/O %/O )/O had/O a/O variant/B-Var that/O impaired/B-NegReg receptor/B-CPA function/I-CPA ./O
One/O new/O frameshift/O (/O p/O ./O F152Sfs/O )/O ,/O an/O yet/O unpublished/O nonsense/O mutation/O (/O p/O ./O Q156X/O )/O and/O one/O nonsynonymous/O variation/O (/O p/O ./O V65E/O )/O described/O in/O the/O Mouse/O Genome/O Database/O were/O detected/O ./O
Across/O the/O whole/O cohort/O ,/O at/O all/O ages/O ,/O mean/O height/O SDS/O in/O subjects/O with/O impaired/O receptor/O function/O was/O higher/O than/O in/O patients/O with/O common/O sequence/O MC4R./O In/O matched/O individuals/O ,/O this/O trend/O persisted/O (/O 8/O of/O the/O 11/O pairs/O )/O within/O the/O case/O -/O control/O setting/O ./O
No/O differences/O were/O found/O regarding/O metabolic/O characteristics/O ./O
CONCLUSIONS/O :/O The/O observed/O prevalence/O of/O mutations/O causing/O impaired/O receptor/O function/O in/O this/O large/O cohort/O is/O comparable/O to/O other/O pediatric/O cohorts/O ./O
MC4R/O deficiency/O tends/O to/O lead/O to/O a/O taller/O stature/O ,/O confirming/O previous/O clinical/O reports/O ./O
The/O association/O of/O MC4R/O mutations/O with/O a/O distinct/O phenotype/O concerning/O metabolic/O characteristics/O remains/O questionable/O ./O
Novel/O MBTPS2/B-Gene missense/B-Var mutation/I-Var causes/B-Reg a/O keratosis/B-Disease follicularis/I-Disease spinulosa/I-Disease decalvans/I-Disease phenotype/O :/O mutation/O update/O and/O review/O of/O the/O literature/O ./O
Keratosis/B-Disease follicularis/I-Disease spinulosa/I-Disease decalvans/I-Disease (/O KFSD/O )/O is/O an/O X/O -/O linked/O condition/O characterized/O by/O keratotic/O follicular/O papules/O and/O progressive/O alopecia/O ,/O which/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O MBTPS2/B-Gene gene/O ./O
We/O carried/O out/O a/O genetic/O study/O on/O a/O child/O who/O was/O suspected/O clinically/O to/O have/O KFSD/O ./O
Sanger/O sequencing/O was/O performed/O to/O detect/O mutations/O in/O the/O entire/O coding/O region/O of/O MBTPS2/O ./O
A/O novel/O missense/O mutation/O (/B-Var c.599C/I-Var >/I-Var T/I-Var )/I-Var was/O identified/O in/O the/O patient/O ,/O confirming/B-Reg a/O diagnosis/O of/O KFSD/B-Disease ./O
We/O reviewed/O related/O cases/O with/O MBTPS2/O mutations/O for/O evidence/O of/O genotype/O -/O phenotype/O correlations/O ./O
Temperature/O -/O dependent/O autoimmunity/O mediated/O by/O chs1/O requires/O its/O neighboring/O TNL/O gene/O SOC3/O ./O
Toll/O //O interleukin/O receptor/O (/O TIR)-nucleotide/O binding/O site/O (/O NB)-type/O (/O TN/O )/O proteins/O are/O encoded/O by/O a/O family/O of/O 21/O genes/O in/O the/O Arabidopsis/O genome/O ./O
Previous/O studies/O have/O shown/O that/O a/O mutation/O in/O the/O TN/O gene/O CHS1/O activates/O the/O activation/O of/O defense/O responses/O at/O low/O temperatures/O ./O
However/O ,/O the/O underlying/O molecular/O mechanism/O remains/O unknown/O ./O
To/O genetically/O dissect/O chs1-mediated/O signaling/O ,/O we/O isolated/O genetic/O suppressors/O of/O chs1/O -/O 2/O (/O soc/O )/O ./O
Several/O independent/O soc/O mutants/O carried/O mutations/O in/O the/O same/O TIR/O -/O NB/O -/O leucine/O -/O rich/O repeat/O (/O LRR/O )/O (/O TNL)-encoding/O gene/O SOC3/O ,/O which/O is/O adjacent/O to/O CHS1/O on/O chromosome/O 1/O ./O
Expression/B-MPA of/O SOC3/B-Gene was/O upregulated/B-PosReg in/O the/O chs1/B-Gene -/I-Gene 2/I-Gene mutant/B-Var ./O
Mutations/O in/O six/O soc3/O alleles/O and/O downregulation/O of/O SOC3/O by/O an/O artificial/O microRNA/O construct/O fully/O rescued/O the/O chilling/O sensitivity/O and/O defense/O defects/O of/O chs1/O -/O 2/O ./O
Biochemical/O studies/O showed/O that/O CHS1/O interacted/O with/O the/O NB/O and/O LRR/O domains/O of/O SOC3/O ;/O however/O ,/O mutated/O chs1/O interacted/O with/O the/O TIR/O ,/O NB/O and/O LRR/O domains/O of/O SOC3/O in/O vitro/O and/O in/O vivo/O ./O
This/O study/O reveals/O that/O the/O TN/O protein/O CHS1/O interacts/O with/O the/O TNL/O protein/O SOC3/O to/O modulate/O temperature/O -/O dependent/O autoimmunity/O ./O
INPPL1/B-Gene gene/O mutations/B-Var in/B-Reg opsismodysplasia/B-Disease ./O
The/O INPPL1/O (/O inositol/O polyphosphate/O phosphatase/O -/O like/O 1/O )/O gene/O encodes/O the/O inositol/O phosphatase/O ,/O SHIP2/O (/O for/O src/O homology/O 2/O domain/O -/O containing/O inositol/O phosphatase/O 2/O )/O ./O
SHIP2/O functions/O to/O dephosphorylate/O ,/O and/O negatively/O regulate/O ,/O the/O lipid/O second/O messenger/O phosphatidylinositol/O (/O 3,4,5)P3/O ./O
SHIP2/O has/O been/O well/O studied/O in/O the/O area/O of/O insulin/O resistance/O and/O obesity/O but/O has/O roles/O in/O cancer/O and/O other/O disorders/O ./O
Recently/O ,/O it/O was/O reported/O that/O mutations/B-Var in/O INPPL1/B-Gene cause/B-Reg opsismodysplasia/B-Disease ,/O a/O rare/O ,/O autosomal/O recessive/O severe/O skeletal/O dysplasia/O ./O
This/O review/O focuses/O on/O the/O mutations/O associated/O with/O opsismodysplasia/O and/O explores/O the/O role/O of/O INPPL1//O SHIP2/O in/O skeletal/O development/O ./O
Genetic/O screening/O of/O the/O FLCN/O gene/O identify/O six/O novel/O variants/O and/O a/O Danish/O founder/O mutation/O ./O
Pathogenic/O germline/O mutations/B-Var in/O the/O folliculin/O (/B-Gene FLCN/I-Gene )/I-Gene tumor/O suppressor/O gene/O predispose/O to/B-Reg Birt/B-Disease -/I-Disease Hogg/I-Disease -/I-Disease Dubé/I-Disease (/O BHD/O )/O syndrome/O ,/O a/O rare/O disease/O characterized/O by/O the/O development/O of/O cutaneous/O hamartomas/O (/O fibrofolliculomas/O )/O ,/O multiple/O lung/O cysts/O ,/O spontaneous/O pneumothoraces/O and/O renal/O cell/O cancer/O ./O
In/O this/O study/O ,/O we/O report/O the/O identification/O of/O 13/O variants/O and/O three/O polymorphisms/O in/O the/O FLCN/O gene/O in/O 143/O Danish/O patients/O or/O families/O with/O suspected/O BHD/O syndrome/O ./O
Functional/O mini/O -/O gene/O splicing/O analysis/O revealed/O that/O two/O intronic/O variants/O (/O c.1062/O +/O 2T/O >/O G/O and/O c.1177/O -/O 5_1177/O -/O 3del/O )/O introduced/O splicing/O aberrations/O ./O
Eleven/O families/O exhibited/O the/O c.1062/O +/O 2T/O >/O G/O mutation/O ./O
Combined/O single/O nucleotide/O polymorphism/O array/O -/O haplotype/O analysis/O showed/O that/O these/O families/O share/O a/O 3-Mb/O genomic/O fragment/O containing/O the/O FLCN/O gene/O ,/O revealing/O that/O the/O c.1062/O +/O 2T/O >/O G/O mutation/O is/O a/O Danish/O founder/O mutation/O ./O
On/O the/O basis/O of/O in/O silico/O prediction/O and/O functional/O splicing/O assays/O ,/O we/O classify/O the/O 16/O identified/O variants/O in/O the/O FLCN/O gene/O as/O follows/O :/O nine/O as/O pathogenic/O ,/O one/O as/O likely/O pathogenic/O ,/O three/O as/O likely/O benign/O and/O three/O as/O polymorphisms/O ./O
In/O conclusion/O ,/O the/O study/O describes/O the/O FLCN/O mutation/O spectrum/O in/O Danish/O BHD/O patients/O ,/O and/O contributes/O to/O a/O better/O understanding/O of/O BHD/O syndrome/O and/O management/O of/O BHD/O patients/O ./O
Structural/O brain/O abnormalities/O in/O a/O single/O gene/O disorder/O associated/O with/O epilepsy/O ,/O language/O impairment/O and/O intellectual/O disability/O ./O
Childhood/O speech/O and/O language/O deficits/O are/O highly/O prevalent/O and/O are/O a/O common/O feature/O of/O neurodevelopmental/O disorders/O ./O
However/O ,/O it/O is/O difficult/O to/O investigate/O the/O underlying/O causal/O pathways/O because/O many/O diagnostic/O groups/O have/O a/O heterogeneous/O aetiology/O ./O
Studying/O disorders/O with/O a/O shared/O genetic/O cause/O and/O shared/O cognitive/O deficits/O can/O provide/O crucial/O insight/O into/O the/O cellular/O mechanisms/O and/O neural/O systems/O that/O give/O rise/O to/O those/O impairments/O ./O
The/O current/O study/O investigated/O structural/O brain/O differences/O of/O individuals/O with/O mutations/B-Var in/O ZDHHC9/B-Gene ,/O which/O is/O associated/B-Reg with/I-Reg a/O specific/O neurodevelopmental/O phenotype/O including/O prominent/O speech/B-Disease and/I-Disease language/I-Disease impairments/I-Disease and/O intellectual/B-Disease disability/I-Disease ./O
We/O used/O multiple/O structural/O neuroimaging/O methods/O to/O characterise/O neuroanatomy/O in/O this/O group/O ,/O and/O observed/O bilateral/O reductions/O in/O cortical/O thickness/O in/O areas/O surrounding/O the/O temporo/O -/O parietal/O junction/O ,/O parietal/O lobule/O ,/O and/O inferior/O frontal/O lobe/O ,/O and/O decreased/O microstructural/O integrity/O of/O cortical/O ,/O subcortical/O -/O cortical/O ,/O and/O interhemispheric/O white/O matter/O projections/O ./O
These/O findings/O are/O compared/O to/O reports/O for/O other/O genetic/O groups/O and/O genetically/O heterogeneous/O disorders/O with/O a/O similar/O presentation/O ./O
Overlap/O in/O the/O neuroanatomical/O phenotype/O suggests/O a/O common/O pathway/O that/O particularly/O affects/O the/O development/O of/O temporo/O -/O parietal/O and/O inferior/O frontal/O areas/O ,/O and/O their/O connections/O ./O
Pharmacological/O Chaperoning/O :/O A/O Potential/O Treatment/O for/O PMM2-CDG/O ./O
The/O congenital/B-Disease disorder/I-Disease of/I-Disease glycosylation/I-Disease (/I-Disease CDG/I-Disease )/I-Disease due/I-Disease to/I-Disease phosphomannomutase/I-Disease 2/I-Disease deficiency/I-Disease (/O PMM2-CDG/O )/O ,/O the/O most/O common/O N/O -/O glycosylation/O disorder/O ,/O is/O a/O multisystem/O disease/O for/O which/O no/O effective/O treatment/O is/O available/O ./O
The/O recent/O functional/O characterization/O of/O disease/O -/O causing/O mutations/O described/O in/O patients/O with/O PMM2-CDG/B-Disease led/O to/O the/O idea/O of/O a/O therapeutic/O strategy/O involving/O pharmacological/O chaperones/O (/O PC/O )/O to/O rescue/O PMM2/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var ./O
The/O present/O work/O describes/O the/O high/O -/O throughput/O screening/O ,/O by/O differential/O scanning/O fluorimetry/O ,/O of/O 10,000/O low/O -/O molecular/O -/O weight/O compounds/O from/O a/O commercial/O library/O ,/O to/O search/O for/O possible/O PCs/O for/O the/O enzyme/O PMM2/O ./O
This/O exercise/O identified/O eight/O compounds/O that/O increased/O the/O thermal/O stability/O of/O PMM2/O ./O
Of/O these/O ,/O four/O compounds/O functioned/O as/O potential/O PCs/O that/O significantly/O increased/O the/O stability/O of/O several/O destabilizing/O and/O oligomerization/O mutants/O and/O also/O increased/O PMM/O activity/O in/O a/O disease/O model/O of/O cells/O overexpressing/O PMM2/O mutations/O ./O
Structural/O analysis/O revealed/O one/O of/O these/O compounds/O to/O provide/O an/O excellent/O starting/O point/O for/O chemical/O optimization/O since/O it/O passed/O tests/O based/O on/O a/O number/O of/O pharmacochemical/O quality/O filters/O ./O
The/O present/O results/O provide/O the/O first/O proof/O -/O of/O -/O concept/O of/O a/O possible/O treatment/O for/O PMM2-CDG/O and/O describe/O a/O promising/O chemical/O structure/O as/O a/O starting/O point/O for/O the/O development/O of/O new/O therapeutic/O agents/O for/O this/O severe/O orphan/O disease/O ./O
Subtypes/O of/O SERPINC1/O mutations/O and/O the/O thrombotic/O phenotype/O of/O inherited/O antithrombin/O deficient/O individuals/O in/O Chinese/O Han/O population/O ./O
Inherited/B-Disease antithrombin/I-Disease (/I-Disease AT/I-Disease )/I-Disease deficiency/I-Disease is/O a/O rare/O autosomal/O disease/O that/O could/O increase/O the/O risk/O of/O venous/O thromboembolism/O (/O VTE/O )/O and/O usually/O caused/B-Reg by/I-Reg mutations/B-Var of/O SERPINC1/B-Gene ./O
Although/O a/O number/O of/O mutations/O of/O SERPINC1/O have/O been/O reported/O in/O Chinese/O Han/O population/O ,/O the/O impact/O of/O different/O subtypes/O of/O these/O mutations/O on/O the/O thrombotic/O phenotype/O is/O still/O unknown/O ./O
Here/O ,/O we/O performed/O a/O retrospective/O cohort/O study/O including/O 169/O AT/O patients/O from/O 63/O families/O to/O compare/O the/O clinical/O features/O between/O null/O mutation/O carriers/O and/O missense/O mutation/O carriers/O ./O
We/O found/O that/O patients/O carrying/O null/O mutations/O have/O a/O higher/O risk/O of/O VTE/O (/O HR/O 2.29/O ,/O 95/O %/O CI/O 1.16/O -/O 4.69/O ,/O P=0.02/O adjusted/O for/O sex/O and/O VTE/O family/O history/O )/O and/O earlier/O median/O onset/O age/O of/O VTE/O (/O 27/O vs./O 32years/O ,/O P=0.045/O )/O as/O well/O as/O lower/O AT/O activities/O (/O 47.6±1.0/O %/O vs./O 59.1±2.3/O %/O ,/O P<0.001/O )/O than/O those/O with/O missense/O mutations/O ./O
We/O also/O observed/O that/O thrombus/O location/O sites/O showed/O no/O difference/O between/O null/O mutation/O carriers/O and/O missense/O mutation/O carriers/O ,/O gene/O locations/O of/O the/O mutations/O did/O not/O relate/O with/O the/O incidence/O rate/O of/O VTE/O ./O
This/O study/O demonstrated/O that/O different/O types/O of/O SERPINC1/O mutations/O may/O play/O different/O roles/O in/O the/O development/O of/O VTE/O and/O should/O be/O considered/O in/O the/O prevention/O of/O VTE/O ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg of/O an/O Arabidopsis/O NADPH/B-Enzyme pyrophosphohydrolase/I-Enzyme ,/O AtNUDX19/O ,/O impacts/B-Reg on/O the/O pyridine/B-MPA nucleotides/I-MPA status/I-MPA and/O confers/B-PosReg photooxidative/B-CPA stress/I-CPA tolerance/I-CPA ./O
The/O levels/O and/O redox/O states/O of/O pyridine/O nucleotides/O ,/O such/O as/O NADP(H/O )/O ,/O regulate/O the/O cellular/O redox/O homeostasis/O ,/O which/O is/O crucial/O for/O photooxidative/O stress/O response/O in/O plants/O ./O
However/O ,/O how/O they/O are/O controlled/O is/O poorly/O understood/O ./O
An/O Arabidopsis/O Nudix/O hydrolase/O ,/O AtNUDX19/O ,/O was/O previously/O identified/O to/O have/O NADPH/O hydrolytic/O activity/O in/O vitro/O ,/O suggesting/O this/O enzyme/O to/O be/O a/O regulator/O of/O the/O NADPH/O status/O ./O
We/O herein/O examined/O the/O physiological/O role/O of/O AtNUDX19/B-Gene using/O its/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutants/B-Var ./O
NADPH/B-CPA levels/I-CPA were/O increased/B-PosReg in/O nudx19/B-Gene mutants/B-Var under/O both/O normal/O and/O high/O light/O conditions/O ,/O while/O NADP(+/B-MPA )/I-MPA and/O NAD(+/B-MPA )/I-MPA levels/I-MPA were/O decreased/B-PosReg ./O
Despite/O the/O high/O redox/O states/O of/O NADP(H/O )/O ,/O nudx19/O mutants/O exhibited/O high/O tolerance/O to/O moderate/O light-/O or/O methylviologen/O -/O induced/O photooxidative/O stresses/O ./O
This/O tolerance/O might/O be/O partially/O attributed/O to/O the/O activation/O of/O either/O or/O both/O photosynthesis/O and/O the/O antioxidant/O system/O ./O
Furthermore/O ,/O a/O microarray/O analysis/O suggested/O the/O role/O of/O ANUDX19/O in/O regulation/O of/O the/O salicylic/O acid/O (/O SA/O )/O response/O in/O a/O negative/O manner/O ./O
Indeed/O ,/O nudx19/O mutants/O accumulated/O SA/O and/O showed/O high/O sensitivity/O to/O the/O hormone/O ./O
Our/O findings/O demonstrate/O that/O ANUDX19/O acts/O as/O an/O NADPH/O pyrophosphohydrolase/O to/O modulate/O cellular/O levels/O and/O redox/O states/O of/O pyridine/O nucleotides/O and/O fine/O -/O tunes/O photooxidative/O stress/O response/O through/O the/O regulation/O of/O photosynthesis/O ,/O antioxidant/O system/O ,/O and/O possibly/O hormonal/O signaling/O ./O
Compound/O heterozygous/O LDLR/O variant/O in/O severely/O affected/O familial/O hypercholesterolemia/O patient/O ./O
Familial/B-Disease hypercholesterolemia/I-Disease (/O FH/O )/O is/O most/O commonly/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O LDL/O receptor/O (/B-Gene LDLR/I-Gene )/I-Gene ,/O which/O is/O responsible/O for/O hepatic/O clearance/O of/O LDL/O from/O the/O blood/O circulation/O ./O
We/O described/O a/O severely/O affected/O FH/O proband/O and/O their/O first/O -/O degree/O blood/O relatives/O ;/O the/O proband/O was/O resistant/O to/O statin/O therapy/O and/O was/O managed/O on/O an/O LDL/O apheresis/O program/O ./O
In/O order/O to/O find/O the/O causative/O genetic/O variant/O in/O this/O family/O ,/O direct/O exon/O sequencing/O of/O the/O LDLR/O ,/O APOB/O and/O PCSK9/O genes/O was/O performed/O ./O
We/O identified/O a/O compound/O heterozygous/O mutation/O in/O the/O proband/O with/O missense/O p.(W577C/O )/O and/O frameshift/O p.(G676Afs33/O )/O variants/O at/O exons/O 12/O and/O 14/O of/O the/O LDLR/O gene/O respectively/O ./O
DNA/O sequencing/O of/O LDLR/O gene/O from/O the/O parents/O demonstrated/O that/O the/O missense/O variant/O was/O inherited/O from/O the/O mother/O and/O frameshift/O variant/O was/O inherited/O from/O the/O father/O ./O
The/O frameshift/B-Var variant/I-Var resulted/O in/O a/O stop/B-MPA signal/I-MPA 33/I-MPA codons/I-MPA downstream/I-MPA of/O the/O deletion/B-NegReg ,/O which/O most/O likely/O led/O to/O a/O truncated/B-Protein protein/I-Protein that/O lacks/B-NegReg important/B-MPA functional/I-MPA domains/I-MPA ,/O including/O the/O trans/O -/O membrane/O domain/O and/O the/O cytoplasmic/O tail/O domain/O ./O
The/O missense/O variant/O is/O also/O predicted/O to/O be/O likely/O pathogenic/O and/O affect/O EGF/O -/O precursor/O homology/O domain/O of/O the/O LDLR/O protein/O ./O
The/O segregation/O pattern/O of/O the/O variants/O was/O consistent/O with/O the/O lipid/O profile/O ,/O suggesting/O a/O more/O severe/O FH/O phenotype/O when/O the/O variants/O are/O in/O the/O compound/O heterozygous/O state/O ./O
The/O finding/O of/O a/O compound/O heterozygous/O mutation/O causing/O severe/O FH/O phenotype/O is/O important/O for/O the/O genotype/O -/O phenotype/O correlation/O and/O also/O enlarges/O the/O spectrum/O of/O FH/O -/O causative/O LDLR/O variants/O in/O the/O Arab/O population/O ,/O including/O the/O Saudi/O population/O ./O
Activity/O of/O NaV1.2/O promotes/O neurodegeneration/O in/O an/O animal/O model/O of/O multiple/O sclerosis/O ./O
Counteracting/O the/O progressive/O neurological/O disability/O caused/O by/O neuronal/O and/O axonal/O loss/O is/O the/O major/O unmet/O clinical/O need/O in/O multiple/O sclerosis/O therapy/O ./O
However/O ,/O the/O mechanisms/O underlying/O irreversible/O neuroaxonal/O degeneration/O in/O multiple/O sclerosis/O and/O its/O animal/O model/O experimental/O autoimmune/O encephalomyelitis/O (/O EAE/O )/O are/O not/O well/O understood/O ./O
A/O long/O -/O standing/O hypothesis/O holds/O that/O the/O distribution/O of/O voltage/O -/O gated/O sodium/O channels/O along/O demyelinated/O axons/O contributes/O to/O neurodegeneration/O by/O increasing/O neuroaxonal/O sodium/O influx/O and/O energy/O demand/O during/O CNS/O inflammation/O ./O
Here/O ,/O we/O tested/O this/O hypothesis/O in/O vivo/O by/O inserting/O a/O human/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutation/B-Var in/O the/O mouse/O NaV1.2-encoding/O gene/O Scn2a/B-Gene that/O is/O known/O to/O increase/O NaV1.2-mediated/O persistent/O sodium/O currents/O ./O
In/O mutant/O mice/O ,/O CNS/B-CPA inflammation/I-CPA during/I-CPA EAE/I-CPA leads/O to/O elevated/B-PosReg neuroaxonal/B-CPA degeneration/I-CPA and/O increased/B-PosReg disability/B-CPA and/O lethality/B-CPA compared/O with/O wild/O -/O type/O littermate/O controls/O ./O
Importantly/O ,/O immune/O cell/O infiltrates/O were/O not/O different/O between/O mutant/O EAE/O mice/O and/O wild/O -/O type/O EAE/O mice/O ./O
Thus/O ,/O this/O study/O shows/O that/O increased/O neuronal/O NaV1.2/O activity/O exacerbates/O inflammation/O -/O induced/O neurodegeneration/O irrespective/O of/O immune/O cell/O alterations/O and/O identifies/O NaV1.2/O as/O a/O promising/O neuroprotective/O drug/O target/O in/O multiple/O sclerosis/O ./O
Exome/O sequencing/O reveals/O germline/O gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg EGFR/B-Gene mutation/B-Var in/O an/O adult/O with/O Lhermitte/B-Disease -/I-Disease Duclos/I-Disease disease/I-Disease ./O
Lhermitte/B-Disease -/I-Disease Duclos/I-Disease disease/I-Disease (/O LDD/O )/O is/O a/O rare/O cerebellar/O disorder/O believed/O to/O be/O pathognomonic/O for/O Cowden/O syndrome/O ./O
Presently/O ,/O the/O only/O known/O etiology/B-Reg is/O germline/O PTEN/B-Gene mutation/B-Var ./O
We/O report/O a/O 41-yr/O -/O old/O white/O female/O diagnosed/O with/O LDD/O and/O wild/O -/O type/O for/O PTEN/O ./O
Exome/O sequencing/O revealed/O a/O germline/O heterozygous/O EGFR/B-Gene mutation/B-Var that/O breaks/B-NegReg a/O disulfide/B-MPA bond/I-MPA in/I-MPA the/I-MPA receptor/I-MPA 's/I-MPA extracellular/I-MPA domain/I-MPA ,/O resulting/O in/O constitutive/B-MPA activation/B-PosReg ./O
Functional/O studies/O demonstrate/O activation/B-PosReg of/O ERK/B-Pathway //I-Pathway AKT/I-Pathway signaling/I-Pathway pathways/I-Pathway ,/O mimicking/O PTEN/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg downstream/O effects/O ./O
The/O identification/O of/O EGFR/O as/O a/O candidate/O LDD/O susceptibility/O gene/O contributes/O to/O advancement/O of/O molecular/O diagnosis/O and/O targeted/O therapy/O for/O this/O rare/O condition/O with/O limited/O treatment/O options/O ./O
GBA2/B-Gene Mutations/B-Var Cause/B-Reg a/O Marinesco/B-Disease -/I-Disease Sjögren/I-Disease -/I-Disease Like/I-Disease Syndrome/I-Disease :/I-Disease Genetic/O and/O Biochemical/O Studies/O ./O
BACKGROUND/O :/O With/O the/O advent/O new/O sequencing/O technologies/O ,/O we/O now/O have/O the/O tools/O to/O understand/O the/O phenotypic/O diversity/O and/O the/O common/O occurrence/O of/O phenocopies/O ./O
We/O used/O these/O techniques/O to/O investigate/O two/O Norwegian/O families/O with/O an/O autosomal/O recessive/O cerebellar/O ataxia/O with/O cataracts/O and/O mental/O retardation/O ./O
METHODS/O AND/O RESULTS/O :/O Single/O nucleotide/O polymorphism/O (/O SNP/O )/O chip/O analysis/O followed/O by/O Exome/O sequencing/O identified/O a/O 2/O bp/O homozygous/O deletion/O in/O GBA2/O in/O both/O families/O ,/O c.1528_1529del/B-Var [/O p/O ./O Met510Valfs*17/O ]/O ./O
Furthermore/O ,/O we/O report/O the/O biochemical/O characterization/O of/O GBA2/O in/O these/O patients/O ./O
Our/O studies/O show/O that/O a/O reduced/B-NegReg activity/B-MPA of/O GBA2/B-Gene is/O sufficient/O to/O elevate/B-PosReg the/O levels/B-MPA of/O glucosylceramide/B-MPA to/O similar/O levels/O as/O seen/O in/O Gaucher/O disease/O ./O
Furthermore/O ,/O leucocytes/O seem/O to/O be/O the/O proper/O enzyme/O source/O for/O in/O vitro/O analysis/O of/O GBA2/O activity/O ./O
CONCLUSIONS/O :/O We/O report/O GBA2/B-Gene mutations/B-Var causing/B-Reg a/O Marinesco/B-Disease -/I-Disease Sjögren/I-Disease -/I-Disease like/I-Disease syndrome/I-Disease in/O two/O Norwegian/O families/O ./O
One/O of/O the/O families/O was/O originally/O diagnosed/O with/O Marinesco/O -/O Sjögren/O syndrome/O based/O on/O an/O autosomal/O recessive/O cerebellar/O ataxia/O with/O cataracts/O and/O mental/O retardation/O ./O
Our/O findings/O highlight/O the/O phenotypic/O variability/O associated/O with/O GBA2/O mutations/O ,/O and/O suggest/O that/O patients/O with/O Marinesco/O -/O Sjögren/O -/O like/O syndromes/O should/O be/O tested/O for/O mutations/O in/O this/O gene/O ./O
Compound/O Heterozygosity/O for/O Null/B-Var Mutations/I-Var and/O a/O Common/O Hypomorphic/O Risk/O Haplotype/O in/O TBX6/B-Gene Causes/B-Reg Congenital/B-Disease Scoliosis/I-Disease ./O
Congenital/O scoliosis/O (/O CS/O )/O occurs/O as/O a/O result/O of/O vertebral/O malformations/O and/O has/O an/O incidence/O of/O 0.5/O -/O 1/1,000/O births/O ./O
Recently/O ,/O TBX6/O on/O chromosome/O 16p11.2/O was/O reported/O as/O a/O disease/O gene/O for/O CS/O ;/O about/O 10/O %/O of/O Chinese/O CS/O patients/O were/O compound/O heterozygotes/O for/O rare/O null/O mutations/O and/O a/O common/O haplotype/O defined/O by/O three/O SNPs/O in/O TBX6/O ./O
All/O patients/O had/O hemivertebrae/O ./O
We/O recruited/O 94/O Japanese/O CS/O patients/O ,/O investigated/O the/O TBX6/O locus/O for/O both/O mutations/O and/O the/O risk/O haplotype/O ,/O examined/O transcriptional/O activities/O of/O mutant/O TBX6/O in/O vitro/O ,/O and/O evaluated/O clinical/O and/O radiographic/O features/O ./O
We/O identified/O TBX6/O null/O mutations/O in/O nine/O patients/O ,/O including/O a/O missense/O mutation/O that/O had/O a/O loss/O of/O function/O in/O vitro/O ./O
All/O had/O the/O risk/O haplotype/O in/O the/O opposite/O allele/O ./O
One/O of/O the/O mutations/O showed/O dominant/O negative/O effect/O ./O
Although/O all/O Chinese/O patients/O had/O one/O or/O more/O hemivertebrae/O ,/O two/O Japanese/O patients/O did/O not/O have/O hemivertebra/O ./O
The/O compound/O heterozygosity/O of/O null/O mutations/O and/O the/O common/O risk/O haplotype/O in/O TBX6/O also/O causes/O CS/O in/O Japanese/O patients/O with/O similar/O incidence/O ./O
Hemivertebra/O was/O not/O a/O specific/O type/O of/O spinal/O malformation/O in/O TBX6-associated/O CS/O (/O TACS/O )/O ./O
A/O heterozygous/O TBX6/B-Gene loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/B-Var has/O been/O reported/O in/O a/O family/O with/O autosomal/B-Disease -/I-Disease dominant/I-Disease spondylocostal/I-Disease dysostosis/I-Disease ,/O but/O it/O may/O represent/O a/O spectrum/O of/O the/O same/O disease/O with/O TACS/O ./O
Aspartylglucosaminuria/B-Disease caused/B-Reg by/I-Reg a/O novel/O homozygous/O mutation/B-Var in/O the/O AGA/B-Gene gene/O was/O identified/O by/O an/O exome/O -/O first/O approach/O in/O a/O patient/O from/O Japan/O ./O
BACKGROUND/O :/O Aspartylglucosaminuria/O (/O AGU/O )/O is/O an/O autosomal/O recessive/O lysosomal/O storage/O disorder/O caused/O by/O a/O deficiency/O of/O the/O lysosomal/O enzyme/O ,/O aspartylglucosaminidase/O (/O AGA/O )/O ./O
This/O disorder/O is/O rare/O in/O the/O general/O population/O except/O in/O Finland/O ./O
Since/O the/O most/O characteristic/O feature/O of/O this/O disorder/O is/O a/O progressive/O developmental/O regression/O ,/O patients/O often/O show/O no/O specific/O symptoms/O in/O the/O initial/O stages/O ,/O and/O thus/O early/O diagnosis/O is/O often/O challenging/O ./O
CASE/O REPORT/O :/O We/O encountered/O a/O 16-year/O -/O old/O boy/O who/O began/O to/O show/O difficulties/O in/O his/O speech/O at/O the/O age/O of/O 6years/O ./O
Due/O to/O a/O mild/O regression/O in/O his/O development/O ,/O he/O gradually/O lost/O common/O daily/O abilities/O ./O
His/O diagnosis/O was/O first/O obtained/O through/O exome/O sequencing/O that/O identified/O a/O novel/O homozygous/O mutation/O in/O the/O AGA/O gene/O ./O
This/O result/O was/O reasonable/O because/O of/O parental/O consanguinity/O ./O
Reduced/O enzymatic/O activity/O of/O AGA/O was/O then/O confirmed/O ./O
His/O urine/O was/O retrospectively/O screened/O by/O matrix/O -/O assisted/O laser/O desorption/O //O ionization/O time/O -/O of/O -/O flight/O mass/O spectrometry/O (/O MALDI/O -/O TOF/O -/O MS/O )/O and/O a/O specific/O pattern/O of/O abnormal/O metabolites/O was/O identified/O ./O
CONCLUSIONS/O :/O Because/O both/O exome/O sequencing/O and/O MALDI/O -/O TOF/O -/O MS/O screening/O are/O adaptable/O and/O comprehensive/O ,/O future/O combinatory/O use/O of/O these/O methods/O would/O be/O useful/O for/O diagnosis/O of/O rare/O inborn/O errors/O of/O metabolism/O such/O as/O AGU/O ./O
WT1/O Haploinsufficiency/O Supports/O Milder/O Renal/O Manifestation/O in/O Two/O Patients/O with/O Denys/O -/O Drash/O Syndrome/O ./O
Denys/B-Disease -/I-Disease Drash/I-Disease syndrome/I-Disease (/O DDS/O )/O is/O characterized/O by/O nephropathy/O ,/O genital/O abnormalities/O ,/O and/O predisposition/O to/O Wilms/O '/O tumor/O ./O
DDS/O patients/O usually/O present/B-Reg heterozygous/O de/O novo/O germline/O WT1/B-Gene mutations/B-Var ./O
The/O WT1/O gene/O comprises/O 10/O exons/O encoding/O the/O N/O -/O terminal/O transactivation/O and/O the/O C/O -/O terminal/O DNA/O -/O binding/O regions/O ./O
Two/O unrelated/O patients/O with/O genital/O ambiguity/O and/O Wilms/O '/O tumor/O were/O analyzed/O by/O sequencing/O of/O the/O WT1/O gene/O ,/O and/O 3/O mutations/O in/O exon/O 1/O were/O identified/O of/O which/O 2/O are/O novel/O ./O
Patient/O 1/O carried/O a/O c.555delC/B-Var mutation/O that/O causes/B-Reg a/O frameshift/B-Var and/O a/O premature/B-MPA stop/I-MPA codon/O ./O
Patient/O 2/O carried/O both/O c.421A/B-Var >/I-Var C/I-Var and/O c.424C/B-Var >/I-Var T/I-Var aberrations/O that/O lead/B-Reg to/I-Reg the/O missense/O p/B-Var ./I-Var Lys141Gln/I-Var and/O the/O nonsense/O p/B-Var ./I-Var Lys142/I-Var */I-Var mutation/O ,/O respectively/O ./O
As/O both/O patients/O were/O heterozygous/O for/O the/O mutations/O ,/O we/O tested/O their/O parents/O who/O did/O not/O carry/O any/O mutation/O ./O
Therefore/O ,/O the/O 3/O WT1/O mutations/O occurred/O de/O novo/O in/O both/O patients/O ./O
Heterozygous/O mutations/B-Var result/O in/O WT1/B-Gene haploinsufficiency/O as/O they/O impair/B-NegReg protein/B-Protein production/B-MPA ./O
They/O are/O associated/O with/O a/O milder/O DDS/O phenotype/O as/O observed/O in/O the/O patients/O studied/O here/O ./O
Delineating/O the/O phenotypic/O spectrum/O of/O Bainbridge/B-Disease -/I-Disease Ropers/I-Disease syndrome/I-Disease :/I-Disease 12/O new/O patients/O with/O de/O novo/O ,/O heterozygous/O ,/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O ASXL3/B-Gene and/O review/O of/O published/O literature/O ./O
BACKGROUND/O :/O Bainbridge/B-Disease -/I-Disease Ropers/I-Disease syndrome/I-Disease (/O BRPS/O )/O is/O a/O recently/O described/O developmental/O disorder/O caused/B-Reg by/I-Reg de/O novo/O truncating/B-Var mutations/I-Var in/O the/O additional/O sex/O combs/O like/O 3/O (/B-Gene ASXL3/I-Gene )/I-Gene gene/O ./O
To/O date/O ,/O there/O have/O been/O fewer/O than/O 10/O reported/O patients/O ./O
OBJECTIVES/O :/O Here/O ,/O we/O delineate/O the/O BRPS/O phenotype/O further/O by/O describing/O a/O series/O of/O 12/O previously/O unreported/O patients/O identified/O by/O the/O Deciphering/O Developmental/O Disorders/O study/O ./O
METHODS/O :/O Trio/O -/O based/O exome/O sequencing/O was/O performed/O on/O all/O 12/O patients/O included/O in/O this/O study/O ,/O which/O found/O a/O de/O novo/O truncating/O mutation/O in/O ASXL3/O ./O
Detailed/O phenotypic/O information/O and/O patient/O images/O were/O collected/O and/O summarised/O as/O part/O of/O this/O study/O ./O
RESULTS/O :/O By/O obtaining/O genotype/O :/O phenotype/O data/O ,/O we/O have/O been/O able/O to/O demonstrate/O a/O second/O mutation/O cluster/O region/O within/O ASXL3/O ./O
This/O report/O expands/O the/O phenotype/O of/O older/O patients/O with/O BRPS/O ;/O common/O emerging/O features/O include/O severe/O intellectual/O disability/O (/O 11/12/O )/O ,/O poor//O absent/O speech/O (/O 12/12/O )/O ,/O autistic/O traits/O (/O 9/12/O )/O ,/O distinct/O face/O (/O arched/O eyebrows/O ,/O prominent/O forehead/O ,/O high/O -/O arched/O palate/O ,/O hypertelorism/O and/O downslanting/O palpebral/O fissures/O )/O ,/O (/O 9/12/O )/O ,/O hypotonia/O (/O 11/12/O )/O and/O significant/O feeding/O difficulties/O (/O 9/12/O )/O when/O young/O ./O
DISCUSSION/O :/O Similarities/O in/O the/O patients/O reported/O previously/O in/O comparison/O with/O this/O cohort/O included/O their/O distinctive/O craniofacial/O features/O ,/O feeding/O problems/O ,/O absent/O //O limited/O speech/O and/O intellectual/O disability/O ./O
Shared/O behavioural/O phenotypes/O include/O autistic/O traits/O ,/O hand/O -/O flapping/O ,/O rocking/O ,/O aggressive/O behaviour/O and/O sleep/O disturbance/O ./O
CONCLUSIONS/O :/O This/O series/O expands/O the/O phenotypic/O spectrum/O of/O this/O severe/O disorder/O and/O highlights/O its/O surprisingly/O high/O frequency/O ./O
With/O the/O advent/O of/O advanced/O genomic/O screening/O ,/O we/O are/O likely/O to/O identify/O more/O variants/O in/O this/O gene/O presenting/O with/O a/O variable/O phenotype/O ,/O which/O this/O study/O will/O explore/O ./O
Rhomboid/O family/O member/O 2/O regulates/O cytoskeletal/O stress/O -/O associated/O Keratin/O 16/O ./O
Keratin/O 16/O (/O K16/O )/O is/O a/O cytoskeletal/O scaffolding/O protein/O highly/O expressed/O at/O pressure/O -/O bearing/O sites/O of/O the/O mammalian/O footpad/O ./O
It/O can/O be/O induced/O in/O hyperproliferative/O states/O such/O as/O wound/O healing/O ,/O inflammation/O and/O cancer/O ./O
Here/O we/O show/O that/O the/O inactive/O rhomboid/O protease/O RHBDF2/O (/O iRHOM2/O )/O regulates/O thickening/O of/O the/O footpad/O epidermis/O through/O its/O interaction/O with/O K16/O ./O
K16/O expression/O is/O absent/O in/O the/O thinned/O footpads/O of/O irhom2(-/-/O )/O mice/O compared/O with/O irhom2(+/+)mice/O ,/O due/O to/O reduced/O keratinocyte/O proliferation/O ./O
Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mutations/B-Var in/O iRHOM2/B-Gene underlie/O Tylosis/B-Disease with/I-Disease oesophageal/I-Disease cancer/I-Disease (/O TOC/O )/O ,/O characterized/O by/O palmoplantar/O thickening/O ,/O upregulate/B-PosReg K16/B-MPA with/O robust/O downregulation/B-NegReg of/O its/O type/B-MPA II/I-MPA keratin/I-MPA binding/I-MPA partner/I-MPA ,/O K6/I-MPA ./O
By/O orchestrating/O the/O remodelling/O and/O turnover/O of/O K16/O ,/O and/O uncoupling/O it/O from/O K6/O ,/O iRHOM2/O regulates/O the/O epithelial/O response/O to/O physical/O stress/O ./O
These/O findings/O contribute/O to/O our/O understanding/O of/O the/O molecular/O mechanisms/O underlying/O hyperproliferation/O of/O the/O palmoplantar/O epidermis/O in/O both/O physiological/O and/O disease/O states/O ,/O and/O how/O this/O '/O stress/O '/O keratin/O is/O regulated/O ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutation/B-Var of/O the/O calcium/B-Protein sensor/I-Protein CBL1/I-Protein increases/B-PosReg aluminum/B-MPA sensitivity/I-MPA in/O Arabidopsis/O ./O
Despite/O the/O physiological/O importance/O of/O aluminum/O (/O Al/O )/O phytotoxicity/O for/O plants/O ,/O it/O remained/O unknown/O if/O ,/O and/O how/O ,/O calcineurin/O B/O -/O like/O calcium/O sensors/O (/O CBLs/O )/O and/O CBL/O -/O interacting/O protein/O kinases/O (/O CIPKs/O )/O are/O involved/O in/O Al/O resistance/O ./O
We/O performed/O a/O comparative/O physiological/O and/O whole/O transcriptome/O investigation/O of/O an/O Arabidopsis/O CBL1/B-Gene mutant/B-Var (/O cbl1/O )/O and/O the/O wild/O -/O type/O (/O WT/O )/O ./O
cbl1/O plants/O exudated/O less/B-NegReg Al/B-MPA -/I-MPA chelating/I-MPA malate/I-MPA ,/O accumulated/O more/B-PosReg Al/B-MPA ,/O and/O displayed/O a/O severe/B-CPA root/I-CPA growth/I-CPA reduction/B-NegReg in/O response/O to/O Al/O ./O
Genes/O involved/O in/O metabolism/O ,/O transport/O ,/O cell/O wall/O modification/O ,/O transcription/O and/O oxidative/O stress/O were/O differentially/O regulated/O between/O the/O two/O lines/O ,/O under/O both/O control/O and/O Al/O stress/O treatments/O ./O
Exposure/O to/O Al/O resulted/O in/O up/O -/O regulation/O of/O a/O large/O set/O of/O genes/O only/O in/O WT/O and/O not/O cbl1/O shoots/O ,/O while/O a/O different/O set/O of/O genes/O were/O down/O -/O regulated/O in/O cbl1/O but/O not/O in/O WT/O roots/O ./O
These/O differences/O allowed/O us/O ,/O for/O the/O first/O time/O ,/O to/O define/O a/O calcium/O -/O regulated/O //O dependent/O transcriptomic/O network/O for/O Al/O stress/O responses/O ./O
Our/O analyses/O reveal/O not/O only/O the/O fundamental/O role/O of/O CBL1/O in/O the/O adjustment/O of/O central/O transcriptomic/O networks/O involved/O in/O maintaining/O adequate/O physiological/O homeostasis/O processes/O ,/O but/O also/O that/O a/O high/O shoot/O -/O root/O dynamics/O is/O required/O for/O the/O proper/O deployment/O of/O Al/O resistance/O responses/O in/O the/O root/O ./O
Clinical/O and/O molecular/O consequences/O of/O disease/O -/O associated/O de/O novo/O mutations/O in/O SATB2/O ./O
PURPOSE/O :/O To/O characterize/O features/O associated/O with/O de/O novo/O mutations/O affecting/O SATB2/O function/O in/O individuals/O ascertained/O on/O the/O basis/O of/O intellectual/O disability/O ./O
METHODS/O :/O Twenty/O previously/O unreported/O individuals/O with/O 19/O different/O SATB2/O mutations/O (/O 11/O loss/O -/O of/O -/O function/O and/O 8/O missense/O variants/O )/O were/O studied/O ./O
Fibroblasts/O were/O used/O to/O measure/O mutant/O protein/O production/O ./O
Subcellular/O localization/O and/O mobility/O of/O wild/O -/O type/O and/O mutant/O SATB2/O were/O assessed/O using/O fluorescently/O tagged/O protein/O ./O
RESULTS/O :/O Recurrent/O clinical/O features/O included/O neurodevelopmental/O impairment/O (/O 19/19/O )/O ,/O absent/O //O near/O absent/O speech/O (/O 16/19/O )/O ,/O normal/O somatic/O growth/O (/O 17/19/O )/O ,/O cleft/O palate/O (/O 9/19/O )/O ,/O drooling/O (/O 12/19/O )/O ,/O and/O dental/O anomalies/O (/O 8/19/O )/O ./O
Six/O of/O eight/O missense/O variants/O clustered/O in/O the/O first/O CUT/O domain/O ./O
Sibling/O recurrence/O due/O to/O gonadal/O mosaicism/O was/O seen/O in/O one/O family/O ./O
A/O nonsense/B-Var mutation/I-Var in/I-Var the/I-Var last/I-Var exon/I-Var resulted/B-Reg in/I-Reg production/O of/O a/O truncated/B-MPA protein/B-Protein retaining/O all/O three/O DNA/O -/O binding/O domains/O ./O
SATB2/B-Gene nuclear/O mobility/O was/O mutation/O -/O dependent/O ;/O p/B-Var ./I-Var Arg389Cys/I-Var in/I-Var CUT1/I-Var increased/B-PosReg mobility/B-MPA and/O both/O p/B-Var ./I-Var Gly515Ser/I-Var in/I-Var CUT2/I-Var and/O p/B-Var ./I-Var Gln566Lys/I-Var between/I-Var CUT2/I-Var and/I-Var HOX/I-Var reduced/B-NegReg mobility/B-MPA ./O
The/O clinical/O features/O in/O individuals/O with/O missense/O variants/O were/O indistinguishable/O from/O those/O with/O loss/O of/O function/O ./O
CONCLUSION/O :/O SATB2/B-Gene haploinsufficiency/B-Var is/O a/O common/O cause/B-Reg of/O syndromic/B-Disease intellectual/I-Disease disability/I-Disease ./O
When/O mutant/B-Var SATB2/B-Gene protein/O is/O produced/O ,/O the/O protein/B-Protein appears/O functionally/B-MPA inactive/B-NegReg with/O a/O disrupted/O pattern/O of/O chromatin/O or/O matrix/O association/O ./O
Genet/O Med/O advance/O online/O publication/O 02/O February/O 2017/O ./O
Loss/B-Var of/O Ssq1/B-Gene leads/B-Reg to/O mitochondrial/B-CPA dysfunction/I-CPA ,/O activation/B-CPA of/I-CPA autophagy/I-CPA and/O cell/B-CPA cycle/I-CPA arrest/I-CPA due/O to/O iron/B-MPA overload/B-PosReg triggered/O by/O mitochondrial/B-MPA iron/I-MPA -/I-MPA sulfur/I-MPA cluster/I-MPA assembly/I-MPA defects/B-NegReg in/O Candida/O albicans/O ./O
Iron/O -/O sulfur/O clusters/O perform/O essential/O functions/O in/O enzymatic/O catalysis/O and/O homeostatic/O regulation/O ./O
Here/O we/O for/O the/O first/O time/O identified/O Ssq1/O as/O an/O essential/O component/O for/O iron/O -/O sulfur/O cluster/O assembly/O in/O Candida/O albicans/O ./O
Ssq1/O played/O an/O important/O role/O in/O cell/O growth/O ./O
Shutting/O off/O SSQ1/O led/O to/O accumulation/O of/O intracellular/O iron/O ,/O especially/O in/O mitochondria/O ,/O and/O disorder/O of/O intracellular/O iron/O regulation/O ./O
In/O tetO/O -/O SSQ1/O ,/O iron/O overloading/O triggered/O the/O oxidative/O damage/O of/O mitochondrial/O function/O ./O
Surprisingly/O ,/O disruption/O of/O SSQ1/O activated/O autophagic/O pathway/O ./O
The/O mitochondrial/B-CPA dysfunction/I-CPA was/O further/O aggravated/B-NegReg when/O CCZ1/B-Gene (/O which/O is/O essential/O for/O autophagy/O )/O and/O SSQ1/B-Gene was/O simultaneously/O deleted/B-Var ,/O suggesting/O that/O autophagy/O played/O a/O critical/O role/O in/O maintenance/O of/O mitochondrial/O function/O in/O tetO/O -/O SSQ1/O ./O
In/O addition/O ,/O double/O deletion/B-Var of/O SSQ1/B-Gene and/O CCZ1/B-Gene further/O elevated/B-PosReg cellular/B-MPA iron/I-MPA levels/I-MPA in/O comparison/O with/O tetO/O -/O SSQ1/O ,/O indicating/O that/O autophagy/O participated/O in/O maintenance/O of/O iron/O homeostasis/O ./O
Furthermore/O ,/O we/O found/O that/O loss/B-Var of/O SSQ1/B-Gene led/O to/O increasing/B-PosReg protein/B-Protein expression/B-MPA of/O Rnr1/B-Gene and/O redistribution/B-MPA of/O Rnr2/B-Gene from/O the/O nucleus/O to/O cytoplasm/O ,/O and/O further/O resulted/B-Reg in/O cell/B-CPA cycle/I-CPA arrest/I-CPA ./O
The/O results/O implied/O that/O cell/O cycle/O arrest/O was/O caused/O by/O activating/O the/O checkpoint/O pathway/O because/O of/O impairing/O the/O iron/O -/O sulfur/O cluster/O assembly/O in/O tetO/O -/O SSQ1/O ./O
Shutting/O off/O SSQ1/O led/O to/O a/O significant/O defect/O in/O filamentous/O development/O ./O
Interestingly/O ,/O the/O tetO/O -/O SSQ1ccz1Δ/O //O Δ/O growth/O was/O inhibited/O on/O hyphae/O -/O inducing/O solid/O media/O ./O
Both/O tetO/O -/O SSQ1/O and/O tetO/O -/O SSQ1ccz1Δ/O //O Δ/O exhibited/O extremely/O attenuated/O virulence/O ,/O indicating/O that/O Ssq1/O might/O provide/O a/O promising/O target/O for/O antifungal/O drugs/O development/O ./O
In/O summary/O ,/O our/O findings/O provide/O new/O insights/O into/O the/O understanding/O of/O iron/O -/O sulfur/O cluster/O assembly/O -/O related/O gene/O in/O C./O albicans/O ./O
Identification/O of/O TAZ/B-Gene mutations/B-Var in/O pediatric/O patients/O with/B-Reg cardiomyopathy/B-Disease by/O targeted/O next/O -/O generation/O sequencing/O in/O a/O Chinese/O cohort/O ./O
BACKGROUND/O :/O Barth/O syndrome/O (/O BTHS/O )/O is/O a/O rare/O X/O -/O linked/O recessive/O disease/O characterized/O by/O cardiomyopathy/O ,/O neutropenia/O ,/O skeletal/O myopathy/O and/O growth/O delay/O ./O
Early/O diagnosis/O and/O appropriate/O treatment/O may/O improve/O the/O prognosis/O of/O this/O disease/O ./O
The/O purpose/O of/O this/O study/O is/O to/O determine/O the/O role/O of/O targeted/O next/O -/O generation/O sequencing/O (/O NGS/O )/O in/O the/O early/O diagnosis/O of/O BTHS/O in/O children/O with/O cardiomyopathy/O ./O
METHODS/O :/O During/O the/O period/O between/O 2012/O and/O 2015/O ,/O a/O gene/O panel/O -/O based/O NGS/O approach/O was/O used/O to/O search/O for/O potentially/O disease/O -/O causing/O genetic/O variants/O in/O all/O patients/O referred/O to/O our/O institution/O with/O a/O clinical/O diagnosis/O of/O primary/O cardiomyopathy/O ./O
NGS/O was/O performed/O using/O the/O Illumina/O sequencing/O system/O ./O
RESULTS/O :/O A/O total/O of/O 180/O Chinese/O pediatric/O patients/O (/O 114/O males/O and/O 66/O females/O )/O diagnosed/O with/O primary/O cardiomyopathy/O were/O enrolled/O in/O this/O study/O ./O
TAZ/O mutations/O were/O identified/O in/O four/O of/O the/O male/O index/O patients/O ,/O including/O two/O novel/O mutations/O (/O c.527A/O >/O G/O ,/O p/O ./O H176R/O and/O c.134_136delinsCC/O ,/O p/O ./O H45PfsX38/O )/O ./O
All/O four/O probands/O and/O two/O additional/O affected/O male/O family/O members/O were/O born/O at/O full/O term/O with/O a/O median/O birth/O weight/O of/O 2350/O g/O (/O range/O ,/O 2000/O -/O 2850/O g/O )/O ./O
The/O median/O age/O at/O diagnosis/O of/O cardiomyopathy/O was/O 3.0/O months/O (/O range/O ,/O 1.0/O -/O 20.0/O months/O )/O ./O
The/O baseline/O echocardiography/O revealed/O prominent/O dilation/O and/O trabeculations/O of/O the/O left/O ventricle/O with/O impaired/O systolic/O function/O in/O the/O six/O patients/O ,/O four/O of/O which/O fulfilled/O the/O diagnostic/O criteria/O of/O left/O ventricular/O noncompaction/O ./O
Other/O aspects/O of/O their/O clinical/O presentations/O included/O hypotonia/O (/O 6/6/O )/O ,/O growth/O delay/O (/O 6/6/O )/O ,/O neutropenia/O (/O 3/6/O )/O and/O 3-methylglutaconic/O aciduria/O (/O 4/5/O )/O ./O
Five/O patients/O died/O at/O a/O median/O age/O of/O 7.5/O months/O (/O range/O ,/O 7.0/O -/O 12.0/O months/O )/O ./O
The/O cause/O of/O death/O was/O heart/O failure/O associated/O with/O infection/O in/O three/O patients/O and/O cardiac/O arrhythmia/O in/O two/O patients/O ./O
The/O remaining/O one/O patient/O survived/O beyond/O infancy/O but/O had/O fallen/O into/O a/O persistent/O vegetative/O state/O after/O suffering/O from/O cardiac/O arrest/O ./O
CONCLUSIONS/O :/O This/O is/O the/O first/O report/O of/O systematic/O mutation/O screening/O of/O TAZ/O in/O a/O large/O cohort/O of/O pediatric/O patients/O with/O primary/O cardiomyopathy/O using/O the/O NGS/O approach/O ./O
TAZ/O mutations/O were/O found/O in/O 4/114/O (/O 3.5/O %/O )/O male/O patients/O with/O primary/O cardiomyopathy/O ./O
Our/O findings/O indicate/O that/O the/O inclusion/O of/O TAZ/O gene/O testing/O in/O cardiomyopathy/O genetic/O testing/O panels/O may/O contribute/O to/O the/O early/O diagnosis/O of/O BTHS/O ./O
Mutations/B-Var in/O DONSON/B-Gene disrupt/B-NegReg replication/B-MPA fork/I-MPA stability/I-MPA and/O cause/B-Reg microcephalic/B-Disease dwarfism/I-Disease ./O
To/O ensure/O efficient/O genome/O duplication/O ,/O cells/O have/O evolved/O numerous/O factors/O that/O promote/O unperturbed/O DNA/O replication/O and/O protect/O ,/O repair/O and/O restart/O damaged/O forks/O ./O
Here/O we/O identify/O downstream/O neighbor/O of/O SON/O (/O DONSON/O )/O as/O a/O novel/O fork/O protection/O factor/O and/O report/O biallelic/O DONSON/O mutations/O in/O 29/O individuals/O with/O microcephalic/O dwarfism/O ./O
We/O demonstrate/O that/O DONSON/O is/O a/O replisome/O component/O that/O stabilizes/O forks/O during/O genome/O replication/O ./O
Loss/B-Var of/O DONSON/B-Gene leads/B-Reg to/I-Reg severe/O replication/B-MPA -/I-MPA associated/I-MPA DNA/I-MPA damage/I-MPA arising/O from/O nucleolytic/O cleavage/O of/O stalled/O replication/O forks/O ./O
Furthermore/O ,/O ATM-/B-MPA and/I-MPA Rad3-related/I-MPA (/I-MPA ATR)-dependent/I-MPA signaling/I-MPA in/O response/O to/O replication/O stress/O is/O impaired/B-NegReg in/O DONSON/B-Var -/I-Var deficient/I-Var cells/O ,/O resulting/O in/O decreased/B-NegReg checkpoint/B-MPA activity/I-MPA and/O the/O potentiation/B-PosReg of/O chromosomal/B-MPA instability/I-MPA ./O
Hypomorphic/B-Var mutations/I-Var in/O DONSON/B-Gene substantially/O reduce/B-NegReg DONSON/B-Gene protein/B-Protein levels/B-MPA and/O impair/B-NegReg fork/B-MPA stability/I-MPA in/O cells/O from/O patients/O ,/O consistent/O with/O defective/O DNA/O replication/O underlying/O the/O disease/O phenotype/O ./O
In/O summary/O ,/O we/O have/O identified/O mutations/B-Var in/O DONSON/B-Gene as/O a/O common/O cause/B-Reg of/O microcephalic/B-Disease dwarfism/I-Disease and/O established/O DONSON/O as/O a/O critical/O replication/O fork/O protein/O required/O for/O mammalian/O DNA/O replication/O and/O genome/O stability/O ./O
Phenotypic/O spectrum/O of/O Charcot/B-Disease -/I-Disease Marie/I-Disease -/I-Disease Tooth/I-Disease disease/O due/B-Reg to/I-Reg LITAF/B-Gene //I-Gene SIMPLE/I-Gene mutations/B-Var :/I-Var a/O study/O of/O 18/O patients/O ./O
BACKGROUND/O AND/O PURPOSE/O :/O Charcot/B-Disease -/I-Disease Marie/I-Disease -/I-Disease Tooth/I-Disease (/O CMT/O )/O 1C/O due/B-Reg to/I-Reg mutations/B-Var in/O LITAF/B-Gene //I-Gene SIMPLE/I-Gene is/O a/O rare/O subtype/O amongst/O the/O autosomal/O dominant/O demyelinating/O forms/O of/O CMT/O ./O
Our/O objective/O was/O to/O report/O the/O clinical/O and/O electrophysiological/O characteristics/O of/O 18/O CMT1C/O patients/O and/O compare/O them/O to/O 20/O patients/O with/O PMP22/O mutations/O :/O 10/O CMT1A/O patients/O and/O 10/O patients/O with/O hereditary/O neuropathy/O with/O liability/O to/O pressure/O palsies/O (/O HNPP/O )/O ./O
METHODS/O :/O Charcot/O -/O Marie/O -/O Tooth/O 1C/O patients/O were/O followed/O -/O up/O in/O referral/O centres/O for/O neuromuscular/O diseases/O or/O were/O identified/O by/O familial/O survey/O ./O
All/O CMT1A/O and/O HNPP/O patients/O were/O recruited/O at/O the/O referral/O centre/O for/O neuromuscular/O diseases/O of/O Pitié/O -/O Salpêtrière/O Hospital/O ./O
RESULTS/O :/O Two/O phenotypes/O were/O identified/O amongst/O 18/O CMT1C/O patients/O :/O the/O classical/O CMT/O form/O (/O '/O CMT/O -/O like/O '/O ,/O 11/O cases/O )/O and/O a/O predominantly/O sensory/O form/O (/O '/O sensory/O form/O '/O ,/O seven/O cases/O )/O ./O
The/O mean/O CMT/O neuropathy/O score/O was/O 4.45/O in/O CMT1C/O patients/O ./O
Motor/O nerve/O conduction/O velocities/O in/O the/O upper/O limbs/O were/O significantly/O more/O reduced/O in/O CMT1A/O than/O in/O CMT1C/O patients/O ./O
On/O the/O other/O hand/O ,/O the/O motor/O nerve/O conduction/O velocity/O of/O the/O median/O nerve/O was/O significantly/O lower/O in/O CMT1C/O compared/O to/O the/O HNPP/O group/O ./O
Distal/O motor/O latency/O was/O significantly/O more/O prolonged/O in/O CMT1A/O patients/O compared/O to/O the/O CMT1C/O and/O HNPP/O groups/O ,/O the/O latter/O two/O groups/O having/O similar/O distal/O motor/O latency/O values/O ./O
Molecular/O analysis/O revealed/O five/O new/O LITAF/O //O SIMPLE/O mutations/O (/O Ala111Thr/O ,/O Gly112Ala/O ,/O Trp116Arg/O ,/O Pro135Leu/O ,/O Arg160Cys/O )/O ./O
CONCLUSIONS/O :/O Our/O study/O delineates/O CMT1C/O as/O mostly/O a/O mild/O form/O of/O neuropathy/O ,/O and/O gives/O clinical/O and/O electrophysiological/O clues/O differentiating/O CMT1C/O from/O CMT1A/O and/O HNPP/O ./O
Delineating/O phenotypes/O in/O CMT/O subtypes/O is/O important/O to/O orient/O molecular/O diagnosis/O and/O to/O help/O to/O interpret/O complex/O molecular/O findings/O ./O
A/O Novel/O Homozygous/O Missense/O Mutation/B-Var in/O HOXC13/B-Gene Leads/B-Reg to/I-Reg Autosomal/O Recessive/O Pure/B-Disease Hair/I-Disease and/I-Disease Nail/I-Disease Ectodermal/I-Disease Dysplasia/I-Disease ./O
Pure/O hair/O and/O nail/O ectodermal/O dysplasia/O (/O PHNED/O )/O is/O a/O rare/O disorder/O that/O presents/O with/O hypotrichosis/O and/O nail/O dystrophy/O while/O sparing/O other/O ectodermal/O structures/O such/O as/O teeth/O and/O sweat/O glands/O ./O
We/O describe/O a/O homozygous/O novel/O missense/O mutation/B-Var in/O the/O HOXC13/B-Gene gene/O that/O resulted/B-Reg in/I-Reg autosomal/O recessive/O PHNED/B-Disease in/O a/O Hispanic/O child/O ./O
The/O mutation/O c.812A/O >/O G/O (/O p/O ./O Gln271Arg/O )/O is/O located/O within/O the/O DNA/O -/O binding/O domain/O of/O the/O HOXC13/O gene/O ,/O cosegregates/O within/O the/O family/O ,/O and/O is/O predicted/O to/O be/O maximally/O damaging/O ./O
This/O is/O the/O first/O reported/O case/O of/O a/O missense/O HOXC13/B-Gene mutation/B-Var resulting/B-Reg in/I-Reg PHNED/B-Disease and/O the/O first/O reported/O case/O of/O PHNED/O identified/O in/O a/O North/O American/O family/O ./O
Our/O findings/O illustrate/O the/O critical/O role/O of/O HOXC13/O in/O human/O hair/O and/O nail/O development/O ./O
SERPINC1/B-Gene gene/O mutations/B-Var in/B-Reg antithrombin/B-Disease deficiency/I-Disease ./O
Existing/O evidence/O suggests/O that/O in/O most/O cases/O antithrombin/B-Disease deficiency/I-Disease can/O be/O explained/B-Reg by/I-Reg mutations/B-Var in/O its/O gene/O ,/O SERPINC1/B-Gene ./O
We/O investigated/O the/O molecular/O background/O of/O antithrombin/O deficiency/O in/O a/O single/O centre/O family/O cohort/O study/O ./O
We/O included/O a/O total/O of/O 21/O families/O comprising/O 15/O original/O probands/O and/O sixty/O -/O six/O relatives/O ,/O 6/O of/O who/O were/O surrogate/O probands/O for/O the/O genetic/O analysis/O ./O
Antithrombin/O activity/O and/O antigen/O levels/O were/O measured/O ./O
The/O heparin/O -/O antithrombin/O binding/O ratio/O assay/O was/O used/O to/O distinguish/O between/O the/O different/O subtypes/O of/O type/O II/O antithrombin/O deficiency/O ./O
SERPINC1/O mutations/O were/O detected/O by/O direct/O sequencing/O of/O all/O 7/O exons/O and/O regulatory/O regions/O ,/O and/O multiplex/O ligation/O -/O dependent/O probe/O amplification/O ./O
Eighty/O -/O six/O per/O cent/O of/O the/O families/O had/O a/O detrimental/O SERPINC1/O gene/O mutation/O that/O segregated/O in/O the/O family/O ./O
We/O detected/O 13/O different/O SERPINC1/O gene/O mutations/O of/O which/O 5/O were/O novel/O ./O
Among/O all/O these/O mutations/O ,/O 44/O %/O was/O associated/O with/O type/O I/O deficiency/O ,/O whereas/O the/O remainder/O was/O associated/O with/O type/O II/O heparin/O binding/O site/O (/O 11/O %/O )/O ,/O type/O II/O pleiotropic/O effect/O (/O 33/O %/O )/O ,/O type/O II/O reactive/O site/O (/O 6/O %/O )/O or/O had/O the/O antithrombin/O Cambridge/O II/O mutation/O (/O 6/O %/O )/O ./O
The/O current/O study/O reports/O several/O novel/O SERPINC1/O mutations/O ,/O thereby/O adding/O to/O our/O knowledge/O of/O the/O molecular/O background/O of/O antithrombin/O deficiency/O ./O
Finally/O ,/O our/O results/O point/O out/O the/O importance/O of/O future/O research/O outside/O the/O conventional/O SERPINC1/O gene/O approach/O ./O
Control/O of/O Kir/O channel/O gating/O by/O cytoplasmic/O domain/O interface/O interactions/O ./O
Inward/O rectifier/O potassium/O (/O Kir/O )/O channels/O are/O expressed/O in/O almost/O all/O mammalian/O tissues/O and/O play/O critical/O roles/O in/O the/O control/O of/O excitability/O ./O
Pancreatic/O ATP/O -/O sensitive/O K/O (/O KATP/O )/O channels/O are/O key/O regulators/O of/O insulin/O secretion/O and/O comprise/O Kir6.2/O subunits/O coupled/O to/O sulfonylurea/O receptors/O ./O
Because/O these/O channels/O are/O reversibly/O inhibited/O by/O cytoplasmic/O ATP/O ,/O they/O link/O cellular/O metabolism/O with/O membrane/O excitability/O ./O
Loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O the/O pore/O -/O forming/O Kir6.2/B-Gene subunit/O cause/O congenital/B-Disease hyperinsulinism/I-Disease as/O a/O result/O of/O diminished/B-NegReg channel/B-MPA activity/I-MPA ./O
Here/O ,/O we/O show/O that/O several/O disease/O mutations/B-Var ,/O which/O disrupt/B-NegReg intersubunit/B-CPA salt/I-CPA bridges/I-CPA at/O the/O interface/O of/O the/O cytoplasmic/O domains/O (/O CD/O -/O I/O )/O of/O adjacent/O subunits/O ,/O induce/O loss/B-NegReg of/O channel/B-MPA activity/I-MPA via/O a/O novel/O channel/O behavior/O :/O after/O ATP/O removal/O ,/O channels/O open/O but/O then/O rapidly/O inactivate/O ./O
Re/O -/O exposure/O to/O inhibitory/O ATP/O causes/O recovery/O from/O this/O inactivation/O ./O
Inactivation/O can/O be/O abolished/O by/O application/O of/O phosphatidylinositol-4,5-bisphosphate/O (/O PIP2/O )/O to/O the/O cytoplasmic/O face/O of/O the/O membrane/O ,/O an/O effect/O that/O can/O be/O explained/O by/O a/O simple/O kinetic/O model/O in/O which/O PIP2/O binding/O competes/O with/O the/O inactivation/O process/O ./O
Kir2.1/O channels/O contain/O homologous/O salt/O bridges/O ,/O and/O we/O find/O that/O mutations/O that/O disrupt/O CD/O -/O I/O interactions/O in/O Kir2.1/O also/O reduce/O channel/O activity/O and/O PIP2/O sensitivity/O ./O
Kir2.1/O channels/O also/O contain/O an/O additional/O CD/O -/O I/O salt/O bridge/O that/O is/O not/O present/O in/O Kir6.2/O channels/O ./O
Introduction/O of/O this/O salt/O bridge/O into/O Kir6.2/O partially/O rescues/O inactivating/O mutants/O from/O the/O phenotype/O ./O
These/O results/O indicate/O that/O the/O stability/O of/O the/O intersubunit/O CD/O -/O I/O is/O a/O major/O determinant/O of/O the/O inactivation/O process/O in/O Kir6.2/O and/O may/O control/O gating/O in/O other/O Kir/O channels/O ./O
Patient/O -/O specific/O induced/O pluripotent/O stem/O cells/O to/O evaluate/O the/O pathophysiology/O of/O TRNT1-associated/O Retinitis/O pigmentosa/O ./O
Retinitis/B-Disease pigmentosa/I-Disease (/O RP/O )/O is/O a/O heterogeneous/O group/O of/O monogenic/O disorders/O characterized/O by/O progressive/O death/O of/O the/O light/O -/O sensing/O photoreceptor/O cells/O of/O the/O outer/O neural/O retina/O ./O
We/O recently/O identified/O novel/O hypomorphic/O mutations/B-Var in/O the/O tRNA/O Nucleotidyl/O Transferase/O ,/O CCA/O -/O Adding/O 1/O (/B-Gene TRNT1/I-Gene )/I-Gene gene/O that/O cause/B-Reg early/O -/O onset/O RP/B-Disease ./O
To/O model/O this/O disease/O in/O vitro/O ,/O we/O generated/O patient/O -/O specific/O iPSCs/O and/O iPSC/O -/O derived/O retinal/O organoids/O from/O dermal/O fibroblasts/O of/O patients/O with/O molecularly/O confirmed/O TRNT1-associated/O RP/O ./O
Pluripotency/O was/O confirmed/O using/O rt/O -/O PCR/O ,/O immunocytochemistry/O ,/O and/O a/O TaqMan/O Scorecard/O Assay/O ./O
Mutations/B-Var in/O TRNT1/B-Gene caused/O reduced/B-NegReg levels/B-MPA of/I-MPA full/I-MPA -/I-MPA length/I-MPA TRNT1/B-Gene protein/B-Protein and/O expression/B-MPA of/I-MPA a/I-MPA truncated/I-MPA smaller/I-MPA protein/B-Protein in/O both/O patient/O -/O specific/O iPSCs/O and/O iPSC/O -/O derived/O retinal/O organoids/O ./O
Patient/O -/O specific/O iPSCs/O and/O iPSC/O -/O derived/O retinal/O organoids/O exhibited/O a/O deficit/O in/O autophagy/O ,/O as/O evidenced/O by/O aberrant/O accumulation/O of/O LC3-II/O and/O elevated/O levels/O of/O oxidative/O stress/O ./O
Autologous/O stem/O cell/O -/O based/O disease/O modeling/O will/O provide/O a/O platform/O for/O testing/O multiple/O avenues/O of/O treatment/O in/O patients/O suffering/O from/O TRNT1-associated/O RP/O ./O
Gain/B-Var -/I-Var of/I-Var -/I-Var function/I-Var p53/B-Gene activates/B-PosReg multiple/O signaling/B-Pathway pathways/I-Pathway to/O induce/B-PosReg oncogenicity/B-CPA in/O lung/B-Disease cancer/I-Disease cells/O ./O
Gain/B-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg (/O GOF/O )/O mutants/B-Var of/O p53/B-Gene upregulate/B-PosReg genes/B-Gene implicated/B-Reg in/O cell/B-CPA proliferation/I-CPA and/O oncogenesis/B-CPA ./O
Here/O ,/O we/O report/O that/O GOF/B-Var p53/B-Gene induces/O tumorigenicity/O through/O simultaneous/O activation/B-PosReg of/O key/B-Pathway oncogenic/I-Pathway pathways/I-Pathway including/O those/O controlling/O putative/O tumor/O -/O initiating/O cell/O functions/O ./O
We/O determined/O that/O in/O cells/O expressing/O p53-R273H/B-Var ,/O GOF/O p53/O simultaneously/O upregulates/B-PosReg genes/O from/O multiple/B-Pathway signaling/I-Pathway pathways/I-Pathway by/O recognizing/O promoters/O containing/O distinct/O transcription/O factor/O (/O TF/O )/O binding/O sites/O ./O
Our/O analytical/O data/O support/O a/O model/O in/O which/O GOF/B-Var p53/B-Gene complexes/O with/O two/O TFs/O on/O the/O promoter/O -/O a/O mediator/O protein/O ,/O Med17/O ,/O and/O a/O histone/O acetyl/O transferase/O ,/O activating/B-PosReg histone/B-MPA acetylation/I-MPA -/I-MPA and/I-MPA enhances/B-PosReg gene/B-MPA expression/I-MPA to/O signal/O cell/O proliferation/O and/O oncogenesis/O ./O
Thus/O ,/O therapeutic/O inhibition/O of/O one/O GOF/O p53-induced/O pathway/O would/O be/O insufficient/O to/O prevent/O tumor/O growth/O as/O the/O oncoprotein/O activates/O a/O multitude/O of/O parallel/O pathways/O ./O
This/O discovery/O suggests/O enormous/O selection/O advantage/O for/O cancer/O cells/O with/O GOF/O p53/O to/O induce/O oncogenic/O growth/O ,/O highlighting/O the/O problems/O of/O cancer/O therapy/O ./O
Hand/O eczema/O ,/O atopic/O dermatitis/O and/O filaggrin/O mutations/O in/O adult/O Danes/O :/O a/O registry/O -/O based/O study/O assessing/O risk/O of/O disability/O pension/O ./O
BACKGROUND/O :/O Atopic/O dermatitis/O and/O hand/O eczema/O often/O impair/O the/O ability/O of/O people/O to/O work/O ./O
Only/O a/O few/O studies/O have/O investigated/O whether/O individuals/O with/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg filaggrin/O gene/O (/B-Gene FLG/I-Gene )/I-Gene mutations/B-Var ,/O who/O often/O have/O severe/O and/O early/O onset/O of/O dermatitis/B-Disease ,/O experience/O occupational/O consequences/O ./O
OBJECTIVE/O :/O To/O investigate/O the/O personal/O consequences/O of/O having/O atopic/O dermatitis/O and/or/O hand/O eczema/O and/O FLG/O mutations/O ./O
METHOD/O :/O Adult/O Danes/O from/O the/O general/O population/O (/O n/O =/O 3247/O )/O and/O patients/O with/O atopic/O dermatitis/O and/or/O hand/O eczema/O (/O n/O =/O 496/O )/O were/O genotyped/O for/O common/O FLG/O mutations/O ,/O and/O completed/O a/O questionnaire/O about/O skin/O symptoms/O and/O hand/O eczema/O ./O
Socioeconomic/O variables/O ,/O including/O disability/O pension/O ,/O and/O information/O on/O work/O in/O risk/O occupations/O were/O retrieved/O from/O national/O registries/O ./O
The/O reasons/O for/O granting/O disability/O pension/O were/O unknown/O ./O
RESULTS/O :/O Disability/O pension/O was/O associated/O with/O hand/O eczema/O in/O the/O general/O population/O ,/O especially/O among/O individuals/O with/O a/O history/O of/O atopic/O dermatitis/O ./O
Moreover/O ,/O self/O -/O reported/O hand/O eczema/O and/O atopic/O dermatitis/O were/O associated/O with/O particularly/O high/O risk/O of/O disability/O pension/O among/O FLG/O mutation/O carriers/O [/O odds/O ratio/O (/O OR/O )/O 4.02/O and/O 95/O %/O confidence/O interval/O (/O CI/O )/O :/O 1.15/O -/O 14.11/O ;/O and/O OR/O 6.01/O and/O 95%CI/O :/O 2.37/O -/O 15.34/O ,/O respectively/O ]/O ./O
Furthermore/O ,/O 60/O %/O of/O the/O FLG/O mutation/O carriers/O with/O atopic/O dermatitis/O who/O developed/O hand/O eczema/O had/O experienced/O symptoms/O before/O adulthood/O ./O
CONCLUSION/O :/O In/O the/O general/O population/O ,/O self/O -/O reported/O hand/O eczema/O and/O atopic/O dermatitis/O ,/O particularly/O in/O individuals/O with/O a/O genetically/O impaired/O skin/O barrier/O ,/O were/O associated/O with/O disability/O pension/O ,/O suggesting/O that/O FLG/B-Gene mutations/B-Var carriers/B-Reg with/I-Reg a/O history/O of/O atopic/B-Disease dermatitis/I-Disease and/O hand/B-Disease eczema/I-Disease could/O benefit/O from/O early/O attention/O with/O respect/O to/O choice/O of/O occupation/O ./O
ATM/O Gene/O Mutation/O Detection/O Techniques/O and/O Functional/O Analysis/O ./O
Ataxia/B-Disease Telangiectasia/I-Disease (/O A/O -/O T/O )/O is/O caused/O by/O biallelic/O inactivation/B-NegReg of/O the/O Ataxia/O Telangiectasia/O Mutated/O (/B-Gene ATM/I-Gene )/I-Gene gene/O ,/O due/O to/O nonsense/B-Var or/I-Var missense/I-Var mutations/I-Var ,/O small/O insertions/O //O deletions/O (/B-Var indels/I-Var )/I-Var ,/O splicing/B-Var alterations/I-Var ,/O and/O large/B-Var genomic/I-Var rearrangements/I-Var ./O
After/O establishing/O A/O -/O T/O clinical/O diagnosis/O ,/O a/O molecular/O confirmation/O is/O needed/O ,/O based/O on/O the/O detection/O of/O one/O of/O these/O loss/O -/O of/O -/O function/O mutations/O in/O at/O least/O one/O allele/O ./O
In/O most/O cases/O ,/O the/O pathogenicity/O of/O the/O detected/O mutations/O is/O sufficient/O to/O make/O a/O definitive/O diagnosis/O ./O
More/O rarely/O ,/O mutations/O of/O unknown/O consequences/O are/O identified/O and/O direct/O biological/O analyses/O are/O required/O to/O establish/O their/O pathogenic/O characters/O ./O
In/O such/O cases/O ,/O complementary/O analyses/O of/O ATM/O expression/O ,/O localization/O ,/O and/O activity/O allow/O fine/O characterization/O of/O these/O mutations/O and/O facilitate/O A/O -/O T/O diagnosis/O ./O
Here/O ,/O we/O present/O genetic/O and/O biochemical/O protocols/O currently/O used/O in/O the/O laboratory/O that/O have/O proven/O to/O be/O highly/O accurate/O ,/O reproducible/O ,/O and/O quantitative/O ./O
We/O also/O provide/O additional/O discussion/O on/O the/O critical/O points/O of/O the/O techniques/O presented/O here/O ./O
Truncating/O mutations/O in/O SPAST/O patients/O are/O associated/O with/O a/O high/O rate/O of/O psychiatric/O comorbidities/O in/O hereditary/O spastic/O paraplegia/O ./O
BACKGROUND/O :/O The/O hereditary/B-Disease spastic/I-Disease paraplegias/I-Disease (/O HSPs/O )/O are/O a/O rare/O and/O heterogeneous/O group/O of/O neurodegenerative/O disorders/O that/O are/O clinically/O characterised/O by/O progressive/O lower/O limb/O spasticity/O ./O
They/O are/O classified/O as/O either/O '/O pure/O '/O or/O '/O complex/O '/O where/O spastic/O paraplegia/O is/O complicated/O with/O additional/O neurological/O features/O ./O
Mutations/B-Var in/O the/O spastin/O gene/O (/B-Gene SPAST/I-Gene )/I-Gene are/O the/O most/O common/O cause/B-Reg of/O HSP/B-Disease and/O typically/O present/O with/O a/O pure/O form/O ./O
METHODS/O :/O We/O assessed/O in/O detail/O the/O phenotypic/O and/O genetic/O spectrum/O of/O SPAST/O -/O related/O HSP/O focused/O on/O 118/O patients/O carrying/O SPAST/O mutations/O ./O
RESULTS/O :/O This/O study/O ,/O one/O of/O the/O largest/O cohorts/O of/O genetically/O confirmed/O spastin/O patients/O to/O date/O ,/O contributes/O with/O the/O discovery/O of/O a/O significant/O number/O of/O novel/O SPAST/O mutations/O ./O
Our/O data/O reveal/O a/O high/O rate/O of/O complex/O cases/O (/O 25/O %/O )/O ,/O with/O psychiatric/O disorders/O among/O the/O most/O common/O comorbidity/O (/O 10/O %/O of/O all/O SPASTpatients/O )/O ./O
Further/O ,/O we/O identify/O a/O genotype/O -/O phenotype/O correlation/O between/O patients/O carrying/O loss/B-NegReg -/I-NegReg of/I-NegReg -/I-NegReg function/I-NegReg mutations/B-Var in/O SPAST/B-Gene and/O the/O presence/O of/O psychiatric/B-Disease disorders/I-Disease ./O
R202Q/B-Var //I-Var M694V/I-Var as/O novel/O MEFV/B-Gene gene/O mutations/O in/B-Reg chronic/B-Disease periodontitis/I-Disease and/O familial/B-Disease Mediterranean/I-Disease fever/I-Disease ./O
BACKGROUND/O AND/O OBJECTIVE/O :/O Familial/O Mediterranean/O fever/O (/O FMF/O )/O and/O chronic/O periodontitis/O are/O inflammatory/O diseases/O leading/O to/O an/O increase/O in/O the/O number/O of/O inflammasomes/O ./O
To/O date/O ,/O no/O published/O studies/O have/O reported/O on/O mutations/O in/O the/O Mediterranean/O fever/O (/O MEFV/O )/O gene/O in/O patients/O with/O chronic/O periodontitis/O ,/O although/O the/O roles/B-Reg of/O MEFV/B-Gene gene/O mutations/B-Var in/O FMF/B-Disease and/O FMF/B-Disease -/I-Disease associated/I-Disease amyloidosis/I-Disease (/O FMF/O -/O A/O )/O are/O well/O known/O ./O
Therefore/O ,/O the/O aim/O of/O this/O study/O was/O to/O evaluate/O the/O frequencies/O of/O MEFV/O gene/O mutations/O and/O serum/O amyloid/O A/O (/O SAA/O )/O and/O high/O -/O sensitivity/O C/O -/O reactive/O protein/O (/O hs/O -/O CRP/O )/O levels/O in/O patients/O with/O chronic/O periodontitis/O ,/O FMF/O and/O FMF/O -/O A./O MATERIAL/O AND/O METHODS/O :/O The/O study/O population/O included/O 122/O patients/O with/O FMF/O and/O 128/O subjects/O who/O were/O systemically/O healthy/O ./O
Clinical/O periodontal/O parameters/O ,/O including/O the/O plaque/O index/O ,/O gingival/O index/O ,/O probing/O pocket/O depth/O ,/O clinical/O attachment/O level/O and/O percentage/O of/O bleeding/O on/O probing/O were/O recorded/O ./O
Blood/O samples/O were/O obtained/O from/O patients/O with/O FMF/O and/O systemically/O healthy/O controls/O ,/O and/O all/O mutations/O located/O on/O exons/O 2/O and/O 10/O of/O the/O MEFV/O gene/O were/O analyzed/O by/O DNA/O Sanger/O Sequencing/O ,/O which/O is/O the/O gold/O standard/O ./O
SAA/O and/O high/O -/O sensitive/O CRP/O levels/O were/O also/O assessed/O ./O
RESULTS/O :/O Mean/O gingival/O index/O ,/O percentage/O of/O bleeding/O on/O probing/O ,/O probing/O pocket/O depth/O and/O clinical/O attachment/O level/O ,/O and/O the/O levels/O of/O SAA/O and/O hs/O -/O CRP/O were/O higher/O in/O the/O FMF/O -/O A/O group/O than/O those/O in/O the/O FMF/O and/O control/O groups/O ./O
The/O two/O most/O relevant/O mutations/O in/O patients/O with/O FMF/O were/O heterozygous/O M694V/O (/O 46.2/O %/O )/O ,/O and/O heterozygous/O R202Q/O (/O 32.7/O %/O )/O ./O
The/O frequencies/O of/O the/O homozygous/O M694V/O and/O R202Q/O mutations/O in/O the/O FMF/O -/O A/O group/O were/O 53.8/O %/O and/O 46.1/O %/O ,/O respectively/O ./O
The/O complex/O R202Q/O //O M694V/O homozygous/O state/O led/O to/O an/O increased/O risk/O of/O chronic/O periodontitis/O (/O odds/O ratio/O :/O 3.6/O )/O ,/O and/O FMF/O -/O A/O (/O odds/O ratio/O :/O 7.6/O )/O ./O
CONCLUSION/O :/O This/O is/O the/O first/O study/O to/O report/O the/O R202Q/O mutation/O in/O patients/O with/O periodontitis/O ./O
Furthermore/O ,/O the/O MEFV/O gene/O -/O mediated/O inflammatory/O pathway/O increased/O serum/O acute/O phase/O reactants/O ,/O and/O the/O changes/O in/O the/O R202Q/B-Var and/O M694V/B-Var could/O play/B-Reg a/I-Reg role/I-Reg in/O inflammatory/B-Disease -/I-Disease genetic/I-Disease diseases/I-Disease ,/O such/O as/O FMF/O ,/O FMF/O -/O associated/O amyloidosis/O and/O chronic/O periodontitis/O ./O
Linking/O the/O degree/O of/O virilization/O in/O females/O with/O congenital/O adrenal/O hyperplasia/O to/O genotype/O ./O
Mutations/B-Var of/O CYP21A2/B-Gene variably/O decrease/B-NegReg 21-hydroxylase/B-Enzyme activity/B-MPA and/O result/B-Reg in/I-Reg a/O spectrum/O of/O disease/O expressions/O in/O patients/O with/O congenital/B-Disease adrenal/I-Disease hyperplasia/I-Disease (/O CAH/O )/O ./O
We/O examined/O the/O association/O between/O CYP21A2/O mutations/O and/O virilization/O (/O Prader/O score/O )/O in/O females/O with/O CAH/O ./O
The/O study/O population/O included/O 187/O CAH/B-Disease females/O with/B-Reg fully/O characterized/O CYP21A2/B-Gene mutations/B-Var ./O
One/O hundred/O fifty/O -/O eight/O patients/O were/O sorted/O into/O groups/O by/O expected/O enzyme/O activity/O (/O percent/O of/O normal/O activity/O )/O of/O the/O less/O severely/O affected/O allele/O :/O (/O A/O )/O null/O ,/O 0/O %/O ;/O (/O B/O )/O I2/O G/O ,/O 1/O %/O ;/O (/O C/O )/O I172N/O ,/O 2/O %/O ;/O and/O (/O D/O )/O V281L/O ,/O >/O 2/O %/O ./O
We/O observed/O an/O inverse/O relationship/O between/O virilization/O and/O residual/O enzyme/O activity/O (/O P/O </O 0.001/O )/O ./O
Subjects/O in/O group/O A/O or/O B/O had/O a/O significantly/O higher/O likelihood/O (/O unadjusted/O odds/O ratio/O :/O 16/O ;/O P/O </O 0.001/O )/O of/O developing/O severe/O virilization/O compared/O with/O those/O in/O group/O C./O Surprisingly/O ,/O 24/O %/O of/O group/O D/O patients/O ,/O whose/O mutation/O is/O usually/O associated/O with/O nonclassical/O (/O NC/O )/O CAH/O ,/O had/O severe/O virilization/O ./O
Among/O subjects/O with/O the/O NC/O P30L/O mutation/O ,/O 66/O %/O expressed/O unexpected/O virilization/O ./O
Virilization/O ,/O usually/O leading/O to/O extensive/O reconstructive/O surgery/O ,/O is/O highly/O likely/O in/O patients/O with/O null/O or/O I2/O G/O mutations/O ;/O however/O ,/O NC/O mutations/O (/O P30L/O //O V281L/O )/O may/O also/O lead/O to/O unexpected/O virilization/O ./O
These/O findings/O have/O implications/O for/O prenatal/O counseling/O and/O highlight/O the/O need/O for/O additional/O investigations/O into/O other/O factors/O that/O influence/O virilization/O in/O CAH/O ./O
A/O Novel/O Missense/B-Var Mutation/I-Var in/O Peripheral/B-Protein Myelin/I-Protein Protein-22/I-Protein Causes/B-Reg Charcot/B-Disease -/I-Disease Marie/I-Disease -/I-Disease Tooth/I-Disease Disease/I-Disease ./O
BACKGROUND/O :/O Charcot/O -/O Marie/O -/O Tooth/O disease/O (/O CMT/O )/O is/O the/O most/O common/O inherited/O peripheral/O neuropathy/O ./O
A/O great/O number/O of/O causative/O genes/O have/O been/O described/O in/O CMT/O ,/O and/O among/O them/O ,/O the/O heterozygous/O duplication/O of/O peripheral/O myelin/O protein-22/O (/O PMP22/O )/O is/O the/O major/O cause/O ./O
Although/O the/O missense/B-Var mutation/I-Var in/O PMP22/B-Gene is/O rarely/O reported/O ,/O it/O has/O been/O demonstrated/O to/O be/O associated/B-Reg with/O CMT/B-Disease ./O
This/O study/O described/O a/O novel/O missense/B-Var mutation/I-Var of/O PMP22/B-Gene in/B-Reg a/O Chinese/O family/O with/O CMT/B-Disease phenotype/O ./O
METHODS/O :/O Targeted/O next/O -/O generation/O sequencing/O (/O NGS/O )/O was/O used/O to/O screen/O the/O causative/O genes/O in/O a/O family/O featured/O with/O an/O autosomal/O dominant/O demyelinating/O form/O of/O CMT/O ./O
The/O potential/O variants/O identified/O by/O targeted/O NGS/O were/O verified/O by/O Sanger/O sequencing/O and/O classified/O according/O to/O the/O American/O College/O of/O Medical/O Genetics/O and/O Genomics/O standards/O and/O guidelines/O ./O
Further/O cell/O transfection/O studies/O were/O performed/O to/O characterize/O the/O function/O of/O the/O novel/O variant/O ./O
RESULTS/O :/O Using/O targeted/O NGS/O ,/O a/O novel/O heterozygous/O missense/O variant/O in/O PMP22/O (/O c.320G/O >/O A/O ,/O p/O ./O G107D/O )/O was/O identified/O ./O
In/O vitro/O cell/O functional/O studies/O revealed/O that/O mutant/O PMP22/B-Gene protein/B-Protein carrying/O p/B-Var ./I-Var G107D/I-Var mutation/O lost/B-NegReg the/O ability/B-CPA to/I-CPA reach/I-CPA the/I-CPA plasma/I-CPA membrane/I-CPA ,/O was/O mainly/O retained/O in/O the/O endoplasmic/O reticulum/O ,/O and/O induced/B-Reg cell/B-CPA apoptosis/I-CPA ./O
CONCLUSIONS/O :/O This/O study/O supported/O the/O notion/O that/O missense/B-Var mutations/I-Var in/O PMP22/B-Gene give/O rise/O to/O a/O CMT/B-Disease phenotype/O ,/O possibly/O through/O a/O toxic/B-PosReg gain/I-PosReg -/I-PosReg of/I-PosReg -/I-PosReg function/I-PosReg mechanism/O ./O
[/O Genetic/O and/O prenatal/O diagnosis/O for/O a/O haemophilia/B-Disease A/I-Disease family/O with/B-Reg two/O novel/O mutations/B-Var of/O F8/B-Gene gene/O ]/O ./O
OBJECTIVE/O :/O To/O conduct/O genetic/O diagnosis/O for/O a/O family/O affected/O with/O hamophilia/O A./O METHODS/O :/O Potential/O mutations/O of/O the/O F8/O gene/O were/O analyzed/O with/O PCR/O and/O Sanger/O sequencing/O ./O
Carriers/O of/O the/O mutation/O were/O identified/O through/O linkage/O analysis/O using/O short/O tandem/O repeat/O (/O STR/O )/O markers/O ./O
Suspected/O mutations/O were/O verified/O among/O 100/O healthy/O controls/O to/O rule/O out/O genetic/O polymorphism/O ./O
Prenatal/O diagnosis/O was/O provided/O based/O on/O the/O above/O results/O ./O
RESULTS/O :/O Sequencing/O analysis/O has/O identified/O two/O mutations/O ,/O c.1/O A/O >/O T/O and/O c.4/O C/O >/O T/O ,/O which/O have/O replaced/O the/O start/O codon/O (/O ATG/O )/O with/O leucine/O (/O TTG/O )/O and/O glutamine/O (/O GAA/O )/O with/O the/O stop/O codon/O (/O TAA/O )/O ,/O respectively/O ./O
The/O same/O mutations/O were/O not/O found/O among/O the/O 100/O healthy/O controls/O ./O
The/O patient/O 's/O mother/O and/O sister/O were/O heterozygous/O for/O the/O same/O mutations/O ./O
Upon/O prenatal/O diagnosis/O ,/O the/O fetus/O was/O determined/O as/O a/O male/O and/O did/O not/O harbor/O the/O above/O mutations/O ./O
Linkage/O analysis/O also/O confirmed/O that/O the/O fetus/O has/O inherited/O the/O non/O -/O risk/O X/O chromosome/O from/O his/O maternal/O grandfather/O ./O
CONCLUSION/O :/O Detection/O of/O pathogenic/O mutations/O can/O enable/O prenatal/O diagnosis/O for/O the/O disease/O ./O
Comprehensive/O analysis/O for/O genetic/O diagnosis/O of/O Dystrophinopathies/O in/O Japan/O ./O
BACKGROUND/O :/O Duchenne/B-Disease muscular/I-Disease dystrophy/I-Disease (/O DMD/O )/O is/O the/O most/O common/O disease/O in/O children/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O DMD/B-Gene gene/O ,/O and/O DMD/O and/O Becker/O muscular/O dystrophy/O (/O BMD/O )/O are/O collectively/O called/O dystrophinopathies/O ./O
Dystrophinopathies/O show/O a/O complex/O mutation/O spectrum/O ./O
The/O importance/O of/O mutation/O databases/O ,/O with/O clinical/O phenotypes/O and/O protein/O studies/O of/O patients/O ,/O is/O increasingly/O recognized/O as/O a/O reference/O for/O genetic/O diagnosis/O and/O for/O the/O development/O of/O gene/O therapy/O ./O
METHODS/O :/O We/O used/O the/O data/O from/O the/O Japanese/O Registry/O of/O Muscular/O Dystrophy/O (/O Remudy/O )/O compiled/O during/O from/O July/O 2009/O to/O March/O 2017/O ,/O and/O reviewed/O 1497/O patients/O with/O dystrophinopathies/O ./O
RESULTS/O :/O The/O spectrum/O of/O identified/O mutations/O contained/O exon/O deletions/O (/O 61/O %/O )/O ,/O exon/O duplications/O (/O 13/O %/O )/O ,/O nonsense/O mutations/O (/O 13/O %/O )/O ,/O small/O deletions/O (/O 5/O %/O )/O ,/O small/O insertions/O (/O 3/O %/O )/O ,/O splice/O -/O site/O mutations/O (/O 4/O %/O )/O ,/O and/O missense/O mutations/O (/O 1/O %/O )/O ./O
Exon/O deletions/O were/O found/O most/O frequently/O in/O the/O central/O hot/O spot/O region/O between/O exons/O 45/O -/O 52/O (/O 42/O %/O )/O ,/O and/O most/O duplications/O were/O detected/O in/O the/O proximal/O hot/O spot/O region/O between/O exons/O 3/O -/O 25/O (/O 47/O %/O )/O ./O
In/O the/O 371/O patients/O harboring/O a/O small/O mutation/O ,/O 194/O mutations/O were/O reported/O and/O 187/O mutations/O were/O unreported/O ./O
CONCLUSIONS/O :/O We/O report/O the/O largest/O dystrophinopathies/O mutation/O dataset/O in/O Japan/O from/O a/O national/O patient/O registry/O ,/O "/O Remudy/O "/O ./O
This/O dataset/O provides/O a/O useful/O reference/O to/O support/O the/O genetic/O diagnosis/O and/O treatment/O of/O dystrophinopathy/O ./O
A/O Defective/O mRNA/O Cleavage/O and/O Polyadenylation/O Complex/O Facilitates/O Expansions/O of/O Transcribed/O (/O GAA)n/O Repeats/O Associated/O with/O Friedreich/O 's/O Ataxia/O ./O
Expansions/O of/O microsatellite/O repeats/O are/O responsible/O for/O numerous/O hereditary/O diseases/O in/O humans/O ,/O including/O myotonic/O dystrophy/O and/O Friedreich/O 's/O ataxia/O ./O
Whereas/O the/O length/O of/O an/O expandable/O repeat/O is/O the/O main/O factor/O determining/O disease/O inheritance/O ,/O recent/O data/O point/O to/O genomic/O trans/O modifiers/O that/O can/O impact/O the/O likelihood/O of/O expansions/O and/O disease/O progression/O ./O
Detection/O of/O these/O modifiers/O may/O lead/O to/O understanding/O and/O treating/O repeat/O expansion/O diseases/O ./O
Here/O ,/O we/O describe/O a/O method/O for/O the/O rapid/O ,/O genome/O -/O wide/O identification/O of/O trans/O modifiers/O for/O repeat/O expansion/O in/O a/O yeast/O experimental/O system/O ./O
Using/O this/O method/O ,/O we/O found/O that/O missense/B-Var mutations/I-Var in/O the/O endoribonuclease/O subunit/O (/B-Gene Ysh1/I-Gene )/I-Gene of/O the/O mRNA/O cleavage/O and/O polyadenylation/O complex/O dramatically/O increase/B-PosReg the/B-MPA rate/I-MPA of/I-MPA (/I-MPA GAA)n/I-MPA repeat/I-MPA expansions/I-MPA but/O only/O when/O they/O are/O actively/O transcribed/O ./O
These/O expansions/O correlate/O with/O slower/B-NegReg transcription/B-MPA elongation/I-MPA caused/O by/O the/O ysh1/B-Gene mutation/B-Var ./O
These/O results/O reveal/O an/O interplay/O between/O RNA/O processing/O and/O repeat/O -/O mediated/O genome/O instability/O ,/O confirming/O the/O validity/O of/O our/O approach/O ./O
Diverse/O phenotype/O of/O hypokalaemic/O periodic/O paralysis/O within/O a/O family/O ./O
Hypokalaemic/O periodic/O paralysis/O typically/O presents/O with/O intermittent/O mild/O -/O to/O -/O moderate/O weakness/O lasting/O hours/O to/O days/O ./O
We/O report/O a/O case/O with/O an/O uncommon/O phenotype/O of/O late/O -/O onset/O myopathy/O without/O episodic/O paralytic/O attacks/O ./O
Initial/O work/O -/O up/O including/O muscle/O biopsy/O was/O inconclusive/O ./O
A/O subsequent/O review/O of/O the/O right/O deltoid/O biopsy/O ,/O long/O exercise/O testing/O and/O repeated/O family/O history/O was/O helpful/O ,/O followed/O by/O appropriate/O genetic/O testing/O ./O
We/O identified/O a/O heterozygous/O pathogenic/O mutation/O in/O calcium/O ion/O channel/O (/B-Var CACNA1S/I-Var :/I-Var c.1583G/I-Var >/I-Var A/I-Var p/I-Var ./I-Var Arg528His/I-Var )/I-Var causing/B-Reg hypokalaemic/B-Disease periodic/I-Disease paralysis/I-Disease ./O
Myopathy/O can/O present/O without/O episodic/O paralysis/O and/O the/O frequency/O of/O paralytic/O episodes/O does/O not/O correlate/O well/O with/O the/O development/O and/O progression/O of/O a/O fixed/O myopathy/O ./O
Our/O report/O also/O highlights/O the/O intrafamilial/O phenotypic/O variation/O of/O hypokalaemic/B-Disease periodic/I-Disease paralysis/I-Disease secondary/O to/B-Reg a/O CACNA1S/B-Gene gene/O mutation/B-Var ./O
Genetic/O anticipation/O in/O Swedish/O Lynch/O syndrome/O families/O ./O
Among/O hereditary/O colorectal/O cancer/O predisposing/O syndromes/O ,/O Lynch/B-Disease syndrome/I-Disease (/O LS/O )/O caused/B-Reg by/I-Reg mutations/B-Var in/O DNA/O mismatch/O repair/O genes/O MLH1/B-Gene ,/O MSH2/B-Gene ,/O MSH6/B-Gene or/O PMS2/B-Gene is/O the/O most/O common/O ./O
Patients/O with/O LS/O have/O an/O increased/O risk/O of/O early/O onset/O colon/O and/O endometrial/O cancer/O ,/O but/O also/O other/O tumors/O that/O generally/O have/O an/O earlier/O onset/O compared/O to/O the/O general/O population/O ./O
However/O ,/O age/O at/O first/O primary/O cancer/O varies/O within/O families/O and/O genetic/O anticipation/O ,/O i.e./O decreasing/O age/O at/O onset/O in/O successive/O generations/O ,/O has/O been/O suggested/O in/O LS/O ./O
Anticipation/O is/O a/O well/O -/O known/O phenomenon/O in/O e.g/O neurodegenerative/O diseases/O and/O several/O reports/O have/O studied/O anticipation/O in/O heritable/O cancer/O ./O
The/O purpose/O of/O this/O study/O is/O to/O determine/O whether/O anticipation/O can/O be/O shown/O in/O a/O nationwide/O cohort/O of/O Swedish/O LS/O families/O referred/O to/O the/O regional/O departments/O of/O clinical/O genetics/O in/O Lund/O ,/O Stockholm/O ,/O Linköping/O ,/O Uppsala/O and/O Umeå/O between/O the/O years/O 1990/O -/O 2013/O ./O
We/O analyzed/O a/O homogenous/O group/O of/O mutation/O carriers/O ,/O utilizing/O information/O from/O both/O affected/O and/O non/O -/O affected/O family/O members/O ./O
In/O total/O ,/O 239/O families/O with/O a/O mismatch/O repair/O gene/O mutation/O (/O 96/O MLH1/O families/O ,/O 90/O MSH2/O families/O including/O one/O family/O with/O an/O EPCAM/O -/O MSH2/O deletion/O ,/O 39/O MSH6/O families/O ,/O 12/O PMS2/O families/O ,/O and/O 2/O MLH1+PMS2/O families/O )/O comprising/O 1028/O at/O -/O risk/O carriers/O were/O identified/O among/O the/O Swedish/O LS/O families/O ,/O of/O which/O 1003/O mutation/O carriers/O had/O available/O follow/O -/O up/O information/O and/O could/O be/O included/O in/O the/O study/O ./O
Using/O a/O normal/O random/O effects/O model/O (/O NREM/O )/O we/O estimate/O a/O 2.1/O year/O decrease/O in/O age/O of/O diagnosis/O per/O generation/O ./O
An/O alternative/O analysis/O using/O a/O mixed/O -/O effects/O Cox/O proportional/O hazards/O model/O (/O COX/O -/O R/O )/O estimates/O a/O hazard/O ratio/O of/O exp(0.171/O )/O ,/O or/O about/O 1.19/O ,/O for/O age/O of/O diagnosis/O between/O consecutive/O generations/O ./O
LS/O -/O associated/O gene/O -/O specific/O anticipation/O effects/O are/O evident/O for/O MSH2/O (/O 2.6/O years/O //O generation/O for/O NREM/O and/O hazard/O ratio/O of/O 1.33/O for/O COX/O -/O R/O )/O and/O PMS2/O (/O 7.3/O years/O //O generation/O and/O hazard/O ratio/O of/O 1.86/O )/O ./O
The/O estimated/O anticipation/O effects/O for/O MLH1/O and/O MSH6/O are/O smaller/O ./O
EYS/O mutation/O update/O :/O In/O silico/O assessment/O of/O 271/O reported/O and/O 26/O novel/O variants/O in/O patients/O with/O retinitis/O pigmentosa/O ./O
Mutations/B-Var in/O Eyes/O shut/O homolog/O (/B-Gene EYS/I-Gene )/I-Gene are/O one/O of/O the/O most/O common/O causes/B-Reg of/O autosomal/B-Disease recessive/I-Disease (/I-Disease ar/I-Disease )/I-Disease retinitis/I-Disease pigmentosa/I-Disease (/O RP/O )/O ,/O a/O progressive/O blinding/O disorder/O ./O
The/O exact/O function/O of/O the/O EYS/O protein/O and/O the/O pathogenic/O mechanisms/O underlying/O EYS/O -/O associated/O RP/O are/O still/O poorly/O understood/O ,/O which/O hampers/O the/O interpretation/O of/O the/O causality/O of/O many/O EYS/O variants/O discovered/O to/O date/O ./O
We/O collected/O all/O reported/O EYS/O variants/O present/O in/O 377/O arRP/O index/O cases/O published/O before/O June/O 2017/O ,/O and/O uploaded/O them/O in/O the/O Leiden/O Open/O Variation/O Database/O (/O www.LOVD.nl/EYS/O )/O ./O
We/O also/O describe/O 36/O additional/O index/O cases/O ,/O carrying/O 26/O novel/O variants/O ./O
Of/O the/O 297/O unique/O EYS/O variants/O identified/O ,/O almost/O half/O (/O n/O =/O 130/O )/O are/O predicted/O to/O result/O in/O premature/O truncation/O of/O the/O EYS/O protein/O ./O
Classification/O of/O all/O variants/O using/O the/O American/O College/O of/O Medical/O Genetics/O and/O Genomics/O guidelines/O revealed/O that/O the/O predicted/O pathogenicity/O of/O these/O variants/O cover/O the/O complete/O spectrum/O ranging/O from/O likely/O benign/O to/O pathogenic/O ,/O although/O especially/O missense/O variants/O largely/O fall/O in/O the/O category/O of/O uncertain/O significance/O ./O
Besides/O the/O identification/O of/O likely/O benign/O alleles/O previously/O reported/O as/O being/O probably/O pathogenic/O ,/O our/O comprehensive/O analysis/O underscores/O the/O need/O of/O functional/O assays/O to/O assess/O the/O causality/O of/O EYS/O variants/O ,/O in/O order/O to/O improve/O molecular/O diagnostics/O and/O counseling/O of/O patients/O with/O EYS/O -/O associated/O RP/O ./O
Ciliopathy/O -/O associated/O mutations/B-Var of/O IFT122/B-Gene impair/B-NegReg ciliary/B-Protein protein/I-Protein trafficking/B-MPA but/O not/O ciliogenesis/O ./O
The/O intraflagellar/O transport/O (/O IFT/O )/O machinery/O containing/O the/O IFT/O -/O A/O and/O IFT/O -/O B/O complexes/O mediates/O ciliary/O protein/O trafficking/O ./O
Mutations/B-Var in/O the/O genes/O encoding/O the/O six/O subunits/O of/O the/O IFT/O -/O A/O complex/O (/B-Gene IFT43/I-Gene ,/O IFT121/B-Gene ,/O IFT122/B-Gene ,/O IFT139/B-Gene ,/O IFT140/B-Gene ,/O and/O IFT144/B-Gene )/I-Gene are/O known/O to/O cause/B-Reg skeletal/O ciliopathies/O ,/O including/O cranioectodermal/B-Disease dysplasia/I-Disease (/O CED/O )/O ./O
As/O the/O IFT122/O subunit/O connects/O the/O core/O and/O peripheral/O subcomplexes/O of/O the/O IFT/O -/O A/O complex/O ,/O it/O is/O expected/O to/O play/O a/O pivotal/O role/O in/O the/O complex/O ./O
Indeed/O ,/O we/O here/O showed/O that/O knockout/O (/O KO/O )/O of/O the/O IFT122/O gene/O in/O hTERT/O -/O RPE1/O cells/O using/O the/O CRISPR/O //O Cas9/O system/O led/O to/O a/O severe/O ciliogenesis/O defect/O ,/O whereas/O KO/O of/O other/O IFT/O -/O A/O genes/O had/O minor/O effects/O on/O ciliogenesis/O but/O impaired/O ciliary/O protein/O trafficking/O ./O
Exogenous/O expression/O of/O not/O only/O wild/O -/O type/O IFT122/O but/O also/O its/O CED/O -/O associated/O missense/O mutants/O ,/O which/O fail/O to/O interact/O with/O other/O IFT/O -/O A/O subunits/O ,/O rescued/O the/O ciliogenesis/O defect/O of/O IFT122-KO/O cells/O ./O
However/O ,/O IFT122-KO/O cells/O expressing/O CED/O -/O type/O IFT122/B-Gene mutants/B-Var showed/O defects/B-NegReg in/O ciliary/B-Protein protein/I-Protein trafficking/B-MPA ,/O such/O as/O ciliary/O entry/O of/O Smoothened/O in/O response/O to/O Hedgehog/O signaling/O activation/O ./O
The/O trafficking/O defects/O partially/O resembled/O those/O observed/O in/O IFT144-KO/O cells/O ,/O which/O demonstrate/O failed/O assembly/O of/O the/O functional/O IFT/O -/O A/O complex/O at/O the/O base/O of/O cilia/O ./O
These/O observations/O make/O it/O likely/O that/O ,/O although/O IFT122/O is/O essential/O for/O ciliogenesis/O ,/O CED/O -/O type/O missense/O mutations/O underlie/O a/O skeletal/O ciliopathy/O phenotype/O by/O perturbing/O ciliary/O protein/O trafficking/O with/O minor/O effects/O on/O ciliogenesis/O per/O se/O ./O
Association/O of/O the/O AADAC/O gene/O and/O Tourette/O syndrome/O in/O a/O Han/O Chinese/O cohort/O ./O
Tourette/B-Disease syndrome/I-Disease (/O TS/O )/O is/O a/O complex/O neuropsychiatric/O disorder/O with/O chronic/O motor/O and/O vocal/O tics/O ./O
Though/O the/O etiology/O is/O elusive/O ,/O strong/O evidence/O for/O a/O genetic/O contribution/O to/O TS/O has/O been/O established/O ./O
To/O date/O ,/O various/O chromosomal/O or/O genetic/O alterations/O have/O been/O implicated/O in/O its/O pathogenesis/O ./O
Recently/O ,/O the/O deletion/O in/O the/O arylacetamide/O deacetylase/O gene/O (/O AADAC/O )/O was/O reported/O to/O be/O associated/O with/O TS/O ./O
To/O investigate/O the/O association/O between/O the/O AADAC/O gene/O variants/O and/O TS/O ,/O we/O conducted/O genetic/O analysis/O of/O the/O AADAC/O gene/O in/O 200/O Han/O Chinese/O patients/O and/O 300/O ethnicity/O -/O matched/O normal/O controls/O ./O
Two/O variants/O ,/O including/O a/O heterozygous/O splice/O -/O site/O variant/O ,/O c.361/O +/O 1/O G/O >/O A/O (/O rs762169706/O )/O ,/O and/O a/O missense/O variant/O ,/O c.744A/O >/O T/O (/O p/O ./O R248S/O ,/O rs186388618/O )/O ,/O were/O identified/O in/O two/O unrelated/O patients/O ./O
The/O c.361/B-Var +/I-Var 1/I-Var G/I-Var >/I-Var A/I-Var variant/O ,/O absent/O in/O 300/O ethnicity/O -/O matched/O controls/O ,/O led/B-Reg to/I-Reg the/O deletion/B-Var of/O exon/O 2/O in/O AADAC/O mRNA/O ,/O probably/O associated/B-Reg with/I-Reg development/O of/O TS/B-Disease ./O
The/O c.744A/O >/O T/O variant/O ,/O predicted/O to/O be/O damaging/O ,/O was/O identified/O in/O two/O normal/O controls/O ./O
The/O findings/O indicate/O that/O the/O AADAC/B-Gene gene/O c.361/B-Var +/I-Var 1/I-Var G/I-Var >/I-Var A/I-Var variant/O may/O be/O a/O potential/O candidate/B-Reg factor/I-Reg for/O TS/B-Disease development/O ,/O though/O further/O investigations/O are/O warranted/O ./O
MeCP2/O as/O an/O Activator/O of/O Gene/O Expression/O ./O
Rett/B-Disease syndrome/I-Disease is/O a/O neurodevelopmental/O disorder/O that/O primarily/O affects/O females/O and/O is/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O methyl/O -/O CpG/O -/O binding/O -/O protein/O 2/O (/B-Gene MECP2/I-Gene )/I-Gene gene/O ./O
Initially/O ,/O MeCP2/O had/O been/O shown/O to/O be/O a/O repressor/O of/O gene/O transcription/O ./O
In/O their/O 2008/O paper/O ,/O Chahrour/O and/O colleagues/O (/O DOI/O :/O 10.1126/O //O science.1153252/O )/O reported/O that/O MeCP2/O could/O also/O function/O as/O a/O transcriptional/O activator/O ./O
Molecular/O Analysis/O -/O Based/O Genetic/O Characterization/O of/O a/O Cohort/O of/O Patients/O with/O Duchenne/O and/O Becker/O Muscular/O Dystrophy/O in/O Eastern/O China/O ./O
Background/O :/O Duchenne/B-Disease muscular/I-Disease dystrophy/I-Disease (/O DMD/O )/O and/O Becker/B-Disease muscular/I-Disease dystrophy/I-Disease (/O BMD/O )/O are/O common/O X/O -/O linked/O recessive/O neuromuscular/O disorders/O caused/B-Reg by/I-Reg mutations/B-Var in/O dystrophin/B-Gene gene/I-Gene ./O
Multiplex/O polymerase/O chain/O reaction/O (/O multiplex/O PCR/O )/O and/O multiplex/O ligation/O -/O dependent/O probe/O amplification/O (/O MLPA/O )/O are/O the/O most/O common/O methods/O for/O detecting/O dystrophin/O gene/O mutations/O ./O
This/O study/O aimed/O to/O contrast/O the/O two/O methods/O and/O discern/O the/O genetic/O characterization/O of/O patients/O with/O DMD/O //O BMD/O in/O Eastern/O China/O ./O
Methods/O :/O We/O collected/O 121/O probands/O ,/O 64/O mothers/O of/O probands/O ,/O and/O 15/O fetuses/O in/O our/O study/O ./O
The/O dystrophin/O gene/O was/O detected/O by/O multiplex/O PCR/O primarily/O in/O 28/O probands/O ,/O and/O MLPA/O was/O used/O in/O multiplex/O PCR/O -/O negative/O cases/O subsequently/O ./O
The/O dystrophin/O gene/O of/O the/O remaining/O 93/O probands/O and/O 62/O female/O potential/O carriers/O was/O tested/O by/O MLPA/O directly/O ./O
In/O fetuses/O ,/O multiplex/O PCR/O and/O MLPA/O were/O performed/O on/O 4/O fetuses/O and/O 10/O fetuses/O ,/O respectively/O ./O
In/O addition/O ,/O sequencing/O was/O also/O performed/O in/O 4/O probands/O with/O negative/O MLPA/O ./O
Results/O :/O We/O found/O that/O 61.98/O %/O of/O the/O subjects/O had/O genetic/O mutations/O including/O deletions/O (/O 50.41/O %/O )/O and/O duplications/O (/O 11.57/O %/O )/O ./O
There/O were/O 43.75/O %/O of/O mothers/O as/O carriers/O of/O the/O mutation/O ./O
In/O 15/O fetuses/O ,/O 2/O out/O of/O 7/O male/O fetuses/O were/O found/O to/O be/O unhealthy/O and/O 2/O out/O of/O 8/O female/O fetuses/O were/O found/O to/O be/O carriers/O ./O
Exons/O 3/O -/O 26/O and/O 45/O -/O 52/O have/O the/O maximum/O frequency/O in/O mutation/O regions/O ./O
In/O the/O frequency/O of/O exons/O individually/O ,/O exon/O 47/O and/O exon/O 50/O were/O the/O most/O common/O in/O deleted/O regions/O and/O exons/O 5/O ,/O 6/O ,/O and/O 7/O were/O found/O most/O frequently/O in/O duplicated/O regions/O ./O
Conclusions/O :/O MLPA/O has/O better/O productivity/O and/O sensitivity/O than/O multiplex/O PCR/O ./O
Prenatal/O diagnosis/O should/O be/O applied/O in/O DMD/O high/O -/O risk/O fetuses/O to/O reduce/O the/O disease/O incidence/O ./O
Furthermore/O ,/O it/O is/O the/O responsibility/O of/O physicians/O to/O inform/O female/O carriers/O the/O importance/O of/O prenatal/O diagnosis/O ./O
A/O novel/O mutation/B-Var in/O RDH5/B-Gene gene/O causes/B-Reg retinitis/B-Disease pigmentosa/I-Disease in/O consanguineous/O Pakistani/O family/O ./O
Retinitis/O pigmentosa/O (/O RP/O )/O is/O the/O most/O frequent/O genetically/O and/O clinically/O heterogeneous/O inherited/O retinal/O degeneration/O ./O
To/O date/O ,/O more/O than/O 80/O genes/O have/O been/O identified/O that/O cause/O autosomal/O dominant/O ,/O autosomal/O recessive/O and/O X/O linked/O RP/O ./O
However/O ,/O locus/O and/O allelic/O heterogeneity/O of/O RP/O has/O not/O been/O fully/O captured/O yet/O ./O
This/O heterogeneity/O and/O lack/O of/O an/O accurate/O genotype/O phenotype/O correlation/O makes/O molecular/O dissection/O of/O the/O disease/O more/O difficult/O ./O
The/O present/O study/O was/O designed/O to/O characterize/O the/O underlying/O pathogenic/O variants/O of/O RP/O in/O Pakistan/O ./O
For/O this/O purpose/O ,/O a/O large/O consanguineous/O family/O with/O RP/O phenotype/O showing/O autosomal/O recessive/O mode/O of/O inheritance/O was/O selected/O after/O a/O complete/O ophthalmological/O examination/O ./O
Next/O generation/O sequencing/O was/O used/O for/O the/O identification/O of/O molecular/O determinant/O followed/O by/O Sanger/O -/O sequencing/O for/O confirmation/O ./O
After/O sequence/O analysis/O a/O novel/O homozygous/O missense/O mutation/O ,/O (/B-Var c.602/I-Var C/I-Var >/I-Var T/I-Var )/I-Var in/O exon/O 4/O of/O the/O RDH5/B-Gene gene/O (/O MIM/O :/O 601617/O )/O was/O identified/O ./O
This/O mutation/O resulted/B-Reg in/I-Reg substitution/O of/O phenyl/O alanine/O for/O serine/O at/O amino/O acid/O 201/O (/B-Var p/I-Var ./I-Var Ser201Phe/I-Var )/I-Var of/O the/O RDH5/B-Gene gene/O ./O
The/O same/O mutation/O was/O not/O detected/O in/O the/O 200/O ethnically/O -/O matched/O control/O samples/O by/O Sanger/O sequencing/O ./O
The/O identified/O mutant/O allele/O segregated/O in/O homozygous/O fashion/O in/O all/O the/O affected/O individuals/O of/O pedigree/O ./O
Identification/O of/O this/O mutation/O reveals/O the/O allelic/O heterogeneity/O of/O RDH5/O in/O patients/O with/O RP/O phenotype/O ./O
The/O findings/O of/O this/O study/O demonstrate/O the/O clinical/O significance/O of/O next/O generation/O sequencing/O to/O understand/O the/O molecular/O basis/O of/O diseases/O and/O would/O help/O to/O reveal/O new/O proteins/O and/O their/O function/O in/O visual/O cycle/O will/O pave/O the/O way/O for/O early/O diagnosis/O ,/O genetic/O counseling/O and/O better/O therapeutic/O inventions/O ./O
Targeted/O Next/O Generation/O Sequencing/O Revealed/O Novel/O PRPF31/B-Gene Mutations/B-Var in/B-Reg Autosomal/B-Disease Dominant/I-Disease Retinitis/I-Disease Pigmentosa/I-Disease ./O
BACKGROUND/O :/O Retinitis/O pigmentosa/O (/O RP/O )/O is/O a/O rare/O type/O of/O inherited/O retinal/O dystrophy/O that/O can/O result/O in/O progressive/O vision/O loss/O ./O
Molecular/O diagnosis/O of/O RP/O is/O challenging/O due/O to/O phenotypic/O and/O genotypic/O heterogeneities/O ./O
AIMS/O :/O This/O study/O aimed/O to/O identify/O the/O pathogenic/O mutations/O in/O two/O Chinese/O families/O with/O autosomal/O dominant/O RP/O (/O adRP/O )/O and/O in/O a/O patient/O with/O sporadic/O RP/O ./O
MATERIALS/O AND/O METHODS/O :/O Peripheral/O blood/O DNA/O samples/O were/O obtained/O from/O the/O participants/O ./O
Targeted/O next/O generation/O sequencing/O (/O NGS/O )/O was/O applied/O to/O identify/O mutations/O in/O these/O patients/O ./O
For/O pathogenic/O mutation/O analyses/O ,/O stringent/O NGS/O data/O analyses/O and/O segregation/O analyses/O were/O applied/O ./O
Primers/O were/O designed/O to/O validate/O the/O identified/O mutations/O by/O Sanger/O sequencing/O analyses/O ./O
RESULTS/O :/O A/O novel/O heterozygous/O insertion/O frameshift/O mutation/O c.1226_1227insA/O ,/O p/O ./O T410Dfs*65/O ,/O and/O a/O novel/O heterozygous/O stopgain/O mutation/O c.1015C/O >/O T/O ,/O p/O ./O Q339/O */O were/O identified/O in/O PRPF31/O ./O
A/O known/O c.527/O +/O 3A/O >/O G/O splicing/O mutation/O was/O identified/O in/O one/O of/O the/O adRP-074/O families/O ./O
All/O mutations/O were/O found/O to/O co/O -/O segregate/O with/O the/O disease/O ,/O and/O none/O of/O these/O mutations/O were/O detected/O in/O 500/O control/O samples/O ./O
CONCLUSIONS/O :/O Our/O data/O identified/O two/O new/O autosomal/O dominant/O mutations/O in/O PRPF31/O ,/O expanding/O the/O mutational/O spectrum/O of/O this/O gene/O ./O
Identification/O of/O deletion/B-Var -/I-Var duplication/I-Var in/O HEXA/B-Gene gene/O in/O five/O children/O with/B-Reg Tay/B-Disease -/I-Disease Sachs/I-Disease disease/I-Disease from/O India/O ./O
BACKGROUND/O :/O Tay/B-Disease -/I-Disease Sachs/I-Disease disease/I-Disease (/O TSD/O )/O is/O a/O sphingolipid/O storage/O disorder/O caused/B-Reg by/I-Reg mutations/B-Var in/O the/O HEXA/B-Gene gene/O ./O
To/O date/O ,/O nearly/O 170/O mutations/O of/O HEXA/O have/O been/O described/O ,/O including/O only/O one/O 7.6/O kb/O large/O deletion/O ./O
METHODS/O :/O Multiplex/O Ligation/O -/O dependent/O Probe/O Amplification/O (/O MLPA/O )/O study/O was/O carried/O out/O in/O 5/O unrelated/O patients/O for/O copy/O number/O changes/O where/O heterozygous/O and/or/O homozygous/O disease/O causing/O mutation/O //O s/O could/O not/O be/O identified/O in/O the/O coding/O region/O by/O sequencing/O of/O HEXA/O gene/O ./O
RESULTS/O :/O The/O study/O has/O identified/O the/O presence/O of/O a/O homozygous/O deletion/O of/O exon-2/O and/O exon-3/O in/O two/O patients/O ,/O two/O patient/O showed/O compound/O heterozygosity/O with/O exon/O 1/O deletion/O combined/O with/O missense/O mutation/O p/O ./O E462V/O and/O one/O patient/O was/O identified/O with/O duplication/O of/O exon-1/O with/O novel/O variants/O c.1527/O -/O 2A/O >/O T/O as/O a/O second/O allele/O ./O
CONCLUSION/O :/O This/O is/O the/O first/O report/O of/O deletion/O //O duplication/O in/O HEXA/O gene/O providing/O a/O new/O insight/O into/O the/O molecular/O basis/O of/O TSD/O and/O use/O of/O MLPA/O assay/O for/O detecting/O large/O copy/O number/O changes/O in/O the/O HEXA/O gene/O ./O
Two/O siblings/O with/O 11qter/O deletion/O syndrome/O that/O had/O been/O rescued/O in/O their/O mother/O by/O uniparental/O disomy/O ./O
Jacobsen/B-Disease syndrome/I-Disease refers/O to/O a/O congenital/O anomaly/O caused/B-Reg by/I-Reg deletion/B-Var at/O 11q23.3-qter/B-Gene ./O
We/O here/O describe/O two/O siblings/O with/O the/O same/O 11q23.3-qter/O deletion/O ./O
Both/O parents/O were/O healthy/O with/O a/O normal/O karyotype/O ./O
Cytogenetic/O microarray/O analysis/O revealed/O no/O mosaicism/O in/O either/O parent/O but/O the/O mother/O showed/O uniparental/O disomy/O encompassing/O the/O deleted/O region/O found/O in/O the/O two/O siblings/O ./O
The/O pattern/O of/O X/O chromosome/O inactivation/O was/O almost/O completely/O skewed/O in/O the/O mother/O ./O
These/O data/O suggested/O that/O the/O mother/O was/O a/O carrier/O of/O the/O 11q23.3-qter/O deletion/O but/O that/O this/O had/O been/O rescued/O by/O disomy/O formation/O during/O early/O embryogenesis/O except/O for/O her/O germinal/O cells/O ./O
Genotyping/O of/O five/O Pakistani/O patients/O with/O severe/O inherited/O factor/O X/O deficiency/O :/O identification/O of/O two/O novel/O mutations/O ./O
:/O Congenital/B-Disease factor/I-Disease X/I-Disease deficiency/I-Disease is/O a/O rare/O coagulation/O defect/O characterized/O by/O variable/O bleeding/O tendency/O ./O
The/O aim/O of/O the/O study/O was/O to/O give/O a/O first/O insight/O of/B-Reg F10/B-Gene gene/O mutations/B-Var in/O Pakistani/O probands/O ./O
Direct/O sequencing/O and/or/O next/O -/O generation/O sequencing/O was/O performed/O on/O the/O coding/O regions/O ,/O boundaries/O and/O 5/O '/O and/O 3/O '/O untranslated/O regions/O of/O the/O F10/O gene/O in/O five/O severe/O factor/O X/O -/O deficient/O patients/O from/O Pakistan/O ./O
All/O patients/O were/O born/O from/O consanguineous/O marriages/O and/O displayed/O FX/O :/O C/O levels/O below/O 2/O %/O ./O
Sequencing/O revealed/O five/O different/O substitutions/O ,/O including/O three/O previously/O reported/O p/O ./O Ala15Asp/O ,/O p/O ./O Gly406Ser/O ,/O and/O p/O ./O Gly420Arg/O missense/O variants/O ,/O and/O also/O two/O novel/O variants/O :/O p/O ./O Cys57Arg/O and/O p/O ./O Gln175/O */O ./O
Though/O one/O genotype/O could/O not/O be/O characterized/O ,/O we/O were/O able/O to/O confirm/O the/O inherited/O nature/O of/O the/O defect/O using/O familial/O studies/O ./O
As/O the/O copy/O number/O variations/O were/O ruled/O out/O ,/O we/O hypothesized/O the/O presence/O of/O deep/O intronic/O mutants/O that/O might/O have/O escaped/O detection/O from/O sequencing/O or/O abnormalities/O in/O epigenetic/O regulation/O ./O
Three/O patients/O presented/O with/O severe/O clinical/O symptoms/O ,/O in/O the/O early/O days/O of/O life/O ,/O whereas/O two/O presented/O only/O with/O trauma/O -/O provoked/O bleeds/O and/O bruises/O later/O in/O life/O ./O
Those/O patients/O with/O milder/O forms/O bore/O the/O p/O ./O Gly406Ser/O at/O the/O homozygous/O state/O and/O F10/O unknown/O alleles/O ,/O respectively/O ./O
F10/O mutation/O spectrum/O in/O Pakistan/O is/O heterogeneous/O as/O seen/O in/O other/O populations/O ./O
Identification/O of/O the/O F10/O mutations/O is/O important/O for/O genetic/O counseling/O and/O prenatal/O diagnosis/O in/O subsequent/O pregnancies/O ./O
Spectrum/O of/O MECP2/B-Gene mutations/B-Var in/O Vietnamese/O patients/O with/B-Reg RETT/B-Disease syndrome/I-Disease ./O
BACKGROUND/O :/O Rett/O syndrome/O (/O RTT/O )/O is/O a/O severe/O neurodevelopmental/O disorder/O in/O children/O characterized/O by/O a/O normal/O neurodevelopmental/O process/O in/O the/O first/O 6/O -/O 18/O months/O followed/O by/O a/O period/O of/O motor/O and/O vocal/O deterioration/O with/O stereotypic/O hand/O movements/O ./O
Incidence/O of/O RTT/B-Disease is/O mostly/O due/B-Reg to/I-Reg de/O novo/O mutation/B-Var in/O the/O MECP2/B-Gene gene/O (/O methyl/O -/O CpG/O -/O binding/O protein/O 2/O )/O ./O
METHODS/O :/O The/O study/O assessed/O 27/O female/O patients/O presented/O with/O classical/O RTT/O phenotype/O age/O range/O from/O 18/O months/O to/O 48/O months/O ./O
Specialist/O carried/O out/O the/O clinical/O evaluation/O and/O diagnosis/O according/O to/O RTT/O diagnosis/O criteria/O ./O
Blood/O samples/O from/O patients/O were/O then/O collected/O for/O genomic/O DNA/O extraction/O ./O
We/O next/O performed/O MECP2/O gene/O amplification/O and/O sequencing/O of/O the/O whole/O coding/O region/O to/O screen/O for/O mutations/O ./O
RESULT/O :/O MECP2/O mutation/O was/O found/O in/O 20/O patients/O (/O 74/O %/O )/O including/O :/O 2/O missense/O ,/O 4/O nonsense/O ,/O 6/O frameshift/O and/O 2/O deletion/O mutation/O ./O
The/O study/O identified/O 14/O pathogenic/O mutations/O which/O we/O found/O 4/O mutation/O ,/O to/O our/O knowledge/O and/O extensive/O search/O ,/O not/O priory/O reported/O in/O any/O mutation/O database/O or/O publication/O :/O c.1384/O -/O 1385DelGT/O ,/O c.1205insT/O ,/O c.717delC/O and/O c.1132_1207del77/O ./O
High/O percentage/O of/O C/O >/O T/O (/O 70/O %/O )/O in/O CpG/O sites/O mutation/O was/O found/O ./O
CONCLUSION/O :/O Our/O result/O reveals/O a/O high/O percentage/O of/O C/O >/O T/O mutation/O in/O CpG/O hot/O spot/O ,/O which/O is/O more/O prone/O to/O modification/O and/O more/O likely/O to/O be/O detected/O in/O RTT/O as/O a/O disorder/O is/O strictly/O due/O to/O de/O novo/O mutations/O ./O
The/O study/O is/O the/O first/O to/O identify/O the/O mutation/O spectrum/O of/O MECP2/O gene/O in/O Vietnamese/O patients/O and/O also/O an/O important/O step/O toward/O better/O diagnosis/O and/O care/O for/O RTT/O patients/O in/O Vietnam/O ./O
Clinical/O presentation/O and/O natural/O history/O of/O infantile/O -/O onset/O ascending/O spastic/O paralysis/O from/O three/O families/O with/O an/O ALS2/O founder/O variant/O ./O
Biallelic/B-Var mutations/I-Var of/O the/O alsin/O Rho/O guanine/O nucleotide/O exchange/O factor/O (/B-Gene ALS2/I-Gene )/I-Gene gene/O cause/B-Reg a/O group/O of/O overlapping/O autosomal/O recessive/O neurodegenerative/O disorders/O including/O infantile/B-Disease -/I-Disease onset/I-Disease ascending/I-Disease hereditary/I-Disease spastic/I-Disease paralysis/I-Disease (/O IAHSP/O )/O ,/O juvenile/B-Disease primary/I-Disease lateral/I-Disease sclerosis/I-Disease (/O JPLS/O )/O ,/O and/O juvenile/B-Disease amyotrophic/I-Disease lateral/I-Disease sclerosis/I-Disease (/O JALS/O //O ALS2/O )/O ,/O caused/B-Reg by/I-Reg retrograde/B-CPA degeneration/I-CPA of/I-CPA the/I-CPA upper/I-CPA motor/I-CPA neurons/I-CPA of/I-CPA the/I-CPA pyramidal/I-CPA tracts/I-CPA ./O
Here/O ,/O we/O describe/O 11/O individuals/O with/O IAHSP/O ,/O aged/O 2/O -/O 48/O years/O ,/O with/O IAHSP/B-Disease from/O three/O unrelated/O consanguineous/O Iranian/O families/O carrying/B-Reg the/O homozygous/O c.1640/B-Var +/I-Var 1G/I-Var >/I-Var A/I-Var founder/O mutation/O in/O ALS2/B-Gene ./O
Three/O affected/O siblings/O from/O one/O family/O exhibit/O generalized/O dystonia/O which/O has/O not/O been/O previously/O described/O in/O families/O with/O IAHSP/O and/O has/O only/O been/O reported/O in/O three/O unrelated/O consanguineous/O families/O with/O JALS/O //O ALS2/O ./O
We/O report/O the/O oldest/O individuals/O with/O IAHSP/O to/O date/O and/O provide/O evidence/O that/O these/O patients/O survive/O well/O into/O their/O late/O 40s/O with/O preserved/O cognition/O and/O normal/O eye/O movements/O ./O
Our/O study/O delineates/O the/O phenotypic/O spectrum/O of/O IAHSP/O and/O ALS2-related/O disorders/O and/O provides/O valuable/O insights/O into/O the/O natural/O disease/O course/O ./O
A/O novel/O MFSD8/B-Gene mutation/B-Var in/O a/O Russian/O patient/O with/B-Reg neuronal/B-Disease ceroid/I-Disease lipofuscinosis/I-Disease type/O 7/O :/O a/O case/O report/O ./O
BACKGROUND/O :/O Neuronal/O ceroid/O lipofuscinoses/O (/O NCLs/O )/O are/O the/O most/O common/O autosomal/O recessive/O neurodegenerative/O disorders/O in/O children/O ./O
Clinical/O manifestations/O include/O progressive/O cognitive/O decline/O ,/O motor/O impairment/O ,/O ataxia/O ,/O visual/O loss/O ,/O seizures/O and/O early/O death/O ./O
To/O date/O more/O than/O 440/O NCL/O -/O causing/O mutations/O in/O 13/O genes/O are/O known/O ./O
CASE/O PRESENTATION/O :/O We/O report/O clinical/O and/O genetic/O characteristics/O of/O a/O 5-year/O -/O old/O girl/O affected/O by/O ceroid/O lipofuscinosis/O type/O 7/O (/O NCL7/O )/O ./O
She/O had/O progressive/O motor/O and/O mental/O deterioration/O since/O the/O age/O of/O 2,5/O years/O ./O
Later/O she/O developed/O progressive/O vision/O loss/O ,/O stereotypies/O ,/O action/O myoclonus/O and/O epilepsy/O ./O
By/O the/O age/O of/O 5/O years/O she/O stopped/O walking/O ./O
Based/O on/O symptoms/O ,/O diagnosis/O of/O Rett/O syndrome/O was/O suggested/O ,/O but/O no/O abnormalities/O were/O detected/O in/O MeCP2/O ./O
We/O identified/O a/O novel/O homozygous/O mutation/O in/O MFSD8/O gene/O (/O c.525/O T/O >/O A/O ,/O p/O ./O Cys175Ter/O )/O ./O
To/O our/O knowledge/O ,/O this/O is/O the/O first/O report/O of/O MFSD8/O gene/O mutation/O in/O a/O Russian/O patient/O with/O variant/O late/O -/O infantile/O NCL/O ./O
CONCLUSIONS/O :/O Our/O results/O enlarge/O mutational/O spectrum/O of/O ceroid/O lipofuscinosis/O type/O 7/O and/O demonstrate/O tremendous/O diagnosis/O value/O of/O exome/O sequencing/O for/O pediatric/O NCLs/O ./O
Also/O we/O confirmed/O that/O NCL/O should/O be/O suspected/O in/O patients/O with/O Rett/O -/O like/O phenotype/O at/O onset/O and/O negative/O MECP2/O mutation/O ./O
Molecular/O genetics/O of/O the/O POMT1-related/O muscular/O dystrophy/O -/O dystroglycanopathies/O ./O
Protein/O O/O -/O mannosyltransferase/O 1/O (/O POMT1/O )/O is/O a/O critical/O enzyme/O participating/O in/O the/O first/O step/O of/O protein/O O/O -/O mannosylation/O ./O
Mutations/B-Var in/O the/O coding/O gene/O ,/O POMT1/B-Gene ,/O have/O been/O described/O to/O be/O related/O to/O a/O series/O of/O autosomal/O recessive/O disorders/O associated/O with/O defective/B-NegReg alpha/B-MPA -/I-MPA dystroglycan/I-MPA glycosylation/I-MPA ,/O later/O termed/O muscular/B-Disease dystrophy/I-Disease -/I-Disease dystroglycanopathies/I-Disease (/O MDDGs/O )/O ./O
MDDGs/O are/O characterized/O by/O a/O broad/O phenotypic/O spectrum/O of/O congenital/O muscular/O dystrophy/O or/O later/O -/O onset/O limb/O -/O girdle/O muscular/O dystrophy/O ,/O accompanied/O by/O variable/O degrees/O of/O intellectual/O disability/O ,/O brain/O defects/O ,/O and/O ocular/O abnormalities/O ./O
To/O date/O ,/O at/O least/O 76/O disease/O -/O associated/O mutations/O in/O the/O POMT1/O gene/O ,/O including/O missense/O ,/O nonsense/O ,/O splicing/O ,/O deletion/O ,/O insertion/O //O duplication/O ,/O and/O insertion/O -/O deletion/O mutations/O ,/O have/O been/O reported/O in/O the/O literature/O ./O
In/O this/O review/O ,/O we/O highlight/O the/O present/O knowledge/O of/O the/O identified/O disease/O -/O associated/O POMT1/O gene/O mutations/O and/O genetic/O animal/O models/O related/O to/O the/O POMT1/O gene/O ./O
This/O review/O may/O help/O further/O normative/O classification/O of/O phenotypes/O ,/O assist/O in/O definite/O clinical/O and/O genetic/O diagnoses/O ,/O and/O genetic/O counseling/O ,/O and/O may/O comprehensively/O improve/O our/O understanding/O of/O the/O basis/O of/O complex/O phenotypes/O and/O possible/O pathogenic/O mechanisms/O involved/O ./O
Segmental/O uniparental/O disomy/O as/O a/O rare/O cause/O of/O congenital/O severe/O factor/O XIII/O deficiency/O in/O a/O girl/O with/O only/O one/O heterozygous/O carrier/O parent/O ./O
Uniparental/B-Disease disomy/I-Disease (/O UPD/O )/O refers/O to/O a/O situation/O when/O a/O person/O inherits/O both/O homologs/O of/O a/O region/O or/O complete/O part/O of/O a/O chromosome/O from/O only/O one/O parent/O ./O
Here/O ,/O we/O present/O an/O unusual/O case/O of/O UPD/O in/O congenital/O severe/O factor/O (/O F/O )/O XIII/O deficiency/O ./O
A/O 6-year/O -/O old/O girl/O experienced/O cephalhematoma/O and/O umbilical/O bleeding/O after/O birth/O and/O easy/O bruising/O ,/O and/O postextraction/O bleeding/O since/O early/O infancy/O ./O
FXIII/O activity/O was/O 0/O %/O [/O mother/O 53.7/O %/O and/O father/O 132.5/O %/O (/O normal/O 70/O -/O 140/O %/O )/O ]/O and/O the/O FXIII/O antigen/O level/O was/O 2.5/O %/O [/O mother/O 38.9/O %/O and/O father/O 151/O %/O (/O normal/O 75/O -/O 155/O %/O )/O ]/O ./O
The/O washed/O platelet/O FXIII/O activity/O was/O 0.1/O %/O in/O the/O patient/O (/O normal/O 64/O -/O 144/O %/O )/O ,/O suggesting/O a/O deficiency/O of/O FXIII/O -/O A/O subunit/O ./O
The/O FXIII/O -/O A/O subunit/O genetic/O analysis/O detected/O a/O homozygous/O p/O ./O Arg382Ser/O mutation/O ./O
A/O similar/O heterozygous/O mutation/O was/O detected/O in/O the/O mother/O but/O surprisingly/O ,/O not/O in/O the/O father/O ./O
Kinship/O was/O confirmed/O by/O a/O paternity/O test/O ./O
To/O confirm/O the/O possibility/O of/O UPD/O ,/O a/O test/O using/O four/O markers/O in/O the/O vicinity/O of/O the/O F13A1/B-Gene gene/O revealed/O that/O she/O inherited/O duplicate/B-Var mutations/I-Var from/O a/O heterozygous/O mutation/O in/O her/O mother/O ,/O presenting/O a/O unique/O case/B-Reg of/I-Reg unusual/O maternal/O segmental/O UPD/B-Disease in/O otherwise/O unexplained/O congenital/O (/O homozygous/O )/O severe/O FXIII/B-Disease deficiency/I-Disease ./O
UPD/O as/O a/O rare/O cause/O of/O autosomal/O recessive/O bleeding/O disorder/O when/O only/O one/O parent/O is/O affected/O is/O critical/O for/O genetic/O counseling/O ./O
